U.S. patent application number 14/466153 was filed with the patent office on 2016-04-07 for alkynyl alcohols and methods of use.
This patent application is currently assigned to GENENTECH, INC.. The applicant listed for this patent is Genentech, Inc.. Invention is credited to Nicole Blaquiere, Jason Burch, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Guosheng Wu, Po-wai Yuen.
Application Number | 20160096850 14/466153 |
Document ID | / |
Family ID | 51417265 |
Filed Date | 2016-04-07 |
United States Patent
Application |
20160096850 |
Kind Code |
A9 |
Blaquiere; Nicole ; et
al. |
April 7, 2016 |
ALKYNYL ALCOHOLS AND METHODS OF USE
Abstract
The invention relates to compounds of Formula (0): ##STR00001##
wherein Q, A.sup.1-A.sup.8, R.sup.4 and R.sup.5 and each has the
meaning as described herein. Compounds of Formula (0) and
pharmaceutical compositions thereof are useful in the treatment of
diseases and disorders in which undesired or over-activation of
NF-kB signaling is observed.
Inventors: |
Blaquiere; Nicole; (San
Francisco, CA) ; Castanedo; Georgette; (Redwood City,
CA) ; Feng; Jianwen A.; (Millbrae, CA) ; Hu;
Baihua; (Plainsboro, NJ) ; Staben; Steven;
(San Francisco, CA) ; Yuen; Po-wai; (Ann Arbor,
MI) ; Wu; Guosheng; (Beijing, CN) ; Burch;
Jason; (Redwood City, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Genentech, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
GENENTECH, INC.
South San Francisco
CA
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20150065482 A1 |
March 5, 2015 |
|
|
Family ID: |
51417265 |
Appl. No.: |
14/466153 |
Filed: |
August 22, 2014 |
Current U.S.
Class: |
514/210.18;
514/233.2; 514/248; 514/256; 514/259.1; 514/303; 514/322; 514/338;
514/364; 514/367; 514/403; 544/127; 544/236; 544/281; 544/333;
546/120; 546/199; 546/275.7; 548/143; 548/153; 548/360.5;
548/362.5 |
Current CPC
Class: |
C07D 417/10 20130101;
C07D 495/04 20130101; A61P 19/02 20180101; C07D 487/04 20130101;
C07D 491/052 20130101; A61P 11/02 20180101; A61P 29/00 20180101;
C07D 401/14 20130101; C07D 491/048 20130101; A61P 13/12 20180101;
C07D 403/14 20130101; A61P 17/02 20180101; A61P 37/06 20180101;
C07D 513/04 20130101; C07D 401/10 20130101; A61P 25/00 20180101;
C07D 471/04 20130101; A61P 15/00 20180101; C07D 413/10 20130101;
C07D 413/14 20130101; A61P 37/02 20180101; C07D 403/10 20130101;
A61P 37/00 20180101 |
International
Class: |
C07D 513/04 20060101
C07D513/04; C07D 471/04 20060101 C07D471/04; C07D 403/10 20060101
C07D403/10; C07D 401/14 20060101 C07D401/14; C07D 413/10 20060101
C07D413/10; C07D 491/052 20060101 C07D491/052; C07D 487/04 20060101
C07D487/04; C07D 401/10 20060101 C07D401/10 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 22, 2013 |
CN |
PCT/CN2013/000993 |
May 28, 2014 |
CN |
PCT/CN2014/078680 |
Jul 22, 2014 |
CN |
PCT/CN2014/082687 |
Claims
1. A compound of Formula (0): ##STR01055## or a stereoisomer or
salt thereof, wherein: ring A is a monocycle or a fused bicycle; Q
is N or C, wherein when Q is N, then the bond between A.sub.1 and Q
is not a double bond and the bond between Q and A.sub.4 is not a
double bond; A.sub.1 is NR.sup.1, S or CR.sup.1; A.sub.2 is
NR.sup.2, S or CR.sup.2; A.sub.3 is N or C; A.sub.4 is N; and one,
two or three of A.sub.1-A.sub.4 are N, wherein: R.sup.1 is selected
from the group consisting of H, halogen, NR.sup.aR.sup.b,
C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.3
alkoxy and 3-11 membered heterocyclyl, wherein R.sup.1 is
optionally substituted by F, OH, CN, SH, CH.sub.3 or CF.sub.3;
R.sup.2 is selected from the group consisting of H,
NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered heterocyclyl,
wherein R.sup.2 is optionally substituted by R.sup.c; or R.sup.1
and R.sup.2 taken together form a cyclic group selected from the
group consisting of C.sub.3-C.sub.7 cycloalkyl, phenyl and 3-11
membered heterocyclyl, wherein the cyclic group is optionally
substituted by R.sup.d; R.sup.4 is selected from the group
consisting of H, C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
R.sup.5 is 3-11 membered heterocyclyl optionally substituted by
R.sup.e or C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2; or R.sup.4 and
R.sup.5 together form a C.sub.3-C.sub.11 cycloalkyl optionally
substituted by R.sup.e or a 3-11 membered heterocyclyl optionally
substituted by R.sup.e; one of A.sub.5-A.sub.8 is N and the
remaining are CR.sup.6 or all are CR.sup.6; R.sup.6, independently
at each occurrence, is selected from the group consisting of H, F,
Cl, NH.sub.2, NHCH.sub.3, N(CH.sub.3).sub.2, OH, OCH.sub.3,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2,
SCH.sub.2F, CN, CH.sub.3, CHF.sub.2, CH.sub.2F, CH.sub.2OH,
CF.sub.3, NO.sub.2 and N.sub.3; R.sup.a is selected from the group
consisting of H and C.sub.1-C.sub.6 alkyl optionally substituted by
C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
R.sup.b is selected from the group consisting of H, C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl,
C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl wherein R.sup.b
may be optionally substituted by C.sub.1-C.sub.3 alkoxy, F, OH, CN,
SH, CH.sub.3 or CF.sub.3; R.sup.c and R.sup.d are each
independently selected from the group consisting of halogen,
--(X.sup.1).sub.0-1--CN, --(X.sup.1).sub.0-1--NO.sub.2,
--(X.sup.1).sub.0-1--SF.sub.5, --(X.sup.1).sub.0-1--OH,
--(X.sup.1).sub.0-1--NH.sub.2, --(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--O--C.sub.3-C.sub.10 cycloalkyl, --(X.sup.1).sub.0-1-3-11 membered
heterocyclyl, --(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
(C.sub.3-C.sub.7 cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered
heterocyclyl, (3-11 membered heterocyclylene)C.sub.1-C.sub.6 alkyl,
C.sub.6 aryl, and (C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl,
or R.sup.1a and R.sup.1b when attached to the same nitrogen atom
are optionally combined to form a 3-11 membered heterocyclyl
comprising 0-3 additional heteroatoms selected from N, O and S;
Y.sup.1 is O, NR.sup.1c or S wherein R.sup.1c is H or
C.sub.1-C.sub.6 alkyl; wherein any portion of an R.sup.c or R.sup.d
substituent, including R.sup.1a, R.sup.1b and R.sup.1c, at each
occurrence is each independently further substituted by from 0 to 4
R.sup.f substituents selected from the group consisting of halogen,
CN, NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6 alkyl),
--NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6 alkyl,
--(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl, wherein
the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl,
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen; R.sup.e
is selected from the group consisting of halogen, OH,
C.sub.1-C.sub.6 alkyl and oxo; and R.sup.g is selected from the
group consisting of C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6
cycloalkyl.
2. The compound of claim 1, further defined as a compound of
Formula (0-0): ##STR01056## or a stereoisomer or salt thereof,
wherein: ring A is a monocycle or a fused bicycle; Q is C; A.sub.1
is NR.sup.1, S or CR.sup.1; A.sub.2 is NR.sup.2 or CR.sup.2;
A.sub.3 is N or C; A.sub.4 is N; and one, two or three of
A.sub.1-A.sub.4 are N, wherein: R.sup.1 is selected from the group
consisting of H, halogen, NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl,
C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.3 alkoxy and 3-11
membered heterocyclyl, wherein R.sup.1 is optionally substituted by
F, OH, CN, SH, CH.sub.3 or CF.sub.3; R.sup.2 is selected from the
group consisting of H, NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.7 cycloalkyl, C.sub.1-C.sub.6 alkoxy, phenyl and 3-11
membered heterocyclyl, wherein R.sup.2 is optionally substituted by
R.sup.c; or R.sup.1 and R.sup.2 taken together form a cyclic group
selected from the group consisting of C.sub.3-C.sub.7 cycloalkyl,
phenyl and 3-11 membered heterocyclyl, wherein the cyclic group is
optionally substituted by R.sup.d; R.sup.4 is selected from the
group consisting of H, C.sub.1-C.sub.6 alkyl, CH.sub.2F and
CH.sub.2OH; R.sup.5 is 3-11 membered heterocyclyl optionally
substituted by R.sup.e; or R.sup.4 and R.sup.5 together form a
C.sub.3-C.sub.11 cycloalkyl optionally substituted by R.sup.e or a
3-11 membered heterocyclyl optionally substituted by R.sup.e; one
of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6 or all are
CR.sup.6; R.sup.6, independently at each occurrence, is selected
from the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and N.sub.3;
R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3; R.sup.b is selected
from the group consisting of H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl, C(O)R.sup.g,
phenyl and 3-11 membered heterocyclyl wherein R.sup.b may be
optionally substituted by C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH,
CH.sub.3 or CF.sub.3; R.sup.c and R.sup.d are each independently
selected from the group consisting of halogen,
--(X.sup.1).sub.0-1--CN, --(X.sup.1).sub.0-1--NO.sub.2,
--(X.sup.1).sub.0-1--SF.sub.5, --(X.sup.1).sub.0-1--OH,
--(X.sup.1).sub.0-1--NH.sub.2, --(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--(X.sup.1).sub.0-1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
(C.sub.3-C.sub.7 cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered
heterocyclyl, (3-11 membered heterocyclylene)C.sub.1-C.sub.6 alkyl,
C.sub.6 aryl, and (C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl,
or R.sup.1a and R.sup.1b when attached to the same nitrogen atom
are optionally combined to form a 3-11 membered heterocyclyl
comprising 0-3 additional heteroatoms selected from N, O and S;
Y.sup.1 is O, NR.sup.1c or S wherein R.sup.1c is H or
C.sub.1-C.sub.6 alkyl; wherein any portion of an R.sup.c or R.sup.d
substituent, including R.sup.1a, R.sup.1b and R.sup.1c, at each
occurrence is each independently further substituted by from 0 to 4
R.sup.f substituents selected from the group consisting of halogen,
CN, NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6
alkyl, --(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl,
wherein the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl,
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen; R.sup.e
is selected from the group consisting of halogen, OH,
C.sub.1-C.sub.6 alkyl and oxo; and R.sup.g is selected from the
group consisting of C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6
cycloalkyl.
3. The compound of claim 1, further defined as a compound of
Formula (I): ##STR01057## or a stereoisomer or salt thereof,
wherein: ring A is a monocycle or a fused bicycle; A.sub.1 is N, S
or CR.sup.1; A.sub.2 is N or CR.sup.2; A.sub.3 is N or C; A.sub.4
is N; and one, two or three of A.sub.1-A.sub.4 are N, wherein:
R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl, wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3; R.sup.2 is selected from the group consisting of H,
NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered heterocyclyl,
wherein R.sup.2 is optionally substituted by R.sup.c; or R.sup.1
and R.sup.2 taken together form a cyclic group selected from the
group consisting of C.sub.3-C.sub.7 cycloalkyl, phenyl and 3-11
membered heterocyclyl, wherein the cyclic group is optionally
substituted by R.sup.d; R.sup.4 is selected from the group
consisting of C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
R.sup.5 is 3-11 membered heterocyclyl optionally substituted by
R.sup.e; or R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl optionally substituted by R.sup.e; one of
A.sub.5-A.sub.8 is N and the remaining are CR.sup.6 or all are
CR.sup.6; R.sup.6, independently at each occurrence, is selected
from the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and N.sub.3;
R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3; R.sup.b is selected
from the group consisting of H, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6 cycloalkyl, C(O)R.sup.g,
phenyl and 3-11 membered heterocyclyl wherein R.sup.b may be
optionally substituted by C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH,
CH.sub.3 or CF.sub.3; R.sup.c and R.sup.d are each independently
selected from the group consisting of halogen,
--(X.sup.1).sub.0-1--CN, --(X.sup.1).sub.0-1--NO.sub.2,
--(X.sup.1).sub.0-1--SF.sub.5, --(X.sup.1).sub.0-1--OH,
--(X.sup.1).sub.0-1--NH.sub.2, --(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--(X.sup.1).sub.0-1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0---NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
(C.sub.3-C.sub.7 cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered
heterocyclyl, (3-11 membered heterocyclylene)C.sub.1-C.sub.6 alkyl,
C.sub.6 aryl, and (C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl,
or R.sup.1a and R.sup.1b when attached to the same nitrogen atom
are optionally combined to form a 3-11 membered heterocyclyl
comprising 0-3 additional heteroatoms selected from N, O and S;
Y.sup.1 is O, NR.sup.1c or S wherein R.sup.1c is H or
C.sub.1-C.sub.6 alkyl; wherein any portion of an R.sup.c or R.sup.d
substituent, including R.sup.1a, R.sup.1b and R.sup.1c, at each
occurrence is each independently further substituted by from 0 to 4
R.sup.f substituents selected from the group consisting of halogen,
CN, NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7 cycloalkyl, 3-11
membered heterocyclyl, --C(.dbd.O)N(H)(C.sub.1-C.sub.6
(halo)alkyl), --C(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--C(.dbd.O)OH, --N(H)C(.dbd.O)(C.sub.1-C.sub.6 (halo)alkyl),
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)(C.sub.1-C.sub.6
(halo)alkyl), --N(H)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)OC.sub.1-C.sub.6
(halo)alkyl, --S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl, --N(C.sub.1-C.sub.6
(halo)alkyl)S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 (halo)alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
(halo)alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6
(halo)alkyl, --NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--NHC(.dbd.O)NH.sub.2, --N(C.sub.1-C.sub.6
(halo)alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 (halo)alkyl,
--OC(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--OP(.dbd.O)(OC.sub.1-C.sub.6 (halo)alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2; R.sup.e is
selected from the group consisting of halogen, OH, C.sub.1-C.sub.6
alkyl and oxo; and R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
4. The compound of claim 1, further defined as a compound of
Formula (II): ##STR01058## or a stereoisomer or salt thereof,
wherein: ring A is a monocycle or a fused bicycle; A.sub.1 is N or
CR.sup.1; A.sub.2 is N or CR.sup.2; A.sub.3 is N or C; A.sub.4 is
N; and one or two of A.sub.1-A.sub.4 are N, wherein: R.sup.1 is
selected from the group consisting of H, halogen and
C.sub.1-C.sub.3 alkyl or 3-6 membered heterocyclyl, wherein R.sup.1
is optionally substituted by F or OH; R.sup.2 is selected from the
group consisting of H, NH.sub.2, C.sub.1-C.sub.3 alkyl,
C.sub.3-C.sub.6 cycloalkyl and 3-6 membered heterocyclyl, wherein
R.sup.2 is optionally substituted by R.sup.c; or R.sup.1 and
R.sup.2 taken together form a cyclic group selected from the group
consisting of C.sub.3-C.sub.7 cycloalkyl, phenyl and 3-6 membered
heterocyclyl, wherein the cyclic group is optionally substituted by
R.sup.d; A.sub.5 is CR.sup.6 or N; A.sub.6 is CR.sup.6 or N;
wherein only one of A.sub.5 and A.sub.6 is N; R.sup.4 is
C.sub.1-C.sub.3 alkyl; R.sup.5 is 5-6 membered heterocyclyl
optionally substituted by R.sup.e; or R.sup.4 and R.sup.5 together
form a 5-11 membered heterocyclyl optionally substituted by
R.sup.e; R.sup.6, independently at each occurrence, is selected
from the group consisting of H, F, Cl, CF.sub.3 and OCH.sub.3;
R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl; R.sup.b is selected from the group
consisting of H, C.sub.1-C.sub.6 alkyl and C(O)R.sup.g; R.sup.c and
R.sup.d are each independently selected from the group consisting
of halogen, OH, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylamino, C.sub.1-C.sub.6
dialkylamino, C(O)(C.sub.1-C.sub.6 alkyl),
C(O).sub.2(C.sub.1-C.sub.6 alkyl), phenyl, and 3-6 membered
heterocyclyl, wherein each of R.sup.c and R.sup.d are each
independently optionally substituted by halogen, OH,
C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy, 5-6 membered
heterocyclyl, or oxo; R.sup.e is selected from the group consisting
of OH, C.sub.1-C.sub.6 alkyl and oxo; and R.sup.g, independently at
each occurrence, is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
5. The compound of claim 1, further defined as a compound of
Formula (III): ##STR01059## or a stereoisomer or salt thereof,
wherein: ring A is a monocycle or a fused bicycle; A.sub.1 is N or
CR.sup.1; A.sub.2 is N or CR.sup.2; A.sub.3 is N or C; A.sub.4 is
N; and one or two of A.sub.1-A.sub.4 are N, wherein: R.sup.1 is
selected from the group consisting of H and halogen; R.sup.2 is
selected from the group consisting of H, NH.sub.2, C.sub.1-C.sub.3
alkyl and C.sub.3-C.sub.6 cycloalkyl; or R.sup.1 and R.sup.2 taken
together form a cyclic group selected from the group consisting of
C.sub.3-C.sub.7 cycloalkyl, phenyl and 3-6 membered heterocyclyl,
wherein the cyclic group is optionally substituted by R.sup.d;
R.sup.4 is methyl; R.sup.5 is 5-6 membered heterocyclyl optionally
substituted by R.sup.e; or R.sup.4 and R.sup.5 together form a 5-11
membered heterocyclyl optionally substituted by R.sup.e; A.sub.6 is
CH, CR.sup.6 or N; R.sup.6, independently at each occurrence, is
selected from the group consisting of F, Cl, CF.sub.3 and
OCH.sub.3; n is 0 or 1; R.sup.a is selected from the group
consisting of H and C.sub.1-C.sub.6 alkyl; R.sup.b is selected from
the group consisting of H, C.sub.1-C.sub.6 alkyl and C(O)R.sup.g;
R.sup.d is selected from the group consisting of OH, CN, halogen,
C.sub.1-C.sub.6 alkoxy, --O--C.sub.1-C.sub.6 alkyl-phenyl,
NR.sup.aR.sup.b, 4-6 membered heterocyclyl, C(O)R.sup.g,
C(O).sub.2R.sup.g and C.sub.1-C.sub.6 alkyl optionally substituted
by OH, CN, or 4-6 membered heterocyclyl; R.sup.e is selected from
the group consisting of methyl and oxo; and R.sup.g, independently
at each occurrence, is selected from the group consisting of
C.sub.1-C.sub.4 alkyl and C.sub.3-C.sub.6 cycloalkyl.
6. The compound of claim 1, wherein R.sup.4 is CH.sub.3.
7. The compound of claim 1, wherein R.sup.5 is a 5-6 membered
heterocyclyl optionally substituted by R.sup.e.
8. The compound of claim 1, wherein the following moiety
##STR01060## is defined as ##STR01061## wherein: A.sub.9 is O,
NR.sup.11 or CR.sup.11R.sup.12, wherein R.sup.11 and R.sup.12 are
each independently selected from the group consisting of H,
halogen, OH and C.sub.1-C.sub.3 alkyl; R.sup.7 and R.sup.8 are each
independently selected from halogen, OH, C.sub.1-C.sub.6 alkyl, or
R.sup.7 and R.sup.8 together form .dbd.O, and R.sup.9 and R.sup.10
are each independently selected from R.sup.e, or R.sup.9 and
R.sup.10 together form a C.sub.5-C.sub.6 cycloalkyl or a 5-6
membered heterocyclyl, wherein said cycloalkyl and said
heterocyclyl are each optionally substituted by R.sup.e.
9. The compound of claim 1, wherein R.sup.4 and R.sup.5 together
form a C.sub.8-C.sub.10 cycloalkyl optionally substituted by
R.sup.e.
10. The compound of claim 1, wherein R.sup.4 and R.sup.5 together
form a 4-9 membered heterocyclyl optionally substituted by
R.sup.e.
11. The compound of claim 1, wherein the following moiety of
##STR01062## is selected from the group consisting of ##STR01063##
##STR01064##
12. The compound of claim 1, wherein one of A.sub.1-A.sub.4 is
N.
13. The compound of claim 1, wherein A.sub.4 is N.
14. The compound of claim 1, wherein two of A.sub.1-A.sub.4 is
N.
15. The compound of claim 1, wherein A.sub.1 and A.sub.4 are each
N.
16. The compound of claim 1, wherein A.sub.3 and A.sub.4 are each
N.
17. The compound of claim 1, wherein R.sup.1 is selected from the
group consisting of H, F and Cl.
18. The compound of claim 1, wherein R.sup.2 is selected from the
group consisting of H, NH.sub.2, CH.sub.3 and cyclopropyl.
19. The compound of claim 1, wherein R.sup.2 is a C.sub.3-C.sub.11
heterocycloalkyl.
20. The compound of claim 1, wherein R.sup.1 and R.sup.2 together
form the following cyclic group, wherein the asterisks indicate the
points of ring fusion to ring A, and each cyclic group is
optionally substituted by R.sup.d: ##STR01065##
21. The compound of claim 1, wherein R.sup.1 and R.sup.2 together
form the following cyclic group, wherein the asterisks indicate the
points of ring fusion to ring A, and each cyclic group is
optionally substituted by R.sup.d: ##STR01066##
22. The compound of claim 1, wherein R.sup.1 and R.sup.2 together
form an unsubstituted cyclic group.
23. The compound of claim 1, wherein R.sup.d is selected from the
group consisting of OH, CN, F, C.sub.1-C.sub.3 alkoxy,
--O--C.sub.1-C.sub.3 alkyl-phenyl, NR.sup.aR.sup.b, 4-6 membered
heterocyclyl, C(O)R.sup.g, C(O).sub.2R.sup.g and C.sub.1-C.sub.6
alkyl optionally substituted by OH, CN, or 4-6 membered
heterocyclyl.
24. The compound of claim 1, wherein ring B is phenyl.
25. The compound of claim 1, wherein A.sup.1 is CR.sup.1, A.sup.2
is CR.sup.2, A.sup.3 is N and A.sup.4 is N.
26. A compound of claim 1, wherein R.sup.4 and R.sup.5 taken
together form the following moiety: ##STR01067##
27. A compound of claim 1, wherein Q is C.
28. A compound selected from the following: ##STR01068##
##STR01069## ##STR01070## ##STR01071## ##STR01072## ##STR01073##
##STR01074## ##STR01075## ##STR01076## ##STR01077## ##STR01078##
##STR01079## ##STR01080## ##STR01081## ##STR01082## ##STR01083##
##STR01084## ##STR01085## ##STR01086## ##STR01087## ##STR01088##
##STR01089## ##STR01090## ##STR01091## ##STR01092## ##STR01093##
##STR01094## ##STR01095## ##STR01096## ##STR01097## ##STR01098##
##STR01099## ##STR01100## ##STR01101## ##STR01102## ##STR01103##
##STR01104## ##STR01105## ##STR01106##
29. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable carrier, diluent or
excipient.
30. A method for the treatment of an inflammatory condition in a
patient, comprising administering an effective amount of a compound
of claim 1 to the patient.
31. The method of claim 30, wherein the inflammatory condition is
selected from the group consisting of lupus, systemic lupus
erythematosus, COPD, rhinitis, multiple sclerosis, IBD, arthritis,
rheumatoid arthritis, dermatitis, endometriosis and transplant
rejection.
32. A method of preparing a compound of Formula (0) of claim 1,
##STR01107## wherein Q, A.sub.1-A.sub.8, R.sup.4 and R.sup.5 are as
defined in claim 1, comprising: contacting a compound of Formula
(A): ##STR01108## wherein X is Cl, Br or I, with a compound of
Formula (B) ##STR01109## wherein [M] is a boronic acid, a boronic
ester, or a trifluoroborate salt, in the presence of (a)(i) a
palladium(0) catalyst or (a)(ii) a copper catalyst and (b) a base
under Suzuki reaction conditions to yield a compound of Formula
(0).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to
International Application No. PCT/CN2014/082687, filed Jul. 22,
2014, International Application No. PCT/CN2014/078680, filed May
28, 2014, and International Application No. PCT/CN2013/000993,
filed Aug. 22, 2013, each of which is incorporated herein by
reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to organic compounds useful
for therapy or prophylaxis in a mammal, and in particular to
inhibitors of NF-kB-inducing kinase (NIK) useful for treating
cancer and inflammatory conditions, among others.
[0003] NF-kB inducing kinase (NIK) is also known as MAPK kinase 14
(MAP3K14) and is a serine/threonine kinase and a member of the MAPK
family. It was originally identified in a two-hybrid screen as a
binding partner of TNF receptor (TNFR) associated factor 2 (TRAF2)
[See, Malinin, N L, et al., Nature, 1997, 385:540-4].
Overexpression of NIK leads to the activation of NF-kB and dominant
negative forms of NIK lacking kinase activity were able to inhibit
NF-kB activation in response to TNF and IL-1 treatment. Thus, NIK
has been identified as an important component of the NF-kB
signaling pathway. Scientific research has shown that in blocking
the NF-kB signaling pathway in cancer cells can cause such cells to
stop proliferating, to die, or to become more sensitive to the
action of other anti-cancer therapies. Additionally, research has
shown that NF-kB controls the expression of many genes involved in
inflammation and that NF-kB signaling is found to be chronically
active in many inflammatory conditions, such as lupus (including
systemic lupus erythematosus), rheumatoid arthritis, inflammatory
bowel disease, arthritis, sepsis, gastritis and asthma, among
others. Accordingly, organic compounds capable of inhibiting NIK
and thereby inhibiting, weakening or lessening the undesired or
over-activation of the NF-kB signaling pathway can have a
therapeutic benefit for the treatment diseases and disorders for
which such undesired or over-activation of NF-kB signaling is
observed.
SUMMARY OF THE INVENTION
[0004] Provided herein are compounds of Formula (0):
##STR00002##
[0005] or a stereoisomer or salt thereof, wherein:
[0006] ring A is a monocycle or a fused bicycle;
[0007] Q is N or C, wherein when Q is N, then the bond between
A.sub.1 and Q is not a double bond and the bond between Q and
A.sub.4 is not a double bond;
[0008] A.sub.1 is NR.sup.1, S or CR.sup.1;
[0009] A.sub.2 is NR.sup.2, S or CR.sup.2;
[0010] A.sub.3 is N or C;
[0011] A.sub.4 is N; and
[0012] one, two or three of A.sub.1-A.sub.4 are N, wherein:
[0013] R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl, wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3;
[0014] R.sup.2 is selected from the group consisting of H,
NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered heterocyclyl,
wherein R.sup.2 is optionally substituted by R.sup.c; or
[0015] R.sup.1 and R.sup.2 taken together form a cyclic group
selected from the group consisting of C.sub.3-C.sub.7 cycloalkyl,
phenyl and 3-11 membered heterocyclyl, wherein the cyclic group is
optionally substituted by R.sup.d;
[0016] R.sup.4 is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
[0017] R.sup.5 is 3-11 membered heterocyclyl optionally substituted
by R.sup.e or C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2; or
[0018] R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl optionally substituted by R.sup.e;
[0019] one of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6
or all are CR.sup.6;
[0020] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and
N.sub.3;
[0021] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0022] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl, C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl
wherein R.sup.b may be optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0023] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, --(X.sup.1).sub.0-1--CN,
--(X.sup.1).sub.0-1--NO.sub.2, --(X.sup.1).sub.0-1--SF.sub.5,
--(X.sup.1).sub.0-1--OH, --(X.sup.1).sub.0-1--NH.sub.2,
--(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--O--C.sub.3-C.sub.10 cycloalkyl, --(X.sup.1).sub.0-1-3-11 membered
heterocyclyl, --(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
(C.sub.3-C.sub.7 cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered
heterocyclyl, (3-11 membered heterocyclylene)C.sub.1-C.sub.6 alkyl,
C.sub.6 aryl, and (C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl,
or R.sup.1a and R.sup.1b when attached to the same nitrogen atom
are optionally combined to form a 3-11 membered heterocyclyl
comprising 0-3 additional heteroatoms selected from N, O and S;
Y.sup.1 is O, NR.sup.1c or S wherein R.sup.1c is H or
C.sub.1-C.sub.6 alkyl; wherein any portion of an R.sup.c or R.sup.d
substituent, including R.sup.1a, R.sup.1b and R.sup.1c, at each
occurrence is each independently further substituted by from 0 to 4
R.sup.f substituents selected from the group consisting of halogen,
CN, NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6
alkyl, --(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl,
wherein the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl,
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.N(C.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen;
[0024] R.sup.e is selected from the group consisting of halogen,
OH, C.sub.1-C.sub.6 alkyl and oxo; and
[0025] R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
[0026] In another aspect, the invention provides for pharmaceutical
compositions comprising a compound of Formula (0) and a
pharmaceutically acceptable carrier, diluent or excipient.
[0027] In another aspect, the invention provides for a compounds of
Formula (0) or pharmaceutical compositions thereof for use in
therapy. In another embodiment, the invention provides the use of a
compound or pharmaceutical composition for the preparation of a
medicament for the treatment of an inflammatory condition.
[0028] In another aspect, the inventions provides for compounds of
Formula (0) and pharmaceutical compositions thereof for the
treatment of diseases and disorders, including, cancer,
inflammatory conditions, and autoimmune diseases, among others.
[0029] In another aspect, the invention provides for a method (or
use) of compounds of Formula (0) or pharmaceutical compositions
thereof in the treatment of diseases and disorders, such as, for
example, cancer, inflammatory conditions, or autoimmune diseases,
among others.
[0030] In another aspect, the invention provides for compounds of
Formula (0) for the preparation of a medicament for the treatment
of cancer, inflammatory conditions, or autoimmune diseases, among
others.
[0031] In another aspect, the invention provides for compound
intermediates useful in synthesis of compounds of Formula (0).
DETAILED DESCRIPTION OF THE INVENTION
[0032] The invention provides for compounds of Formula (0),
pharmaceutical compositions comprising compounds of Formula (0) and
methods of using such compounds and compositions in treating
diseases and disorders related to undesired or overactivation of
the NF-kB signaling pathway, such as, for example, certain cancers
and inflammatory conditions.
DEFINITIONS
[0033] The term "alkyl" refers to a saturated linear or
branched-chain monovalent hydrocarbon radical, wherein the alkyl
radical may be optionally substituted independently with one or
more substituents described herein. In one example, the alkyl
radical is one to eighteen carbon atoms (C.sub.1-C.sub.18). In
other examples, the alkyl radical is C.sub.0-C.sub.6,
C.sub.0-C.sub.5, C.sub.0-C.sub.3, C.sub.1-C.sub.12,
C.sub.1-C.sub.10, C.sub.1-C.sub.8, C.sub.1-C.sub.6,
C.sub.1-C.sub.5, C.sub.1-C.sub.4, or C.sub.1-C.sub.3. C.sub.0 alkyl
refers to a bond. Examples of alkyl groups include methyl (Me,
--CH.sub.3), ethyl (Et, --CH.sub.2CH.sub.3), 1-propyl (n-Pr,
n-propyl, --CH.sub.2CH.sub.2CH.sub.3), 2-propyl (i-Pr, i-propyl,
--CH(CH.sub.3).sub.2), 1-butyl (n-Bu, n-butyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-methyl-1-propyl (1-Bu,
i-butyl, --CH.sub.2CH(CH.sub.3).sub.2), 2-butyl (s-Bu, s-butyl,
--CH(CH.sub.3)CH.sub.2CH.sub.3), 2-methyl-2-propyl (t-Bu, t-butyl,
--C(CH.sub.3).sub.3), 1-pentyl (n-pentyl,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-pentyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.3), 3-pentyl
(--CH(CH.sub.2CH.sub.3).sub.2), 2-methyl-2-butyl
(--C(CH.sub.3).sub.2CH.sub.2CH.sub.3), 3-methyl-2-butyl
(--CH(CH.sub.3)CH(CH.sub.3).sub.2), 3-methyl-1-butyl
(--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2), 2-methyl-1-butyl
(--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.3), 1-hexyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 2-hexyl
(--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.3), 3-hexyl
(--CH(CH.sub.2CH.sub.3)(CH.sub.2CH.sub.2CH.sub.3)),
2-methyl-2-pentyl (--C(CH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.3),
3-methyl-2-pentyl (--CH(CH.sub.3)CH(CH.sub.3)CH.sub.2CH.sub.3),
4-methyl-2-pentyl (--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2),
3-methyl-3-pentyl (--C(CH.sub.3)(CH.sub.2CH.sub.3).sub.2),
2-methyl-3-pentyl (--CH(CH.sub.2CH.sub.3)CH(CH.sub.3).sub.2),
2,3-dimethyl-2-butyl (--C(CH.sub.3).sub.2CH(CH.sub.3).sub.2),
3,3-dimethyl-2-butyl (--CH(CH.sub.3)C(CH.sub.3).sub.3, 1-heptyl and
1-octyl. In some embodiments, substituents for "optionally
substituted alkyls" include one to six instances of F, Cl, Br, I,
OH, SH, CN, NH.sub.2, NO.sub.2, N.sub.3, COOH, methyl, ethyl,
propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy,
propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, or pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted.
[0034] The term "alkylene" by itself or as part of another
substituent means a divalent radical derived from an alkane, as
exemplified by --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--. Typically, an
alkyl (or alkylene) group will have from 1 to 12 carbon atoms, such
as 1-8, 1-6 or 1-3 carbon atoms. "Alkenylene" and "alkynylene"
refer to the unsaturated forms of "alkylene" having double or
triple bonds, respectively, and typically have from 2 to 12 carbon
atoms, such as 2-8, 2-6 or 2-3 carbon atoms. "Alkylene",
"alkenylene" and "alkynylene" groups may be optionally
substituted.
[0035] The term "heteroalkyl" refers to a straight or branched
chain monovalent hydrocarbon radical, consisting of the stated
number of carbon atoms, or, if none are stated, up to 18 carbon
atoms, and from one to five heteroatoms selected from the group
consisting of O, N, Si and S, and wherein the nitrogen and sulfur
atoms can optionally be oxidized and the nitrogen heteroatom can
optionally be quaternized. In some embodiments, the heteroatom is
selected from O, N and S, wherein the nitrogen and sulfur atoms can
optionally be oxidized and the nitrogen heteroatom can optionally
be quaternized. The heteroatom(s) can be placed at any interior
position of the heteroalkyl group, including the position at which
the alkyl group is attached to the remainder of the molecule (e.g.,
--O--CH.sub.2--CH.sub.3). Examples include
--CH.sub.2--CH.sub.2--O--CH.sub.3,
--CH.sub.2--CH.sub.2--O--CF.sub.3,
--CH.sub.2--CH.sub.2--NH--CH.sub.3,
--CH.sub.2--CH.sub.2--N(CH.sub.3)--CH.sub.3,
--CH.sub.2--S--CH.sub.2--CH.sub.3, --S(O)--CH.sub.3,
--CH.sub.2--CH.sub.2--S(O).sub.2--CH.sub.3, --Si(CH.sub.3).sub.3,
--CH.sub.2--CH.dbd.N--OCH.sub.3, and --OCF.sub.3. Up to two
heteroatoms can be consecutive, such as, for example,
--CH.sub.2--NH--OCH.sub.3 and --CH.sub.2--O--Si(CH.sub.3).sub.3.
Heteroalkyl groups can be optionally substituted. In some
embodiments, substituents for "optionally substituted heteroalkyls"
include one to four instances of F, Cl, Br, I, OH, SH, CN,
NH.sub.2, NO.sub.2, N.sub.3, COOH, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted.
[0036] The term "heteroalkylene" means a divalent radical derived
from heteroalkyl, as exemplified by
--CH.sub.2CH.sub.2SCH.sub.2CH.sub.2,
--CH.sub.2SCH.sub.2CH.sub.2NHCH.sub.3 and --OCH.sub.2CH.sub.3. For
heteroalkylene groups, heteroatoms can also occupy either or both
of the chain termini (e.g., alkyleneoxy, alkylenedioxy,
alkyleneamino, alkylenediamino, and the like). A heteroalkylene
group may be optionally substituted.
[0037] "Cycloalkyl" refers to a non-aromatic, saturated or
partially unsaturated hydrocarbon ring group wherein the cycloalkyl
group may be optionally substituted with one or more substituents
described herein. In one example, the cycloalkyl group is 3 to 12
carbon atoms (C.sub.3-C.sub.12). In other examples, cycloalkyl is
C.sub.3-C.sub.6, C.sub.3-C.sub.8, C.sub.3-C.sub.10 or
C.sub.5-C.sub.10. In other examples, the cycloalkyl group, as a
monocycle, is C.sub.3-C.sub.8, C.sub.3-C.sub.6 or C.sub.5-C.sub.6.
In another example, the cycloalkyl group, as a bicycle, is
C.sub.7-C.sub.12. In another example, the cycloalkyl group, as a
spiro system, is C.sub.5-C.sub.12. Examples of monocyclic
cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl,
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-1-enyl,
1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl,
cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl.
Exemplary arrangements of bicyclic cycloalkyls having 7 to 12 ring
atoms include, but are not limited to, [4,4], [4,5], [5,5], [5,6]
or [6,6] ring systems. Exemplary bridged bicyclic cycloalkyls
include, but are not limited to, bicyclo[4.1.0]heptane,
bicycle[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane,
bicyclo[4.1.0]heptane and bicyclo[3.2.2]nonane. Examples of spiro
cycloalkyl include, spiro[2.2]pentane, spiro[2.3]hexane,
spiro[2.4]heptane, spiro[2.5]octane and spiro[4.5]decane. In some
embodiments, substituents for "optionally substituted cycloalkyls"
include one to four instances of F, Cl, Br, I, OH, SH, CN,
NH.sub.2, NO.sub.2, N.sub.3, COOH, methyl, ethyl, propyl,
iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy,
oxo, trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted.
[0038] The term "cycloalkylene" means a divalent radical derived
from a cycloalkyl group. A cycloalkylene group may be optionally
substituted.
[0039] "Heterocyclic group", "heterocyclic", "heterocycle",
"heterocyclyl", or "heterocyclo" are used interchangeably and refer
to any monocyclic, bicyclic, or spiro, saturated or unsaturated,
aromatic (heteroaryl) or non-aromatic (e.g., heterocycloalkyl),
ring system, where the ring atoms are carbon, and at least one atom
in the ring or ring system is a heteroatom selected from nitrogen,
sulfur or oxygen. If any ring atom of a cyclic system is a
heteroatom, that system is a heterocycle, regardless of the point
of attachment of the cyclic system to the rest of the molecule. In
one example, heterocyclyl includes 3-11 ring atoms ("members", that
is, a 3-11 membered heterocycle) and includes monocycles, bicycles,
and spiro ring systems, wherein the ring atoms are carbon, and at
least one atom in the ring or ring system is a heteroatom selected
from nitrogen, sulfur or oxygen. In one example, heterocyclyl
includes 1 to 4 heteroatoms. In another example, heterocyclyl
includes 3- to 7-membered monocycles having one or more heteroatoms
selected from nitrogen, sulfur or oxygen. In another example,
heterocyclyl includes 4- to 6-membered monocycles having one or
more heteroatoms selected from nitrogen, sulfur or oxygen. In
another example, heterocyclyl includes 3-membered monocycles. In
another example, heterocyclyl includes 4-membered monocycles. In
another example, heterocyclyl includes 5-6-membered monocycles. In
one example, the heterocyclyl group includes 0 to 3 double bonds.
Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g.,
NO, SO, SO.sub.2), and any nitrogen heteroatom may optionally be
quaternized (e.g., [NR.sub.4].sup.+Cl.sup.-,
[NR.sub.4].sup.+OH.sup.-). In another example, heterocyclyl
includes 3- to 9-membered spiro cycles having one or more
heteroatoms selected from nitrogen, sulfur or oxygen. Example
heterocycles are oxiranyl, aziridinyl, thiiranyl, azetidinyl,
oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl,
pyrrolidinyl, dihydro-1H-pyrrolyl, dihydrofuranyl,
tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl,
imidazolidinyl, piperidinyl, piperazinyl, isoquinolinyl,
tetrahydroisoquinolinyl, morpholinyl, thiomorpholinyl,
1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl,
hexahydrothiopyranyl, hexahydropyrimidinyl, oxazinanyl,
thiazinanyl, thioxanyl, homopiperazinyl, homopiperidinyl, azepanyl,
oxepanyl, thiepanyl, oxazepinyl, oxazepanyl, diazepanyl,
1,4-diazepanyl, diazepinyl, thiazepinyl, thiazepanyl,
tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl,
isothiazolidinyl, 1,1-dioxoisothiazolidinonyl, oxazolidinonyl,
imidazolidinonyl, 4,5,6,7-tetrahydro[2H]indazolyl,
tetrahydrobenzoimidazolyl, 4,5,6,7-tetrahydrobenzo[d]imidazolyl,
1,6-dihydroimidazol[4,5-d]pyrrolo[2,3-b]pyridinyl, thiazinyl,
oxazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl,
oxathiazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl,
imidazolinyl, dihydropyrimidyl, tetrahydropyrimidyl, 1-pyrrolinyl,
2-pyrrolinyl, 3-pyrrolinyl, indolinyl, thiapyranyl, 2H-pyranyl,
4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl,
dithianyl, dithiolanyl, pyrimidinonyl, pyrimidindionyl,
pyrimidin-2,4-dionyl, piperazinonyl, piperazindionyl,
pyrazolidinylimidazolinyl, 3-azabicyclo[3.1.0]hexanyl,
3,6-diazabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl,
3-azabicyclo[3.1.1]heptanyl, 3-azabicyclo[4.1.0]heptanyl,
azabicyclo[2.2.2]hexanyl, 2-azabicyclo[3.2.1]octanyl,
8-azabicyclo[3.2.1]octanyl, 2-azabicyclo[2.2.2]octanyl,
8-azabicyclo[2.2.2]octanyl, 7-oxabicyclo[2.2.1]heptane,
azaspiro[3.5]nonanyl, azaspiro[2.5]octanyl, azaspiro[4.5]decanyl,
1-azaspiro[4.5]decan-2-only, azaspiro[5.5]undecanyl,
tetrahydroindolyl, octahydroindolyl, tetrahydroisoindolyl,
tetrahydroindazolyl, 1,1-dioxohexahydrothiopyranyl. Examples of
5-membered heterocycles containing a sulfur or oxygen atom and one
to three nitrogen atoms are thiazolyl, including thiazol-2-yl and
thiazol-2-yl N-oxide, thiadiazolyl, including 1,3,4-thiadiazol-5-yl
and 1,2,4-thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and
oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and
1,2,4-oxadiazol-5-yl. Example 5-membered ring heterocycles
containing 2 to 4 nitrogen atoms include imidazolyl, such as
imidazol-2-yl; triazolyl, such as 1,3,4-triazol-5-yl;
1,2,3-triazol-5-yl, 1,2,4-triazol-5-yl, and tetrazolyl, such as
1H-tetrazol-5-yl. Example benzo-fused 5-membered heterocycles are
benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl. Example
6-membered heterocycles contain one to three nitrogen atoms and
optionally a sulfur or oxygen atom, for example pyridyl, such as
pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as
pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as
1,3,4-triazin-2-yl and 1,3,5-triazin-4-yl; pyridazinyl, in
particular pyridazin-3-yl, and pyrazinyl. The pyridine N-oxides and
pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl,
pyridazinyl and the 1,3,4-triazin-2-yl groups, are other example
heterocycle groups. Heterocycles may be optionally substituted. For
example, substituents for "optionally substituted heterocycles"
include one to six instances of F, Cl, Br, I, OH, SH, CN, NH.sub.2,
NO.sub.2, N.sub.3, COOH, methyl, ethyl, propyl, iso-propyl, butyl,
isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo,
trifluoromethyl, difluoromethyl, sulfonylamino,
methanesulfonylamino, SO, SO.sub.2, phenyl, piperidinyl,
piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and
heterocyclic portions thereof may be optionally substituted.
[0040] The term "heterocyclylene" means a divalent radical derived
from a heterocyclyl group. A heterocyclylene group may be
optionally substituted.
[0041] "Heteroaryl" refers to any mono-, bi-, or tricyclic ring
system where at least one ring is a 5- or 6-membered aromatic ring
containing from 1 to 4 heteroatoms selected from nitrogen, oxygen,
and sulfur, and in an example embodiment, at least one heteroatom
is nitrogen. See, for example, Lang's Handbook of Chemistry (Dean,
J. A., ed.) 13.sup.th ed. Table 7-2 [1985]. Included in the
definition are any bicyclic groups where any of the above
heteroaryl rings are fused to an aryl ring, wherein the aryl ring
or the heteroaryl ring is joined to the remainder of the molecule.
In one embodiment, heteroaryl includes 4-6 membered monocyclic
aromatic groups where one or more ring atoms is nitrogen, sulfur or
oxygen. In another embodiment, heteroaryl includes 5-6 membered
monocyclic aromatic groups where one or more ring atoms is
nitrogen, sulfur or oxygen. Example heteroaryl groups include
thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl,
oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl,
tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl,
pyrazinyl, pyridazinyl, triazinyl, tetrazinyl,
tetrazolo[1,5-b]pyridazinyl, imidazol[1,2-a]pyrimidinyl and
purinyl, as well as benzo-fused derivatives, for example
benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazolyl,
benzotriazolyl, benzoimidazolyl and indolyl. Heteroaryl groups can
be optionally substituted. In some embodiments, substituents for
"optionally substituted heteroaryls" include one to six instances
of F, Cl, Br, I, OH, SH, CN, NH.sub.2, NO.sub.2, N.sub.3, COOH,
methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl,
methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl,
sulfonylamino, methanesulfonylamino, SO, SO.sub.2, phenyl,
piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl
and heterocyclic portions thereof may be optionally
substituted.
[0042] In particular embodiments, a heterocyclyl group is attached
at a carbon atom of the heterocyclyl group. By way of example,
carbon bonded heterocyclyl groups include bonding arrangements at
position 2, 3, 4, 5, or 6 of a pyridine ring, position 3, 4, 5, or
6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine ring,
position 2, 3, 5, or 6 of a pyrazine ring, position 2, 3, 4, or 5
of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole ring, position 2, 4, or 5 of an oxazole,
imidazole or thiazole ring, position 3, 4, or 5 of an isoxazole,
pyrazole, or isothiazole ring, position 2 or 3 of an aziridine
ring, position 2, 3, or 4 of an azetidine ring, position 2, 3, 4,
5, 6, 7, or 8 of a quinoline ring or position 1, 3, 4, 5, 6, 7, or
8 of an isoquinoline ring.
[0043] In certain embodiments, the heterocyclyl group is
N-attached. By way of example, the nitrogen bonded heterocyclyl or
heteroaryl group include bonding arrangements at position 1 of an
aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline,
3-pyrroline, imidazole, imidazolidine, 2-imidazoline,
3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine, indole, indoline, 1H-indazole, position 2
of an isoindole, or isoindoline, position 4 of a morpholine, and
position 9 of a carbazole, or .beta.-carboline.
[0044] The term "alkoxy" refers to those alkyl groups attached to
the remainder of the molecule via an oxygen atom. Non-limiting
examples include methoxy, ethoxy and propoxy. Alkoxy groups may be
optionally substituted, such as by halogen.
[0045] The term "alkylthio" refers to those alkyl groups attached
to the remainder of the molecule via an sulfur atom. Non-limiting
examples include SCH.sub.3, --SCH.sub.2CH.sub.3 and
--SCH.sub.2CH.sub.2CH.sub.3. Alkylthio groups may be optionally
substituted, such as by halogen.
[0046] The terms "halo" or "halogen," by themselves or as part of
another substituent, mean, unless otherwise stated, a fluorine,
chlorine, bromine, or iodine atom. The term "haloalkyl" is meant to
include both an "alkyl" and a "haloalkyl" substituent.
Additionally, the term "haloalkyl," is meant to include
monohaloalkyl and polyhaloalkyl.
[0047] The term "oxo" refers to .dbd.O or (.dbd.O).sub.2.
[0048] The term "aryl" means, unless otherwise stated, a
polyunsaturated, typically aromatic, hydrocarbon ring radical,
which can be a single ring or multiple rings (up to three rings)
which are fused together and having the stated number of aryl ring
atoms. An aryl group can be optionally substituted.
[0049] A "phenylene" group refers to a divalent radical derived
from a phenyl group. A phenylene group may be optionally
substituted.
[0050] "Optionally substituted" unless otherwise specified means
that a group may be unsubstituted or substituted by one or more
(e.g., 0, 1, 2, 3, 4, or 5 or more) of the substituents listed for
that group in which said substituents may be the same or different.
That is, an optionally substituted substituent is independent at
each occurrence. In an embodiment an optionally substituted group
has 1 substituent. In another embodiment an optionally substituted
group has 2 substituents. In another embodiment an optionally
substituted group has 3 substituents. In another embodiment an
optionally substituted group has 4 substituents.
[0051] Optional substituents for alkyl and cycloalkyl can be a
variety of groups including, but not limited to, halogen, oxo, CN,
NO.sub.2, N.sub.3, OR', perfluoro-C.sub.1-4 alkoxy, unsubstituted
cycloalkyl, unsubstituted aryl (e.g., phenyl), unsubstituted
heterocyclyl, NR'R'', SR', SiR'R''R''', OC(O)R', C(O)R',
CO.sub.2R', CONR'R'', OC(O)NR'R'', NR''C(O)R', NR'''C(O)NR'R'',
NR''C(O).sub.2R', S(O).sub.2R', S(O).sub.2NR'R'', NR'S(O).sub.2R'',
NR'''S(O).sub.2NR'R'', amidino, guanidine, (CH.sub.2).sub.1-4OR',
(CH.sub.2).sub.1-4NR'R'', (CH.sub.2).sub.1-4SR',
(CH.sub.2).sub.1-4SiR'R''R''', (CH.sub.2).sub.1-4OC(O)R',
(CH.sub.2).sub.1-4C(O)R', (CH.sub.2).sub.1-4CO.sub.2R', and
(CH.sub.2).sub.1-4CONR'R'', or combinations thereof, in a number
ranging from zero to (2m'+1), where m' is the total number of
carbon atoms in such radical. R', R'' and R''' each independently
refer to groups including, for example, hydrogen; unsubstituted
C.sub.1-6 alkyl; unsubstituted heteroalkyl; unsubstituted aryl;
aryl substituted with 1-3 halogens, unsubstituted C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 alkoxy or C.sub.1-C.sub.6 thioalkoxy groups,
unsubstituted aryl-C.sub.1-C.sub.4 alkyl groups, and unsubstituted
heteroaryl. When R' and R'' are attached to the same nitrogen atom,
they can be combined with the nitrogen atom to form a 3-, 4-, 5-,
6-, or 7-membered ring wherein a ring atom is optionally
substituted with N, O or S. For example, NR'R'' is meant to include
1-pyrrolidinyl and 4-morpholinyl.
[0052] Similarly, optional substituents for the aryl and
heterocyclyl groups are varied. In some embodiments, substituents
for aryl and heterocyclyl groups are selected from the group
including, but not limited to, halogen, OR', OC(O)R', NR'R'', SR',
R', CN, NO.sub.2, CO.sub.2R', CONR'R'', C(O)R', OC(O)NR'R'',
NR''C(O)R', NR''C(O).sub.2R', NR'C(O)NR''R''', S(O)R',
S(O).sub.2R', S(O).sub.2NR'R'', NR'S(O).sub.2R'', N.sub.3,
perfluoro-C.sub.1-C.sub.4 alkoxy, perfluoro-C.sub.1-C.sub.4 alkoxy,
(CH.sub.2).sub.1-4OR', (CH.sub.2).sub.1-4NR'R'',
(CH.sub.2).sub.1-4SR', (CH.sub.2).sub.1-4SiR'R''R''',
(CH.sub.2).sub.1-4OC(O)R', (CH.sub.2).sub.1-4C(O)R',
(CH.sub.2).sub.1-4CO.sub.2R', (CH.sub.2).sub.1-4CONR'R'', or
combinations thereof, in a number ranging from zero to the total
number of open valences on the aromatic ring system; and where R',
R'' and R''' are independently selected from hydrogen,
C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.2-C.sub.6
alkenyl, C.sub.2-C.sub.6 alkynyl, unsubstituted aryl, and
unsubstituted heteroaryl. Other suitable substituents include each
of the above aryl substituents attached to a ring atom by an
alkylene tether of from 1-4 carbon atoms.
[0053] As used herein, the term "heteroatom" is meant to include
oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). In some
embodiments, heteroatom refers to O, N or S. In some embodiments,
heteroatom refers to O or N.
[0054] As used herein, the term "chiral" refers to molecules which
have the property of non-superimposability of the mirror image
partner, while the term "achiral" refers to molecules which are
superimposable on their mirror image partner.
[0055] As used herein, the term "stereoisomers" refers to compounds
which have identical chemical constitution, but differ with regard
to the arrangement of the atoms or groups in space.
[0056] "Diastereomer" refers to a stereoisomer with two or more
centers of chirality and whose molecules are not mirror images of
one another. Diastereomers have different physical properties, e.g.
melting points, boiling points, spectral properties, and
reactivities. Mixtures of diastereomers can separate under high
resolution analytical procedures such as electrophoresis and
chromatography.
[0057] "Enantiomers" refer to two stereoisomers of a compound which
are non-superimposable mirror images of one another.
[0058] Stereochemical definitions and conventions used herein
generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of
Chemical Terms (1984) McGraw-Hill Book Company, New York; and
Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds",
John Wiley & Sons, Inc., New York, 1994. The compounds of the
invention can contain asymmetric or chiral centers, and therefore
exist in different stereoisomeric forms. It is intended that all
stereoisomeric forms of the compounds of the invention, including
but not limited to, diastereomers, enantiomers and atropisomers, as
well as mixtures thereof such as racemic mixtures, form part of the
present invention. Many organic compounds exist in optically active
forms, i.e., they have the ability to rotate the plane of
plane-polarized light. In describing an optically active compound,
the prefixes D and L, or R and S, are used to denote the absolute
configuration of the molecule about its chiral center(s). The
prefixes d and 1 or (+) and (-) are employed to designate the sign
of rotation of plane-polarized light by the compound, with (-) or 1
meaning that the compound is levorotatory. A compound prefixed with
(+) or d is dextrorotatory. For a given chemical structure, these
stereoisomers are identical except that they are mirror images of
one another. A specific stereoisomer can also be referred to as an
enantiomer, and a mixture of such isomers is often called an
enantiomeric mixture. A 50:50 mixture of enantiomers is referred to
as a racemic mixture or a racemate, which can occur where there has
been no stereoselection or stereospecificity in a chemical reaction
or process. The terms "racemic mixture" and "racemate" refer to an
equimolar mixture of two enantiomeric species, devoid of optical
activity.
[0059] As used herein, the term "tautomer" or "tautomeric form"
refers to structural isomers of different energies which are
interconvertible via a low energy barrier. For example, proton
tautomers (also known as prototropic tautomers) include
interconversions via migration of a proton, such as keto-enol and
imine-enamine isomerizations. Valence tautomers include
interconversions by reorganization of some of the bonding
electrons.
[0060] In the structures shown herein, where the stereochemistry of
any particular chiral atom is not specified, then all stereoisomers
are contemplated and included as the compounds of the invention.
Where stereochemistry is specified by a solid wedge or dashed line
representing a particular configuration, then that stereoisomer is
so specified and defined. Unless otherwise specified, if solid
wedges or dashed lines are used, relative stereochemistry is
intended. If a discrepancy exists between a structure and its name,
the structure governs.
[0061] As used herein, the term "solvate" refers to an association
or complex of one or more solvent molecules and a compound of the
invention. Examples of solvents that form solvates include, but are
not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl
acetate, acetic acid, and ethanolamine. The term "hydrate" refers
to the complex where the solvent molecule is water.
[0062] As used herein, the term "protecting group" refers to a
substituent that is commonly employed to block or protect a
particular functional group on a compound. For example, an
"amino-protecting group" is a substituent attached to an amino
group that blocks or protects the amino functionality in the
compound. Suitable amino-protecting groups include acetyl,
trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ)
and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a
"hydroxy-protecting group" refers to a substituent of a hydroxy
group that blocks or protects the hydroxy functionality. Suitable
protecting groups include acetyl and silyl. A "carboxy-protecting
group" refers to a substituent of the carboxy group that blocks or
protects the carboxy functionality. Common carboxy-protecting
groups include phenylsulfonylethyl, cyanoethyl,
.sub.2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl,
2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl,
2-(diphenylphosphino)-ethyl, nitroethyl and the like. For a general
description of protecting groups and their use, see P. G. M. Wuts
and T. W. Greene, Greene's Protective Groups in Organic Synthesis
4.sup.th edition, Wiley-Interscience, New York, 2006.
[0063] As used herein, the term "mammal" includes, but is not
limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats,
horses, cows, pigs, and sheep.
[0064] A "subject," "individual," or "patient" is a vertebrate. In
certain embodiments, the vertebrate is a mammal. A subject,
individual or patient may be in need of a compound of the present
invention.
[0065] As used herein, the term "pharmaceutically acceptable salts"
is meant to include salts of the active compounds which are
prepared with relatively nontoxic acids or bases, depending on the
particular substituents found on the compounds described herein.
When compounds of the present invention contain relatively acidic
functionalities, base addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired base, either neat or in a suitable inert solvent. Examples
of salts derived from pharmaceutically-acceptable inorganic bases
include aluminum, ammonium, calcium, copper, ferric, ferrous,
lithium, magnesium, manganic, manganous, potassium, sodium, zinc
and the like. Salts derived from pharmaceutically-acceptable
organic bases include salts of primary, secondary and tertiary
amines, including substituted amines, cyclic amines,
naturally-occurring amines and the like, such as arginine, betaine,
caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine,
2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine,
ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine,
glucosamine, histidine, hydrabamine, isopropylamine, lysine,
methylglucamine, morpholine, piperazine, piperidine, polyamine
resins, procaine, purines, theobromine, triethylamine,
trimethylamine, tripropylamine, tromethamine and the like. When
compounds of the present invention contain relatively basic
functionalities, acid addition salts can be obtained by contacting
the neutral form of such compounds with a sufficient amount of the
desired acid, either neat or in a suitable inert solvent. Examples
of pharmaceutically acceptable acid addition salts include those
derived from inorganic acids like hydrochloric, hydrobromic,
nitric, carbonic, monohydrogencarbonic, phosphoric,
monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohydrogensulfuric, hydriodic, or phosphorous acids and the like,
as well as the salts derived from relatively nontoxic organic acids
like acetic, propionic, isobutyric, malonic, benzoic, succinic,
suberic, fumaric, mandelic, phthalic, benzenesulfonic,
p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
Also included are salts of amino acids such as arginate and the
like, and salts of organic acids like glucuronic or galactunoric
acids and the like (see, for example, Berge, S. M., et al.,
"Pharmaceutical Salts", J. Pharm. Sci., 1977, 66, 1-19). Certain
specific compounds of the present invention contain both basic and
acidic functionalities that allow the compounds to be converted
into either base or acid addition salts.
[0066] The neutral forms of the compounds can be regenerated by
contacting the salt with a base or acid and isolating the parent
compound in the conventional manner. The parent form of the
compound differs from the various salt forms in certain physical
properties, such as solubility in polar solvents, but otherwise the
salts are equivalent to the parent form of the compound for the
purposes of the present invention.
[0067] In addition to salt forms, the present invention provides
compounds which are in a prodrug form. As used herein the term
"prodrug" refers to those compounds that readily undergo chemical
changes under physiological conditions to provide the compounds of
the present invention. Additionally, prodrugs can be converted to
the compounds of the present invention by chemical or biochemical
methods in an ex vivo environment. For example, prodrugs can be
slowly converted to the compounds of the present invention when
placed in a transdermal patch reservoir with a suitable enzyme or
chemical reagent.
[0068] Prodrugs of the invention include compounds wherein an amino
acid residue, or a polypeptide chain of two or more (e.g., two,
three or four) amino acid residues, is covalently joined through an
amide or ester bond to a free amino, hydroxy or carboxylic acid
group of a compound of the present invention. The amino acid
residues include but are not limited to the 20 naturally occurring
amino acids commonly designated by three letter symbols and also
includes phosphoserine, phosphothreonine, phosphotyrosine,
4-hydroxyproline, hydroxylysine, demosine, isodemosine,
gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic
acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,
penicillamine, ornithine, 3-methylhistidine, norvaline,
beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine,
homoserine, methyl-alanine, para-benzoylphenylalanine,
phenylglycine, propargylglycine, sarcosine, methionine sulfone and
tert-butylglycine.
[0069] Additional types of prodrugs are also encompassed. For
instance, a free carboxyl group of a compound of the invention can
be derivatized as an amide or alkyl ester. As another example,
compounds of this invention comprising free hydroxy groups can be
derivatized as prodrugs by converting the hydroxy group into a
group such as, but not limited to, a phosphate ester,
hemisuccinate, dimethylaminoacetate, or
phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D.
et al., (1996) Improved oral drug delivery: solubility limitations
overcome by the use of prodrugs Advanced Drug Delivery Reviews,
19:115. Carbamate prodrugs of hydroxy and amino groups are also
included, as are carbonate prodrugs, sulfonate esters and sulfate
esters of hydroxy groups. Derivatization of hydroxy groups as
(acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group
can be an alkyl ester optionally substituted with groups including,
but not limited to, ether, amine and carboxylic acid
functionalities, or where the acyl group is an amino acid ester as
described above, are also encompassed. Prodrugs of this type are
described in J. Med. Chem., (1996), 39:10. More specific examples
include replacement of the hydrogen atom of the alcohol group with
a group such as (C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N--(C.sub.1-C.sub.6)alkoxycarbonylaminomethyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, alpha-amino(C.sub.1-4)alkanoyl, arylacyl
and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where each
alpha-aminoacyl group is independently selected from the naturally
occurring L-amino acids, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-6)alkyl).sub.2 or glycosyl (the radical resulting
from the removal of a hydroxyl group of the hemiacetal form of a
carbohydrate).
[0070] For additional examples of prodrug derivatives, see, for
example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier,
1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K.
Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design
and Development, edited by Krogsgaard-Larsen and H. Bundgaard,
Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard p.
113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews,
8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical
Sciences, 77: 285 (1988); and e) N. Kakeya, et al., Chem. Pharm.
Bull., 32:692 (1984), each of which is specifically incorporated
herein by reference.
[0071] Additionally, the present invention provides for metabolites
of compounds of the invention. As used herein, a "metabolite"
refers to a product produced through metabolism in the body of a
specified compound or salt thereof. Such products can result for
example from the oxidation, reduction, hydrolysis, amidation,
deamidation, esterification, deesterification, enzymatic cleavage,
and the like, of the administered compound.
[0072] Metabolite products typically are identified by preparing a
radiolabelled (e.g., .sup.14C or .sup.3H) isotope of a compound of
the invention, administering it in a detectable dose (e.g., greater
than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig,
monkey, or to man, allowing sufficient time for metabolism to occur
(typically about 30 seconds to 30 hours) and isolating its
conversion products from the urine, blood or other biological
samples. These products are easily isolated since they are labeled
(others are isolated by the use of antibodies capable of binding
epitopes surviving in the metabolite). The metabolite structures
are determined in conventional fashion, e.g., by MS, LC/MS or NMR
analysis. In general, analysis of metabolites is done in the same
way as conventional drug metabolism studies well known to those
skilled in the art. The metabolite products, so long as they are
not otherwise found in vivo, are useful in diagnostic assays for
therapeutic dosing of the compounds of the invention.
[0073] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. Compounds of the present invention may exist in multiple
crystalline or amorphous forms. In general, all physical forms are
intended to be within the scope of the present invention.
[0074] The compounds of the present invention can also contain
unnatural proportions of atomic isotopes at one or more of the
atoms that constitute such compounds. For example, the present
invention also embraces isotopically-labeled variants of the
present invention which are identical to those recited herein, but
for the fact that one or more atoms are replace by an atom having
the atomic mass or mass number different from the predominant
atomic mass or mass number usually found in nature for the atom.
All isotopes of any particular atom or element as specified are
contemplated within the scope of the compounds of the invention,
and their uses. Exemplary isotopes that can be incorporated in to
compounds of the invention include isotopes of hydrogen, carbon,
nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and
iodine, such as .sup.2H ("D"), .sup.3H, .sup.11C, .sup.13C,
.sup.14C, .sup.13N, .sup.15N, .sup.15O, .sup.17O, .sup.18O,
.sup.3.sub.2P, .sup.33P, .sup.35S, .sup.18F, .sup.36Cl, .sup.123I
and .sup.125I. Certain isotopically labeled compounds of the
present invention (e.g., those labeled with .sup.3H or .sup.14C)
are useful in compound or substrate tissue distribution assays.
Tritiated (.sup.3H) and carbon-14 (.sup.14C) isotopes are useful
for their ease of preparation and detectability. Further
substitution with heavier isotopes such as deuterium (i.e.,
.sup.2H) may afford certain therapeutic advantages resulting from
greater metabolic stability (e.g., increased in vivo half-life or
reduced dosage requirements) and hence may be preferred in some
circumstances. Positron emitting isotopes such as .sup.15O,
.sup.13N, .sup.11C, and .sup.18F are useful for positron emission
tomography (PET) studies to examine substrate receptor occupancy.
Isotopically labeled compounds of the present inventions can
generally be prepared by following procedures analogous to those
disclosed in the Schemes and Examples herein, by substituting an
isotopically labeled reagent for a non-isotopically labeled
reagent. One non-limiting example of an isotopically substituted
moiety is the following:
##STR00003##
[0075] The terms "compound(s) of this invention," and "compound(s)
of the present invention" and the like, unless otherwise indicated,
include compounds of Formula (0) and stereoisomers (including
atropisomers), geometric isomers, tautomers, solvates, metabolites,
isotopes, salts (e.g., pharmaceutically acceptable salts), and
prodrugs thereof. In some embodiments, solvates, metabolites,
isotopes or prodrugs are excluded, or any combination thereof.
[0076] "Treatment" (and variations such as "treat" or "treating")
refers to clinical intervention in an attempt to alter the natural
course of the individual or cell being treated, and can be
performed either for prophylaxis or during the course of clinical
pathology. Desirable effects of treatment include preventing
occurrence or recurrence of disease, alleviation of symptoms,
diminishment of any direct or indirect pathological consequences of
the disease, stabilized (i.e., not worsening) state of disease,
decreasing the rate of disease progression, amelioration or
palliation of the disease state, prolonging survival as compared to
expected survival if not receiving treatment and remission or
improved prognosis. In some embodiments, compounds of the invention
are used to delay development of a disease or disorder or to slow
the progression of a disease or disorder. Those in need of
treatment include those already with the condition or disorder as
well as those prone to have the condition or disorder, (for
example, through a genetic mutation) or those in which the
condition or disorder is to be prevented. In some embodiments,
prophylaxis is excluded from the definition of "treatment."
[0077] The phrase "therapeutically effective amount" or "effective
amount" means an amount of a compound of the present invention that
(i) treats or prevents the particular disease, condition, or
disorder, (ii) attenuates, ameliorates, or eliminates one or more
symptoms of the particular disease, condition, or disorder, or
(iii) prevents or delays the onset of one or more symptoms of the
particular disease, condition, or disorder described herein. For
cancer therapy, efficacy can, for example, be measured by assessing
the time to disease progression (TTP) or determining the response
rate (RR). In the case of immunological disease, the
therapeutically effective amount is an amount sufficient to
decrease or alleviate an allergic disorder, the symptoms of an
autoimmune or inflammatory condition (e.g., psoriasis or
inflammatory bowel disease), or the symptoms of an acute
inflammatory reaction (e.g. asthma). In some embodiments, a
therapeutically effective amount is an amount of a chemical entity
described herein sufficient to significantly decrease the activity
or number of B-cells.
[0078] The terms "inhibiting" and "reducing," or any variation of
these terms, includes any measurable decrease or complete
inhibition to achieve a desired result. For example, there may be a
decrease of about, at most about, or at least about 5%, 10%, 15%,
20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 99%, or more, or any range derivable therein,
reduction of activity (e.g., NIK activity) compared to normal.
[0079] The term "bioavailability" refers to the systemic
availability (i.e., blood/plasma levels) of a given amount of drug
administered to a patient. Bioavailability is an absolute term that
indicates measurement of both the time (rate) and total amount
(extent) of drug that reaches the general circulation from an
administered dosage form.
[0080] "Inflammatory condition" as used herein refers to any
disease, disorder, or syndrome in which an excessive or unregulated
inflammatory response leads to excessive inflammatory symptoms,
host tissue damage, or loss of tissue function.
[0081] "Inflammation" as used herein refers to a localized,
protective response elicited by injury or destruction of tissues,
which serves to destroy, dilute, or wall off (sequester) both the
injurious agent and the injured tissue. Inflammation is notably
associated with influx of leukocytes or neutrophil chemotaxis.
Inflammation can result from infection with pathogenic organisms
and viruses and from noninfectious means such as trauma or
reperfusion following myocardial infarction or stroke, immune
response to foreign antigen, and autoimmune responses.
[0082] The terms "cancer" and "cancerous" refer to or describe the
physiological condition in mammals that is typically characterized
by unregulated cell growth or proliferation. A "tumor" comprises
one or more cancerous cells. Examples of cancer include, but are
not limited to, carcinoma, lymphoma, blastoma, sarcoma, and
leukemia or lymphoid malignancies.
[0083] "Autoimmune disease" as used herein refers to any group of
disorders in which tissue injury is associated with humoral or
cell-mediated responses to the body's own constituents.
[0084] It is specifically contemplated that any limitation
discussed with respect to one embodiment of the invention may apply
to any other embodiment of the invention. Furthermore, any compound
or composition of the invention may be used in any method of the
invention, and any method of the invention may be used to produce
or to utilize any compound or composition of the invention.
[0085] The use of the term "or" is used to mean "and/or" unless
explicitly indicated to refer to alternatives only or the
alternative are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or."
[0086] Throughout this application, the term "about" is used to
indicate that a value includes the standard deviation of error for
the device or method being employed to determine the value.
[0087] As used herein, "a" or "an" means one or more, unless
clearly indicated otherwise. As used herein, "another" means at
least a second or more.
[0088] Headings used herein are intended only for organizational
purposes.
[0089] Inhibitors of NIK
[0090] One aspect of the invention provides compounds of Formula
(0):
##STR00004##
or a stereoisomer or salt thereof, wherein:
[0091] ring A is a monocycle or a fused bicycle;
[0092] Q is N or C, wherein when Q is N, then the bond between
A.sub.1 and Q is not a double bond and the bond between Q and
A.sub.4 is not a double bond;
[0093] A.sub.1 is NR.sup.1, S or CR.sup.1;
[0094] A.sub.2 is NR.sup.2, S or CR.sup.2;
[0095] A.sub.3 is N or C;
[0096] A.sub.4 is N; and
[0097] one, two or three of A.sub.1-A.sub.4 are N, wherein: [0098]
R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3; [0099] R.sup.2 is selected from the group consisting of
H, NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7
cycloalkyl, C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), wherein R.sup.2 is optionally substituted by
R.sup.c; or [0100] R.sup.1 and R.sup.2 taken together form a cyclic
group selected from the group consisting of C.sub.3-C.sub.7
cycloalkyl, phenyl and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
the cyclic group is optionally substituted by R.sup.d;
[0101] R.sup.4 is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
[0102] R.sup.5 is 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) optionally
substituted by R.sup.e or C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or
[0103] R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0104] one of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6
or all are CR.sup.6;
[0105] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and
N.sub.3;
[0106] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0107] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl, C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl) wherein R.sup.b may be optionally substituted by
C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0108] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, --(X.sup.1).sub.0-1--CN,
--(X.sup.1).sub.0-1--NO.sub.2, --(X.sup.1).sub.0-1--SF.sub.5,
--(X.sup.1).sub.0-1--OH, --(X.sup.1).sub.0-1--NH.sub.2,
--(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--O--C.sub.3-C.sub.10 cycloalkyl, --(X.sup.1).sub.0-1-3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), --(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene (e.g.,
a 4-7 membered heterocycloalkylene or a 5-6 membered heteroarylene)
and phenylene; R.sup.1a and R.sup.1b are each independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.3-C.sub.7 cycloalkyl, (C.sub.3-C.sub.7
cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl), (3-11 membered heterocyclylene (e.g., a 4-7 membered
heterocycloalkylene or a 5-6 membered
heteroarylene))C.sub.1-C.sub.6 alkyl, C.sub.6 aryl, and
(C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl, or R.sup.1a and
R.sup.1b when attached to the same nitrogen atom are optionally
combined to form a 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) comprising 0-3
additional heteroatoms selected from N, O and S; Y.sup.1 is O,
NR.sup.1c or S wherein R.sup.1c is H or C.sub.1-C.sub.6 alkyl;
wherein any portion of an R.sup.c or R.sup.d substituent, including
R.sup.1a, R.sup.1b and R.sup.1c, at each occurrence is each
independently further substituted by from 0 to 4 R.sup.f
substituents selected from the group consisting of halogen, CN,
NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6 alkyl,
--(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl (e.g., a
4-7 membered heterocycloalkyl or a 5-6 membered heteroaryl),
wherein the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl),
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen;
[0109] R.sup.e is selected from the group consisting of halogen,
OH, C.sub.1-C.sub.6 alkyl and oxo; and
[0110] R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
[0111] In some embodiments, a compound of Formula (0) is further
defined as a compound of Formula (0a):
##STR00005##
or a stereoisomer or salt thereof, wherein:
[0112] ring A is a monocycle or a fused bicycle;
[0113] Q is N or C, wherein when Q is N, then the bond between
A.sub.1 and Q is not a double bond and the bond between Q and
A.sub.4 is not a double bond;
[0114] A.sub.1 is NR.sup.1, S or CR.sup.1;
[0115] A.sub.2 is NR.sup.2 or CR.sup.2;
[0116] A.sub.3 is N or C;
[0117] A.sub.4 is N; and
[0118] one, two or three of A.sub.1-A.sub.4 are N, wherein: [0119]
R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3; [0120] R.sup.2 is selected from the group consisting of
H, NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7
cycloalkyl, C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), wherein R.sup.2 is optionally substituted by
R.sup.c; or [0121] R.sup.1 and R.sup.2 taken together form a cyclic
group selected from the group consisting of C.sub.3-C.sub.7
cycloalkyl, phenyl and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
the cyclic group is optionally substituted by R.sup.d;
[0122] R.sup.4 is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
[0123] R.sup.5 is 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) optionally
substituted by R.sup.e or C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or
[0124] R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0125] one of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6
or all are CR.sup.6;
[0126] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and
N.sub.3;
[0127] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0128] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl, C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl) wherein R.sup.b may be optionally substituted by
C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0129] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, --(X.sup.1).sub.0-1--CN,
--(X.sup.1).sub.0-1--NO.sub.2, --(X.sup.1).sub.0-1--SF.sub.5,
--(X.sup.1).sub.0-1--OH, --(X.sup.1).sub.0-1--NH.sub.2,
--(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--O--C.sub.3-C.sub.10 cycloalkyl, --(X.sup.1).sub.0-1-3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), --(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene (e.g.,
a 4-7 membered heterocycloalkylene or a 5-6 membered heteroarylene)
and phenylene; R.sup.1a and R.sup.1b are each independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.3-C.sub.7 cycloalkyl, (C.sub.3-C.sub.7
cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl), (3-11 membered heterocyclylene (e.g., a 4-7 membered
heterocycloalkylene or a 5-6 membered
heteroarylene))C.sub.1-C.sub.6 alkyl, C.sub.6 aryl, and
(C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl, or R.sup.1a and
R.sup.1b when attached to the same nitrogen atom are optionally
combined to form a 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) comprising 0-3
additional heteroatoms selected from N, O and S; Y.sup.1 is O,
NR.sup.1c or S wherein R.sup.1c is H or C.sub.1-C.sub.6 alkyl;
wherein any portion of an R.sup.c or R.sup.d substituent, including
R.sup.1a, R.sup.1b and R.sup.1c, at each occurrence is each
independently further substituted by from 0 to 4 R.sup.f
substituents selected from the group consisting of halogen, CN,
NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6 alkyl,
--(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl (e.g., a
4-7 membered heterocycloalkyl or a 5-6 membered heteroaryl),
wherein the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl),
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen;
[0130] R.sup.e is selected from the group consisting of halogen,
OH, C.sub.1-C.sub.6 alkyl and oxo; and
[0131] R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
[0132] In some embodiments, a compound of Formula (0) is further
defined as a compound of Formula (0-0):
##STR00006##
[0133] or a stereoisomer or salt thereof, wherein:
[0134] ring A is a monocycle or a fused bicycle;
[0135] Q is C;
[0136] A.sub.1 is NR.sup.1, S or CR.sup.1;
[0137] A.sub.2 is NR.sup.2 or CR.sup.2;
[0138] A.sub.3 is N or C;
[0139] A.sub.4 is N; and
[0140] one, two or three of A.sub.1-A.sub.4 are N, wherein: [0141]
R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3; [0142] R.sup.2 is selected from the group consisting of
H, NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7
cycloalkyl, C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), wherein R.sup.2 is optionally substituted by
R.sup.c; or [0143] R.sup.1 and R.sup.2 taken together form a cyclic
group selected from the group consisting of C.sub.3-C.sub.7
cycloalkyl, phenyl and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
the cyclic group is optionally substituted by R.sup.d;
[0144] R.sup.4 is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
[0145] R.sup.5 is 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) optionally
substituted by R.sup.e; or
[0146] R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0147] one of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6
or all are CR.sup.6;
[0148] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and
N.sub.3;
[0149] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0150] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl, C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl) wherein R.sup.b may be optionally substituted by
C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0151] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, --(X.sup.1).sub.0-1--CN,
--(X.sup.1).sub.0-1--NO.sub.2, --(X.sup.1).sub.0-1--SF.sub.5,
--(X.sup.1).sub.0-1--OH, --(X.sup.1).sub.0-1--NH.sub.2,
--(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--(X.sup.1).sub.0-1-3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl),
--(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd..sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene (e.g.,
a 4-7 membered heterocycloalkylene or a 5-6 membered heteroarylene)
and phenylene; R.sup.1a and R.sup.1b are each independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.3-C.sub.7 cycloalkyl, (C.sub.3-C.sub.7
cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl), (3-11 membered heterocyclylene (e.g., a 4-7 membered
heterocycloalkylene or a 5-6 membered
heteroarylene))C.sub.1-C.sub.6 alkyl, C.sub.6 aryl, and
(C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl, or R.sup.1a and
R.sup.1b when attached to the same nitrogen atom are optionally
combined to form a 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) comprising 0-3
additional heteroatoms selected from N, O and S; Y.sup.1 is O,
NR.sup.1c or S wherein R.sup.1c is H or C.sub.1-C.sub.6 alkyl;
wherein any portion of an R.sup.c or R.sup.d substituent, including
R.sup.1a, R.sup.1b and R.sup.1c, at each occurrence is each
independently further substituted by from 0 to 4 R.sup.f
substituents selected from the group consisting of halogen, CN,
NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6 alkyl,
--(C.sub.2-C.sub.6 alkynylene)-(3-11 membered heterocyclyl (e.g., a
4-7 membered heterocycloalkyl or a 5-6 membered heteroaryl),
wherein the heterocyclyl is optionally substituted by R.sup.e),
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7
cycloalkyl, 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl),
--C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --C(.dbd.O)OH,
--N(H)C(.dbd.O)(C.sub.1-C.sub.6 alkyl), --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)(C.sub.1-C.sub.6 alkyl),
--N(H)C(.dbd.O)OC.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 alkyl, --N(C.sub.1-C.sub.6
alkyl)S(O).sub.1-2C.sub.1-C.sub.6 alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6 alkyl,
--NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, --NHC(.dbd.O)NH.sub.2,
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 alkyl),
--N(C.sub.1-C.sub.6 alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 alkyl, --OC(.dbd.O)OC.sub.1-C.sub.6
alkyl, --OP(.dbd.O)(OC.sub.1-C.sub.6 alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 alkyl).sub.2, wherein any alkyl
portion of R.sup.f is optionally substituted with halogen;
[0152] R.sup.e is selected from the group consisting of halogen,
OH, C.sub.1-C.sub.6 alkyl and oxo; and
[0153] R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl.
[0154] In some embodiments, a compound of Formula (0) is further
defined as a compound of Formula (I):
##STR00007##
or a stereoisomer or salt thereof, wherein:
[0155] ring A is a monocycle or a fused bicycle;
[0156] A.sub.1 is N, S or CR.sup.1;
[0157] A.sub.2 is N or CR.sup.2;
[0158] A.sub.3 is N or C;
[0159] A.sub.4 is N; and
[0160] one, two or three of A.sub.1-A.sub.4 are N, wherein: [0161]
R.sup.1 is selected from the group consisting of H, halogen,
NR.sup.aR.sup.b, C.sub.1-C.sub.3 alkyl, C.sub.3-C.sub.7 cycloalkyl,
C.sub.1-C.sub.3 alkoxy and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
R.sup.1 is optionally substituted by F, OH, CN, SH, CH.sub.3 or
CF.sub.3; [0162] R.sup.2 is selected from the group consisting of
H, NR.sup.aR.sup.b, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7
cycloalkyl, C.sub.1-C.sub.6 alkoxy, phenyl and 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl), wherein R.sup.2 is optionally substituted by
R.sup.c; or [0163] R.sup.1 and R.sup.2 taken together form a cyclic
group selected from the group consisting of C.sub.3-C.sub.7
cycloalkyl, phenyl and 3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl), wherein
the cyclic group is optionally substituted by R.sup.d;
[0164] R.sup.4 is selected from the group consisting of
C.sub.1-C.sub.6 alkyl, CH.sub.2F and CH.sub.2OH;
[0165] R.sup.5 is 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) optionally
substituted by R.sup.e; or
[0166] R.sup.4 and R.sup.5 together form a C.sub.3-C.sub.11
cycloalkyl optionally substituted by R.sup.e or a 3-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0167] one of A.sub.5-A.sub.8 is N and the remaining are CR.sup.6
or all are CR.sup.6;
[0168] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and
N.sub.3;
[0169] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl optionally substituted by C.sub.1-C.sub.3
alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0170] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.3-C.sub.6
cycloalkyl, C(O)R.sup.g, phenyl and 3-11 membered heterocyclyl
(e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered
heteroaryl) wherein R.sup.b may be optionally substituted by
C.sub.1-C.sub.3 alkoxy, F, OH, CN, SH, CH.sub.3 or CF.sub.3;
[0171] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, --(X.sup.1).sub.0-1--CN,
--(X.sup.1).sub.0-1--NO.sub.2, --(X.sup.1).sub.0-1--SF.sub.5,
--(X.sup.1).sub.0-1--OH, --(X.sup.1).sub.0-1--NH.sub.2,
--(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.10 cycloalkyl,
--(X.sup.1).sub.0-1-3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl),
--(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.10 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1--3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--C(.dbd.NOH)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.NOR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--NHC(.dbd.Y.sup.1)N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.0-1--N(R.sup.1a)C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)R.sup.1a,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)H,
--(X.sup.1).sub.0-1--OC(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--OP(.dbd.Y.sup.1)(OR.sup.1a)(OR.sup.1b),
--(X.sup.1)--SC(.dbd.Y.sup.1)OR.sup.1a and
--(X.sup.1)--SC(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b) wherein X.sup.1
is selected from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
(C.sub.3-C.sub.7 cycloalkylene)C.sub.1-C.sub.6 alkyl, 3-11 membered
heterocyclyl, (3-11 membered heterocyclylene)C.sub.1-C.sub.6 alkyl,
C.sub.6 aryl, and (C.sub.6-C.sub.10 arylene)C.sub.1-C.sub.6 alkyl,
or R.sup.1a and R.sup.1b when attached to the same nitrogen atom
are optionally combined to form a 3-11 membered heterocyclyl
comprising 0-3 additional heteroatoms selected from N, O and S;
Y.sup.1 is O, NR.sup.1c or S wherein R.sup.1c is H or
C.sub.1-C.sub.6 alkyl; wherein any portion of an R.sup.c or R.sup.d
substituent, including R.sup.1a, R.sup.1b and R.sup.1c, at each
occurrence is each independently further substituted by from 0 to 4
R.sup.f substituents selected from the group consisting of halogen,
CN, NO.sub.2, SF.sub.5, OH, NH.sub.2, --N(C.sub.1-C.sub.6
alkyl).sub.2, --NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7 cycloalkyl, 3-11
membered heterocyclyl, --C(.dbd.O)N(H)(C.sub.1-C.sub.6
(halo)alkyl), --C(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--C(.dbd.O)OH, --N(H)C(.dbd.O)(C.sub.1-C.sub.6 (halo)alkyl),
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)(C.sub.1-C.sub.6
(halo)alkyl), --N(H)C(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)OC.sub.1-C.sub.6
(halo)alkyl, --S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl,
--N(H)S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl, --N(C.sub.1-C.sub.6
(halo)alkyl)S(O).sub.1-2C.sub.1-C.sub.6 (halo)alkyl,
--S(O).sub.0-1N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--S(O).sub.0-1N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--S(O).sub.0-1NH.sub.2, --C(.dbd.O)C.sub.1-C.sub.6 (halo)alkyl,
--C(.dbd.O)C.sub.3-C.sub.7 cycloalkyl, --C(.dbd.NOH)C.sub.1-C.sub.6
(halo)alkyl, --C(.dbd.NOC.sub.1-C.sub.6 alkyl)C.sub.1-C.sub.6
(halo)alkyl, --NHC(.dbd.O)N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--NHC(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2,
--NHC(.dbd.O)NH.sub.2, --N(C.sub.1-C.sub.6
(halo)alkyl)C(.dbd.O)N(H)(C.sub.1-C.sub.6 (halo)alkyl),
--N(C.sub.1-C.sub.6 (halo)alkyl)C(.dbd.O)NH.sub.2,
--OC(.dbd.O)C.sub.1-C.sub.6 (halo)alkyl,
--OC(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl,
--OP(.dbd.O)(OC.sub.1-C.sub.6 (halo)alkyl).sub.2,
--SC(.dbd.O)OC.sub.1-C.sub.6 (halo)alkyl and
--SC(.dbd.O)N(C.sub.1-C.sub.6 (halo)alkyl).sub.2;
[0172] R.sup.e is selected from the group consisting of halogen,
OH, C.sub.1-C.sub.6 alkyl and oxo; and
[0173] R.sup.g is selected from the group consisting of
C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6 cycloalkyl, wherein
R.sup.g may be optionally substituted, such as by halogen or
oxo.
[0174] In some embodiments, a compound of Formula (0) is further
defined as a compound of Formula (II):
##STR00008##
or a stereoisomer or salt thereof, wherein:
[0175] ring A is a monocycle or a fused bicycle;
[0176] A.sub.1 is N or CR.sup.1;
[0177] A.sub.2 is N or CR.sup.2;
[0178] A.sub.3 is N or C;
[0179] A.sub.4 is N; and
[0180] one or two of A.sub.1-A.sub.4 are N, wherein: [0181] R.sup.1
is selected from the group consisting of H, halogen and
C.sub.1-C.sub.3 alkyl or 3-6 membered heterocyclyl, wherein R.sup.1
is optionally substituted by F or OH; [0182] R.sup.2 is selected
from the group consisting of H, NH.sub.2, C.sub.1-C.sub.3 alkyl,
C.sub.3-C.sub.6 cycloalkyl and 3-6 membered heterocyclyl, wherein
R.sup.2 is optionally substituted by R.sup.c; or [0183] R.sup.1 and
R.sup.2 taken together form a cyclic group selected from the group
consisting of C.sub.3-C.sub.7 cycloalkyl, phenyl and 3-6 membered
heterocyclyl, wherein the cyclic group is optionally substituted by
R.sup.d;
[0184] A.sub.5 is CR.sup.6 or N;
[0185] A.sub.6 is CR.sup.6 or N;
[0186] wherein only one of A.sub.5 and A.sub.6 is N;
[0187] R.sup.4 is C.sub.1-C.sub.3 alkyl;
[0188] R.sup.5 is 5-6 membered heterocyclyl optionally substituted
by R.sup.e; or
[0189] R.sup.4 and R.sup.5 together form a 5-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0190] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, CF.sub.3 and OCH.sub.3;
[0191] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl;
[0192] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl and C(O)R.sup.g;
[0193] R.sup.c and R.sup.d are each independently selected from the
group consisting of halogen, OH, C.sub.1-C.sub.6 alkyl,
C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6
alkylamino, C.sub.1-C.sub.6 dialkylamino, C(O)(C.sub.1-C.sub.6
alkyl), C(O).sub.2(C.sub.1-C.sub.6 alkyl), phenyl, and 3-6 membered
heterocyclyl, wherein each of R.sup.c and R.sup.d are each
independently optionally substituted by halogen, OH,
C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy, 5-6 membered
heterocyclyl, or oxo;
[0194] R.sup.e is selected from the group consisting of OH,
C.sub.1-C.sub.6 alkyl and oxo; and
[0195] R.sup.g, independently at each occurrence, is selected from
the group consisting of C.sub.1-C.sub.6 alkyl and C.sub.3-C.sub.6
cycloalkyl.
[0196] In some embodiments, a compound of Formula (0) is further
defined as a compound of Formula (III):
##STR00009##
or a stereoisomer or salt thereof, wherein:
[0197] ring A is a monocycle or a fused bicycle;
[0198] A.sub.1 is N or CR.sup.1;
[0199] A.sub.2 is N or CR.sup.2;
[0200] A.sub.3 is N or C;
[0201] A.sub.4 is N; and
[0202] one or two of A.sub.1-A.sub.4 are N, wherein: [0203] R.sup.1
is selected from the group consisting of H and halogen; [0204]
R.sup.2 is selected from the group consisting of H, NH.sub.2,
C.sub.1-C.sub.3 alkyl and C.sub.3-C.sub.6 cycloalkyl; or [0205]
R.sup.1 and R.sup.2 taken together form a cyclic group selected
from the group consisting of C.sub.3-C.sub.7 cycloalkyl, phenyl and
3-6 membered heterocyclyl, wherein the cyclic group is optionally
substituted by R.sup.d;
[0206] R.sup.4 is C.sub.1-C.sub.6 alkyl, such as methyl;
[0207] R.sup.5 is 5-6 membered heterocyclyl optionally substituted
by R.sup.e; or
[0208] R.sup.4 and R.sup.5 together form a 5-11 membered
heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a 5-6
membered heteroaryl) optionally substituted by R.sup.e;
[0209] A.sub.6 is CH, CR.sup.6 or N;
[0210] R.sup.6, independently at each occurrence, is selected from
the group consisting of H, F, Cl, NH.sub.2, NHCH.sub.3,
N(CH.sub.3).sub.2, OH, OCH.sub.3, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3, SH, SCH.sub.3, SCHF.sub.2, SCH.sub.2F, CN, CH.sub.3,
CHF.sub.2, CH.sub.2F, CH.sub.2OH, CF.sub.3, NO.sub.2 and N.sub.3,
such as a group consisting of F, Cl, CF.sub.3 and OCH.sub.3;
[0211] n is 0, 1, or 2, such as 0 or 1;
[0212] R.sup.a is selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl;
[0213] R.sup.b is selected from the group consisting of H,
C.sub.1-C.sub.6 alkyl and C(O)R.sup.g;
[0214] R.sup.d is selected from the group consisting of OH, CN,
halogen, C.sub.1-C.sub.6 alkoxy, --O--C.sub.1-C.sub.6 alkyl-phenyl,
NR.sup.aR.sup.b, 4-6 membered heterocyclyl, C(O)R.sup.g,
C(O).sub.2R.sup.g and C.sub.1-C.sub.6 alkyl optionally substituted
by OH, CN, or 4-6 membered heterocyclyl;
[0215] R.sup.e is selected from the group consisting of methyl and
oxo; and
[0216] R.sup.g, independently at each occurrence, is selected from
the group consisting of C.sub.1-C.sub.4 alkyl and C.sub.3-C.sub.6
cycloalkyl.
[0217] In some embodiments, R.sup.4 is CH.sub.3. In some
embodiments, R.sup.5 is a 5-6 membered heterocyclyl optionally
substituted by R.sup.e.
[0218] In some embodiments, such as in a compound of Formula (0),
(0a), (0-0), (I), (II), or (III), the following moiety
##STR00010##
is defined as
##STR00011##
wherein:
[0219] A.sub.9 is O, NR.sup.11 or CR.sup.11R.sup.12, wherein
R.sup.11 and R.sup.12 are each independently selected from the
group consisting of H, halogen, OH and C.sub.1-C.sub.3 alkyl;
[0220] R.sup.7 and R.sup.8 are each independently selected from
halogen, OH, C.sub.1-C.sub.6 alkyl, or R.sup.7 and R.sup.8 together
form .dbd.O, and
[0221] R.sup.9 and R.sup.10 are each independently selected from
R.sup.e, or R.sup.9 and R.sup.10 together form a C.sub.5-C.sub.6
cycloalkyl or a 5-6 membered heterocyclyl, wherein said cycloalkyl
and said heterocyclyl are each optionally substituted by
R.sup.e.
[0222] In some embodiments, R.sup.4 and R.sup.5 together form a
C.sub.8-C.sub.10 cycloalkyl optionally substituted by R.sup.e. In
some embodiments, R.sup.4 and R.sup.5 together form a 4-9 membered
heterocyclyl optionally substituted by R.sup.e.
[0223] In some embodiments, the following moiety
##STR00012##
is selected from the group consisting of
##STR00013## ##STR00014##
[0224] In some embodiments, one of A.sub.1-A.sub.4 is N. In some
embodiments, A.sub.4 is N. In some embodiments, two of
A.sub.1-A.sub.4 is N. For example, in some embodiments, A.sub.1 and
A.sub.4 are each N. In other embodiments, A.sub.3 and A.sub.4 are
each N. In any such embodiment, ring B may be phenyl or phenyl
independently substituted by one or two R.sup.6.
[0225] In some embodiments, R.sup.1 is selected from the group
consisting of H, F and Cl. In some embodiments, R.sup.2 is selected
from the group consisting of H, NH.sub.2, CH.sub.3 and cyclopropyl.
In other embodiments, R.sup.2 is a C.sub.3-C.sub.11
heterocycloalkyl. In some embodiments, R.sup.1 and R.sup.2 together
form the following cyclic group, wherein the asterisks indicate the
points of ring fusion to ring A, and each cyclic group is
optionally substituted by R.sup.d:
##STR00015## ##STR00016##
[0226] In some embodiments, R.sup.1 and R.sup.2 together form an
unsubstituted cyclic group.
[0227] In some embodiments, R.sup.d is selected from the group
consisting of OH, CN, F, C.sub.1-C.sub.3 alkoxy,
--O--C.sub.1-C.sub.3 alkyl-phenyl, NR.sup.aR.sup.b, 4-6 membered
heterocyclyl, C(O)R.sup.g, C(O).sub.2R.sup.g and C.sub.1-C.sub.6
alkyl optionally substituted by OH, CN, or 4-6 membered
heterocyclyl.
[0228] In some embodiments, ring B is phenyl.
[0229] In some embodiments, A.sup.1 is CR.sup.1, A.sup.2 is
CR.sup.2, A.sup.3 is N and A.sup.4 is N.
[0230] In some embodiments, R.sup.4 and R.sup.5 taken together form
the following moiety:
##STR00017##
[0231] In some embodiments, R.sup.c and R.sup.d are each
independently selected from the group consisting of halogen,
--(X.sup.1).sub.0-1--CN, --(X.sup.1).sub.0-1--NO.sub.2,
--(X.sup.1).sub.0-1--SF.sub.5, --(X.sup.1).sub.0-1--OH,
--(X.sup.1).sub.0-1--NH.sub.2, --(X.sup.1).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)(R.sup.1a),
--(X.sup.1).sub.0-1--CF.sub.3, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 heteroalkyl,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkylthio, oxo,
--(X.sup.1).sub.0-1--C.sub.1-C.sub.6 alkyl,
--(X.sup.1).sub.0-1--C.sub.3-C.sub.7 cycloalkyl,
--(X.sup.1).sub.0-1-3-11 membered heterocyclyl (e.g., a 4-7
membered heterocycloalkyl or a 5-6 membered heteroaryl),
--(X.sup.1).sub.0-1--C.sub.6-C.sub.10 aryl,
--C(.dbd.O)(X.sup.1).sub.1--C.sub.3-C.sub.7 cycloalkyl,
--C(.dbd.O)(X.sup.1).sub.1-3-11 membered heterocyclyl,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)NH.sub.2,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)N(R.sup.1a)(R.sup.1b),
--(X.sup.1).sub.01--C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)OH,
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)(R.sup.1a),
--(X.sup.1).sub.0-1--(R.sup.1b)C(.dbd.Y.sup.1(H),
--(X.sup.1).sub.0-1--N(H)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)C(.dbd.Y.sup.1)OR.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(H)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--N(R.sup.1b)S(O).sub.1-2R.sup.1a,
--(X.sup.1).sub.0-1--S(O).sub.0-1--N(H)(R.sup.1a),
--(X.sup.1).sub.0-1--S(O).sub.0-1N(R.sup.1b)(R.sup.1a),
(X.sup.1).sub.0-1--S(O).sub.0-1NH.sub.2,
--(X.sup.1).sub.0-1--S(.dbd.O)(.dbd.NR.sup.1b)R.sup.1a,
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)R.sup.1a, and
--(X.sup.1).sub.0-1--C(.dbd.Y.sup.1)H, wherein X.sup.1 is selected
from the group consisting of C.sub.1-C.sub.6 alkylene,
C.sub.1-C.sub.6 heteroalkylene, C.sub.2-C.sub.6 alkenylene,
C.sub.2-C.sub.6 alkynylene, C.sub.1-C.sub.6 alkyleneoxy,
C.sub.3-C.sub.7 cycloalkylene, 3-11 membered heterocyclylene and
phenylene; R.sup.1a and R.sup.1b are each independently selected
from the group consisting of C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 heteroalkyl, C.sub.3-C.sub.7 cycloalkyl,
3-11 membered heterocyclyl, and phenyl, or R.sup.1a and R.sup.1b
when attached to the same nitrogen atom are optionally combined to
form a 3-11 membered heterocyclyl (e.g., a 4-7 membered
heterocycloalkyl or a 5-6 membered heteroaryl) comprising 0-3
additional heteroatoms selected from N, O and S; Y.sup.1 is O,
NR.sup.1c or S wherein R.sup.1c is H or C.sub.1-C.sub.6 alkyl;
wherein any portion of an R.sup.c or R.sup.d substituent, including
R.sup.1a, R.sup.1b and R.sup.1c, at each occurrence is each
independently further substituted by from 0 to 4 R.sup.f
substituents selected from the group consisting of halogen, CN,
NO.sub.2, OH, NH.sub.2, --N(C.sub.1-C.sub.6 alkyl).sub.2,
--NH(C.sub.1-C.sub.6 alkyl), oxo, C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.6 heteroalkyl, C.sub.1-C.sub.6 alkoxy,
C.sub.1-C.sub.6 alkylthio, C.sub.3-C.sub.7 cycloalkyl, or 3-11
membered heterocyclyl (e.g., a 4-7 membered heterocycloalkyl or a
5-6 membered heteroaryl).
[0232] In some embodiments, a heterocyclyl group contains one to
three nitrogen atoms, one oxygen atom, or one sulfur atom, or any
combination thereof.
[0233] In some embodiments, Q is C.
[0234] In some embodiments, a compound of the present invention is
defined as any one or more of the following:
##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022##
##STR00023## ##STR00024## ##STR00025## ##STR00026## ##STR00027##
##STR00028## ##STR00029## ##STR00030## ##STR00031## ##STR00032##
##STR00033## ##STR00034## ##STR00035## ##STR00036## ##STR00037##
##STR00038## ##STR00039## ##STR00040## ##STR00041## ##STR00042##
##STR00043## ##STR00044## ##STR00045## ##STR00046## ##STR00047##
##STR00048## ##STR00049## ##STR00050## ##STR00051##
[0235] Some embodiments provide a pharmaceutical composition
comprising a compound of the present invention and a
pharmaceutically acceptable carrier, diluent or excipient. A
compound or pharmaceutical composition described herein can be used
in therapy, such as the treatment of an inflammatory condition
(e.g., lupus, such as systemic lupus erythematosus, extra-renal
lupus, or lupus nephritis, COPD, rhinitis, multiple sclerosis, IBD,
arthritis, rheumatoid arthritis, dermatitis, endometriosis and
transplant rejection). Also provided is the use of a compound or a
pharmaceutical composition described herein for the preparation of
a medicament for the treatment of an inflammatory condition (e.g.,
lupus, such as systemic lupus erythematosus, extra-renal lupus, or
lupus nephritis, COPD, rhinitis, multiple sclerosis, IBD,
arthritis, rheumatoid arthritis, dermatitis, endometriosis and
transplant rejection).
[0236] Also provided is a method for the treatment of an
inflammatory condition in a patient, comprising administering an
effective amount of a compound or pharmaceutical composition as
described herein to the patient. The inflammatory condition can be
selected from the group consisting of lupus, such as systemic lupus
erythematosus, extra-renal lupus, or lupus nephritis, COPD,
rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis,
dermatitis, endometriosis and transplant rejection.
[0237] Further provided is a method of preparing a compound of
Formula (0),
##STR00052##
wherein Q, A.sub.1-A.sub.8, R.sup.4 and R.sup.5 are as defined
above, comprising: contacting a compound of Formula (A):
##STR00053##
wherein X is Cl, Br or I, with a compound of Formula (B)
##STR00054##
wherein [M] is a boronic acid, a boronic ester, or a
trifluoroborate salt, in the presence of (a)(i) a palladium(0)
catalyst or (a)(ii) a copper catalyst and (b) a base under Suzuki
reaction conditions to yield a compound of Formula (0). Persons of
skill in the art are familiar with Suzuki reactions and the
reagents employed in such reactions. See, e.g., Suzuki, J.
Organometallic Chem., 576:147-168 (1999). Non-limiting examples of
palladium catalysts include Pd(PPh.sub.3).sub.4, Pd(OAc).sub.2 and
Pd(PPh.sub.3).sub.2Cl.sub.2. A non-limiting example of a copper
catalyst is copper(II) acetate. Non-limiting examples of bases
include sodium carbonate, potassium carbonate and cesium carbonate,
or mixtures thereof. In some embodiments, copper(II) acetate and
pyridine as the base are employed under Chan-Lam coupling
conditions, as is known in the art. For example, the
carbon-nitrogen bond in an indazole or an aza-indazole can be
formed using Chan-Lam coupling conditions. A variety of organic
solvents may be employed, including toluene, THF, dioxane,
1,2-dichloroethane, DMF, DMSO and acetonitrile. Reaction
temperatures vary depending on conditions but typically range from
room temperature to 150.degree. C.
[0238] In some embodiments, the invention provides a compound of
Table 1:
TABLE-US-00001 TABLE 1 Ex. Structure Name 1 ##STR00055##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]indazole-3- carboxamide 2 ##STR00056##
(4R)-4-hydroxy-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl] phenyl]-4,5,6,7-tetrahydro-
indazole-3-carboxamide 3 ##STR00057## (4S)-4-hydroxy-1-[3-[2-[(3R)-
3-hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]
phenyl]-4,5,6,7-tetrahydro- indazole-3-carboxamide 4 ##STR00058##
1-[4-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl]-6,6- dimethyl-5,7-dihydro-4H-
indazole-3-carboxamide 5 ##STR00059## (4aR,5aS)-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-
2-pyridyl]-5a-methyl-4,4a,5,6- tetrahydrocyclopropa[f]
indazole-3-carboxamide 6 ##STR00060## (4aS,5aR)-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]-5a-methyl-4,4a,5,6- tetrahydrocyclopropa[f]
indazole-3-carboxamide 7 ##STR00061## (5S)-5-benzyloxy-1-[4-[2-
[(3R)-3-hydroxy-1-methyl-2- oxo-pyrrolidin-3-yl]ethynyl]-
2-pyridyl]-6,6-dimethyl- 5,7-dihydro-4H-indazole-3- carboxamide 8
##STR00062## (5R)-5-benzyloxy-1-[4-[2- [(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]- 2-pyridyl]-6,6-dimethyl-
5,7-dihydro-4H-indazole-3- carboxamide 9 ##STR00063##
(5R)-5-hydroxy-1-[4-[2- [(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]- 2-pyridyl]-6,6-dimethyl-5,7-
dihydro-4H-indazole-3- carboxamide 10 ##STR00064##
4-fluoro-1-[4-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]-2- pyridyl]indazole-3- carboxamide 11
##STR00065## (5S)-5-hydroxy-1-[4-[2- [(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl]ethynyl]- 2-pyridyl]-6,6-dimethyl-5,7-
dihydro-4H-indazole-3- carboxamide 12 ##STR00066##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5,6- dihydro-4H-pyrano[2,3-c]
pyrazole-3-carboxamide 13 ##STR00067## 5-fluoro-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
indazole-3-carboxamide 14 ##STR00068## 1-[3-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
methoxy-indazole-3- carboxamide 15 ##STR00069##
(4R)-4-(cyclopropanecarbonyl- amino)-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]-4,5,6,7-tetrahydro- indazole-3-carboxamide 16 ##STR00070##
tert-butyl 3-carbamoyl-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]-6,7-dihydro-4H-
pyrazolo[4,3-c]pyridine-5- carboxylate 17 ##STR00071##
(4S)-4-(cyclopropanecarbonyl- amino)-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]-4,5,6,7-tetra- hydroindazole-3-carboxamide 18 ##STR00072##
1-[3-fluoro-5-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[3,4-b]pyridine-3-
carboxamide 19 ##STR00073## 5-acetyl-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]-
6,7-dihydro-4H-pyrazolo [4,3-c]pyridine-3- carboxamide 20
##STR00074## 5-(cyclopropanecarbonyl)- 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6,7-
dihydro-4H-pyrazolo[4,3-c] pyridine-3-carboxamide 21 ##STR00075##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-4,5,6,7- tetrahydropyrazolo[4,3-c]
pyridine-3-carboxamide 22 ##STR00076## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-methoxy-
indazole-3-carboxamide 23 ##STR00077## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-7-
methoxy-indazole-3- carboxamide 24 ##STR00078##
4,4-difluoro-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]-6,7-dihydro-5H-
indazole-3-carboxamide 25 ##STR00079## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
methyl-pyrazolo[3,4-d] thiazole-3-carboxamide 26 ##STR00080##
1-[3-[(3R)-3-hydroxy-3-(5- methyl-1,3,4-oxadiazol-2-
yl)but-1-ynyl]phenyl]indazole- 3-carboxamide 27 ##STR00081##
6-fluoro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-3-
piperidyl]ethynyl]phenyl] indazole-3-carboxamide 28 ##STR00082##
1-[3-[(3R)-hydroxy-3- pyrimidin-2-yl-but-1-ynyl]
phenyl]indazole-3-carboxamide 29 ##STR00083##
1-[3-[(3R)-3-hydroxy-3-(5- methyl-1,2,4-oxadiazol-3-
yl)but-1-ynyl]phenyl]indazole- 3-carboxamide 30 ##STR00084##
1-[3-[2-[(3S)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]indazole- 3-carboxamide 31 ##STR00085##
1-[4-fluoro-3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[3,4-b]pyridine-3-
carboxamide 32 ##STR00086## (4R)-4-(cyclopropanecarbonyl-
amino)-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]-4,5,6,7-tetrahydro-
indazole-3-carboxamide 33 ##STR00087## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
(oxetan-3-yl)-6,7-dihydro-4H- pyrazolo[4,3-c]pyridine-3-
carboxamide 34 ##STR00088## (4R)-1-[3-[2-[(3R)-3-hydroxy-
1-methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-4-
pyrazol-1-yl-4,5,6,7-tetrahydro- indazole-3-carboxamide 35
##STR00089## 5-(hydroxymethyl)-1-[3-[2- [(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]indazole-3- carboxamide 36
##STR00090## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-5-(trifluoromethyl) phenyl]pyrazolo[3,4-b]
pyridine-3-carboxamide 37 ##STR00091##
(4S)-4-(cyclopropanecarbonyl- amino)-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]
phenyl]-4,5,6,7-tetrahydro- indazole-3-carboxamide 38 ##STR00092##
(4S)-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]-4-pyrazol-1-yl-
4,5,6,7-tetrahydroindazole-3- carboxamide 39 ##STR00093##
4-chloro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 40
##STR00094## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(2- hydroxy-2-methyl-propyl)-6,7-
dihydro-4H-pyrazolo[4,3-c] pyridine-3-carboxamide 41 ##STR00095##
5-(cyanomethyl)-1-[3-[2- [(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl] phenyl]indazole-3- carboxamide 42
##STR00096## 5-cyano-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 43
##STR00097## 5-[(1R)-1-hydroxyethyl]-1- [3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]indazole-3-
carboxamide 44 ##STR00098## 1-[3-chloro-5-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
pyrazolo[3,4-b]pyridine-3- carboxamide 45 ##STR00099##
5-[(1S)-1-hydroxyethyl]-1- [3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]indazole-3-
carboxamide 46 ##STR00100## 6-cyano-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
indazole-3-carboxamide 47 ##STR00101## (5aS)-5,5-difluoro-1-[3-[2-
[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5a-methyl- 4a,6-dihydro-4H-cyclopropa
[f]indazole-3-carboxamide 48 ##STR00102##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5- (pyrrolidin-1-ylmethyl)
indazole-3-carboxamide 49 ##STR00103## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-4-
(methylamino)pyrazolo[4,3-c] pyridine-3-carboxamide 50 ##STR00104##
(5aR)-5,5-difluoro-1-[3-[2- [(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]-5a-methyl-
4a,6-dihydro-4H-cyclopropa[f] indazole-3-carboxamide 51
##STR00105## 1-[4-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl]-4,5,6, 7-tetrahydroindazole-3- carboxamide
52 ##STR00106## 1-[4-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]-2-pyridyl]
indazole-3-carboxamide 53 ##STR00107## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[3,4-b]pyridine-3- carboxamide 54 ##STR00108##
5-fluoro-1-[4-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]-2- pyridyl]indazole-3- carboxamide 55
##STR00109## 1-[4-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl] pyrazole-3-carboxamide 56 ##STR00110##
1-[4-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl]-5,6- dihydro-4H-cyclopenta[c]
pyrazole-3-carboxamide 57 ##STR00111## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-4,5,6,7-
tetrahydroindazole-3- carboxamide 58 ##STR00112##
(R)-1-(4-((3-hydroxy-1- methyl-2-oxopyrrolidin-3-yl)
ethynyl)pyridin-2-yl)-4,5,6,7- tetrahydro-1H-5,7-methano
indazole-3-carboxamide 59 ##STR00113## (R)-1-(4-((3-hydroxy-1-
methyl-2-oxopyrrolidin-3-yl) ethynyl]pyridin-2-yl)-4,5,6,7-
tetrahydro-1H-4,6-methano indazole-3-carboxamide 60 ##STR00114##
1-[4-[(3R)-3-hydroxy-3-(5- methylisoxazol-3-yl)but-1-
ynyl]-2-pyridyl]-4,5,6,7- tetrahydroindazole-3- carboxamide 61
##STR00115## (6R)-6-hydroxy-1-[4-[2-[(3R)- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]- 2-pyridyl]-4,5,6,7-tetrahydro-
indazole-3-carboxamide 62 ##STR00116##
(6S)-6-hydroxy-1-[4-[2-[(3R)- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]- 2-pyridyl]-4,5,6,7-tetrahydro-
indazole-3-carboxamide 63 ##STR00117## 6-fluoro-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]indazole-3- carboxamide 64 ##STR00118##
1-[4-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl]-5,5- dimethyl-6,7-dihydro-4H-
indazole-3-carboxamide 65 ##STR00119## 1-[4-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]-2-pyridyl]-5-
methoxy-indazole-3- carboxamide 66 ##STR00120##
5-bromo-1-[4-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]-2- pyridyl]indazole-3- carboxamide 67
##STR00121## 1-[3-[(3R)-3-hydroxy-3-(5- methyl-1,3,4-oxadiazol-2-
yl)but-1-ynyl]phenyl] pyrazolo[3,4-b]pyridine-3- carboxamide 68
##STR00122## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6,6- dioxo-5,7-dihydro-4H-
thiopyrano[3,4-c]pyrazole- 3-carboxamide 69 ##STR00123##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5,7- dihydro-4H-pyrano[3,4-c]
pyrazole-3-carboxamide 70 ##STR00124## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6,7-
dihydro-4H-pyrano[4,3-c] pyrazole-3-carboxamide 71 ##STR00125##
6-fluoro-1-[4-[2-[(3R)-3- hydroxy-2-oxo-pyrrolidin-3-
yl]ethynyl]-2-pyridyl] indazole-3-carboxamide
72 ##STR00126## 6-fluoro-1-[4-[2-[(7R)-7- hydroxy-5,6-dihydro-
cyclopenta[b]pyridin-7-yl] ethynyl]-2-pyridyl]indazole-
3-carboxamide 73 ##STR00127## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]-5-methoxy-
phenyl]pyrazolo[3,4-b] pyridine-3-carboxamide 74 ##STR00128##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5- methoxy-pyrazolo[3,4-b]
pyridine-3-carboxamide 75 ##STR00129## 5-fluoro-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
pyrazolo[3,4-b]pyridine-3- carboxamide 76 ##STR00130##
6-chloro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[4,3-c]pyridine-3-
carboxamide 77 ##STR00131## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo
[1,5-a]pyridine-3-carboxamide 78 ##STR00132##
4-chloro-1-[4-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]-2- pyridyl]-5-methyl-pyrazole-3-
carboxamide 79 ##STR00133## 1-[4-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]-2-pyridyl]-5-
methyl-pyrazole-3- carboxamide 80 ##STR00134##
1-[4-[(3R)-3-hydroxy-3-(5- methylisoxazol-3-yl)but-1-
ynyl]-2-pyridyl]-5-methyl- pyrazole-3-carboxamide 81 ##STR00135##
5-cyclopropyl-1-[4-[2-[(3R)- 3-hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]- 2-pyridyl]pyrazole-3- carboxamide 82
##STR00136## 4-chloro-1-[4-[(3R)-3- hydroxy-3-(5-methylisoxazol-3-
yl)but-1-ynyl]-2-pyridyl]-5- methyl-pyrazole-3-carboxamide 83
##STR00137## 5-amino-1-[4-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]-2- pyridyl]pyrazole-3- carboxamide 84
##STR00138## 3-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5,6,7,8- tetrahydroimidazo[1,5-a]
pyridine-1-carboxamide 85 ##STR00139## 8-[3-[2-[(3R)-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo
[1,5-a]pyrimidine-6- carboxamide 86 ##STR00140##
7-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]imidazo [1,5-b]pyridazine-5- carboxamide 87
##STR00141## 7-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-2,3- dihydro-1H-imidazo[1,5-a]
imidazole-5-carboxamide 88 ##STR00142## 3-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo
[1,5-a]pyridine-1-carboxamide 89 ##STR00143##
4-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]thiazole- 2-carboxamide 90 ##STR00144##
7-cyano-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] imidazo[1,5-a]pyridine-3-
carboxamide 91 ##STR00145## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-7-
(trifluoromethyl)imidazo[1,5-a] pyridine-3-carboxamide 92
##STR00146## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]imidazo [1,5-a]pyrazine-3-carboxamide 93
##STR00147## 6-chloro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] imidazo[1,5-a]pyridine-3-
carboxamide 94 ##STR00148## 7-chloro-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
imidazo[1,5-a]pyridine-3- carboxamide 95 ##STR00149##
1,7-bis[3-[2-[(3R)-3-hydroxy- 1-methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl] imidazo[1,5-a]pyridine-3- carboxamide 96
##STR00150## 7-(cyclobutoxy)-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl] phenyl]imidazo[1,5-a]
pyridine-3-carboxamide 97 ##STR00151## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-7-
methoxy-imidazo[1,5-a] pyridine-3-carboxamide 98 ##STR00152##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- methoxy-imidazo[1,5-a] pyridine-3-carboxamide
99 ##STR00153## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-7-
(morpholinomethyl)imidazo [1,5-a]pyridine-3-carboxamide 100
##STR00154## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- (morpholinomethyl)imidazo
[1,5-a]pyridine-3-carboxamide 101 ##STR00155##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(1- methylpyrazol-3-yl) indazole-3-carboxamide
102 ##STR00156## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-(1-
methylpyrazol-4-yl)indazole-3- carboxamide 103 ##STR00157##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(1- methylpyrazol-3-yl)pyrazolo
[3,4-b]pyridine-3-carboxamide 104 ##STR00158##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(1- methylpyrazol-4-yl)pyrazolo
[3,4-b]pyridine-3-carboxamide 105 ##STR00159##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5- morpholino-pyrazolo[3,4-b]
pyridine-3-carboxamide 106 ##STR00160## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-(4-
methylimidazol-1-yl)indazole- 3-carboxamide 107 ##STR00161##
5-(1-acetylazetidin-3-yl)-1- [3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[3,4-b]pyridine-3-carboxamide 108 ##STR00162##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-oxo-4H- pyrazolo[4,3-b]pyridine- 3-carboxamide
109 ##STR00163## (4R)-1-[3-[2-[(3R)-3-hydroxy-
1-methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-4-
methyl-5,6-dihydro-4H- cyclopenta[c]pyrazole-3- carboxamide 110
##STR00164## (4S)-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 4-methyl-5,6-dihydro-4H-
cyclopenta[c]pyrazole-3- carboxamide 111 ##STR00165##
1-[3-cyano-5-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[3,4-b]pyridine-3-
carboxamide 112 ##STR00166## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-N5-
methyl-indazole-3,5- dicarboxamide 113 ##STR00167##
5-[1-(2-hydroxyethyl)- pyrazol-4-yl]-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo pyrrolidin-3-yl]ethynyl]phenyl]
indazole-3-carboxamide 114 ##STR00168## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[3,4-d]pyrimidine-3- carboxamide 115 ##STR00169##
1-[3-[2-[(1S)-1-hydroxy-2- oxo-cyclopentyl]ethynyl]
phenyl]indazole-3-carboxamide 116 ##STR00170##
1-[3-[2-[(3R)-1-hydroxy-2- oxo-cyclopentyl]ethynyl]
phenyl]indazole-3- carboxamide 117 ##STR00171##
1-[3-[(3R)-3-hydroxy-3-(1H- triazol-4-yl)but-1-ynyl]
phenyl]indazole-3- carboxamide 118 ##STR00172##
1-[3-[(3S)-3-hydroxy-3-(1H- triazol-4-yl)but-1-ynyl]
phenyl]indazole-3- carboxamide 119 ##STR00173##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5,6- dihydro-4H-cyclopenta[c]
pyrazole-3-carboxamide 120 ##STR00174## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
pyrimidin-4-yl-6,7-dihydro-4H- pyrazolo[4,3-c]pyridine-3-
carboxamide 121 ##STR00175## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
pyrimidin-2-yl-6,7-dihydro-4H- pyrazolo[4,3-c]pyridine-3-
carboxamide 122 ##STR00176## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
thiazol-1-yl-6,7-dihydro-4H- pyrazolo[4,3-c]pyridine-3- carboxamide
123 ##STR00177## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-[(R)-
methylsulfinyl]-6,7- dihydro-4H-pyrazolo[4,3-c]
pyridine-3-carboxamide 124 ##STR00178## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-[(S)-
methylsulfinyl]-6,7- dihydro-4H-pyrazolo[4,3-c]
pyridine-3-carboxamide 125 ##STR00179##
1-[3-[2-[(3S,4S)-3,4-dihydroxy- 1-methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl] indazole-3-carboxamide 126 ##STR00180##
1-[3-[2-[(3S,4R)-3,4-dihydroxy- 1-methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl] indazole-3-carboxamide 127 ##STR00181##
1-[3-[2-[(3R,4R)-3,4- dihydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 128
##STR00182## 1-[3-[2-[(3R,4S)-3,4- dihydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 129
##STR00183## 4-(ethylamino)-1-[3-[2-[(3- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl] phenyl]pyrazolo[4,3-c]
pyridine-3-carboxamide 130 ##STR00184## 4-(cyclopropylamino)-1-[3-
[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]pyrazolo [4,3-c]pyridine-3-carboxamide 131
##STR00185## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6-methyl- pyrazolo[4,3-c]pyridine-3- carboxamide
132 ##STR00186## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[4,3-c]pyridine-3-carboxamide 133 ##STR00187##
6-cyano-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[4,3-c]pyridine-3-
carboxamide 134 ##STR00188## 6-cyano-1-[3-[2-[(7R)-7-
hydroxy-5,6-dihydrocyclo- penta[b]pyridin-7-yl]ethynyl]
phenyl]pyrazolo[4,3-c] pyridine-3-carboxamide 135 ##STR00189##
6-cyano-1-[3-[2-[(7S)-7- hydroxy-5,6-dihydrocyclopenta
[b]pyridin-7-yl]ethynyl] phenyl]pyrazolo[4,3-c]pyridine-
3-carboxamide 136 ##STR00190## 6-ethoxy-1-[3-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
pyrazolo[4,3-c]pyridine-3- carboxamide 137 ##STR00191##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- pyrrolidin-1-yl-pyrazolo[4,3-c]
pyridine-3-carboxamide 138 ##STR00192## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-[(3R)-
3-hydroxypyrrolidin-1-yl] pyrazolo[4,3-c]pyridine-3- carboxamide
139 ##STR00193## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-[(3S)-
3-hydroxypyrrolidin-1-yl] pyrazolo[4,3-c]pyridine-3- carboxamide
140 ##STR00194## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-
methoxy-pyrazolo[4,3-c] pyridine-3-carboxamide 141 ##STR00195##
5-[[4-aminobutanoyl(methyl) amino]methyl]-1-[4-[2-[(3R)-
3-hydroxy-1-methyl-2- oxo-pyrrolidin-3-yl]ethynyl]-
2-pyridyl]indazole-3- carboxamide 142 ##STR00196##
5-[[butanoyl(methyl)amino] methyl]-1-[4-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]indazole-3-carboxamide 143 ##STR00197##
1-[3-[2-[(3S)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6-oxo-4,5- dihydropyrrolo[3,4-c]
pyrazole-3-carboxamide 144 ##STR00198## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[3,4-d]thiazole-3-carboxamide 145 ##STR00199##
1-[2-fluoro-5-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 5,6-dihydro-4H-cyclopenta[c]
pyrazole-3-carboxamide 146 ##STR00200## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-4,6- dihydrofuro[3,4-c]pyrazole-3- carboxamide
147 ##STR00201## 3-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]indazole-1-
carboxamide 148 ##STR00202## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]pyrazolo
[3,4-c]pyridine-3-carboxamide 149 ##STR00203##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5- methyl-pyrazolo[3,4-c] pyridine-3-carboxamide
150 ##STR00204## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
methoxy-pyrazolo[3,4-c] pyridine-3-carboxamide 151 ##STR00205##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-4,5,6,7- tetrahydropyrazolo[4,3-b]
pyridine-3-carboxamide 152 ##STR00206## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]-5-methyl-phenyl]
pyrazolo[3,4-b]pyridine-3- carboxamide 153 ##STR00207##
6-chloro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] pyrazolo[3,4-b]pyridine-3-
carboxamide 154 ##STR00208## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-
methoxy-pyrazolo[3,4-b] pyridine-3-carboxamide 155 ##STR00209##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- morpholino-pyrazolo[3,4-b]
pyridine-3-carboxamide 156 ##STR00210## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6-(1-
methylpyrazol-4-yl)pyrazolo [3,4-b]pyridine-3-carboxamide 157
##STR00211## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- methyl-pyrazolo[3,4-d]
pyrimidine-3-carboxamide 158 ##STR00212##
6-cyclopropyl-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]pyrazolo[3,4-d]
pyrimidine-3-carboxamide 159 ##STR00213##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- (trifluoromethyl)pyrazolo
[3,4-d]pyrimidine-3- carboxamide 160 ##STR00214##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6- methoxy-pyrazolo[3,4-d]
pyrimidine-3-carboxamide 161 ##STR00215##
5-[2-(azetidin-1-yl)ethoxy]- 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]indazole-3-
carboxamide 162 ##STR00216## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-(2-
morpholinoethoxy)indazole-3- carboxamide 163 ##STR00217##
1-[3-[4-(dimethylamino)-3- hydroxy-4-oxo-but-1-ynyl]
phenyl]indazole-3-carboxamide 164 ##STR00218##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]pyrazolo [4,3-b]pyridine-3-carboxamide 165
##STR00219## ethyl 3-carbamoyl-1-[4-[2-[(3R)-
3-hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]-2-
pyridyl]-6,7-dihydro-4H- pyrazolo[4,3-c]pyridine-5- carboxylate 166
##STR00220## 1-[2-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]-4-pyridyl]-4,5,6,7- tetrahydroindazole-3- carboxamide
167 ##STR00221## 1-[4-cyano-3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 4,5,6,7-tetrahydroindazole-
3-carboxamide 168 ##STR00222## (6S)-6-hydroxy-1-[3-[2-[(3R)-
3-hydroxy-1-methyl-2- oxo-pyrrolidin-3-yl]ethynyl]
phenyl]-5,6-dihydro-4H- cyclopenta[c]pyrazole-3- carboxamide 169
##STR00223## (6R)-6-hydroxy-1-[3-[2-[(3R)- 3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl] phenyl]-5,6-dihydro-4H-
cyclopenta[c]pyrazole-3- carboxamide 170 ##STR00224##
1-[3-[(3R)-3-hydroxy-3- thiazol-2-yl-but-1-ynyl]phenyl]
indazole-3-carboxamide 171 ##STR00225## 1-[3-[2-[(3R)-3-hydroxy-2-
oxo-tetrahydrofuran-3-yl] ethynyl]phenyl]indazole-3- carboxamide
172 ##STR00226## 1-[3-[2-[(3S)-3-hydroxy-2-
oxo-tetrahydrofuran-3-yl] ethynyl]phenyl]indazole-3- carboxamide
173 ##STR00227## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
methoxy-pyrazolo[3,4-c] pyridazine-3-carboxamide 174 ##STR00228##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]pyrazolo [3,4-c]pyridazine-3- carboxamide 175
##STR00229## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-6-methyl- pyrazolo[3,4-b]pyridine-3- carboxamide
176 ##STR00230## 7-fluoro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 177
##STR00231## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5,6,7,8- tetrahydroimidazo[1,5-a]
pyridine-3-carboxamide 178 ##STR00232## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo
[1,5-a]pyridine-3,7- dicarboxamide 179 ##STR00233##
3-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]imidazo [1,5-a]pyridine-1,6- dicarboxamide 180
##STR00234## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-oxo-6,7- dihydro-4H-pyrazolo[4,3-b]
pyridine-3-carboxamide 181 ##STR00235## 1-[3-[(3R)-3-hydroxy-3-(5-
methyl-1,3,4-oxadiazol-2- yl)but-1-ynyl]phenyl]-7-
methoxy-imidazo[1,5-a] pyridine-3-carboxamide 182 ##STR00236##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(1H- imidazol-2-yl)indazole-3- carboxamide 183
##STR00237## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-(3- methoxyazetidin-1-yl)pyrazolo
[3,4-b]pyridine-3-carboxamide 184 ##STR00238##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-N5,N5- dimethyl-indazole-3,5- dicarboxamide 185
##STR00239## 6-chloro-1-[3-[(3R)-3- hydroxy-3-(5-methyl-1,3,4-
oxadiazol-2-yl)but-1-ynyl] phenyl]imidazo[1,5-a]pyridine-
3-carboxamide 186 ##STR00240## 6-chloro-1-[2-fluoro-5-[2-
[(3R)-3-hydroxy-1-methyl-2- oxo-pyrrolidin-3-yl]ethynyl]
phenyl]imidazo[1,5-a] pyridine-3-carboxamide 187 ##STR00241##
7-chloro-1-[3-[(3R)-3- hydroxy-3-(5-methyl-1,3,4-
oxadiazol-2-yl)but-1-ynyl] phenyl]imidazo[1,5-a]pyridine-
3-carboxamide 188 ##STR00242## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-5-
methyl-5,6-dihydro-4H- cyclopenta[c]pyrazole-3- carboxamide 189
##STR00243## 6-fluoro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl] indazole-3-carboxamide 190
##STR00244## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]pyrazolo [3,4-d]pyridazine-3- carboxamide 191
##STR00245## 1-[2-fluoro-5-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 4,6-dihydrofuran[3,4-c]
pyrazole-3-carboxamide 192 ##STR00246## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]-6,7-
dihydro-5H-pyrrolo[1,2-c] imidazole-1-carboxamide 193 ##STR00247##
(5S)-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 5-methyl-5,6-dihydro-4H-
cyclopenta[c]pyrazole-3- carboxamide 194 ##STR00248##
(5R)-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl]phenyl]- 5-methyl-5,6-dihydro-4H-
cyclopenta[c]pyrazole-3- carboxamide 195 ##STR00249##
5-amino-2-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-
pyrrolidin-3-yl]ethynyl] phenyl]thiazole-4-carboxamide 196
##STR00250## 1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5- (methylamino)pyrazolo[3,4-d]
thiazole-3-carboxamide 197 ##STR00251## 2-[2-fluoro-5-[2-[(3R)-3-
hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]phenyl]
5-methyl-thiazole-4- carboxamide 198 ##STR00252##
1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-4,5,6,7- tetrahydropyrazolo[3,4-b]
pyridine-3-carboxamide 199 ##STR00253## 5,5-difluoro-1-[3-[2-[(3R)-
3-hydroxy-1-methyl-2-oxo- pyrrolidin-3-yl]ethynyl]
phenyl]-4,6-dihydrocyclo- penta[c]pyrazole-3- carboxamide
[0239] In some embodiments, the invention provides a compound of
Examples A-R8 below.
Synthesis of NIK Inhibitors
[0240] Methods for preparing intermediates and compounds of the
present invention are presented in the Examples section below.
Those skilled in the art will appreciate that other synthetic
routes may be used to synthesize the inventive compounds. Although
specific starting materials and reagents are depicted in the
Schemes and discussed below, other starting materials and reagents
can be easily substituted to provide a variety of derivatives or
reaction conditions. In addition, many of the compounds prepared by
the methods described below can be further modified in light of
this disclosure using conventional chemistry well known to those
skilled in the art.
[0241] The starting materials are generally available from
commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or
are readily prepared using methods well known to those skilled in
the art (e.g., prepared by methods generally described in Louis F.
Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-23,
Wiley, N.Y. (1967-2006 ed.), or Beilstein's Handbuch der
organishcen chemie, 4, Aufl. Ed. Springer-Verlag, Berlin including
supplements also included via the Beilstein online database.
[0242] In preparing compounds of Formula (0), protection of remote
functionality (e.g., primary or secondary amine) of intermediates
may be necessary. The need for such protection will vary depending
on the nature of the remote functionality and the conditions of the
preparation methods. The need for such protection is readily
determined by one skilled in the art. Exemplary protecting groups
are provided herein. For a general description of protecting groups
and their use, see T. W. Greene, Protective Groups in Organic
Synthesis, John Wiley & Sons, New York, 1991.
[0243] Diastereomeric mixtures can be separated into their
individual diastereoisomers on the basis of their physical chemical
differences by methods well known to those skilled in the art, such
as by chromatography or fractional crystallization. Enantiomers can
be separated by converting the enantiomeric mixture into a
diastereomeric mixture by reaction with an appropriate optically
active compound (e.g., chiral auxiliary such as a chiral alcohol or
Mosher's acid chloride), separating the diastereoisomers and
converting (e.g., hydrolyzing) the individual diastereoisomers to
the corresponding pure enantiomers. Also, some of the compounds of
the present invention may be atropisomers (e.g., substituted
biaryls) and are considered as part of this invention. Enantiomers
can also be separated by use of a chiral HPLC column or
supercritical fluid chromatography.
[0244] A single stereoisomer, e.g., an enantiomer, substantially
free of its stereoisomer may be obtained by resolution of the
racemic mixture using a method such as formation of diastereomers
using optically active resolving agents (Eliel, E. and Wilen, S.,
Stereochemistry of Organic Compounds, John Wiley & Sons, Inc.,
New York, 1994; Lochmuller, C. H., J. Chromatogr., 113(3):283-302
(1975)). Racemic mixtures of chiral compounds of the invention can
be separated and isolated by any suitable method, including: (1)
formation of ionic, diastereomeric salts with chiral compounds and
separation by fractional crystallization or other methods, (2)
formation of diastereomeric compounds with chiral derivatizing
reagents, separation of the diastereomers, and conversion to the
pure stereoisomers, and (3) separation of the substantially pure or
enriched stereoisomers directly under chiral conditions. See: Drug
Stereochemistry, Analytical Methods and Pharmacology, Irving W.
Wainer, Ed., Marcel Dekker, Inc., New York (1993).
[0245] Diastereomeric salts can be formed by reaction of
enantiomerically pure chiral bases such as brucine, quinine,
ephedrine, strychnine, .alpha.-methyl-.beta.-phenylethylamine
(amphetamine), and the like with asymmetric compounds bearing
acidic functionality, such as carboxylic acid and sulfonic acid.
The diastereomeric salts may be induced to separate by fractional
crystallization or ionic chromatography. For separation of the
optical isomers of amino compounds, addition of chiral carboxylic
or sulfonic acids, such as camphorsulfonic acid, tartaric acid,
mandelic acid, or lactic acid can result in formation of the
diastereomeric salts.
[0246] Alternatively, the substrate to be resolved is reacted with
one enantiomer of a chiral compound to form a diastereomeric pair
(Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds,
John Wiley & Sons, Inc., New York, 1994, p. 322).
Diastereomeric compounds can be formed by reacting asymmetric
compounds with enantiomerically pure chiral derivatizing reagents,
such as menthyl derivatives, followed by separation of the
diastereomers and hydrolysis to yield the pure or enriched
enantiomer. A method of determining optical purity involves making
chiral esters, such as a menthyl ester, e.g., (-) menthyl
chloroformate in the presence of base, or Mosher ester,
.alpha.-methoxy-.alpha.-(trifluoromethyl)phenyl acetate (Jacob, J.
Org. Chem. 47:4165 (1982)), of the racemic mixture, and analyzing
the NMR spectrum for the presence of the two atropisomeric
enantiomers or diastereomers. Stable diastereomers of atropisomeric
compounds can be separated and isolated by normal- and
reverse-phase chromatography following methods for separation of
atropisomeric naphthyl-isoquinolines (WO 96/15111). By method (3),
a racemic mixture of two enantiomers can be separated by
chromatography using a chiral stationary phase (Chiral Liquid
Chromatography W. J. Lough, Ed., Chapman and Hall, New York,
(1989); Okamoto, J. of Chromatogr. 513:375-378 (1990)). Enriched or
purified enantiomers can be distinguished by methods used to
distinguish other chiral molecules with asymmetric carbon atoms,
such as optical rotation and circular dichroism. The absolute
stereochemistry of chiral centers and enantiomers can be determined
by x-ray crystallography.
[0247] Positional isomers, for example E and Z forms, of compounds
of Formula I and intermediates for their synthesis, may be observed
by characterization methods such as NMR and analytical HPLC. For
certain compounds where the energy barrier for interconversion is
sufficiently high, the E and Z isomers may be separated, for
example by preparatory HPLC.
[0248] Pharmaceutical Compositions and Administration
[0249] The compounds with which the invention is concerned are NIK
kinase inhibitors, and are useful in the treatment of several
diseases, for example, cancer or inflammatory conditions.
[0250] The invention also provides for compositions and medicaments
comprising a compound of Formula (0) and at least one
pharmaceutically acceptable carrier, diluent or excipient. The
compositions of the invention can be used for inhibiting NF-kB
signaling activity in mammals (e.g, human patients), by for
example, inhibiting NIK activity.
[0251] By "pharmaceutically acceptable" it is meant the carrier,
diluent or excipient must be compatible with the other ingredients
of the formulation and not deleterious to the recipient
thereof.
[0252] In one embodiment, the invention provides for pharmaceutical
compositions (or medicaments) comprising a compound of Formula (0)
and a pharmaceutically acceptable carrier, diluent or excipient. In
another embodiment, the invention provides for preparing
compositions (or medicaments) comprising compounds of the
invention. In another embodiment, the invention provides for
administering compounds of Formula (0) and compositions comprising
compounds of Formula (0) to a mammal (e.g., a human patient) in
need thereof.
[0253] Compositions are formulated, dosed, and administered in a
fashion consistent with good medical practice. Factors for
consideration in this context include the particular disorder being
treated, the particular mammal being treated, the clinical
condition of the individual patient, the cause of the disorder, the
site of delivery of the agent, the method of administration, the
scheduling of administration, and other factors known to medical
practitioners. The effective amount of the compound to be
administered will be governed by such considerations, and is the
minimum amount necessary to inhibit NIK activity as required to
prevent or treat the undesired disease or disorder, such as for
example, neurodegeneration, amyloidosis, formation of
neurofibrillary tangles, or undesired cell growth (e.g., cancer
cell growth). For example, such amount may be below the amount that
is toxic to normal cells, or the mammal as a whole.
[0254] In one example, the therapeutically effective amount of the
compound of the invention administered parenterally per dose will
be in the range of about 0.01-100 mg/kg, alternatively about e.g.,
0.1 to 20 mg/kg of patient body weight per day, such as 0.3 to 15
mg/kg/day. The daily does is, in certain embodiments, given as a
single daily dose or in divided doses two to six times a day, or in
sustained release form. In the case of a 70 kg adult human, the
total daily dose will generally be from about 7 mg to about 1,400
mg. This dosage regimen may be adjusted to provide the optimal
therapeutic response. The compounds may be administered on a
regimen of 1 to 4 times per day, preferably once or twice per
day.
[0255] The compounds of the present invention may be administered
in any convenient administrative form, e.g., tablets, powders,
capsules, solutions, dispersions, suspensions, syrups, sprays,
suppositories, gels, emulsions, patches, etc. Such compositions may
contain components conventional in pharmaceutical preparations,
e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents,
and further active agents.
[0256] The compounds of the invention may be administered by any
suitable means, including oral, topical (including buccal and
sublingual), rectal, vaginal, transdermal, parenteral,
subcutaneous, intraperitoneal, intrapulmonary, intradermal,
intrathecal and epidural and intranasal, and, if desired for local
treatment, intralesional administration. Parenteral infusions
include intramuscular, intravenous, intraarterial, intraperitoneal,
or subcutaneous administration.
[0257] The compositions comprising compounds of Formula (0) are
normally formulated in accordance with standard pharmaceutical
practice as a pharmaceutical composition. A typical formulation is
prepared by mixing a compound of the present invention and a
diluent, carrier or excipient. Suitable diluents, carriers and
excipients are well known to those skilled in the art and are
described in detail in, e.g., Ansel, Howard C., et al., Ansel's
Pharmaceutical Dosage Forms and Drug Delivery Systems.
Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro,
Alfonso R., et al. Remington: The Science and Practice of Pharmacy.
Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe,
Raymond C. Handbook of Pharmaceutical Excipients. Chicago,
Pharmaceutical Press, 2005. The formulations may also include one
or more buffers, stabilizing agents, surfactants, wetting agents,
lubricating agents, emulsifiers, suspending agents, preservatives,
antioxidants, opaquing agents, glidants, processing aids,
colorants, sweeteners, perfuming agents, flavoring agents, diluents
and other known additives to provide an elegant presentation of the
drug (i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament).
[0258] Suitable carriers, diluents and excipients are well known to
those skilled in the art and include materials such as
carbohydrates, waxes, water soluble or swellable polymers,
hydrophilic or hydrophobic materials, gelatin, oils, solvents,
water and the like. The particular carrier, diluent or excipient
used will depend upon the means and purpose for which a compound of
the present invention is being applied. Solvents are generally
selected based on solvents recognized by persons skilled in the art
as safe (GRAS) to be administered to a mammal. In general, safe
solvents are non-toxic aqueous solvents such as water and other
non-toxic solvents that are soluble or miscible in water. Suitable
aqueous solvents include water, ethanol, propylene glycol,
polyethylene glycols (e.g., PEG 400, PEG 300), etc. and mixtures
thereof. The formulations can also include one or more buffers,
stabilizing agents, surfactants, wetting agents, lubricating
agents, emulsifiers, suspending agents, preservatives,
antioxidants, opaquing agents, glidants, processing aids,
colorants, sweeteners, perfuming agents, flavoring agents and other
known additives to provide an elegant presentation of the drug
(i.e., a compound of the present invention or pharmaceutical
composition thereof) or aid in the manufacturing of the
pharmaceutical product (i.e., medicament).
[0259] Acceptable diluents, carriers, excipients and stabilizers
are nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate and other
organic acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g., Zn-protein complexes); or non-ionic
surfactants such as TWEEN.TM., PLURONICS.TM. or polyethylene glycol
(PEG). A active pharmaceutical ingredient of the invention (e.g.,
compound of Formula (0)) can also be entrapped in microcapsules
prepared, for example, by coacervation techniques or by interfacial
polymerization, for example, hydroxymethylcellulose or
gelatin-microcapsules and poly-(methylmethacrylate) microcapsules,
respectively, in colloidal drug delivery systems (for example,
liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in macroemulsions. Such techniques are disclosed
in Remington: The Science and Practice of Pharmacy: Remington the
Science and Practice of Pharmacy (2005) 21.sup.st Edition,
Lippincott Williams & Wilkins, Philidelphia, Pa.
[0260] Sustained-release preparations of a compound of the
invention can be prepared. Suitable examples of sustained-release
preparations include semipermeable matrices of solid hydrophobic
polymers containing a compound of Formula (0), which matrices are
in the form of shaped articles, e.g., films, or microcapsules.
Examples of sustained-release matrices include polyesters,
hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or
poly(vinyl alcohol)), polylactides (U.S. Pat. No. 3,773,919),
copolymers of L-glutamic acid and gamma-ethyl-L-glutamate,
non-degradable ethylene-vinyl acetate, degradable lactic
acid-glycolic acid copolymers such as the LUPRON DEPOT.TM.
(injectable microspheres composed of lactic acid-glycolic acid
copolymer and leuprolide acetate) and poly-D-(-)-3-hydroxybutyric
acid.
[0261] The formulations include those suitable for the
administration routes detailed herein. The formulations can
conveniently be presented in unit dosage form and can be prepared
by any of the methods well known in the art of pharmacy. Techniques
and formulations generally are found in Remington: The Science and
Practice of Pharmacy: Remington the Science and Practice of
Pharmacy (2005) 21.sup.st Edition, Lippincott Williams &
Wilkins, Philidelphia, Pa. Such methods include the step of
bringing into association the active ingredient with the carrier
which constitutes one or more accessory ingredients.
[0262] In general the formulations are prepared by uniformly and
intimately bringing into association the active ingredient with
liquid carriers, diluents or excipients or finely divided solid
carriers, diluents or excipients, or both, and then, if necessary,
shaping the product. A typical formulation is prepared by mixing a
compound of the present invention and a carrier, diluent or
excipient. The formulations can be prepared using conventional
dissolution and mixing procedures. For example, the bulk drug
substance (i.e., compound of the present invention or stabilized
form of the compound (e.g., complex with a cyclodextrin derivative
or other known complexation agent) is dissolved in a suitable
solvent in the presence of one or more of the excipients described
above. A compound of the present invention is typically formulated
into pharmaceutical dosage forms to provide an easily controllable
dosage of the drug and to enable patient compliance with the
prescribed regimen.
[0263] In one example, compounds of Formula (0) may be formulated
by mixing at ambient temperature at the appropriate pH, and at the
desired degree of purity, with physiologically acceptable carriers.
The pH of the formulation depends mainly on the particular use and
the concentration of compound, but typically ranges anywhere from
about 3 to about 8. In one example, a compound of Formula (0) is
formulated in an acetate buffer, at pH 5. In another embodiment,
the compounds of Formula (0) are sterile. The compound may be
stored, for example, as a solid or amorphous composition, as a
lyophilized formulation or as an aqueous solution.
[0264] Formulations of a compound of the invention suitable for
oral administration can be prepared as discrete units such as
pills, capsules, cachets or tablets each containing a predetermined
amount of a compound of the invention.
[0265] Compressed tablets can be prepared by compressing in a
suitable machine the active ingredient in a free-flowing form such
as a powder or granules, optionally mixed with a binder, lubricant,
inert diluent, preservative, surface active or dispersing agent.
Molded tablets can be made by molding in a suitable machine a
mixture of the powdered active ingredient moistened with an inert
liquid diluent. The tablets can optionally be coated or scored and
optionally are formulated so as to provide slow or controlled
release of the active ingredient therefrom.
[0266] Tablets, troches, lozenges, aqueous or oil suspensions,
dispersible powders or granules, emulsions, hard or soft capsules,
e.g., gelatin capsules, syrups or elixirs can be prepared for oral
use. Formulations of a compound of the invention intended for oral
use can be prepared according to any method known to the art for
the manufacture of pharmaceutical compositions and such
compositions can contain one or more agents including sweetening
agents, flavoring agents, coloring agents and preserving agents, in
order to provide a palatable preparation. Tablets containing the
active ingredient in admixture with non-toxic pharmaceutically
acceptable excipient which are suitable for manufacture of tablets
are acceptable. These excipients can be, for example, inert
diluents, such as calcium or sodium carbonate, lactose, calcium or
sodium phosphate; granulating and disintegrating agents, such as
maize starch, or alginic acid; binding agents, such as starch,
gelatin or acacia; and lubricating agents, such as magnesium
stearate, stearic acid or talc. Tablets can be uncoated or can be
coated by known techniques including microencapsulation to delay
disintegration and adsorption in the gastrointestinal tract and
thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or
glyceryl distearate alone or with a wax can be employed.
[0267] An example of a suitable oral administration form is a
tablet containing about 1 mg, 5 mg, 10 mg, 25 mg, 30 mg, 50 mg, 80
mg, 100 mg, 150 mg, 250 mg, 300 mg and 500 mg of the compound of
the invention, or any range derivable therein, compounded with
about 5-30 mg anhydrous lactose, about 5-40 mg sodium
croscarmellose, about 5-30 mg polyvinylpyrrolidone (PVP) K30, and
about 1-10 mg magnesium stearate. The powdered ingredients are
first mixed together and then mixed with a solution of the PVP. The
resulting composition can be dried, granulated, mixed with the
magnesium stearate and compressed to tablet form using conventional
equipment. An example of an aerosol formulation can be prepared by
dissolving the compound, for example 5-400 mg, of the invention in
a suitable buffer solution, e.g. a phosphate buffer, adding a
tonicifier, e.g. a salt such sodium chloride, if desired. The
solution may be filtered, e.g., using a 0.2 micron filter, to
remove impurities and contaminants.
[0268] For treatment of the eye or other external tissues, e.g.,
mouth and skin, the formulations are preferably applied as a
topical ointment or cream containing the active ingredient(s) in an
amount of, for example, 0.075 to 20% w/w. When formulated in an
ointment, the active ingredient can be employed with either a
paraffinic or a water-miscible ointment base. Alternatively, the
active ingredients can be formulated in a cream with an
oil-in-water cream base.
[0269] If desired, the aqueous phase of the cream base can include
a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl
groups such as propylene glycol, butane 1,3-diol, mannitol,
sorbitol, glycerol and polyethylene glycol (including PEG 400) and
mixtures thereof. The topical formulations can desirably include a
compound which enhances absorption or penetration of the active
ingredient through the skin or other affected areas. Examples of
such dermal penetration enhancers include dimethyl sulfoxide and
related analogs.
[0270] The oily phase of the emulsions of this invention can be
constituted from known ingredients in a known manner. While the
phase can comprise merely an emulsifier, it desirably comprises a
mixture of at least one emulsifier with a fat or an oil or with
both a fat and an oil. Preferably, a hydrophilic emulsifier is
included together with a lipophilic emulsifier which acts as a
stabilizer. It is also preferred to include both an oil and a fat.
Together, the emulsifier(s) with or without stabilizer(s) make up
the so-called emulsifying wax, and the wax together with the oil
and fat make up the so-called emulsifying ointment base which forms
the oily dispersed phase of the cream formulations. Emulsifiers and
emulsion stabilizers suitable for use in the formulation of the
invention include Tween.RTM. 60, Span.RTM. 80, cetostearyl alcohol,
benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium
lauryl sulfate.
[0271] Aqueous suspensions of a compound of the invention contain
the active materials in admixture with excipients suitable for the
manufacture of aqueous suspensions. Such excipients include a
suspending agent, such as sodium carboxymethylcellulose,
croscarmellose, povidone, methylcellulose, hydroxypropyl
methylcellulose, sodium alginate, polyvinylpyrrolidone, gum
tragacanth and gum acacia, and dispersing or wetting agents such as
a naturally occurring phosphatide (e.g., lecithin), a condensation
product of an alkylene oxide with a fatty acid (e.g.,
polyoxyethylene stearate), a condensation product of ethylene oxide
with a long chain aliphatic alcohol (e.g.,
heptadecaethyleneoxycetanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous
suspension can also contain one or more preservatives such as ethyl
or n-propyl p-hydroxybenzoate, one or more coloring agents, one or
more flavoring agents and one or more sweetening agents, such as
sucrose or saccharin.
[0272] Formulations of a compound of the invention can be in the
form of a sterile injectable preparation, such as a sterile
injectable aqueous or oleaginous suspension. This suspension can be
formulated according to the known art using those suitable
dispersing or wetting agents and suspending agents which have been
mentioned above. The sterile injectable preparation can also be a
sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent, such as a solution in
1,3-butanediol or prepared as a lyophilized powder. Among the
acceptable vehicles and solvents that can be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile fixed oils can conventionally be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
can be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid can likewise be used in
the preparation of injectables.
[0273] The amount of active ingredient that can be combined with
the carrier material to produce a single dosage form will vary
depending upon the host treated and the particular mode of
administration. For example, a time-release formulation intended
for oral administration to humans can contain approximately 1 to
1000 mg of active material compounded with an appropriate and
convenient amount of carrier material which can vary from about 5
to about 95% of the total compositions (weight:weight). The
pharmaceutical composition can be prepared to provide easily
measurable amounts for administration. For example, an aqueous
solution intended for intravenous infusion can contain from about 3
to 500 .mu.g of the active ingredient per milliliter of solution in
order that infusion of a suitable volume at a rate of about 30
mL/hr can occur.
[0274] Formulations suitable for parenteral administration include
aqueous and non-aqueous sterile injection solutions which can
contain anti-oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
can include suspending agents and thickening agents.
[0275] Formulations suitable for topical administration to the eye
also include eye drops wherein the active ingredient is dissolved
or suspended in a suitable carrier, especially an aqueous solvent
for the active ingredient. The active ingredient is preferably
present in such formulations in a concentration of about 0.5 to 20%
w/w, for example about 0.5 to 10% w/w, for example about 1.5%
w/w.
[0276] Formulations suitable for topical administration in the
mouth include lozenges comprising the active ingredient in a
flavored basis, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert basis such as gelatin
and glycerin, or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[0277] Formulations for rectal administration can be presented as a
suppository with a suitable base comprising for example cocoa
butter or a salicylate.
[0278] Formulations suitable for intrapulmonary or nasal
administration have a particle size for example in the range of 0.1
to 500 microns (including particle sizes in a range between 0.1 and
500 microns in increments microns such as 0.5, 1, 30 microns, 35
microns, etc.), which is administered by rapid inhalation through
the nasal passage or by inhalation through the mouth so as to reach
the alveolar sacs. Suitable formulations include aqueous or oily
solutions of the active ingredient. Formulations suitable for
aerosol or dry powder administration can be prepared according to
conventional methods and can be delivered with other therapeutic
agents such as compounds heretofore used in the treatment of
disorders as described below.
[0279] Formulations suitable for vaginal administration can be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient
such carriers as are known in the art to be appropriate.
[0280] The formulations can be packaged in unit-dose or multi-dose
containers, for example sealed ampoules and vials, and can be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water, for
injection immediately prior to use. Extemporaneous injection
solutions and suspensions are prepared from sterile powders,
granules and tablets of the kind previously described. Preferred
unit dosage formulations are those containing a daily dose or unit
daily sub-dose, as herein above recited, or an appropriate fraction
thereof, of the active ingredient.
[0281] Indications and Methods of Treatment
[0282] The compounds of Formula (0) inhibit the activity of NIK.
Accordingly, in another aspect of the invention the compounds of
the invention can be used for the treatment of diseases and
disorders in a mammal, for example a human patient, in which the
inhibition of NIK in the patient would be therapeutically
effective. For example, the compounds of the invention are useful
for the treatment of diseases or disorders in a mammal (e.g., a
human patient) associated with overactive or undesired NF-kB
signaling through, for example, the overactivation of NIK. In one
embodiment, the compounds of the invention are used to inhibit the
activity of NIK, for example in an in vitro assay setting, by
contacting said compound of Formula (0) with NIK. For example,
compounds of Formula (0) can be used as a control compound in an in
vitro assay setting.
[0283] In another embodiment, the compounds of the invention are
used to inhibit the undesired signaling of NF-kB, e.g. in an cell
proliferation assay, by introducing into a cell a compound of
Formula (0). In another embodiment, the present invention provides
the treatment of diseases or disorders in a mammal (e.g., human
patient) associated with overactive or undesired NF-kB signaling
(e.g., cancer, inflammatory diseases, among others) said method
comprising administering to a mammal (e.g., a human patient) in
need thereof a therapeutically effective amount of a compound of
the invention.
[0284] Diseases and disorders treatable according to the methods of
this invention include, cancer, inflammatory conditions, autoimmune
disease and proliferation induced after medical procedures (e.g.,
arthritis, graft rejection, inflammatory bowel disease, cell
proliferation induced after surgery angioplasty, among others). In
one embodiment, a mammal (e.g., a human patient) is treated with a
compound of the invention and a pharmaceutically acceptable
carrier, adjuvant, or vehicle, wherein said compound of the
invention is present in an amount to inhibit NF-kB signaling
through, for example, but not limited to, inhibition of NIK.
[0285] In one embodiment, a compound of the invention can be used
in the treatment of cell proliferative disorders.
[0286] In one embodiment of the invention, cancers that may be
treated by the compounds of Formula (0) are selected from the group
consisting of Lung (brochogenic carcinoma (non-small cell lung);
Gastrointestinal--rectal, colorectal and colon; Genitourinary
tract--kidney (papillary renal cell carcinoma); and skin--head and
neck squamous cell carcinoma.
[0287] In one embodiment, compounds of Formula (0) can be use for
the treatment of a cancer selected from the group consisting of
head and neck squamous cell carcinomas, histiocytic lymphoma, lung
adenocarcinoma, small cell lung cancer, non-small cell lung cancer,
pancreatic cancer, papillary renal cell carcinoma, liver cancer,
gastric cancers, colon cancer, leukemias, lymphomas, multiple
myeloma, glioblastomas and breast carcinoma.
[0288] In one embodiment, compounds of Formula (0) can be used for
the treatment of a cancer selected from the group consisting of
histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer,
pancreatic cancer, liver cancer, gastric cancer, colon cancer,
leukemias, lymphomas, multiple myeloma, glioblastomas and breast
carcinoma.
[0289] In one embodiment, compound of Formula (0) can be used for
the treatment of cancer selected from the group consisting of
lymphomas, leukemias and multiple myeloma.
[0290] In one embodiment, the invention provides for the
preparation of a medicament comprising a compound of Formula (0)
for the treatment of lymphoma, leukemia or multiple myeloma.
[0291] In one embodiment, the invention provides for the treatment
of lymphoma, leukemia or multiple myeloma, which method comprises
administering an effective amount of a compound of Formula (0).
[0292] In one embodiment, compounds of the invention are useful for
the treatment of inflammatory diseases and conditions including,
but not limited to, lupus (including systemic lupus erythematosus,
extra-renal lupus and lupus nephritis), asthma, COPD, rhinitis,
multiple sclerosis, IBD, arthritis, gastritis, rheumatoid
arthritis, dermatitis, endometriosis, transplant rejection, cardiac
infarction, Alzheimer's diseases, diabetes Type II, inflammatory
bowel disease, sepsis, and artherosclerosis.
[0293] In one embodiment, the invention provides for the use of a
compound of Formula (0) for the treatment of an inflammatory
condition.
[0294] In one embodiment, the invention provided for the use of a
compound of Formula (0) for the preparation of a medicament for the
treatment of an inflammatory condition.
[0295] In one embodiment, the invention provides for a compound of
Formula (0) for the treatment of an inflammatory condition.
[0296] In one embodiment, the invention provides for a method for
the treatment of an inflammatory condition, which method comprises
administering an effective amount of a compound of Formula (0) to a
patient in need thereof.
[0297] In one embodiment, the invention provides for the treatment
of an inflammatory condition selected from the group consisting of
lupus (including systemic lupus erythematosus, extra-renal lupus
and lupus nephritis), COPD, rhinitis, multiple sclerosis, IBD,
arthritis, rheumatoid arthritis, dermatitis, endometriosis and
transplant rejection, which method comprises administering an
effective amount of a compound of Formula (0).
[0298] Combinations
[0299] The compounds of Formula (0) may be employed alone or in
combination with other therapeutic agents for treatment. In one
embodiment, compounds of this invention may be employed alone or in
combination with chemotherapeutic agents. In one embodiment,
compounds of this invention may be employed alone or in combination
with anti-inflammatory agents. The compounds of the present
invention can be used in combination with one or more additional
drugs, for example an anti-inflammatory compound or anti-cancer
compounds, that work by a different mechanism of action. The second
compound of the pharmaceutical combination formulation or dosing
regimen preferably has complementary activities to the compound of
this invention such that they do not adversely affect each other.
Such molecules are suitably present in combination in amounts that
are effective for the purpose intended. The compounds may be
administered together in a unitary pharmaceutical composition or
separately and, when administered separately this may occur
simultaneously or sequentially in any order. Such sequential
administration may be close in time or remote in time.
[0300] In certain embodiments, a compound of Formula (0) is
combined in a pharmaceutical combination formulation, or dosing
regimen as combination therapy, with a second therapeutic compound
that has anti-inflammatory or anti-cancer properties or that is
useful for treating an inflammation, immune-response disorder, or
hyperproliferative disorder (e.g., cancer). The second therapeutic
agent may be a NSAID (Non-Steroidal Anti-Inflammatory Drug) or
other anti-inflammatory agent. The second therapeutic agent may be
a chemotherapeutic agent. In one embodiment, a pharmaceutical
composition of this invention comprises a compound of Formula (0)
in combination with a therapeutic agent such as an NSAID.
EXAMPLES
[0301] The invention will be more fully understood by reference to
the following examples. They should not, however, be construed as
limiting the scope of the invention. These examples are not
intended to limit the scope of the present invention, but rather to
provide guidance to a skilled artisan to prepare and use the
compounds, compositions, and methods of the present invention.
While particular embodiments of the present invention are
described, the skilled artisan will appreciate that various changes
and modifications can be made without departing from the spirit and
scope of the invention.
[0302] The chemical reactions in the Examples described can be
readily adapted to prepare a number of other compounds of the
invention, and alternative methods for preparing the compounds of
this invention are deemed to be within the scope of this invention.
For example, the synthesis of non-exemplified compounds according
to the invention can be successfully performed by modifications
apparent to those skilled in the art, e.g., by appropriately
protecting interfering groups, by utilizing other suitable reagents
known in the art other than those described, or by making routine
modifications of reaction conditions. Alternatively, other
reactions disclosed herein or known in the art will be recognized
as having applicability for preparing other compounds of the
invention.
[0303] Intermediates and compounds of the invention can be
synthesized according to Schemes A-AA presented below, in which, R,
R', R'', R.sub.1 and R.sub.2 at each occurrence independently
represents generally a non-interfering substituent (unless
otherwise a specific substituent is specified in the description of
the scheme); the symbol Ar at each occurrence represents
independently an aromatic group; the symbol Het at each occurrence
represents independently a heteroaryl group; and the symbol X at
each occurrence represents independently any halogen (unless
otherwise a specific halogen is specified in the description of the
scheme).
General Procedure A: SNAr
##STR00254##
[0305] To a solution of nitrogen-containing nucleophile (1 eq.) and
cesium carbonate (3.0 eq.) in N,N-dimethylformamide (2 mL/mmol) was
added 2-haloheterocycle (1.1 eq.). The reaction was heated to
100.degree. C. and stirred at this temperature for 2 hours. The
reaction was then cooled to room temperature and acidified to pH=1
with 10% aqueous HCl solution if product contains a carboxylic
acid, or diluted with water if neutral. The solution was extracted
with twice with dichloromethane. The organic layers were combined,
dried with sodium sulfate and concentrated under vacuum. The crude
material was either used directly in subsequent reactions or
purified by flash chromatography.
General Procedure B: Amide Synthesis from Heterocyclic Carboxylic
Acids
##STR00255##
[0307] Aromatic or non-aromatic heterocyclic acid (1 eq) and HATU
(1.2 eq) were weighed out and transferred to a vial to which DMF
and DIPEA (3-5 eq) were subsequently added. The amine (HNRR) was
added to the reaction mixture as a free base or HCl salt after a
short period and the reaction was stirred at room temperature or at
50.degree. C. for 2-18 hours. Reaction conversion was monitored by
LCMS. Upon completion, the reaction was cooled and the crude
product was triterated via addition of water and collected by
filtration or extracted with sat ammonium chloride and DCM.
Trituration or purification by chromatography gave the amide.
General Procedure C: Chan-Lam Cross-Coupling
##STR00256##
[0309] To a small vial was added the nitrogen-containing
nucleophile (1 eq.), arylboronic acid (1.5 eq.), copper(II) acetate
monohydrate (0.3 eq.) in N,N-dimethylformamide (2 mL/mmol) and
pyridine (3.0 eq.). The reaction was stirred under an oxygen
atmosphere at 90.degree. C. for 6 hours. The reaction was then
cooled to room temperature and diluted with a saturated aqueous
sodium bicarbonate solution, and the aqueous phase was extracted
with 3 times with dichloromethane. The organic phases were
combined, washed with brine, dried with sodium sulfate and
concentrated under vacuum. The crude material was purified by flash
chromatography.
General Procedure D: Hydrolysis of Nitrile to Primary Amide
##STR00257##
[0311] To a solution of an aryl nitrile (1 eq.) in ethanol (0.8
mL/mmol) and water (0.04 mL/mmol) was added
hydrido(dimethylphosphinous acid-kp)[hydrogen
bis(dimethylphosphinito-kp)]platinum(II) (0.05 eq.). The reaction
was stirred at 90.degree. C. for 2 h under air. The solution was
then cooled to room temperature and extracted twice with ethyl
acetate or dichloromethane. The organic layers were combined, dried
with sodium sulfate and concentrated under vacuum. The crude
material was either used directly in subsequent reactions or
purified by flash chromatography.
[0312] General Procedures for aryl-halide (ArX) to terminal alkyne
cross-coupling:
##STR00258##
General Procedure E
[0313] Aryl halide was weighed out, transferred to a sealed tube
and brought up in Acetonitrile (3 mL/mmol) and Triethylamine (3
mL/mmol). The solution was degassed with nitrogen and Copper(I)
Iodide (0.05 eq) and Bis(triphenylphosphine)palladium(II)chloride
(0.1 eq) were added. DMF (3 mL/mmol) was then added followed by
dropwise addition of alkyne (2-3 eq). The reaction mixture heated
for 3-18 h at 80.degree. C. and monitored by LCMS for consumption
of starting material. Upon completion, the reaction was cooled and
the crude product was either triterated via addition of water and
collected by filtration or extracted with saturated ammonium
chloride and DCM whereupon the organic layer was dried, filtered
and concentrated to dryness. Crude products were submitted for
reverse phase HPLC purification.
General Procedure F
[0314] Aryl halide (where X=bromide) (1 eq), Copper (I) Iodide
(0.06 eq), tri-t-butylphosphonium tetrafluoroborate (0.2 eq) and
dichlorobis(phenyl cyanide)palladium (0.1 eq) were weighed out and
transferred to a microwave vessel. Upon addition of DMSO (3
mL/mmol), the reaction mixture was subsequently degassed whereupon
a solution of alkyne (3 eq) in Diisopropylamine (3 eq) was added
dropwise. The reaction mixture was capped and heated thermally at
80.degree. C. and monitored by LCMS for consumption of starting
material. Workup is the same for as in procedure E.
General Procedure G
[0315] Aryl halide (wherein X=bromide) was weighed out, transferred
to a sealed tube and brought up in DMSO or DMF (3 mL/mmol) and
Triethylamine (3 mL/mmol). The solution was degassed with nitrogen
and Bis(triphenylphosphine)palladium(II)chloride (0.2 eq) and
alkyne (2-3 eq) were added ("copper-free" conditions). The reaction
mixture heated for 2-18 hrs at 80.degree. C. and monitored by LCMS
for consumption of starting material. Workup is the same for as in
above procedure E.
General Procedure H: Ester to Amide Conversion with Sodium
Methoxide/Formamide
##STR00259##
[0317] To a solution of Heterocyclic ester in N,N-Dimethylformamide
was added formamide (10 eq) followed by dropwise addition of sodium
methoxide (3 eq). The mixture was either stirred at room
temperature or heated to 40.degree. C. and monitored by LC-MS for
completion. The crude reaction mixture was triturated via addition
of saturated ammonium chloride or extracted with Dichloromethane in
cases where the product did not crash out. In situations where this
was an intermediate, the crude material was used directly in
subsequent reactions.
General Procedure I: Ester to Amide Conversion with Ammonium
Hydroxide in Dioxane
##STR00260##
[0319] To a solution of Heterocyclic ester in Dioxane (10 mL/mmol)
was added ammonium hydroxide (25% mass) in water (50 eq., 14 mmol).
The reaction mixture was stirred at 40.degree. C. and monitored by
LC-MS for completion. The crude reaction mixture was concentrated
to dryness and purified by reverse phase HPLC to afford
product.
General Procedure J: Ester Saponification
##STR00261##
[0321] To a solution of heterocylic ester in 1:1
Tetrahydrofuran/Water was added lithium hydroxide monohydrate (3-10
eq). The reaction was either stirred at room temperature or heated
to 50.degree. C. and monitored by LC-MS for completion. The
tetrahydrofuran was then evaporated and the pH of the aqueous crude
reaction mixture was adjusted to 3 whereupon the product either
crashed out and was isolated, or the aqueous layer was extracted
with Dichloromethane or ethyl acetate in cases where the product
did not crash out. In situations where this was an intermediate,
the crude material was used directly in subsequent reactions.
General Procedure K: Ketone/Aldehyde Reduction
##STR00262##
[0323] To a solution of heterocylic ketone/aldehyde in Methanol was
added sodium borohydride (1-3 eq). The reaction was stirred at
0.degree. C. or room temperature until bubbling subsided and
monitored by LC-MS for completion. The reaction mixture was
extracted with dichloromethane and saturated ammonium chloride
whereupon the organic layer was dried, filtered and concentrated to
afford crude heterocylic alcohol intermediate and was used directly
in subsequent reactions.
General Procedure L: Fluorination
##STR00263##
[0325] To a solution of alcohol, aldehyde or ketone in
Dichloromethane or Dichloroethane was added 4 equivalents of
Diethylaminosulfur trifluoride (DAST) or
Bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor). The
reaction was either stirred at room temperature or heated to
45.degree. C. and monitored by LC-MS for completion. The reaction
mixture was concentrated to dryness and the crude intermediate was
triturated via addition of water which was used in subsequent
reactions without further purification.
General Procedure M: Suzuki Coupling of Boronic Acids or Boronic
Esters with Aryl Halides
##STR00264##
[0327] Aryl Halide, tetrakis (triphenylphosphine)palladium or
Palladium (II) bis(triphenylphosphine) dichloride (0.05 eq) and
boronic acid or pinacol ester (1.2 eq) were weighed out into a
microwave vessel or sealed tube. Acetonitrile (3 mL/mmol) and a 1M
aqueous solution of Sodium Carbonate (3 eq) were added. The vessel
was capped and heated thermally 3-18 hrs at 100.degree. C. Upon
completion, the reaction was cooled and crude product was either
triterated via addition of water and collection by filtration or
extracted with sat ammonium chloride and DCM. If the crude product
was an intermediate, it was taken into the next step in most cases
w/o further purification or alternatively submitted for reverse
phase HPLC purification when it was a final product.
General Procedure N: Reductive Amination of Arylaldehydes
##STR00265##
[0329] To a vial containing aryl aldehyde (1 eq) in 10% Acetic Acid
in DMF (6 mL/mmol) was added molecular sieves (1 eq by wt), amine
(HNRR, 4 eq) then sodium cyanoborohydride (1.2 eq). The reaction
was either heated at 45.degree. C. or stirred at room temperature.
Upon completion, the reaction was extracted with DCM and saturated
ammonium chloride. The organic layer was dried with magnesium
sulfate, filtered and concentrated to give crude product which was
taken into the next step without purification.
General Procedure O: Carbonylative Methanolysis of Aryl Iodides
##STR00266##
[0331] To a nitrogen-purged solution of aryl iodide in TEA (3
mL/mmol), DMF (3 mL/mmol) and MeOH (3 mL/mmol) was added Palladium
(II)Acetate (0.03 eq) and Xantphos (0.06 eq). The reaction mixture
was flushed with Carbon Monoxide gas for several minutes and then
sealed with CO balloon attached and heated to 60.degree. C. for 3
hours. Upon completion, the reaction was cooled to room temperature
and the crude product was triterated via addition of water and
collected by filtration. The crude intermediate was taken into the
next step w/o further purification.
General Procedure P: Carbonylative Amidation with HMDS
##STR00267##
[0333] To a nitrogen-degassed solution of generic aryl iodide
(Ar--I) in DMF (170 eq) was added
Palladium(II)bis(triphenylphosphine) dichloride (0.05 eq) and
hexamethyldisilazane (6 eq). The reaction mixture was flushed with
Carbon Monoxide gas for several minutes and then sealed with CO
balloon attached and heated to 70.degree. C. for 18 hrs. Upon
completion, the reaction was cooled to room temperature and the
crude was triterated via addition of water and collected by
filtration. The crude intermediate was taken into the next step w/o
further purification.
General Procedure S: Ester to Amide Conversion Using Ammonia in
Methanol
##STR00268##
[0335] To a stirred solution of ester (1 equiv) in methanol was
treated with saturated ammonia (>20 eq.) in methanol. The
mixture was either stirred at room temperature or heated to
40.degree. C. and the reaction was monitored by LC-MS. The crude
reaction mixture was concentrated and purified by reverse phase
HPLC.
General Procedure T: SEM Deprotection with HCl
##STR00269##
[0337] The SEM-protected amine or alcohol and 4.0 M hydrochloric
acid in dioxane (17.0 eq.) were combined in ethanol (4.0 mL/mmol)
and stirred at 50.degree. C. for 2 h. The sample was then
concentrated under vacuum and used directly in subsequent reactions
or purified by flash chromatography.
[0338] General Procedures for Suzuki Couplings with
Aryltrifluoroborates:
##STR00270##
General Procedure U
[0339] A tube containing a solution of arylchloride/bromide (1 eq)
and aryltrifluoroborate (1 eq) in Ethanol was purged with nitrogen
before addition of Pd(OAc).sub.2 (0.06 eq), RuPhos (0.12 eq), and
Sodium Carbonate (2 eq). The tube was sealed with a cap lined with
a disposable Teflon septum was heated at 85.degree. C. for 12-20
hours. The reaction mixture was allowed to cool to room temperature
and was either filtered thru celite and submitted directly to
reverse phase HPLC purification or extracted with dichloromethane
and a solution of saturated ammonium chloride before drying,
evaporating and submitting to reverse phase purification or using
in the subsequent step without purification.
General Procedure V
[0340] A solution of arylchloride/bromide (1 eq) and
aryltrifluoroborate (1 eq) in 20% aq dioxane (0.28 M) was degassed
before addition of cesium carbonate (3 eq) and
tetrakis(triphenylphosphine)palladium(0) (0.05 eq). The reaction
mixture was heated at 100.degree. C. for 1 hr then cooled to room
temperature. Workup same as General Procedure U.
General Procedure W
[0341] A solution of arylchloride/bromide (1 eq) and
aryltrifluoroborate (1 eq) in Acetonitrile (0.25M) was degassed
before addition of tetrakis(triphenylphosphine)palladium(0) (0.05
eq) and a 1:1 mixture of 1M Sodium Carbonate (2 eq) and 1M
Potassium Acetate (2 eq). The reaction was performed in a 5 mL
biotage microwave tube and heated to 140.degree. C. for 20-40
minutes then cooled to room temperature. Workup same as General
Procedure U.
General Procedure X: Synthesis of SEM-Protected
Tetrahydroindazoles
##STR00271##
[0343] Step 1: A solution of diisopropylamine (1.7 eq.) in THF (4.6
mL/mmol) was cooled to -78.degree. C., then a solution of n-butyl
lithium in hexanes (1.6 M, 1.5 eq.) was added dropwise. After
stirring for 5 minutes, this mixture was added via cannula to a
-78.degree. C. solution of ethyl diazoacetate (1.6 eq.) and
cycloalkylketone (1.0 eq.) in THF (4.6 mL/mmol). The mixture was
stirred for 1 hour at -78.degree. C., then quenched by the addition
of sat. NH.sub.4Cl(aq). The mixture was diluted with water and
extracted with EtOAc (2 times). The combined organic extracts were
dried (MgSO.sub.4) and concentrated in vacuo. Purification by
CombiFlash (heptane:EtOAc) provided the desired product.
[0344] Step 2: To a solution of product from the previous step (1.0
eq.) in pyridine (4.6 mL/mmol) was added POCl.sub.3 (4.35 eq.) and
the mixture was allowed to stir at room temperature overnight.
After in vacuo concentration, the mixture was poured onto ice, then
extracted with EtOAc (3 times). The combined organic extracts were
dried (MgSO.sub.4) and concentrated in vacuo. This residue was
diluted with octane (2.1 mL/mmol) and heated to 110.degree. C. for
two hours. After in vacuo concentration, purification by CombiFlash
(heptane:EtOAc) provided the desired product.
[0345] Step 3: A solution of product from the previous step (1.0
eq.) in THF (20 mL/mmol) was cooled to 0.degree. C., then sodium
hydride (60%, 3.0 eq.) was added. After stirring for 1 hour, SEMCl
(1.2 eq.) was added and the mixture was allowed to warm to room
temperature overnight. After excess hydride was quenched by the
addition of water at 0.degree. C., the mixture was extracted with
EtOAc (3 times), the organic extracts dried (MgSO.sub.4) and
concentrated in vacuo. Purification by CombiFlash (heptane:EtOAc)
provided the desired ester containing product. This ester was
diluted with THF (5.4 mL/mmol), acetonitrile (5.4 mL/mmol) and
water (5.4 mL/mmol) and lithium hydroxide monohydrate (7.0 eq.) was
added and the mixture was stirred overnight. The mixture was
diluted with water, acidified to pH 3 with 1 N HCl(aq) and
extracted with Et.sub.2O (once) and 10% MeOH/CH.sub.2Cl.sub.2 (3
times). The combined organic extracts were dried (MgSO.sub.4) and
concentrated in vacuo to provide the desired carboxylic acid of
sufficient purity to be used directly.
General Procedure Y: Alternative Synthesis of SEM-Protected
Tetrahydroindazoles
##STR00272##
[0347] Step 1: A solution of cycloalkyl ketone (1.0 eq.) in EtOH
(0.5 mL/mmol) was cooled to 0.degree. C., then sodium ethoxide (21%
wt solution in EtOH, 1.1 eq.) was added. To this mixture was added
diethyl oxalate (1.0 eq.) and the mixture was allowed to warm to
room temperature overnight. In vacuo concentration provided the
desired product of sufficient purity to be used directly (yield
assumed to be quantitative).
[0348] Step 2: A solution of product from the previous step (1.0
eq.) in glacial acetic acid (0.5 mL/mmol) was cooled to 0.degree.
C., then hydrazine hydrate (1.1 eq.) was added. After warming to
room temperature, the mixture was stirred for 1 hour, then diluted
with sat. NaHCO.sub.3(aq) and extracted with 10%
MeOH/CH.sub.2Cl.sub.2. The organic extracts were dried (MgSO.sub.4)
and concentrated in vacuo. Purification by CombiFlash
(heptane:EtOAc) provided the desired
tetrahydroindazole-3-carboxylate.
[0349] Step 3: Performed in an analogous manner to Step 3 General
Procedure X.
General Procedure Z: 2,3-dihydro-1H-indole-2,3-dione to
methyl-1H-indazole-3-carboxylate
##STR00273##
[0351] A solution of 2,3-dihydro-1H-indole-2,3-dione (1 eq.) and
sodium hydroxide (1.1 eq.) in water was stirred for 5-30 min at
25.degree. C. Then a solution of sodium nitrite (1.1 eq.) in water
and concentrated sulfuric acid (2 eq.) were added dropwise with
stirring at 0.about.10.degree. C. After 5.about.30 min a solution
of SnCl.sub.2 (2.5 eq.) in concentrated hydrochloric acid
(15.about.30 eq.) was added slowly. After being stirred for
1.about.5 h at 25.degree. C. the reaction mixture was filtered and
the solid was dissolved in methanol. Sulfuric acid (0.5.about.1
eq.) was added to the solution and the solution was heated to
reflux overnight. The resulting mixture was concentrated under
vacuum, diluted with water, extracted with ethyl acetate, dried
over anhydrous sodium sulfate, and concentrated under vacuum to
give the ester which may need further purification such as fresh
chromatography.
Synthesis of 3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
##STR00274##
[0353] Into a 100-L barrel was placed a solution of
4-amino-2-hydroxybutanoic acid (5 kg, 41.97 mol, 1.00 equiv) in
water (25 L), potassium carbonate (16.6 kg, 3.00 equiv), followed
by the addition of a solution of Boc.sub.2O (10.08 kg, 1.10 equiv)
in dioxane (16 L) dropwise with stirring at 0-10.degree. C. The
resulting solution was stirred for overnight at 20-25.degree. C.
and then washed with 2.times.7 L of ether to remove the remained
Boc.sub.2O. The pH value of the aqueous layer was adjusted to 4-5
with 6N hydrochloric acid and the resulting solution was extracted
with 4.times.10 L of ethyl acetate. The organic layers were
combined and concentrated under vacuum to afford 9.1 kg (99%) of
4-((tert-butoxycarbonyl)amino)-2-hydroxybutanoic acid as a yellow
oil.
[0354] LC-MS (ES, m/z): 218 (M-1)
##STR00275##
[0355] Into a 100-L barrel was placed a solution of
4-[[(tert-butoxy)carbonyl]amino]-2-hydroxybutanoic acid (9.11 kg,
41.55 mol, 1.00 equiv) in methanol (90 L), EDCI (11.9 kg, 1.50
equiv), HOBT (8.43 kg, 1.50 equiv), followed by the addition of
DIEA (10.6 kg, 2.00 equiv) dropwise with stirring at 0-10.degree.
C. The resulting solution was stirred at r.t. for 2 h and
concentrated under vacuum to remove MeOH. The residue was dissolved
in 45 L of EA. The resulting mixture was washed with 3.times.30 L
of H.sub.2O, dried over anhydrous sodium sulfate and concentrated
to afford 6.885 kg (71%) of methyl
4-[[(tert-butoxy)carbonyl]amino]-2-hydroxybutanoate as a yellow
oil.
[0356] LC-MS (ES, m/z): 234 (M+1); 134 (M-100+1)
##STR00276##
[0357] Into a 100-L barrel was placed a solution of methyl
4-[[(tert-butoxy)carbonyl]amino]-2-hydroxybutanoate (6.885 kg,
29.52 mol, 1.00 equiv) in dichloromethane (50 L), imidazole (4.02
kg, 2.00 equiv), followed by the addition of a solution of TBDMSCl
(8.85 kg, 2.00 equiv) in dichloromethane (10 L) dropwise with
stirring at 0-5.degree. C. The resulting solution was stirred for
overnight at 20-25.degree. C. The solids were filtered out and the
filtrate was concentrated under vacuum. The residue was applied
onto a silica gel column eluting with ethyl acetate:petroleum ether
(1:50) to afford 8.8 kg (86%) of methyl
4-[[(tert-butoxy)carbonyl]amino]-2-[(tert-butyldimethylsilyl)oxy]butanoat-
e as a yellow oil.
[0358] LC-MS (ES, m/z): 348 (M+1); 248 (M-100+1)
##STR00277##
[0359] Into a 10-L 4-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen was placed a
solution of methyl
4-[[(tert-butoxy)carbonyl]amino]-2-[(tert-butyldimethylsilyl)oxy]butanoat-
e (1.1 kg, 3.17 mol, 1.00 equiv) in N,N-dimethylformamide (5 L),
followed by the addition of sodium hydride (250 g, 2.00 equiv,
60%), in portions at 0-10.degree. C. and then MeI (4.5 kg, 10.00
equiv) dropwise at 0-10.degree. C. The resulting solution was
stirred at 20-25.degree. C. for 2 h, diluted with 20 L of H.sub.2O
and extracted with 3.times.10 L of ethyl acetate. The organic
layers were combined and concentrated under vacuum. There were 5
batches altogether. The products were combined to afford 8 kg
(crude) of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-[(tert-butyldimethylsilyl)oxy]-
butanoate as a yellow oil.
[0360] LC-MS (ES, m/z): 362 (M+1); 262 (M-100+1)
##STR00278##
[0361] Into a 100-L barrel was placed a solution of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-[(tert-butyldimethylsilyl)oxy]-
butanoate (8 kg, 22.13 mol, 1.00 equiv) in tetrahydrofuran (30 L),
followed by the addition of a solution of TBAF (6 kg, 1.40 equiv)
in tetrahydrofuran (10 L) dropwise with stirring at 0-10.degree. C.
The resulting solution was stirred at 20-25.degree. C. for 2 h,
diluted with 40 L of H.sub.2O and extracted with 3.times.25 L of
ethyl acetate. The organic layers were combined and concentrated
under vacuum. The residue was applied onto a silica gel column
eluting with ethyl acetate:petroleum ether (1:20) to afford 3.053
kg of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-hydroxybutanoate as a
yellow oil.
[0362] LC-MS (ES, m/z): 248 (M+1); 148 (M-100+1)
##STR00279##
[0363] Into a 100-L barrel was placed a solution of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-hydroxybutanoate (3.053
kg, 12.35 mol, 1.00 equiv) in dichloromethane (40 L), followed by
the addition of Dess-Martin reagent (7.33 kg, 1.40 equiv) in
portions at 0-10.degree. C. The resulting solution was stirred at
20-25.degree. C. for 1.5 h and diluted with 40 L of
sat.NaHCO.sub.3. The organic layer was washed with 2.times.40 L of
sat.NaHCO.sub.3 and concentrated under vacuum. The residue was
applied onto a silica gel column eluting with ethyl
acetate:petroleum ether (1:5) to afford 2.435 kg (80%) of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-oxobutanoate as a yellow
oil.
[0364] LC-MS (ES, m/z): 246 (M+1); 146 (M-100+1)
##STR00280##
[0365] Into a 10-L 4-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen was placed a
solution of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-2-oxobutanoate (120 g,
489.25 mmol, 1.00 equiv) in tetrahydrofuran (5 L), followed by the
addition of ethynylmagnesium bromide/THF (1 L, 1.03 equiv) dropwise
with stirring at -70.degree. C. The resulting solution was stirred
at -70.degree. C. for 10 min, quenched by the addition of 5 L of
sat.aq.NH.sub.4Cl and extracted with 3.times.5 L of ethyl acetate.
The organic layers were combined and concentrated under vacuum. The
residue was applied onto a silica gel column eluting with ethyl
acetate:petroleum ether (1:5). This reaction was done 16 times. The
products were combined to afford 1.563 kg (74%) of methyl
2-(2-[[(tert-butoxy)carbonyl](methyl)amino]ethyl)-2-hydroxybut-3-ynoate
as a yellow oil. LC-MS (ES, m/z): 272 (M+1); 172 (M-100+1)
##STR00281##
[0366] Into a 100-L barrel was placed a solution of methyl
2-(2-[[(tert-butoxy)carbonyl](methyl)amino]ethyl)-2-hydroxybut-3-ynoate
(1.563 kg, 5.76 mol, 1.00 equiv) in dichloromethane (20 L),
followed by the addition of trifluoroacetic acid (3 L) dropwise
with stirring. The resulting mixture was concentrated under vacuum
to remove TFA and the residue was dissolved in 20 L
dichloromethane. To this solution was added TEA (5.83 kg, 10.00
equiv) dropwise with stirring at 0-5.degree. C. The resulting
solution was stirred at 20-25.degree. C. for 2 h and overnight at
20-25.degree. C. The resulting mixture was concentrated under
vacuum and the residue was applied onto a silica gel column eluting
with ethyl acetate:petroleum ether (1:1) to afford 220 g (27%) of
3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one as a brown solid. The
enantiomers were separated by chiral preparatory SFC. The racemate
(502 g) was separated by Prep-SFC with the following conditions
(prep SFC 350): Column, CHIRALPAK IC SFC, 5.times.25 cm, 5 .mu.m;
mobile phase, CO.sub.2(65%), IPA (0.2% DEA)(35%); Detector, UV 220
nm. This resulted in 172.3 g (28.4%) of
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one as a brown
solid.
[0367] LC-MS (ES, m/z): 140 (M+1)
Synthesis of
1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,7-tetrahydropyrano[3,4-e]pyraz-
ole-3-carboxylic acid
##STR00282##
[0369] Step 1: A solution of diisopropylamine (2.6 mL, 18.4 mmol)
in THF (50 mL) was cooled to -78.degree. C., then a solution of
n-butyl lithium in hexanes (1.6 M, 10.0 mL, 16.20 mmol) was added
dropwise. After stirring for 5 minutes, this mixture was added via
cannula to a -78.degree. C. solution of ethyl diazoacetate (1.83
mL, 17.3 mmol) and tetrahydropyran-4-one (1.08 g, 10.8 mmol;
commercial) in THF (50 mL). The mixture was stirred for 1 hour at
-78.degree. C., then quenched by the addition of sat.
NH.sub.4Cl(aq). The mixture was diluted with water and extracted
with EtOAc (2 times). The combined organic extracts were dried
(MgSO.sub.4) and concentrated in vacuo. Purification by CombiFlash
(100:0 to 60:40 heptane:EtOAc) provided 2.3 g (10.8 mmol) of ethyl
2-diazo-2-(4-hydroxytetrahydro-2H-pyran-4-yl)acetate.
[0370] Step 2: To a solution of ethyl
2-diazo-2-(4-hydroxytetrahydro-2H-pyran-4-yl)acetate (2.3 g, 10.8
mmol) in pyridine (50 mL) was added POCl.sub.3 (4.4 mL 47 mmol) and
the mixture was allowed to stir at room temperature overnight.
After in vacuo concentration, the mixture was poured onto ice, then
extracted with EtOAc (3 times). The combined organic extracts were
dried (MgSO.sub.4) and concentrated in vacuo. This residue was
diluted with octane (23 mL) and heated to 110.degree. C. for two
hours. After in vacuo concentration, purification by CombiFlash
(100:0 to 0:100 heptane:EtOAc) provided 1.09 g (5.56 mmol) of ethyl
1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate.
[0371] Step 3: A solution of ethyl
1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate (1.09 g, 5.56
mmol) in THF (110 mL) was cooled to 0.degree. C., then sodium
hydride (60%, 667 mg, 16.7 mmol) was added. After stirring for 1
hour, SEMCl (1.18 mL, 6.67 mmol) was added and the mixture was
allowed to warm to room temperature overnight. After excess hydride
was quenched by the addition of water at 0.degree. C., the mixture
was extracted with EtOAc (3 times), the organic extracts dried
(MgSO.sub.4) and concentrated in vacuo. Purification by CombiFlash
(40 g; 100:0 to 70:30 heptane:EtOAc) provided 1.58 g (4.84 mmol) of
ethyl
1-(2-trimethylsilylethoxymethyl)-5,7-dihydro-4H-pyrano[3,4-c]pyrazole-3-c-
arboxylate. This ester was diluted with THF (30 mL), acetonitrile
(30 mL) and water (30 mL) and lithium hydroxide monohydrate (1.64
g, 38.7 mmol) was added and the mixture was stirred overnight. The
mixture was diluted with water, acidified to pH 3 with 1 N HCl(aq)
and extracted with Et.sub.2O (once) and 10% MeOH/CH.sub.2Cl.sub.2
(3 times). The combined organic extracts were dried (MgSO.sub.4)
and concentrated in vacuo to provide
1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,7-tetrahydropyrano[3,4-
-c]pyrazole-3-carboxylic acid of sufficient purity to be used
directly (1.44 g, 4.84 mmol).
Synthesis of
5,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-1H-i-
ndazole-3-carboxylic acid
##STR00283##
[0373] Step 1: A solution of 4,4-dimethylcyclohexanone (2.00 g,
15.8 mmol; commercial) in EtOH (7 mL) was cooled to 0.degree. C.,
then sodium ethoxide (21% wt solution in EtOH, 6.51 mL, 17.4 mmol)
was added. To this mixture was added diethyl oxalate (2.2 mL, 15.8
mmol) and the mixture was allowed to warm to room temperature
overnight. In vacuo concentration provided ethyl
2-(5,5-dimethyl-2-oxo-cyclohexyl)-2-oxo-acetate of sufficient
purity to be used directly (yield assumed to be quantitative).
[0374] Step 2: A solution of ethyl
2-(5,5-dimethyl-2-oxo-cyclohexyl)-2-oxo-acetate (3.6 g, unpurified)
in glacial acetic acid (7 mL) was cooled to 0.degree. C., then
hydrazine hydrate (1.33 mL, 17.4 mmol) was added. After warming to
room temperature, the mixture was stirred for 1 hour, then diluted
with sat. NaHCO.sub.3(aq) and extracted with 10%
MeOH/CH.sub.2Cl.sub.2. The organic extracts were dried (MgSO.sub.4)
and concentrated in vacuo. Purification by CombiFlash (12 g; 100:0
to 60:40 heptane:EtOAc) provided 1.76 g (7.92 mmol) of ethyl
5,5-dimethyl-1,4,6,7-tetrahydroindazole-3-carboxylate.
[0375] Step 3: Performed in an analogous manner to Step 3 for
1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyraz-
ole-3-carboxylic acid (Example 1), replacing ethyl
1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate with ethyl
5,5-dimethyl-1,4,6,7-tetrahydroindazole-3-carboxylate.
Synthesis of
1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,7-tetrahydrothiopyrano[3,4-e]p-
yrazole-3-carboxylic acid 6,6-dioxide
##STR00284##
[0377] Prepared in an analogous manner to General Procedure X,
replacing dihydro-2H-thiopyran-4(3H)-one 1,1-dioxide
(commercial).
Synthesis of ethyl
4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carboxylate
##STR00285##
[0379] Prepared in an analogous manner to General Procedure Y,
replacing 4,4-dimethylcyclohexanone with bicyclo[3.1.1]heptan-2-one
(see J. Am. Chem. Soc. 1980, 102, 1404) and not performing step
3.
Synthesis of ethyl
4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carboxylate
##STR00286##
[0381] Prepared in an analogous manner to General Procedure X,
replacing tetrahydropyran-4-one with bicyclo[3.1.1]heptan-2-one
(see J. Am. Chem. Soc. 1980, 102, 1404), and not performing step
3.
Synthesis of ethyl
6-hydroxy-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00287##
[0383] Prepared in an analogous manner to General Procedure X,
replacing tetrahydropyran-4-one with 4-hydroxycyclohexanone
(commercial), and not performing step 3.
Synthesis of
1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid
##STR00288##
[0385] Similar to General Procedure A, to a solution of
4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (50 mg, 0.30 mmol)
and cesium carbonate (3.0 equiv., 294 mg, 0.902 mmol) in
N,N-dimethylformamide (0.60 mL) was added 2-fluoro-4-iodo-pyridine
(1.1 equiv., 73.8 mg, 0.331 mmol). The reaction was heated to
100.degree. C. and stirred at this temperature for 2 hours. The
reaction was then cooled to room temperature and acidified to pH=1
with 10% aqueous HCl solution. The solution was extracted with
twice with dichloromethane. The organic layers were combined, dried
with sodium sulfate and concentrated under vacuum. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00289##
[0387] Similar to General Procedure B, to a solution of
1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic acid
(70 mg, 0.190 mmol) in tetrahydrofuran (1.23 mL) was added ammonium
chloride (6.0 eq., 61.2 mg, 1.138 mmol) and
N,N-diisopropylethylamine (6.0 eq., 0.20 mL, 1.138 mmol) followed
by HATU (2.0 eq., 145.6 mg, 0.379 mmol). The reaction was stirred
at room temperature overnight. A solution of saturated sodium
bicarbonate was added and the mixture was extracted 3 times with
dichloromethane. The organic layers were combined, dried with
sodium sulfate and concentrated under vacuum. The crude material
was purified by flash chromatography (Silicycle HP, 1-10% methanol
in dichloromethane) to afford a light yellow solid.
Synthesis of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carbonitrile
##STR00290##
[0389] Similar to General Procedure C, to a small vial was added
1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (45 mg, 0.312 mmol),
(3-bromophenyl)boronic acid (1.5 eq., 94.0 mg, 0.468 mmol),
copper(II) acetate monohydrate (0.3 eq., 19.7 mg, 0.093 mmol) in
N,N-dimethylformamide (0.62 mL) and pyridine (3.0 eq., 0.076 mL,
0.936 mmol). The reaction was stirred under an oxygen atmosphere at
90.degree. C. for 6 hours. The reaction was then cooled to room
temperature and diluted with a saturated aqueous sodium bicarbonate
solution, and the aqueous phase was extracted with 3 times with
dichloromethane. The organic phases were combined, washed with
brine, dried with sodium sulfate and concentrated under vacuum. The
crude material was purified by flash chromatography (5-80% iPrOAc
in heptanes) to afford 40 mg (43% yield) of a light yellow
solid.
Synthesis of 1-(4-iodo-2-pyridyl)indazole-3-carboxylic acid
##STR00291##
[0391] Similar to as described in General Procedure A, methyl
1H-indazole-3-carboxylate was reacted with 2-fluoro-4-iodo-pyridine
to give the title compound. The crude material was used directly in
subsequent reactions.
Synthesis of 1-(4-iodo-2-pyridyl)indazole-3-carboxamide
##STR00292##
[0393] Similar to as described in General Procedure B,
1-(4-iodo-2-pyridyl)indazole-3-carboxylic acid was reacted with
ammonium chloride to give the title compound (60% yield).
Synthesis of
1-(3-bromophenyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00293##
[0395] Similar to as described in General Procedure B,
1-(3-bromophenyl)-4,5,6,7-tetrahydroindazole-3-carboxylic acid was
reacted with ammonium chloride to give the title compound. The
crude material was used directly in subsequent reactions.
Synthesis of 1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid
##STR00294##
[0397] Similar to as described in General Procedure A, ethyl
1H-pyrazole-3-carboxylate was reacted with 2-fluoro-4-iodo-pyridine
to give the title compound. The crude material was used directly in
subsequent reactions.
Synthesis of 1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide
##STR00295##
[0399] Similar to as described in General Procedure B,
1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid was reacted with
ammonium chloride to give the title compound (43% yield).
Synthesis of
1-(4-iodo-2-pyridyl)-5,6-dihydro-4H-cyclopenta[c]pyrazole-3-carboxylic
acid
##STR00296##
[0401] Similar to as described in General Procedure A, ethyl
1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate was reacted
with 2-fluoro-4-iodo-pyridine to give the title compound, as well
as some remaining ester. Lithium hydroxide (1.0 eq.) in water (1.0
M) was added and the reaction was stirred at 50.degree. C. for 1 h
to afford complete conversion to the desired acid. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(4-iodo-2-pyridyl)-5,6-dihydro-4H-cyclopenta[c]pyrazole-3-carboxamide
##STR00297##
[0403] Similar to as described in General Procedure B,
1-(4-iodo-2-pyridyl)-5,6-dihydro-4H-cyclopenta[c]pyrazole-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(28% yield).
Synthesis of
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carbox-
ylic acid
##STR00298##
[0405] Similar to as described in General Procedure A, ethyl
4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carboxylate was reacted
with 2-fluoro-4-iodo-pyridine to give the title compound, as well
as some remaining ester. Lithium hydroxide (1.0 eq.) in water (1.0
M) was added and the reaction was stirred at 50.degree. C. for 1 h
to afford complete conversion to the desired acid. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carbox-
amide
##STR00299##
[0407] Similar to as described in General Procedure B,
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carbox-
ylic acid was reacted with ammonium chloride to give the title
compound (71% yield).
Synthesis of
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carbox-
ylic acid
##STR00300##
[0409] Similar to as described in General Procedure A, ethyl
4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carboxylate was reacted
with 2-fluoro-4-iodo-pyridine to give the title compound, as well
as some remaining ester. Lithium hydroxide (1.0 eq.) in water (1 M)
was added and the reaction was stirred at 50.degree. C. for 1 h to
afford complete conversion to the desired acid. The crude material
was used directly in subsequent reactions.
Synthesis of
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carbox-
amide
##STR00301##
[0411] Similar to as described in General Procedure B,
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carbox-
ylic acid was reacted with ammonium chloride to give the title
compound (50% yield).
Synthesis of
6-hydroxy-1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid
##STR00302##
[0413] Similar to as described in General Procedure A, ethyl
6-hydroxy-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted
with 2-fluoro-4-iodo-pyridine to give the title compound, as well
as some remaining ester. Lithium hydroxide (1.0 eq.) in water (1 M)
was added and the reaction was stirred at 50.degree. C. for 1 h to
afford complete conversion to the desired acid. The crude material
was used directly in subsequent reactions.
Synthesis of
6-hydroxy-1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00303##
[0415] Similar to as described in General Procedure B,
6-hydroxy-1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(78% yield).
Synthesis of 5,5-dimethyl-1,4,6,7-tetrahydroindazole-3-carboxylic
acid
##STR00304##
[0417] Similar to as described in General Procedure T,
5,5-dimethyl-1-(2-trimethylsilylethoxymethyl)-6,7-dihydro-4H-indazole-3-c-
arboxylic acid (200 mg, 0.616 mmol) and 4.0 M hydrochloric acid in
dioxane (17.0 eq., 10.5 mmol, 2.6 mL) were combined in ethanol (2.5
mL) and stirred at 50.degree. C. for 2 h. The sample was then
concentrated under vacuum and used directly in subsequent
reactions.
Synthesis of
1-(4-iodo-2-pyridyl)-5,5-dimethyl-6,7-dihydro-4H-indazole-3-carboxylic
acid
##STR00305##
[0419] Similar to as described in General Procedure A,
5,5-dimethyl-1,4,6,7-tetrahydroindazole-3-carboxylic acid was
reacted with 2-fluoro-4-iodo-pyridine to give the title compound.
The crude material was used directly in subsequent reactions.
Synthesis of
1-(4-iodo-2-pyridyl)-5,5-dimethyl-6,7-dihydro-4H-indazole-3-carboxamide
##STR00306##
[0421] Similar to as described in General Procedure B,
1-(4-iodo-2-pyridyl)-5,5-dimethyl-6,7-dihydro-4H-indazole-3-carboxylic
acid was reacted with ammonium chloride in 2-methyltetrahydrofuran
to give 149 mg of the title compound (61% yield).
Synthesis of 6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxylic
acid
##STR00307##
[0423] Similar to as described in General Procedure A,
6-fluoro-1H-indazole-3-carboxylic acid was reacted with
2-fluoro-4-iodo-pyridine to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide
##STR00308##
[0425] Similar to as described in General Procedure B,
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxylic acid was reacted
with ammonium chloride to give 308 mg of the title compound (63%
yield).
Synthesis of 5-bromo-1-(4-iodo-2-pyridyl)indazole-3-carboxylic
acid
##STR00309##
[0427] Similar to as described in General Procedure A,
5-bromo-1H-indazole-3-carboxylic acid was reacted with
2-fluoro-4-iodo-pyridine to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of 5-bromo-1-(4-iodo-2-pyridyl)indazole-3-carboxamide
##STR00310##
[0429] Similar to as described in General Procedure B,
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxylic acid was reacted
with ammonium chloride to give 167 mg of the title compound (30%
yield).
Synthesis of 1-(4-iodo-2-pyridyl)-5-methoxy-indazole-3-carboxylic
acid
##STR00311##
[0431] Similar to as described in General Procedure A,
5-methoxy-1H-indazole-3-carboxylic acid was reacted with
2-fluoro-4-iodo-pyridine to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(4-iodo-2-pyridyl)-5-methoxy-indazole-3-carboxamide
##STR00312##
[0433] Similar to as described in General Procedure B,
1-(4-iodo-2-pyridyl)-5-methoxy-indazole-3-carboxylic acid was
reacted with ammonium chloride to give 72 mg of the title compound
(35% yield).
Synthesis of 5-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxylic
acid
##STR00313##
[0435] Similar to as described in General Procedure A,
5-methoxy-1H-indazole-3-carboxylic acid was reacted with
2-fluoro-4-iodo-pyridine to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of
5-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide
##STR00314##
[0437] Similar to as described in General Procedure B,
5-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxylic acid was reacted
with ammonium chloride to give 500 mg of the title compound (99%
yield).
Synthesis of
1-(3-bromophenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile
##STR00315##
[0439] Similar to General Procedure C,
1H-pyrrolo[2,3-b]pyridine-3-carbonitrile was reacted with
(3-bromophenyl)boronic acid to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(3-bromophenyl)pyrrolo[2,3-b]pyridine-3-carboxamide
##STR00316##
[0441] Similar as to General Procedure D, to a solution of
1-(3-bromophenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile (104 mg,
0.349 mmol) in ethanol (0.3 mL) and water (0.14 mL) was added
hydrido(dimethylphosphinous acid-kp)[hydrogen
bis(dimethylphosphinito-kp)]platinum(II) (0.05 eq., 7.5 mg, 0.017
mmol). The reaction was stirred at 80.degree. C. for 2 h. LC/MS
indicated slow conversion. Methanol (0.2 mL) was added and the
reaction was allowed to stir at this temperature overnight. The
solution was cooled to room temperature and extracted twice with
dichloromethane. The organic layers were combined, dried with
sodium sulfate and concentrated under vacuum. The crude material
was used directly in subsequent reactions.
Synthesis of
1-(5-bromo-3-pyridyl)pyrazolo[3,4-b]pyridine-3-carboxylic acid
##STR00317##
[0443] Similar to as described in General Procedure A,
1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid was reacted with
3-bromo-5-fluoro-pyridine to give the title compound. The crude
material was used directly in subsequent reactions.
Synthesis of
1-(5-bromo-3-pyridyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00318##
[0445] Similar to as described in General Procedure B,
1-(5-bromo-3-pyridyl)pyrazolo[3,4-b]pyridine-3-carboxylic acid was
reacted with ammonium chloride to give the title compound. The
crude material was used directly in subsequent reactions.
Synthesis of ethyl 2-(2-fluoro-3-pyridyl)-2-oxo-acetate
##STR00319##
[0447] To a solution of 2-fluoropyridine (0.44 mL, 500 mg, 5.150
mmol) in tetrahydrofuran (13.4 mL) under nitrogen atmosphere at
-78.degree. C. was added a solution of lithium diisopropylamide
(2.0 mol/L) in thf/heptane/ethylbenzene (1.2 eq., 3.1 mL, 6.180
mmol). The reaction was allowed to stir at this temperature for 1.5
hours, and then diethyl oxalate (1.2 eq., 0.84 mL, 6.180 mmol) was
added dropwise via syringe and allowed to stir for 30 minutes. The
reaction was quenched with aqueous saturated ammonium chloride
solution and extracted 3 times with iPrOAc. The organics were
combined, washed with brine, dried with sodium sulfate and
concentrated under vacuum. The crude material was used directly in
subsequent reactions.
Synthesis of ethyl
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00320##
[0449] To a solution of ethyl 2-(2-fluoro-3-pyridyl)-2-oxo-acetate
(43 mg, 0.218 mmol) in 1-methyl-2-pyrrolidinone (0.44 mL) was added
3-bromophenylhydrazine hydrochloride (1.0 eq., 48.7 mg, 0.218
mmol). The reaction was heated to 120.degree. C. in a sealed tube
overnight. The reaction was diluted with water and extracted 2
times with dichloromethane. The organics were combined, washed with
brine, dried with sodium sulfate and concentrated under vacuum. The
crude material was purified by flash chromatography (5-100% iPrOAc
in heptanes) to afford a yellow oil.
Synthesis of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00321##
[0451] Similar to as described in General Procedure H, To a
solution of ethyl
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate (75 mg,
0.217 mmol) in N,N-dimethylformamide (1.1 mL) under nitrogen
atmosphere was added formamide (10.0 eq., 0.086 mL, 2.166 mmol)
followed by dropwise addition of sodium methoxide (3.0 eq., 0.15
mL, 0.649 mmol). The reaction was stirred at room temperature for 1
h. The reaction was then quenched with an aqueous saturated
ammonium chloride solution and extracted 3 times with
dichloromethane. The organic phases were combined, dried with
sodium sulfate and concentrated to give the title compound. The
crude material was used directly in subsequent reactions.
Synthesis of 1H-pyrazolo[3,4-b]pyridine-3-carbonitrile
##STR00322##
[0453] To a solution of 3-bromo-1H-pyrazolo[3,4-b]pyridine (200 mg,
1.010 mmol), zinc cyanide (1.0 eq., 121.0 mg, 1.010 mmol),
tris(dibenzylideneacetone)dipalladium(0) (0.04 eq., 38.1 mg, 0.040
mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.08 eq., 46.6 mg,
0.081 mmol) and zinc (0.24 eq., 15.8 mg, 0.242 mmol) were dissolved
in degassed N,N-dimethylacetamide (5.0 mL) under inert atmosphere.
The reaction was heated to 120.degree. C. for 5 hours. The reaction
was then diluted with aqueous saturated sodium bicarbonate and
extracted 2 times with dichloromethane. The organics were combined,
washed with brine, dried with sodium sulfate and concentrated under
vacuum. The crude material was crashed out in diethyl ether to
afford 93 mg of the title compound (64%).
Synthesis of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carbonitrile
##STR00323##
[0455] Similar to General Procedure C,
1H-pyrazolo[3,4-b]pyridine-3-carbonitrile was reacted with
(3-bromophenyl)boronic acid to give 40 mg of the title compound
after purification by flash chromatography (43%).
Synthesis of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00324##
[0457] Similar as to General Procedure D, to a solution of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carbonitrile (40 mg,
0.134 mmol) in ethanol (0.11 mL) and water (0.05 mL) was added
hydrido(dimethylphosphinous acid-kp)[hydrogen
bis(dimethylphosphinito-kp)]platinum(II) (0.05 eq., 2.9 mg, 0.007
mmol). The reaction was stirred at 90.degree. C. for 2 h under air.
The solution was cooled to room temperature and extracted twice
with dichloromethane. The organic layers were combined, dried with
sodium sulfate and concentrated under vacuum. The crude material
was used directly in subsequent reactions.
Synthesis of ethyl
6,6-dioxo-1,4,5,7-tetrahydrothiopyrano[3,4-c]pyrazole-3-carboxylate
##STR00325##
[0459] Similar to as described in General Procedure T,
6,6-dioxo-1-(2-trimethylsilylethoxymethyl)-5,7-dihydro-4H-thiopyrano[3,4--
c]pyrazole-3-carboxylic acid was reacted was reacted with
hydrochloric acid to afford 47.2 mg of the title compound after
purification by flash chromatography (77%).
Synthesis of ethyl
2-(3-bromophenyl)-6,6-dioxo-5,7-dihydro-4H-thiopyrano[3,4-e]pyrazole-3-ca-
rboxylate
##STR00326##
[0461] Similar to General Procedure C, ethyl
6,6-dioxo-1,4,5,7-tetrahydrothiopyrano[3,4-c]pyrazole-3-carboxylate
was reacted with (3-bromophenyl)boronic acid to give a mixture of
regioisomers which were purified by flash chromatography to afford
12 mg of the title compound (second peak to elute, 16% yield).
Synthesis of
1-(3-bromophenyl)-6,6-dioxo-5,7-dihydro-4H-thiopyrano[3,4-e]pyrazole-3-ca-
rboxamide
##STR00327##
[0463] Similar to as described in General Procedure H, ethyl
1-(3-bromophenyl)-6,6-dioxo-5,7-dihydro-4H-thiopyrano[3,4-c]pyrazole-3-ca-
rboxylate was reacted with formamide and sodium methoxide to give
the title compound. The crude material was used directly in
subsequent reactions.
Synthesis of ethyl
1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate
##STR00328##
[0465] Similar to as described in General Procedure T,
1-(2-trimethylsilylethoxymethyl)-5,7-dihydro-4H-pyrano[3,4-c]pyrazole-3-c-
arboxylic acid was reacted was reacted with hydrochloric acid to
afford 86 mg of the title compound after purification by flash
chromatography (90%).
Synthesis of ethyl
1-(3-bromophenyl)-5,7-dihydro-4H-pyrano[3,4-e]pyrazole-3-carboxylate
##STR00329##
[0467] Similar to General Procedure C, ethyl
1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate was reacted
with (3-bromophenyl)boronic acid to give a mixture of regioisomers
which were purified by flash chromatography to afford 22.7 mg of
the title compound (second peak to elute, 15% yield).
Synthesis of
1-(3-bromophenyl)-5,7-dihydro-4H-pyrano[3,4-e]pyrazole-3-carboxamide
##STR00330##
[0469] Similar to as described in General Procedure H, ethyl
1-(3-bromophenyl)-5,7-dihydro-4H-pyrano[3,4-c]pyrazole-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of ethyl
1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate
##STR00331##
[0471] To a solution of
1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylic acid (200 mg,
1.189 mmol) in ethanol (4.8 mL) was added 4.0 M hydrochloric acid
in dioxane (12.0 eq., 14.273 mmol, 4.0 mol/L). The reaction was
stirred at 60.degree. C. for 24 h. The solution was cooled to room
temperature and concentrated under vacuum. The crude material was
used directly in subsequent reactions.
Synthesis of ethyl
1-(3-bromophenyl)-6,7-dihydro-4H-pyrano[4,3-c]pyrazole-3-carboxylate
##STR00332##
[0473] Similar to General Procedure C, ethyl
1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate was reacted
with (3-bromophenyl)boronic acid to give a mixture of regioisomers
which were purified by flash chromatography to afford 79 mg of the
title compound (second peak, 19% yield).
Synthesis of
1-(3-bromophenyl)-6,7-dihydro-4H-pyrano[4,3-c]pyrazole-3-carboxamide
##STR00333##
[0475] Similar to as described in General Procedure H, ethyl
1-(3-bromophenyl)-6,7-dihydro-4H-pyrano[4,3-c]pyrazole-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of methyl
1-(3-bromo-5-morpholino-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00334##
[0477] Similar to General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromo-5-morpholino-phenyl)boronic acid and purified by flash
chromatography to afford 171 mg of the title compound (73%
yield).
Synthesis of
1-(3-bromo-5-morpholino-phenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00335##
[0479] Similar to as described in General Procedure H, methyl
1-(3-bromo-5-morpholino-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of methyl
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00336##
[0481] Similar to General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid and purified by flash chromatography to
afford 838 mg of the title compound (50% yield).
Synthesis of 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine
##STR00337##
[0483] To a solution of 5-bromo-1H-pyrazolo[3,4-b]pyridine (1000
mg, 5.05 mmol) in N,N-dimethylformamide (25.2 mL) was added
potassium hydroxide (3.0 eq., 859 mg, 15.1 mmol) followed by iodine
(1.8 eq., 2310 mg, 9.09 mmol). The reaction was heated to
50.degree. C. for 1.5 hours. The reaction was then cooled to room
temperature and quenched with aqueous sodium thiosulfate until the
dark colour disappeared. The solution was diluted with water and
extracted 2 times with iPrOAc. The organic layers were combined,
dried with sodium sulfate and concentrated to afford a yellow
solid. The crude material was used directly in subsequent
reactions.
Synthesis of
2-[(5-bromo-3-iodo-pyrazolo[3,4-b]pyridin-1-yl)methoxy]ethyl-trimethyl-si-
lane
##STR00338##
[0485] To a solution of 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine
(1640 mg, 5.05 mmol) in N,N-dimethylformamide (10.1 mL) cooled to
0.degree. C. was added sodium hydride (60% in mineral oil, 1.33
eq., 269 mg, 6.73 mmol) slowly and the reaction was stirred at this
temperature for 20 minutes. 2-(trimethylsilyl)ethoxymethyl chloride
(1.33 eq., 1.19 mL, 6.73 mmol) was added and the reaction was
warmed to room temperature and stirred for 3 h. The reaction was
then quenched with saturated aqueous ammonium chloride. The
solution was extracted 2 times with iPrOAc. The organic layers were
combined, dried with sodium sulfate and concentrated. The crude
material was purified by flash chromatography (5-30% iPrOAc in
heptanes) to afford 1.0123 g of a light yellow solid (44%).
Synthesis of
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00339##
[0487] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate was reacted
with formamide and sodium methoxide to give the title compound. The
crude material was used directly in subsequent reactions.
Synthesis of methyl
1-(3-bromo-5-methoxy-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00340##
[0489] Similar to General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromo-5-methoxy-phenyl)boronic acid and purified by flash
chromatography to afford 153.6 mg of the title compound (75%
yield).
Synthesis of
1-(3-bromo-5-methoxy-phenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00341##
[0491] Similar to as described in General Procedure H, methyl
1-(3-bromo-5-methoxy-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of
2-(3-bromo-5-methylsulfonyl-phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborola-
ne
##STR00342##
[0493] Under inert atmosphere, 1-bromo-3-methylsulfonyl-benzene
(300 mg, 1.276 mmol), bis(pinacolato)diboron (0.878 eq., 287.4 mg),
bis(1,5-cyclooctadiene)di-mu-methoxydiiridium(I) (0.005 eq., 4.2
mg) and 4,4'-di-tert-butyl-2,2'-bipyridine (0.0105 eq., 3.6 mg)
were dissolved in degassed tetrahydrofuran (1.3 mL). The reaction
was heated in a sealed vial at 80.degree. C. for 16 h. The solution
was cooled to room temperature, diluted with dichloromethane,
filtered through celite and concentrated to afford a beige solid.
The crude material was used directly in subsequent reactions.
Synthesis of methyl
1-(3-bromo-5-methylsulfonyl-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00343##
[0495] Similar to General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
2-(3-bromo-5-methylsulfonyl-phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborola-
ne and purified by flash chromatography to afford 163.5 mg of the
title compound (70% yield).
Synthesis of
1-(3-bromo-5-methylsulfonyl-phenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00344##
[0497] Similar to as described in General Procedure H, methyl
1-(3-bromo-5-methylsulfonyl-phenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of methyl
5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00345##
[0499] To a solution of methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate (500 mg, 2.822 mmol) and
sodium acetate (6.0 eq., 1417.5 mg, 16.934 mmol) in acetic acid
(11.3 mL) was added bromine (3.0 eq., 0.43 mL, 8.467 mmol). The
reaction was heated in a sealed tube at 115.degree. C. overnight.
The reaction was then cooled to room temperature, diluted with
isopropyl acetate and concentrated under vacuum. The crude material
was purified by flash chromatography (5-100% iPrOAc in heptanes) to
afford 339.5 mg of a white solid (47%).
Synthesis of methyl
5-bromo-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carboxy-
late and methyl
5-bromo-2-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carboxy-
late
##STR00346##
[0501] To a solution of methyl
5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (339.5 mg, 1.326
mmol) in N,N-dimethylformamide (2.7 mL) cooled to 0.degree. C.
under inert atmosphere was added sodium hydride (60% in mineral
oil, 1.33 eq., 70.1 mg, 1.767 mmol) slowly and the reaction was
stirred at this temperature for 30 minutes.
2-(trimethylsilyl)ethoxymethyl chloride (1.33 eq., 0.31 mL, 1.767
mmol) was added and the reaction was warmed to room temperature and
stirred overnight. The reaction was then quenched with saturated
aqueous ammonium chloride. The solution was extracted 2 times with
iPrOAc. The organic layers were combined, dried with sodium sulfate
and concentrated. The crude material was purified by flash
chromatography (5-30% iPrOAc in heptanes) to afford 337.3 mg and
130.3 mg of each regioisomer as light yellow oils (90%).
Synthesis of methyl
1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00347##
[0503] To a solution of methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate (1000 mg, 5.645 mmol) in
N,N-dimethylformamide (11.3 mL) cooled to 0.degree. C. under inert
atmosphere was added sodium hydride (60% in mineral oil, 1.33 eq.,
300.9 mg, 7.524 mmol) slowly and the reaction was stirred at this
temperature for 30 minutes. 2-(Trimethylsilyl)ethoxymethyl chloride
(1.33 eq., 1.33 mL, 7.524 mmol) was added and the reaction was
warmed to room temperature and stirred overnight. The reaction was
then quenched with saturated aqueous ammonium chloride. The
solution was extracted 2 times with iPrOAc. The organic layers were
combined, dried with sodium sulfate and concentrated. The crude
material was purified by flash chromatography (5-30% iPrOAc in
heptanes) to afford 995 mg of the title compound as a white solid
(57%).
Synthesis of methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2-trimethylsilylethoxy-
methyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00348##
[0505] Under inert atmosphere, methyl
1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carboxylate
(117 mg, 0.381 mmol), bis(pinacolato)diboron (0.878 eq., 85.7 mg),
bis(1,5-cyclooctadiene)di-mu-methoxydiiridium(I) (0.02 eq., 5.0 mg)
and 4,4'-di-tert-butyl-2,2'-bipyridine (0.045 eq., 4.6 mg) were
dissolved in degassed 2-methyltetrahydrofuran (0.38 mL). The
reaction was heated in a sealed vial at 80.degree. C. for 2 h. The
solution was cooled to room temperature, diluted with
dichloromethane, filtered through celite and concentrated under
vacuum. The crude material was purified by flash chromatography
(5-80% 3:1 iPrOAc:MeOH in heptanes) to afford 98 mg of a light
yellow solid (60%).
Synthesis of methyl
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate and
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridi-
ne-3-carboxylic acid
##STR00349##
[0507] To a solution of methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2-trimethylsilylethoxy-
methyl)pyrazolo[3,4-b]pyridine-3-carboxylate (500 mg, 1.154 mmol)
in tetrahydrofuran (11.5 mL) and aqueous sodium hydroxide (2 mass
%) (11.5 mL) was added hydrogen peroxide (35 mass %) in water (10.0
eq., 1.16 mL, 11.54 mmol) at room temperature. The reaction was
stirred at room temperature for 3 h, and then was extracted twice
with EtOAc. The combined organic phases were dried with sodium
sulfate. The solution was concentrated under vacuum to afford 144.5
mg of the title compound methyl
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate as a colorless solid (39%). The crude material was used
directly in subsequent reactions.
[0508] The aqueous layer was acidified with 1N HCl and extracted
twice with dichloromethane. The organic layers were combined, dried
with sodium sulfate and concentrated to afford the acid
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylic acid as a white solid. The crude material was used directly
in subsequent reactions.
Synthesis of methyl
5-hydroxy-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00350##
[0510] Similar as to General Procedure T,
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylic acid (200 mg, 0.646 mmol) in methanol (6.5 mL) and
hydrochloric acid (4.0 M in dioxane, 12.5 eq., 2.02 mL, 8.080 mmol)
was refluxed for 4 hours. After cooling to room temperature,
aqueous saturated sodium bicarbonate was added and the product
extracted twice with EtOAc. The combined organic extracts were
washed with brine, dried with sodium sulfate, filtered and
concentrated under vacuum to afford 72 of the title compound as a
yellow solid (58%).
Synthesis of methyl
5-methoxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate
##STR00351##
[0512] To a small vial was added methyl
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate (100 mg, 0.309 mmol), potassium carbonate (1.5 eq., 64.1 mg,
0.464 mmol), iodomethane (1.2 eq., 0.023 mL, 0.371 mmol) in
N,N-dimethylformamide (0.9 mL). The reaction was stirred at room
temperature for 2 h. Water and iPrOAc were added and the mixture
was extracted 2 times with isopropyl acetate. The organic layers
were combined, washed with brine, dried with sodium sulfate and
concentrated under vacuum to afford a yellow oil. The crude
material was used directly in subsequent reactions.
Synthesis of methyl
5-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00352##
[0514] Similar to as described in General Procedure T, methyl
5-methoxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate was reacted was reacted with hydrochloric acid to afford 59
mg of the title compound (92%).
Synthesis of methyl
1-(3-bromophenyl)-5-methoxy-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00353##
[0516] Similar to General Procedure C methyl
5-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid and purified by flash chromatography to
afford 36 mg of the title compound (35% yield).
Synthesis of
1-(3-bromophenyl)-5-methoxy-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00354##
[0518] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-methoxy-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of methyl
5-fluoro-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbox-
ylate
##STR00355##
[0520] CsF was added to a small vial and dried at 200.degree. C.
for 1 h under high vacuum. To an oven-dried vial containing methyl
5-hydroxy-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbo-
xylate (100 mg, 0.309 mmol) in dry toluene (3.1 mL) under nitrogen
at room temperature was added cesium fluoride (3.0 eq., 142.3 mg,
0.927 mmol) and phenofluor(TM) (1.2 eq., 166.6 mg, 0.371 mmol). The
reaction was stirred at room temperature for 30 minutes then at
110.degree. C. for 20 h. The reaction was then cooled to room
temperature, filtered through celite and concentrated under vacuum.
The crude was purified by flash chromatography (5-50% iPrOAc in
heptanes) to afford 43.5 mg of the title compound (43%).
Synthesis of methyl
5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00356##
[0522] Similar to as described in General Procedure T, methyl
5-fluoro-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carbox-
ylate was reacted was reacted with hydrochloric acid to afford the
title compound.
Synthesis of methyl
1-(3-bromophenyl)-5-fluoro-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00357##
[0524] Similar to General Procedure C methyl
5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid and purified by flash chromatography to
afford 33 mg of the title compound (45% yield).
Synthesis of
1-(3-bromophenyl)-5-fluoro-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00358##
[0526] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-fluoro-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of 6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00359##
[0528] To a solution of 6-chloro-1H-pyrazolo[4,3-c]pyridine (300
mg, 1.953 mmol) in N,N-dimethylformamide (9.8 mL) was added
potassium hydroxide (3.0 eq., 332 mg, 5.861 mmol) followed by
iodine (1.8 eq., 892.4 mg, 3.516 mmol). The reaction was heated to
50.degree. C. for 1.5 hours. The reaction was then cooled to room
temperature and quenched with aqueous sodium thiosulfate until the
dark colour disappeared. The solution was diluted with water and
extracted 2 times with iPrOAc. The organic layers were combined,
dried with sodium sulfate and concentrated to afford 475 mg of a
yellow solid as the title compound (87% yield). The crude material
was used directly in subsequent reactions.
Synthesis of methyl
6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00360##
[0530] To a solution of 6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
(475 mg, 1.699 mmol) in triethylamine (8.0 mL) and methanol (20.0
eq., 1.38 mL, 33.993 mmol) was sparged with nitrogen. palladium(II)
acetate (0.02 eq., 22.9 mg, 0.034 mmol) and xantphos (0.04 eq.,
40.14 mg, 0.068 mmol) were added and a carbon monoxide balloon was
affixed to the vial. The reaction was heated to 50.degree. C. for 6
h. The reaction was cooled to room temperature, diluted with
dichloromethane and filtered over celite. The crude material was
purified by flash chromatography (5-100% iPrOAc in heptanes) to
afford 186.3 mg of the title compound (52%).
Synthesis of methyl
1-(3-bromophenyl)-6-chloro-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00361##
[0532] Similar to General Procedure C methyl
6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid and purified by flash chromatography to
afford 59 mg of the title compound (43% yield).
Synthesis of
1-(3-bromophenyl)-6-chloro-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00362##
[0534] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-6-chloro-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Synthesis of
1-(3-bromophenyl)-6-methoxy-pyrazolo[4,3-c]pyridine-3-carboxylic
acid
##STR00363##
[0536] To a solution of methyl
1-(3-bromophenyl)-6-chloro-pyrazolo[4,3-c]pyridine-3-carboxylate
(63 mg, 0.172 mmol) in N,N-dimethylformamide (0.86 mL) was added
sodium methoxide (3.0 eq., 0.12 mL, 0.515 mmol). The reaction was
stirred at room temperature for 1 h. After 1 h, LCMS analysis
showed saponification of starting material with a small amount of
saponified product. Sodium methoxide (1.0 eq., 0.04 mL) was added
and the reaction was heated to 50.degree. C. for 4 h. The reaction
was cooled to room temperature. 1N aqueous sodium hydroxide
solution was added and the mixture was extracted 2 times with
iPrOAc to remove undesired by-products. The aqueous phase was then
acidified with 1N HCl to pH=1 and extracted twice with
dichloromethane. The organic layers were combined, washed with
brine, dried with sodium sulfate and concentrated under vacuum. The
crude material was used directly in subsequent reactions.
Synthesis of
1-(3-bromophenyl)-6-methoxy-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00364##
[0538] Similar to as described in General Procedure B,
1-(3-bromophenyl)-6-methoxy-pyrazolo[4,3-c]pyridine-3-carboxylic
acid was reacted with ammonium chloride to give the title compound.
The crude material was used directly in subsequent reactions.
Synthesis of methyl
5-cyclopropyl-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-c-
arboxylate
##STR00365##
[0540] A microwave vial was charged with a solution of methyl
5-bromo-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-carboxy-
late (150 mg, 0.388 mmol) and potassium phosphate (3.0 eq., 247 mg,
1.165 mmol) in tetrahydrofuran (1.9 mL) and water (1.9 mL). The
solution was thoroughly purged with nitrogen. Cyclopropylboronic
acid pinacol ester (3.0 eq., 0.21 mL, 1.165 mmol) and
tetrakis(triphenylphosphine)palladium(0) (0.10 eq., 44.9 mg, 0.039
mmol) were added and the vial was sealed immediately. The reaction
was heated in the microwave at 120.degree. C. for 20 minutes. The
reaction was cooled to room temperature, diluted with
dichloromethane and filtered through celite. Water was added and
the mixture was extracted 3 times with dichloromethane. The organic
layers were combined, dried with sodium sulfate and concentrated
under vacuum. The crude material was purified by flash
chromatography (5-100% iPrOAc in heptanes) to give 53.1 mg of a
clear oil as the title compound (39%).
Synthesis of methyl
5-cyclopropyl-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00366##
[0542] Similar to as described in General Procedure T, methyl
5-cyclopropyl-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridine-3-c-
arboxylate was reacted was reacted with hydrochloric acid to afford
the title compound.
Synthesis of methyl
1-(3-bromophenyl)-5-cyclopropyl-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00367##
[0544] Similar to General Procedure C methyl
5-cyclopropyl-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted
with (3-bromophenyl)boronic acid and purified by flash
chromatography to afford 36 mg of the title compound (57%
yield).
Synthesis of
1-(3-bromophenyl)-5-cyclopropyl-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00368##
[0546] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-cyclopropyl-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with formamide and sodium methoxide to give the title
compound. The crude material was used directly in subsequent
reactions.
Example A
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]indazole-3-carboxamide
##STR00369##
[0548] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 41 mg of
the title compound (67%). M+H=376.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.83-8.75 (m, 1H), 8.63-8.58 (m, 1H), 8.35-8.24 (m, 3H),
7.68-7.57 (m, 2H), 7.43 (ddd, J=8.0, 7.1, 0.9 Hz, 1H), 7.38 (dd,
J=5.0, 1.5 Hz, 1H), 6.65 (s, 1H), 3.45-3.35 (m, 2H), 2.83 (s, 3H),
2.54-2.46 (m, 1H), 2.24 (dt, J=12.9, 7.1 Hz, 1H).
Example B
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]pyr-
azolo[3,4-b]pyridine-3-carboxamide
##STR00370##
[0550] Similar to as described in General Procedure E,
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 27
mg of the title compound (34%). M+H=376.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.77 (dd, J=4.5, 1.6 Hz, 1H), 8.67 (dd, J=8.1, 1.7
Hz, 1H), 8.54-8.45 (m, 2H), 8.23 (br s, 1H), 7.70 (br s, 1H),
7.66-7.60 (m, 1H), 7.51 (dd, J=8.1, 4.5 Hz, 1H), 7.48-7.43 (m, 1H),
6.52 (s, 1H), 3.44-3.34 (m, 2H), 2.82 (s, 3H), 2.50-2.42 (m, 1H),
2.22 (dt, J=12.9, 7.0 Hz, 1H).
Example C
Synthesis of
5-fluoro-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]--
2-pyridyl]indazole-3-carboxamide
##STR00371##
[0552] Similar to as described in General Procedure E,
5-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 41
mg of the title compound (37%). M+H=394.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.81 (dd, J=9.4, 4.5 Hz, 1H), 8.61 (dd, J=5.1, 0.7
Hz, 1H), 8.34 (br s, 1H), 8.27 (d, J=1.1 Hz, 1H), 7.94 (dd, J=8.7,
2.6 Hz, 1H), 7.67 (br s, 1H), 7.54 (td, J=9.2, 2.6 Hz, 1H), 7.40
(dd, J=5.0, 1.5 Hz, 1H), 6.65 (s, 1H), 3.45-3.34 (m, 2H), 2.82 (s,
3H), 2.53-2.45 (m, 1H), 2.24 (dt, J=13.5, 7.1 Hz, 1H).
Example D
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00372##
[0554] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 44 mg of the title compound (66%). M+H=380.0; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.54-8.40 (m, 1H), 8.06 (d, J=1.3 Hz, 1H),
7.76 (br s, 1H), 7.34 (dd, J=5.3, 1.4 Hz, 1H), 7.23 (br s, 1H),
6.62 (s, 1H), 3.43-3.34 (m, 2H), 3.10 (t, J=6.0 Hz, 2H), 2.81 (s,
3H), 2.70 (t, J=5.8 Hz, 2H), 2.48-2.41 (m, 1H), 2.28-2.15 (m, 1H),
1.83-1.59 (m, 4H).
Example E
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]pyrazole-3-carboxamide
##STR00373##
[0556] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 49 mg of
the title compound (67%). M+H=326.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.64 (d, J=2.5 Hz, 1H), 8.52 (dd, J=5.0, 0.8 Hz, 1H), 8.07
(d, J=1.2 Hz, 1H), 7.95 (br s, 1H), 7.43 (br s, 1H), 7.42 (dd,
J=5.1, 1.4 Hz, 1H), 6.89 (d, J=2.5 Hz, 1H), 6.65 (s, 1H), 3.43-3.34
(m, 2H), 2.82 (s, 3H), 2.49-2.43 (m, 1H), 2.27-2.18 (m, 1H).
Example F
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-5,6-dihydro-4H-cyclopenta[c]pyrazole-3-carboxamide
##STR00374##
[0558] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-5,6-dihydro-4H-cyclopenta[c]pyrazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 6 mg of the title compound (11%). M+H=365.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.49-8.42 (m, 1H), 8.03 (d, J=1.3 Hz,
1H), 7.75 (br s, 1H), 7.33 (dd, J=5.0, 1.5 Hz, 1H), 7.30 (br s,
1H), 6.63 (s, 1H), 3.40-3.35 (m, 2H), 3.12 (t, J=7.3 Hz, 2H), 2.81
(s, 3H), 2.69 (t, J=7.2 Hz, 2H), 2.58-2.51 (m, 2H), 2.50-2.42 (m,
1H), 2.22 (dt, J=12.9, 7.1 Hz, 1H).
Example G
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-4,-
5,6,7-tetrahydroindazole-3-carboxamide
##STR00375##
[0560] Similar to as described in General Procedure E,
1-(3-bromophenyl)-4,5,6,7-tetrahydroindazole-3-carboxamide was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 30 mg of the title compound (53%). M+H=379.0; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 7.70-7.61 (m, 2H), 7.54 (t, J=7.8 Hz, 1H),
7.49 (br s, 1H), 7.46-7.43 (m, 1H), 7.15 (br s, 1H), 6.48 (s, 1H),
3.40-3.32 (m, 2H), 2.80 (s, 3H), 2.77-2.68 (m, 4H), 2.44 (ddd,
J=12.7, 6.4, 5.0 Hz, 1H), 2.18 (dt, J=13.0, 7.1 Hz, 1H), 1.78-1.65
(m, 4H).
Example H
Synthesis of
(R)-1-(4-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pyridin-2-yl)--
4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carboxamide
##STR00376##
[0562] Similar to as described in General Procedure E,
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-5,7-methanoindazole-3-carbox-
amide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 23 mg of
the title compound (28%). M+H=392.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.46 (d, J=5.0 Hz, 1H), 8.03 (d, J=1.5 Hz, 1H), 7.76 (br s,
1H), 7.36 (dd, J=5.0, 1.5 Hz, 1H), 7.28 (br s, 1H), 6.63 (s, 1H),
4.28 (dd, J=5.4, 5.4 Hz, 1H), 3.43-3.33 (m, 2H), 2.94 (d, J=2.7 Hz,
2H), 2.85-2.78 (m, 1H), 2.81 (s, 3H), 2.57-2.51 (m, 2H), 2.50-2.42
(m, 1H), 2.28-2.17 (m, 1H), 1.56-1.44 (m, 2H).
Example I
Synthesis of
(R)-1-(4-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pyridin-2-yl)--
4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carboxamide
##STR00377##
[0564] Similar to as described in General Procedure E,
1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-4,6-methanoindazole-3-carbox-
amide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 36 mg of
the title compound (58%). M+H=392.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.48 (d, J=4.9 Hz, 1H), 8.13 (d, J=1.2 Hz, 1H), 7.79 (br s,
1H), 7.35 (dd, J=5.0, 1.5 Hz, 1H), 7.27 (br s, 1H), 6.63 (s, 1H),
3.57 (dd, J=5.3, 5.3 Hz, 1H), 3.41 (d, J=2.8 Hz, 2H), 3.42-3.31 (m,
2H), 2.90-2.80 (m, 1H), 2.81 (s, 3H), 2.49-2.37 (m, 3H), 2.27-2.16
(m, 1H), 1.40 (dt, J=8.0, 4.0 Hz, 2H).
Example J
Synthesis of
1-[4-[(3R)-3-hydroxy-3-(5-methylisoxazol-3-yl)but-1-ynyl]-2-pyridyl]-4,5,-
6,7-tetrahydroindazole-3-carboxamide
##STR00378##
[0566] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide was
reacted with (2R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol to give 43
mg of the title compound (67%). M+H=392.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.46 (dd, J=5.1, 0.7 Hz, 1H), 8.06 (d, J=1.2 Hz,
1H), 7.77 (br s, 1H), 7.35 (dd, J=5.0, 1.4 Hz, 1H), 7.23 (br s,
1H), 6.68 (s, 1H), 6.38 (d, J=0.9 Hz, 1H), 3.11 (t, J=5.9 Hz, 2H),
2.70 (t, J=5.6 Hz, 2H), 2.41 (s, 3H), 1.82 (s, 3H), 1.79-1.62 (m,
4H).
Example K and Example L
Synthesis of
(6R)-6-hydroxy-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]eth-
ynyl]-2-pyridyl]-4,5,6,7-tetrahydroindazole-3-carboxamide and
(6S)-6-hydroxy-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]eth-
ynyl]-2-pyridyl]-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00379##
[0568] Similar to as described in General Procedure E,
6-hydroxy-1-(4-iodo-2-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
and the enantiomers were separated by chiral SFC purification to
give 7.3 mg and 7 mg each of the title compounds respectively
(23%).
[0569] M+H=396.0; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.48 (d,
J=4.9 Hz, 1H), 8.06 (d, J=1.3 Hz, 1H), 7.77 (br s, 1H), 7.35 (dd,
J=5.1, 1.4 Hz, 1H), 7.24 (br s, 1H), 6.63 (s, 1H), 4.85 (d, J=3.9
Hz, 1H), 4.05-3.96 (m, 1H), 3.41-3.35 (m, 3H), 2.98 (dd, J=17.5,
6.3 Hz, 1H), 2.86-2.77 (m, 1H), 2.81 (s, 3H), 2.73-2.60 (m, 1H),
2.50-2.42 (m, 1H), 2.27-2.17 (m, 1H), 1.84-1.74 (m, 1H), 1.75-1.61
(m, 1H).
[0570] M+H=396.0; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.48 (d,
J=4.9 Hz, 1H), 8.06 (d, J=1.2 Hz, 1H), 7.77 (br s, 1H), 7.35 (dd,
J=5.0, 1.5 Hz, 1H), 7.24 (br s, 1H), 6.63 (s, 1H), 4.85 (d, J=3.9
Hz, 1H), 4.07-3.94 (m, 1H), 3.42-3.35 (m, 3H), 2.98 (dd, J=17.6,
6.4 Hz, 1H), 2.87-2.77 (m, 1H), 2.81 (s, 3H), 2.73-2.61 (m, 1H),
2.51-2.42 (m, 1H), 2.27-2.16 (m, 1H), 1.85-1.73 (m, 1H), 1.75-1.62
(m, 1H).
Example M
Synthesis of
6-fluoro-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]--
2-pyridyl]indazole-3-carboxamide
##STR00380##
[0572] Similar to as described in General Procedure E,
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 48
mg of the title compound (47%). M+H=394.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.65-8.60 (m, 1H), 8.51 (dd, J=10.1, 2.2 Hz, 1H),
8.34 (br s, 1H), 8.33-8.28 (m, 1H), 8.28-8.24 (m, 1H), 7.67 (br s,
1H), 7.39 (dd, J=5.0, 1.4 Hz, 1H), 7.34 (td, J=9.1, 2.2 Hz, 1H),
6.64 (br s, 1H), 3.44-3.35 (m, 2H), 2.82 (s, 3H), 2.51-2.40 (m,
1H), 2.24 (dt, J=13.7, 7.0 Hz, 1H).
Example N
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-5,5-dimethyl-6,7-dihydro-4H-indazole-3-carboxamide
##STR00381##
[0574] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-5,5-dimethyl-6,7-dihydro-4H-indazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 55 mg of the title compound (66%). M+H=408.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.47 (d, J=5.0 Hz, 1H), 8.07 (d, J=1.3
Hz, 1H), 7.77 (br s, 1H), 7.34 (dd, J=5.1, 1.3 Hz, 1H), 7.24 (br s,
1H), 6.62 (s, 1H), 3.43-3.33 (m, 2H), 3.11 (t, J=6.2 Hz, 2H), 2.81
(s, 3H), 2.52 (s, 2H), 2.49-2.43 (m, 1H), 2.29-2.16 (m, 1H), 1.55
(t, J=6.4 Hz, 2H), 0.97 (s, 6H).
Example O
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-5-methoxy-indazole-3-carboxamide
##STR00382##
[0576] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-5-methoxy-indazole-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 1
mg of the title compound (1%). M+H=406.0
Example P
Synthesis of
5-bromo-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-
-pyridyl]indazole-3-carboxamide
##STR00383##
[0578] Similar to as described in General Procedure E,
5-bromo-1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 10 mg of
the title compound (24%). M+H=454.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.73 (d, J=9.1 Hz, 1H), 8.61 (d, J=5.1 Hz, 1H), 8.44 (d,
J=1.8 Hz, 1H), 8.37 (br s, 1H), 8.27 (s, 1H), 7.77 (dd, J=9.1, 2.0
Hz, 1H), 7.71 (br s, 1H), 7.44-7.36 (m, 1H), 6.65 (s, 1H), 3.39
(td, J=6.7, 5.9, 1.8 Hz, 2H), 2.82 (s, 3H), 2.49-2.44 (m, 1H), 2.24
(dt, J=13.4, 7.0 Hz, 1H).
Example Q
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-ynyl]phenyl]p-
yrazolo[3,4-b]pyridine-3-carboxamide
##STR00384##
[0580] Similar to as described in General Procedure E,
1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxamide was reacted
with (2R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol to give 19
mg of the title compound (37%). M+H=389.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.77 (dd, J=4.5, 1.5 Hz, 1H), 8.67 (dd, J=8.1, 1.5
Hz, 1H), 8.55-8.48 (m, 2H), 8.23 (br s, 1H), 7.70 (br s, 1H),
7.68-7.61 (m, 1H), 7.55-7.45 (m, 2H), 7.07 (s, 1H), 2.56 (s, 3H),
1.94 (s, 3H).
Example R
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-6,-
6-dioxo-5,7-dihydro-4H-thiopyrano[3,4-c]pyrazole-3-carboxamide
##STR00385##
[0582] Similar to as described in General Procedure E,
1-(3-bromophenyl)-6,6-dioxo-5,7-dihydro-4H-thiopyrano[3,4-c]pyrazole-3-ca-
rboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 3 mg of
the title compound (20%). M+H=429.0
Example S
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-5,-
7-dihydro-4H-pyrano[3,4-c]pyrazole-3-carboxamide
##STR00386##
[0584] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5,7-dihydro-4H-pyrano[3,4-c]pyrazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 6 mg of the title compound (24%). M+H=381.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 7.70-7.67 (m, 1H), 7.63 (br s, 1H),
7.57-7.49 (m, 2H), 7.48-7.41 (m, 1H), 7.27 (br s, 1H), 6.49 (br s,
1H), 4.88 (s, 2H), 3.83 (t, J=5.6 Hz, 2H), 3.35 (td, J=6.3, 5.5,
4.2 Hz, 2H), 2.87-2.74 (m, 5H), 2.48-2.39 (m, 1H), 2.19 (dt,
J=12.8, 7.1 Hz, 1H).
Example T
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-6,-
7-dihydro-4H-pyrano[4,3-c]pyrazole-3-carboxamide
##STR00387##
[0586] Similar to as described in General Procedure E,
1-(3-bromophenyl)-6,7-dihydro-4H-pyrano[4,3-c]pyrazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 32 mg of the title compound (38%). M+H=381.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 7.75-7.72 (m, 1H), 7.72-7.61 (m, 2H),
7.56 (t, J=7.9 Hz, 1H), 7.50-7.43 (m, 1H), 7.31 (br s, 1H), 6.48
(s, 1H), 4.76 (s, 2H), 3.81 (t, J=5.4 Hz, 2H), 3.40 3.33 (m, 2H),
2.91 (t, J=5.4 Hz, 2H), 2.80 (s, 3H), 2.44 (ddd, J=12.8, 6.6, 5.0
Hz, 1H), 2.19 (dt, J=12.9, 7.1 Hz, 1H).
Example U
Synthesis of
6-fluoro-1-[4-[2-[(3R)-3-hydroxy-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]indazole-3-carb oxamide
##STR00388##
[0588] Similar to as described in General Procedure E,
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-pyrrolidin-2-one to give 18 mg of the
title compound (30%). M+H=380.0; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.62 (d, J=5.1 Hz, 1H), 8.51 (dd, J=10.4, 2.4 Hz, 1H),
8.40-8.29 (m, 2H), 8.26 (s, 1H), 8.09 (br s, 1H), 7.66 (br s, 1H),
7.40 (dd, J=5.1, 1.1 Hz, 1H), 7.33 (ddd, J=9.1, 9.1, 2.5 Hz, 1H),
6.53 (s, 1H), 3.28 3.18 (m, 2H), 2.55-2.51 (m, 1H), 2.27 (dt,
J=13.4, 7.2 Hz, 1H).
Example V
Synthesis of
6-fluoro-1-[4-[2-[(7R)-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-7-yl]eth-
ynyl]-2-pyridyl]indazole-3-carboxamide
##STR00389##
[0590] Similar to as described in General Procedure E,
6-fluoro-1-(4-iodo-2-pyridyl)indazole-3-carboxamide was reacted
with (7R)-7-ethynyl-5,6-dihydrocyclopenta[b]pyridin-7-ol to give 41
mg of the title compound (63%). M+H=414.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.60 (d, J=5.3 Hz, 1H), 8.51 (dd, J=10.2, 2.4 Hz,
1H), 8.48 (dd, J=5.0, 1.5 Hz, 1H), 8.36-8.29 (m, 2H), 8.24 (d,
J=1.2 Hz, 1H), 7.76 (dd, J=7.9, 1.4 Hz, 1H), 7.65 (br s, 1H), 7.37
(dd, J=5.0, 1.5 Hz, 1H), 7.36-7.29 (m, 2H), 6.37 (br s, 1H), 3.13
3.00 (m, 1H), 2.95 (ddd, J=16.2, 8.2, 4.6 Hz, 1H), 2.62 (ddd,
J=13.1, 8.3, 6.6 Hz, 1H), 2.44 (ddd, J=12.9, 7.8, 4.6 Hz, 1H).
Example W
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-5-methoxy-
-phenyl]pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00390##
[0592] Similar to as described in General Procedure E,
1-(3-bromo-5-methoxy-phenyl)pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 93 mg of the title compound (54%). M+H=406.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.78 (dd, J=4.5, 1.6 Hz, 1H), 8.66 (dd,
J=8.0, 1.3 Hz, 1H), 8.26 (br s, 1H), 8.21-8.16 (m, 1H), 8.13-8.10
(m, 1H), 7.69 (br s, 1H), 7.51 (dd, J=8.1, 4.6 Hz, 1H), 7.03 6.95
(m, 1H), 6.50 (s, 1H), 3.90 (s, 3H), 3.37 (t, J=6.4 Hz, 2H), 2.82
(s, 3H), 2.48 2.42 (m, 1H), 2.21 (dt, J=13.5, 7.0 Hz, 1H).
Example X
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-5--
methoxy-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00391##
[0594] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-methoxy-pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 18 mg of the title compound (44%). M+H=406.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.53 (d, J=3.0 Hz, 1H), 8.48-8.46 (m,
1H), 8.46 8.41 (m, 1H), 8.16 (br s, 1H), 8.02 (d, J=2.8 Hz, 1H),
7.65 (br s, 1H), 7.64-7.59 (m, 1H), 7.46-7.41 (m, 1H), 6.51 (br s,
1H), 3.94 (s, 3H), 3.41-3.34 (m, 2H), 2.81 (s, 3H), 2.50-2.41 (m,
1H), 2.27 2.16 (m, 1H).
Example Y
Synthesis of
5-fluoro-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]p-
henyl]pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00392##
[0596] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-fluoro-pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 12 mg of the title compound (31%). M+H=394.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.84 (dd, J=2.9, 1.5 Hz, 1H), 8.44-8.36
(m, 3H), 8.26 (br s, 1H), 7.74 (br s, 1H), 7.64 (dd, J=7.9, 7.9 Hz,
1H), 7.51-7.42 (m, 1H), 6.53 (s, 1H), 3.42 3.34 (m, 2H), 2.81 (s,
3H), 2.49 2.41 (m, 1H), 2.21 (dt, J=13.0, 7.1 Hz, 1H).
Example Z
Synthesis of
6-chloro-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]p-
henyl]pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00393##
[0598] Similar to as described in General Procedure E,
1-(3-bromophenyl)-6-chloro-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 26 mg of the title compound (45%). M+H=410.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 9.30 (s, 1H), 8.27 (br s, 1H), 8.00 (d,
J=0.8 Hz, 1H), 7.97 7.89 (m, 2H), 7.81 (br s, 1H), 7.65 (dd, J=7.9,
7.9 Hz, 1H), 7.58-7.52 (m, 1H), 6.51 (br s, 1H), 3.41-3.33 (m, 2H),
2.81 (s, 3H), 2.48 2.41 (m, 1H), 2.20 (dt, J=12.5, 7.0 Hz, 1H).
Example AA
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-6--
methoxy-pyraolo[4,3-c]pyridine-3-carboxamide
##STR00394##
[0600] Similar to as described in General Procedure E,
1-(3-bromophenyl)-6-methoxy-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 13 mg of the title compound (22%). M+H=406.2; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 9.15 (s, 1H), 8.15 (br s, 1H), 7.95-7.84
(m, 2H), 7.70 (br s, 1H), 7.63 (dd, J=7.9, 7.9 Hz, 1H), 7.50 (d,
J=7.8 Hz, 1H), 7.10 (s, 1H), 6.50 (br s, 1H), 3.98 (s, 3H), 3.42
3.31 (m, 2H), 2.80 (s, 3H), 2.50-2.41 (m, 1H), 2.20 (dt, J=13.3,
7.1 Hz, 1H).
Example BB
Synthesis of
5-cyclopropyl-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethy-
nyl]phenyl]pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00395##
[0602] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-cyclopropyl-pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 9 mg of the title compound (37%). M+H=416.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.62 (d, J=2.3 Hz, 1H), 8.50-8.48 (m,
1H), 8.47-8.43 (m, 1H), 8.24 (d, J=2.1 Hz, 1H), 8.18 (br s, 1H),
7.67 (br s, 1H), 7.64-7.57 (m, 1H), 7.48-7.39 (m, 1H), 6.52 (s,
1H), 3.44-3.33 (m, 2H), 2.82 (s, 3H), 2.49-2.41 (m, 1H), 2.28-2.14
(m, 2H), 1.15-1.02 (m, 2H), 0.87-0.77 (m, 2H).
Example CC
Synthesis of
1-(3-chloro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of
2-(3-bromo-5-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
##STR00396##
[0604] To a stirred solution of 1-bromo-3-chlorobenzene (1.0 g,
5.22 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), was added
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxabo-
rolane (800 mg, 3.15 mmol, 0.60 equiv),
4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine (43 mg, 0.16
mmol, 0.03 equiv),
bis((1Z,5Z)-cycloocta-1,5-diene)dimethyl-2,4-dioxa-1,3-diiridabic-
yclo[1.1.0]butane-2,4-diium-1,3-diuide (33 mg, 0.05 mmol, 0.01
equiv) under nitrogen. The mixture was stirred for overnight at
80.degree. C. The solid was filtered out and the filtrate was
concentrated under vacuum. Crude product was purified by a silica
gel column with ethyl acetate/petroleum ether (1:10) to give 1.29 g
(78%) of the title compound as colorless oil.
Step 2: Synthesis of methyl
1-(3-bromo-5-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00397##
[0606] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
2-(3-bromo-5-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
to give the title compound (110 mg, 19%) as a white solid. LC-MS
(ES, m/z): 366, 368 [M+1].sup.+, 407, 409
[M+CH.sub.3CN+H].sup.+.
Step 3: Synthesis of methyl
1-(3-chloro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00398##
[0608] Similar to as described in General Procedure E, methyl
1-(3-bromo-5-chlorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (150 mg crude product mixed with
PPh.sub.3O) as an off-white solid. LC-MS (ES, m/z): 425
[M+1].sup.+.
Step 4: Synthesis of
1-(3-chloro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00399##
[0610] Similar to as described in General Procedure S, methyl
1-(3-chloro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
ammonia in methanol to give the title compound (19 mg, 13%) as a
white solid. LC-MS: (ES, m/z): 410 [M+1].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 8.77-8.72 (m, 2H), 8.66-8.62 (m, 2H),
7.53-7.49 (m, 2H), 3.56-3.49 (m, 2H), 2.97 (s, 3H), 2.69-2.61 (m,
1H), 2.41-2.31 (m, 1H).
Example DD
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(pyrimidin-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxamide
Step 1: Synthesis of methyl
1-[3-[(3R)-3-hydroxy-3-(pyrimidin-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxylate
##STR00400##
[0612] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
(2R)-2-(pyrimidin-2-yl)but-3-yn-2-ol to give the title compound
(100 mg, 31%) as yellowish oil. LC-MS (ES, m/z): 399
[M+H].sup.+.
Step 2: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(pyrimidin-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxamide
##STR00401##
[0614] Similar to as described in General Procedure S, methyl
1-[3-[(3R)-3-hydroxy-3-(pyrimidin-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxylate was reacted with ammonia in methanol to give the
title compound (34.3 mg, 35%) as a white solid. LC-MS (ES, m/z):
384 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d6) .delta. 8.89 (d,
J=5.1 Hz, 2H), 8.31 (d, J=8.1 Hz, 1H), 8.02 (s, 1H), 7.92-7.84 (m,
3H), 7.65-7.47 (m, 5H), 7.46-7.37 (m, 1H), 6.26 (s, 1H), 1.89 (s,
3H).
Example EE
Synthesis of
6-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopiperidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl 6-fluoro-1H-indazole-3-carboxylate
##STR00402##
[0616] Similar to as described in General Procedure Z,
6-fluoro-2,3-dihydro-1H-indole-2,3-dione was converted to the title
compound as a yellow solid (1 g, 15%). LC-MS (ES, m/z): 195
[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-6-fluoro-1H-indazole-3-carboxylate
##STR00403##
[0618] Similar to as described in General Procedure C, methyl
6-fluoro-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (600 mg,
83%) as a yellow solid. LC-MS (ES, m/z): 349, 351 [M+H].sup.+.
Step 3: Synthesis of methyl
6-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopiperidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate
##STR00404##
[0620] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-6-fluoro-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpiperidin-2-one to give the
title compound (200 mg, 75%) as a yellow oil. LC-MS (ES, m/z): 422
[M+H].sup.+.
Step 4: Synthesis of
6-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopiperidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
##STR00405##
[0622] Similar to as described in General Procedure S, methyl
6-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopiperidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate was reacted with ammonia in methanol
to give the title compound (30.9 mg, 31%) as a white solid. LC-MS
(ES, m/z): 407 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d6) .delta.
8.33-8.28 (m, 1H), 8.08 (s, 1H), 7.92-7.87 (m, 2H), 7.72-7.60 (m,
3H), 7.51 (d, J=8.1 Hz, 1H), 7.32-7.25 (m, 1H), 6.18 (s, 1H),
3.36-3.31 (m, 2H), 2.86 (s, 3H), 2.21-2.16 (m, 1H), 2.04-1.92 (m,
3H).
Example FF
Synthesis of
1-(3-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of (3-bromo-5-fluorophenyl)boronic acid
##STR00406##
[0624] To a stirred solution of 1,3-dibromo-5-fluorobenzene (1 g,
3.94 mmol, 1.00 equiv) in tetrahydrofuran (20 mL) under nitrogen
was added n-butyl lithium (1.58 mL, 2.5 M) dropwise with stirring
at -78.degree. C. One hour later triisopropyl borate (1.1 g, 1.50
equiv) was added to the stirred mixture slowly and the reaction was
kept for overnight at room temperature. The resulting mixture was
washed with 10 mL of diluted hydrochloric acid and the solid was
collected by filtration to give 120 mg (14%) of the title compound
as a yellow solid. LC-MS (ES, m/z): 217, 219 [M-H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromo-5-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00407##
[0626] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromo-5-fluorophenyl)boronic acid to give the title compound
(100 mg, 31%) as a white solid. LC-MS (ES, m/z): 350, 352
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00408##
[0628] Similar to as described in General Procedure E, methyl
1-(3-bromo-5-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (80 mg, 76%) as a white solid. LC-MS
(ES, m/z): 409 [M+H].sup.+.
Step 4: Synthesis of
1-(3-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00409##
[0630] Similar to as described in General Procedure S, methyl
1-(3-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
ammonia in methanol to give the title compound as a white solid.
LC-MS (ES, m/z): 394 [M+H].sup.+. .sup.1H NMR (CD.sub.3OD) .delta.
8.38 (d, J=5.2 Hz, 1H), 8.15 (d, J=1.6 Hz, 1H), 7.45 (d, J=8.4 Hz,
1H), 7.27 (, J=8.4, 1.6 Hz, 1H), 7.08 (s, 1H), 6.97 (d, J=5.2 Hz,
1H), 6.44 (s, 1H), 6.38 (s, 1H), 4.67-4.62 (m, 2H), 2.41 (s, 3H),
1.81 (s, 3H), 1.45 (t, J=7.2 Hz, 3H).
Example GG
Synthesis of
1-(4-fluoro-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00410##
[0632] Similar to as described in General Procedure O,
3-iodo-1H-pyrazolo[3,4-b]pyridine was reacted with carbon monoxide
to give the title compound (418 mg, 62%) as a white solid. LC-MS
(ES, m/z): 178 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromo-4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00411##
[0634] To a stirred solution of methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate (200.00 mg, 1.13 mmol,
1.00 equiv) in N,N-dimethylformamide (10 ml, 121.20 equiv) was
added 2-bromo-1-fluoro-4-iodobenzene (407.62 mg, 1.35 mmol, 1.20
equiv), copper(I) iodide (21.50 mg, 0.11 mmol, 0.10 equiv), cesium
carbonate (735.65 mg, 2.26 mmol, 2.00 equiv) and
1,10-phenanthroline (40.69 mg, 0.23 mmol, 0.20 equiv). The
resulting solution was stirred for 10 hours at 110.degree. C.,
diluted with ethyl acetate, washed with water, extracted with ethyl
acetate, dried over sodium sulfate, and concentrated under vacuum.
The crude product was purified by a silica gel column with ethyl
acetate/petroleum ether (1:4) to give 20 mg (30%) of the title
compound as a white solid. LC-MS (ES, m/z): 350, 352
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(4-fluoro-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00412##
[0636] Similar to as described in General Procedure E, methyl
1-(3-bromo-4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (80 mg, 57%) as a white solid. LC-MS
(ES, m/z): 409 [M+H].sup.+.
Step 4: Synthesis of
1-(4-fluoro-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00413##
[0638] Similar to as described in General Procedure S, methyl
1-(4-fluoro-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
ammonia in methanol to give the title compound (13.6 mg, 18%) as a
white solid. LC-MS (ES, m/z): 394 [M+H].sup.+. .sup.1H NMR
(CD.sub.3OD) .delta. 8.60 (d, J=6.0 Hz, 2H), 8.49-8.46 (m, 1H),
8.38-8.33 (m, 1H), 7.38-7.34 (m, 1H), 7.24 (t, J=9.0 Hz, 1H),
3.46-3.38 (m, 2H), 2.85 (s, 1H), 2.57-2.49 (m, 1H), 2.29-2.20 (m,
1H).
Example HH
Synthesis of
4,4-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyny-
l]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4,4-difluoro-4,5,6,7-tetrahydro-1H-indazole-3-carboxyla-
te
##STR00414##
[0640] Similar to as described in General Procedure L, ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
was reacted with DAST to give the title compound (110 mg, 80%) as a
red oil. LC-MS (ES, m/z): 385, 387 [M+1].sup.+;
Step 2
##STR00415##
[0642] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-4,4-difluoro-4,5,6,7-tetrahydro-1H-indazole-3-carboxyla-
te was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (165 mg, crude) as a red solid. LC-MS (ES, m/z): 444
[M+1].sup.+.
Step 3: Synthesis of
4,4-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyny-
l]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
##STR00416##
[0644] Similar to as described in General Procedure S, ethyl
4,4-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyny-
l]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted
with ammonia in methanol to give the title compound (25.3 mg, 21%)
as a yellowish solid. LC-MS (ES, m/z): 415 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 7.75 (s, 1H), 7.75-7.56 (m, 3H), 3.49
(dd, J=7.2, 6.0 Hz, 1H), 2.94 (s, 3H), 2.88-2.84 (m, 2H), 2.64-2.56
(m, 1H), 2.37-2.24 (m, 3H), 2.08-2.06 (m, 2H).
Example II
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-7-m-
ethoxy-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl 7-methoxy-1H-indazole-3-carboxylate
##STR00417##
[0646] Similar to as described in General Procedure Z,
7-methoxy-2,3-dihydro-1H-indole-2,3-dione was converted to the
title compound as a yellow solid (yield 700 mg, 12%). LC-MS (ES,
m/z): 207 [M+H].sup.+;
Step 2: Synthesis of methyl
1-(3-bromophenyl)-7-methoxy-1H-indazole-3-carboxylate
##STR00418##
[0648] Similar to as described in General Procedure C, methyl
7-methoxy-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (200 mg,
29%) as a white solid. LC-MS (ES, m/z): 361, 363 [M+H].sup.+;
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-7-m-
ethoxy-1H-indazole-3-carboxylate
##STR00419##
[0650] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-7-methoxy-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (100 mg, 77%) as a yellow solid. LC-MS (ES, m/z):
420 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-7-m-
ethoxy-1H-indazole-3-carboxamide
##STR00420##
[0652] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-7-m-
ethoxy-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (55.9 mg, 58%) as a white
solid. LC-MS (ES, m/z): 405 [M+H].sup.+. .sup.1H NMR (300 MHz,
DMSO-d6) .delta. 7.88-7.84 (m, 2H), 7.67-7.62 (m, 2H), 7.56-7.47
(m, 3H), 7.28 (t, J=7.8 Hz, 1H), 7.03 (d, J=7.5 Hz, 1H), 6.49 (s,
1H), 3.78 (s, 3H), 3.37-3.33 (m, 2H), 2.80 (s, 3H), 2.46-2.42 (m,
1H), 2.20-2.18 (m, 1H).
Example JJ
Synthesis of
4-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of 4-chloro-1H-indazole
##STR00421##
[0654] A solution of 2-chloro-6-fluorobenzaldehyde (10 g, 63.07
mmol, 1.00 equiv) and hydrazine hydrate (80%, 20 g, 399.52 mmol,
6.30 equiv) in ethylene glycol dimethyl ether (20 mL, 206.63 mmol,
3.30 equiv) was heated to reflux overnight. The reaction was
quenched by water, extracted with ethyl acetate, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified on a silica gel column eluting with ethyl
acetate/petroleum ether (1:10) to give 6 g (62%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 153 [M+H].sup.+.
Step 2: Synthesis of 4-chloro-3-iodo-1H-indazole
##STR00422##
[0656] Iodine (21 g, 82.74 mmol, 2.00 equiv) was added dropwise
into a solution of 4-chloro-1H-indazole (6.3 g, 41.29 mmol, 1.00
equiv) and potassium hydroxide (8.4 g, 149.72 mmol, 3.60 equiv) in
N,N-dimethylformamide (100 mL). The resulting solution was stirred
overnight at room temperature, quenched with 200 mL of sat. aq.
Na.sub.2S.sub.2O.sub.3, extracted with ethyl acetate, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified by a silica gel column with ethyl
acetate/petroleum ether (1:5) to give 5 g (43%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 279[M+H].sup.+.
Step 3: Synthesis of methyl 4-chloro-1H-indazole-3-carboxylate
##STR00423##
[0658] Similar to as described in General Procedure O,
4-chloro-3-iodo-1H-indazole was reacted with carbon monoxide to
give the title compound (440 mg, 70%) as a yellow solid. LC-MS (ES,
m/z): 211 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-4-chloro-1H-indazole-3-carboxylate
##STR00424##
[0660] Similar to as described in General Procedure C, methyl
4-chloro-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (100 mg,
12%) as a yellow solid. LC-MS (ES, m/z): 365, 367 [M+H].sup.+.
Step 5: Synthesis of methyl
4-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxylate
##STR00425##
[0662] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-4-chloro-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (100 mg, 37%) as a yellow oil. LC-MS (ES, m/z): 424
[M+H].sup.+.
Step 6: Synthesis of
4-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxamide
##STR00426##
[0664] Similar to as described in General Procedure S, methyl
4-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (29.1 mg) as a white solid.
LC-MS (ES, m/z): 409 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d6)
.delta. 8.14 (br s, 1H), 7.87-7.80 (m, 3H), 7.74 (br s, 1H), 7.65
(t, J=7.8 Hz, 1H), 7.56-7.51 (m, 2H), 7.26 (d, J=7.2 Hz, 1H), 6.54
(s, 1H), 3.38-3.32 (m, 2H), 2.80 (s, 3H), 2.46-2.43 (m, 1H),
2.24-2.15 (m, 1H).
Example KK
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl 6-methoxy-1H-indazole-3-carboxylate
##STR00427##
[0666] Similar to as described in General Procedure Z,
6-methoxy-2,3-dihydro-1H-indole-2,3-dione was converted to the
title compound as a yellow solid (600 mg, 10%). LC-MS (ES, m/z):
207 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-6-methoxy-1H-indazole-3-carboxylate
##STR00428##
[0668] Similar to as described in General Procedure C, methyl
6-methoxy-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (200 mg,
29%) as a white solid. LC-MS (ES, m/z): 361, 363 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-indazole-3-carboxylate
##STR00429##
[0670] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-6-methoxy-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (100 mg, 86%) as a yellow solid. LC-MS (ES, m/z):
420 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-indazole-3-carboxamide
##STR00430##
[0672] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (40.8 mg, 42%) as a white
solid. LC-MS (ES, m/z): 405[M+H].sup.+. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 8.28 (d, J=9.0 Hz, 1H), 7.70 (br s, 1H),
7.65-7.57 (m, 1H), 7.48-7.46 (m, 1H), 6.99-6.91 (m, 3H), 6.05 (br
s, 1H), 4.15 (br s, 1H), 3.87 (s, 3H), 3.51-3.41 (m, 2H), 2.97 (s,
3H), 2.65-2.62 (m, 1H), 2.46-2.39 (m, 1H).
Example LL and MM
Synthesis of
(5R)-5-hydroxy-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamid-
e and
(5S)-5-hydroxy-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carbo-
xamide
Step 1: Synthesis of
5-hydroxy-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic
acid
##STR00431##
[0674] Under a hydrogen (1 atm) atmosphere, a suspension of
5-(benzyloxy)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic
acid (230 mg, 0.77 mmol, 1.00 equiv) and Pd(OH).sub.2/C (107 mg,
0.76 mmol, 1.00 equiv) in acetic acid (40 mL) was stirred overnight
at room temperature. The solid was filtered out and the filtrate
was concentrated under vacuum to give 150 mg (93%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 211 [M+H].sup.+.
Step 2: Synthesis of
5-hydroxy-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indaz-
ole-3-carboxylic acid
##STR00432##
[0676] Similar to as described in General Procedure A,
5-hydroxy-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic
acid was reacted with 2-fluoro-4-iodopyridine to give the title
compound (300 mg, 57%) as yellow oil. LC-MS (ES, m/z): 414
[M+H].sup.+.
Step 3: Synthesis of
5-hydroxy-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indaz-
ole-3-carboxamide
##STR00433##
[0678] Similar to as described in General Procedure B,
5-hydroxy-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indaz-
ole-3-carboxylic acid was reacted with amine hydrochloride to give
the title compound (100 mg, 29%) as a yellow solid. LC-MS (ES,
m/z): 413 [M+H].sup.+.
Step 4: Synthesis of
(5R)-5-hydroxy-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamid-
e and
(5S)-5-hydroxy-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carbo-
xamide
##STR00434##
[0680] Similar to as described in General Procedure E,
5-hydroxy-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indaz-
ole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compounds which were separated by Chiral-Prep-HPLC with the
following conditions: Column, Chiralpak IA, 2.times.25 cm, 5 um;
mobile phase, Hex and ethanol (hold 45.0% ethanol in 75 min);
Detector, UV 254/220 nm. The stereochemistry of both compounds was
arbitrarily assigned.
[0681] Isomer A (5R): white solid; t.sub.R=0.823 min (Chiralpak
IA-3, 25.degree. C., UV-254 nm, Hex (0.1% TEA):EtOH=50:50, 2.0
mL/min). LC-MS (ES, m/z): 424 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.35 (d, J=5.2 Hz, 1H), 7.99 (d, J=1.2 Hz, 1H),
7.23 (dd, J=5.2, 1.2 Hz, 1H), 3.57-3.56 (m, 1H), 3.41-3.37 (m, 2H),
3.04-2.87 (m, 3H), 2.83 (s, 3H), 2.72-2.71 (m, 1H), 2.53-2.47 (m,
1H), 2.27-2.20 (m, 1H), 1.17 (s, 3H), 0.94 (s, 3H).
[0682] Isomer B (5S): white solid, t.sub.R=2.872 min (Chiralpak
IA-3, 25.degree. C., UV-254 nm, Hex (0.1% TEA):EtOH=50:50, 2.0
mL/min). LC-MS (ES, m/z) 424 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.35 (d, J=5.2 Hz, 1H), 7.99 (d, J=1.2 Hz, 1H),
7.23 (dd, J=5.2, 1.2 Hz, 1H), 3.57-3.56 (m, 1H), 3.41-3.37 (m, 2H),
3.04-2.87 (m, 3H), 2.83 (s, 3H), 2.72-2.71 (m, 1H), 2.53-2.47 (m,
1H), 2.27-2.20 (m, 1H), 1.17 (s, 3H), 0.94 (s, 3H).
Example NN
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
meth ylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
Step 1: Synthesis of 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00435##
[0684] A solution of 4-chloro-1H-pyrazolo[4,3-c]pyridine (2 g,
13.02 mmol, 1.00 equiv), iodine (6.6 g, 26.00 mmol, 2.00 equiv),
potassium hydroxide (2.69 g, 47.95 mmol, 3.70 equiv) in 1,4-dioxane
(32 mL) was stirred for 4 h at 75.degree. C. After cooling the
reaction mixture was diluted with 3 mL of saturated sodium
thiosulphate. The precipitate was collected by filtration and
washed with water to afford 2 g (55%) of the title compound as a
yellow solid. LC-MS (ES, m/z): 280[M+H].sup.+
Step 2: Synthesis of
3-iodo-N-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine
##STR00436##
[0686] A solution of 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
(250 mg, 0.89 mmol, 1.00 equiv), methanamine (2 mL) in n-butanol (3
mL) was heated with microwave radiation for 1 h at 160.degree. C.
The mixture was concentrated under vacuum and the residue was
purified by silica gel chromatography eluting with ethyl
acetate/petroleum ether (1:1) to afford 80 mg (33%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 275[M+H].sup.+.
Step 3: Synthesis of methyl
4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00437##
[0688] Similar to as described in General Procedure O,
3-iodo-N-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine was reacted with
carbon monoxide to give the title compound (596 mg, crude) as a
yellow solid. LC-MS (ES, m/z): 207[M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylat-
e
##STR00438##
[0690] Similar to as described in General Procedure C, methyl
4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with (3-bromophenyl)boronic acid to give the title compound
(180 mg, 21%) as a yellow solid. LC-MS (ES, m/z):
362[M+H].sup.+.
Step 5: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00439##
[0692] Similar to as described in General Procedure M, methyl
1-(3-bromophenyl)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylat-
e was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (100 mg, 48%) as a yellow oil. LC-MS (ES, m/z): 420
[M+H].sup.+.
Step 6: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00440##
[0694] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted
with ammonia in methanol to give the title compound (30.4 mg, 32%)
as a white solid. LC-MS: (ES, m/z): 405 [M+H].sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 7.78-7.70 (m, 2H), 7.70-7.68 (m, 1H),
7.53-7.46 (m, 2H), 6.77 (d, J=6.0 Hz, 1H), 3.40-3.35 (m, 2H),
3.03-2.98 (m, 3H), 2.83 (s, 3H), 2.53-2.47 (m, 1H), 2.26-2.19 (m,
1H).
Example OO
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxamide
Step 1: Synthesis of ethyl
5-amino-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate
##STR00441##
[0696] A suspension of (3-bromophenyl)hydrazine hydrochloride (8.86
g, 39.64 mmol, 1.00 equiv), potassium
(Z)-1-cyano-3-ethoxy-3-oxoprop-1-en-2-olate (7.1 g, 39.62 mmol,
1.00 equiv) in ethanol (100 mL) was heated to reflux for 12 h.
After completion the mixture was concentrated under vacuum and the
residue was purified by silica gel column chromatography eluting
with ethyl acetate/petroleum ether (1:2) to afford 9.5 g (77%) of
the title compound as a yellow solid. LC-MS (ES, m/z): 310, 312
[M+H].sup.+.
Step 2: Synthesis of ethyl
5-amino-1-(3-bromophenyl)-4-(cyanosulfanyl)-1H-pyrazole-3-carboxylate
##STR00442##
[0698] A solution of bromine (2.88 g, 18.02 mmol, 2.00 equiv) in
ethanol (5 mL) was added dropwise to a stirred mixture of ethyl
5-amino-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate (2.79 g, 9.00
mmol, 1.00 equiv), potassium thiocyanate (2.62 g, 27.01 mmol, 3.00
equiv) in ethanol (30 mL) at 0.degree. C. After being stirred for
12 h at 0.degree. C. the reaction mixture was diluted with water
and the solution pH was adjusted to 9 with sodium carbonate
solution. The precipitated solid was collected by filtration and
dried under high vacuum to afford 2.8 g (85%) of the title compound
as an off-white solid. LC-MS (ES, m/z): 367, 369 [M+H].sup.+.
Step 3: Synthesis of ethyl
5-amino-4-[[5-amino-[(3-bromophenyl)-3-(ethoxycarbonyl)-1H-pyrazol-4-yl]d-
isulfanyl]-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate
##STR00443##
[0700] Sodium borohydride (114 mg, 2.94 mmol, 1.00 equiv) was added
to a solution of ethyl
5-amino-1-(3-bromophenyl)-4-(cyanosulfanyl)-1H-pyrazole-3-carboxylate
(1.1 g, 3.00 mmol, 1.0 equiv) in ethanol (10 mL). The resulting
mixture was stirred for 1 h at room temperature, quenched with
water, extracted with ethyl acetate, dried over anhydrous sodium
sulfate, and concentrated under vacuum. The residue was purified by
silica gel chromatography eluting with ethyl acetate/petroleum
ether (1:2) to afford 880 mg (43%) of the title compound as a light
yellow solid. LC-MS (ES, m/z): 683, 685 [M+H].sup.+.
Step 4: Synthesis of ethyl
1-(3-bromophenyl)-5-methyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate
##STR00444##
[0702] A mixture of ethyl
5-amino-4-[[5-amino-[(3-bromophenyl)-3-(ethoxycarbonyl)-1H-pyrazol-4-yl]d-
isulfanyl]-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate (800 mg,
1.17 mmol, 1.00 equiv), ethanethioamide (176 mg, 2.34 mmol, 1.00
equiv), hydrochloric acid (0.1 mL) in ethylene glycol (10 mL) was
stirred for 3 h at 100.degree. C. The reaction mixture was diluted
with water, extracted with ethyl acetate, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
purified by silica gel chromatography eluting with ethyl
acetate/petroleum ether (1:3) to afford 75 mg (17%) of the title
compound as an off-white solid. LC-MS (ES, m/z): 366, 368
[M+H].sup.+.
Step 5: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate
##STR00445##
[0704] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5-methyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (100 mg, 86%) as an off-white solid.
LC-MS (ES, m/z): 425 [M+H].sup.+.
Step 6: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxamide
##STR00446##
[0706] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate was reacted
with ammonia in methanol to give the title compound (27 mg, 29%) as
an off-white solid. LC-MS (ES, m/z): 396 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.33 (s, 1H), 8.31 (d, J=7.5 Hz, 1H),
7.59-7.43 (m, 2H), 3.51-3.48 (m, 2H), 2.95 (s, 3H), 2.87 (s, 3H),
2.66-2.59 (m, 1H), 2.39-2.30 (m, 1H).
Example PP
Synthesis of
(4aS,5aR)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
yridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxa-
mide
Step 1: Synthesis of (4aS,5aS)-5a-methyl-1H,3
aH,4H,4aH,5H,5aH,6H,6aH-cyclopropa[f]indazole-3-carboxylic acid
##STR00447##
[0708] Similar to as described in General Procedure J, ethyl
(4aS,5aS)-5a-methyl-1H,3
aH,4H,4aH,5H,5aH,6H,6aH-cyclopropa[f]indazole-3-carboxylate was
reacted with sodium hydroxide to give the title compound (1.6 g,
83%) as an off-white solid. LC-MS (ES, m/z): 195 [M+H].sup.+.
Step 2: Synthesis of
(4aS,5aR)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxylic acid
##STR00448##
[0710] Similar to as described in General Procedure A,
(4aR,5aR)-5a-methyl-1H,3
aH,4H,4aH,5H,5aH,6H,6aH-cyclopropa[f]indazole-3-carboxylic acid was
reacted with 2-fluoro-4-iodopyridine to give the title compound
(366 mg) as a brown solid. LC-MS (ES, m/z): 396 [M+H].sup.+.
Step 3: Synthesis of
(4aS,5aR)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxamide
##STR00449##
[0712] Similar to as described in General Procedure B,
(4aS,5aR)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxylic acid was reacted with ammonium chloride to
give the title compound (260 mg, 72%) as a light yellow solid.
LC-MS (ES, m/z): 395 [M+H].sup.+.
Step 4: Synthesis of
(4aS,5aR)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
yridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxa-
mide
##STR00450##
[0714] Similar to as described in General Procedure E,
(4aS,5aR)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (53.7 mg) as a light yellow solid. The stereochemistry of
the cyclopropyl group was arbitrarily assigned. LC-MS (ES, m/z):
406 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.44 (d,
J=4.8 Hz, 1H), 8.03 (s, 1H), 7.32 (dd, J=5.2, 1.2 Hz, 1H), 3.72 (d,
J=18.0 Hz, 1H), 3.50-3.46 (m, 2H), 3.33-3.28 (m, 1H), 3.06 (d,
J=18.0 Hz, 1H), 3.01-2.95 (m, 1H), 2.92 (s, 3H), 2.61-2.56 (m, 1H),
2.36-2.31 (m, 1H), 1.26 (s, 3H), 1.11-1.09 (m, 1H), 0.39 (dd,
J=8.8, 4.4 Hz, 1H), 0.21 (t, J=5.2 Hz, 1H).
Example QQ
Synthesis of
(4aR,5aS)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
yridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxa-
mide
Step 1: Synthesis of (4aR,5a
S)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]inda-
zole-3-carboxylic acid
##STR00451##
[0716] Similar to as described in General Procedure A,
(4aS,5aS)-5a-methyl-1H,3
aH,4H,4aH,5H,5aH,6H,6aH-cyclopropa[f]indazole-3-carboxylic acid was
reacted with 2-fluoro-4-iodopyridine to give the title compound
(320 mg) as a dark red crude oil which was used for the next step
without purification. LC-MS-(ES, m/z): 396 [M+H].sup.+.
Step 2: Synthesis of
(4aR,5aS)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxamide
##STR00452##
[0718] Similar to as described in General Procedure B,
(4aR,5aS)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxylic acid was reacted with ammonium chloride to
give the title compound (150 mg) as an off-white solid. LC-MS (ES,
m/z): 395 [M+H].sup.+.
Step 3: Synthesis of
(4aR,5aS)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
yridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxa-
mide
##STR00453##
[0720] Similar to as described in General Procedure E,
(4aR,5aS)-1-(4-iodopyridin-2-yl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa-
[f]indazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (14.6 mg, 14%) as a light yellow solid. The
stereochemistry for the cyclopropyl group was arbitrarily assigned.
LC-MS (ES, m/z): 406 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.44 (dd, J=4.8, 0.4 Hz, 1H), 8.03 (s, 1H), 7.32 (dd,
J=5.2, 1.2 Hz, 1H), 3.72 (d, J=18.0 Hz, 1H), 3.50-3.46 (m, 2H),
3.33-3.28 (m, 1H), 3.06 (d, J=18.0 Hz, 1H), 3.01-2.95 (m, 1H), 2.92
(s, 3H), 2.61-2.56 (m, 1H), 2.36-2.31 (m, 1H), 1.26 (s, 3H),
1.11-1.09 (m, 1H), 0.39 (dd, J=8.8, 4.4 Hz, 1H), 0.21 (t, J=5.2 Hz,
1H).
Example RR
Synthesis of
1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]pyridin-2-y-
l)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
Step 1: Synthesis of
1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carb-
oxylic acid
##STR00454##
[0722] Similar to as described in General Procedure A,
6,6-dimethyl-3a,4,5,6,7,7a-hexahydro-1H-indazole-3-carboxylic acid
was reacted with 2-fluoro-4-iodopyridine to give the title compound
(340 mg) as an off-white crude solid. LC-MS (ES, m/z): 398
[M+H].sup.+.
Step 2: Synthesis of
1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carb-
oxamide
##STR00455##
[0724] Similar to as described in General Procedure B,
1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carb-
oxylic acid was reacted with ammonium chloride to give the title
compound (157 mg, 46%) as an off-white solid. LC-MS (ES, m/z): 397
[M+H].sup.+.
Step 3: Synthesis of
1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]pyridin-2-y-
l)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
##STR00456##
[0726] Similar to as described in General Procedure E,
1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carb-
oxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (49.9 mg, 49%) as an off-white solid. LC-MS (ES, m/z): 408
[M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.43 (dd,
J=5.1, 0.6 Hz, 1H), 8.07 (s, 1H), 7.33 (dd, J=5.1, 1.5 Hz, 1H),
3.49 (dd, J=7.2, 5.7 Hz, 2H), 2.96-2.94 (m, 5H), 2.82 (t, J=6.3 Hz,
2H), 2.65-2.57 (m, 1H), 2.33-2.29 (m, 1H), 1.57 (t, J=6.3 Hz, 2H),
1.04 (s, 6H).
Example SS
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(1R)-1-hydroxy ethyl]-1H-indazole-3-carboxamide and
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(1S)-1-hydroxy ethyl]-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(1-hydroxyethyl)-1H-indazole-3-carboxylate
##STR00457##
[0728] Under nitrogen methyl magnesium bromide (3M in Et.sub.2O,
0.64 mL, 1.91 mmol, 2.90 equiv) was added dropwise to a stirred
solution of methyl
1-(3-bromophenyl)-5-formyl-1H-indazole-3-carboxylate (240 mg, 0.67
mmol, 1.00 equiv) in tetrahydrofuran (20 mL) at 0.degree. C. After
being stirred for 40 min at 0.degree. C. the reaction was quenched
by ammonium chloride solution, extracted with ethyl acetate, dried
over anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified by a silica gel column eluting with ethyl
acetate/petroleum ether (1:3) to afford 160 mg (64%) of the title
compound as an off-white solid. LC-MS (ES, m/z): 375
[M+H].sup.+
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
1-hydroxyethyl)-1H-indazole-3-carboxylate
##STR00458##
[0730] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-(1-hydroxyethyl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (200 mg, crude) as a yellow solid. LC-MS
(ES, m/z): 434 [M+H]
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(1R)-1-hydroxy ethyl]-1H-indazole-3-carboxamide and
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(1S)-1-hydroxy ethyl]-1H-indazole-3-carboxamide
##STR00459##
[0732] Similar to as described in General Procedure S,
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
1-hydroxyethyl)-1H-indazole-3-carboxylate was reacted with ammonia
in methanol to give the title compounds which were separated by
Chiral-Prep-HPLC with the following conditions: Column, CHIRALPAK
OJ-H, 2.times.25 cm; mobile phase, Hex and ethanol (hold 40.0%
ethanol in 19 min); Detector, UV 254/220 nm. The stereochemistry of
the two isomers was arbitrarily assigned.
[0733] Isomer A (5R): 47.1 mg (24%), off-white solid. t.sub.R=7.21
min (Chiralcel OJ-3, 25.degree. C., UV-254 nm, Hex (0.1% TEA):EtOH
60:40, 1.0 mL/min). LC-MS (ES, m/z): 419 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.36 (s, 1H), 7.96 (t, J=1.8 Hz, 1H),
7.87-7.83 (m, 2H), 7.66-7.58 (m, 3H), 5.03-4.96 (m, 1H), 3.53-3.49
(m, 2H), 2.96 (s, 3H), 2.80-2.65 (m, 1H), 2.37-2.29 (m, 1H), 1.55
(d, J=6.6 Hz, 3H).
[0734] Isomer B (5S): 51.1 mg (26%), off-white solid. t.sub.R=10.10
min (Chiralcel OJ-3, 25.degree. C., UV-254 nm, Hex (0.1% TEA):EtOH
60:40, 1.0 mL/min). LC-MS (ES, m/z): 419 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.32 (s, 1H), 7.92 (t, J=1.8 Hz, 1H),
7.86-7.79 (m, 2H), 7.62-7.55 (m, 3H), 5.03-4.96 (m, 1H), 3.50-3.45
(m, 2H), 2.92 (s, 3H), 2.63-2.55 (m, 1H), 2.36-2.27 (m, 1H), 1.54
(d, J=6.6 Hz, 3H).
Example TT
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
hydroxymethyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
hydroxymethyl)-1H-indazole-3-carboxylate
##STR00460##
[0736] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (100 mg, crude) as a yellow solid. LC-MS
(ES, m/z): 420 [M+H].sup.+.
Step 2: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
hydroxymethyl)-1H-indazole-3-carboxamide
##STR00461##
[0738] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
hydroxymethyl)-1H-indazole-3-carboxylate was reacted with ammonia
in methanol to give the title compound (10.3 mg, 11%) of as an
off-white solid. LC-MS (ES, m/z): 405 [M+H].sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.35 (s, 1H), 7.96 (s, 1H), 7.89-7.83 (m,
2H), 7.65-7.56 (m, 3H), 4.78 (s, 2H), 3.55-3.46 (m, 2H), 2.95 (s,
3H), 2.65-2.59 (m, 1H), 2.37-2.31 (m, 1H).
Example UU
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
oxetan-3-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-(oxetan-3-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine--
3-carboxylate
##STR00462##
[0740] Sodium cyanoborohydride (540 mg, 8.59 mmol, 3.30 equiv) was
added in portions to a stirred solution of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
(TFA salt, 1.2 g, 2.58 mmol, 1.00 equiv), oxetan-3-one (1.2 g,
16.65 mmol, 6.40 equiv), acetic acid (5 mL) in tetrahydrofuran (40
mL) at 0.degree. C. The reaction mixture was stirred for 30 min at
room temperature, quenched with saturated ammonium chloride
solution, extracted with ethyl acetate, washed with brine, dried
over anhydrous sodium sulfate, and concentrated under vacuum. This
resulted in 1.2 g (crude) of the title compound as a yellow solid.
LC-MS (ES, m/z): 392 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
oxetan-3-yl)-1H,3aH,4H,5H,6H,7H,7aH-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00463##
[0742] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5-(oxetan-3-yl)-1H,3aH,4H,5H,6H,7H,7aH-pyrazolo[4,3-c]p-
yridine-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (400 mg, crude) as a yellow solid. LC-MS (ES, m/z): 451
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
oxetan-3-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00464##
[0744] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
oxetan-3-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia in methanol to give the title compound
(50.8 mg, 11%) as an off-white solid. LC-MS (ES, m/z): 436
[M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.78 (s,
1H), 7.68-7.66 (m, 1H), 7.56-7.54 (m, 2H), 4.82 (t, J=6.6 Hz, 2H),
4.72 (t, J=6.3 Hz, 2H), 3.88-3.84 (m, 1H), 3.71 (s, 2H), 3.50 (t,
J=5.7 Hz, 2H), 2.99-2.97 (m, 2H), 2.95 (s, 3H), 2.71 (t, J=5.7 Hz,
2H), 2.61-2.59 (m, 1H), 2.39-2.32 (m, 1H).
Example VV
Synthesis of
4-fluoro-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]py-
ridin-2-yl)-1H-indazole-3-carboxamide
Step 1: Synthesis of 4-fluoro-3-iodo-1H-indazole
##STR00465##
[0746] A suspension of 4-fluoro-1H-indazole (500 mg, 3.67 mmol,
1.00 equiv), iodine (1.87 g, 2.00 equiv) and potassium hydroxide
(741 mg, 13.21 mmol, 3.60 equiv) in N,N-dimethylformamide (5 mL)
was stirred overnight at room temperature. The reaction was
quenched by 10% aqueous NaHSO.sub.3, extracted with ethyl acetate,
washed with brine, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The resulting solid was washed with
petroleum ether to give 800 mg (83%) of the title compound as a
yellow solid. LC-MS (ES, m/z): 263 [M+H].sup.+.
Step 2: Synthesis of methyl 4-fluoro-1H-indazole-3-carboxylate
##STR00466##
[0748] Similar to as described in General Procedure O,
4-fluoro-3-iodo-1H-indazole was reacted with carbon monoxide to
give the title compound (210 mg, 71%) as a yellow solid. LC-MS (ES,
m/z): 195 [M+H].sup.+.
Step 3: Synthesis of methyl
4-fluoro-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxylate
##STR00467##
[0750] Similar to as described in General Procedure A, methyl
4-fluoro-1H-indazole-3-carboxylate was reacted with
2-fluoro-4-iodopyridine to give the title compound (120 mg, 27%) as
a white solid. LC-MS (ES, m/z): 398 [M+H].sup.+.
Step 4: Synthesis of methyl
4-fluoro-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]py-
ridin-2-yl)-1H-indazole-3-carboxylate
##STR00468##
[0752] Similar to as described in General Procedure E, methyl
4-fluoro-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (85 mg, 75%) as a yellow solid. LC-MS (ES,
m/z): 409[M+H].sup.+.
Step 5: Synthesis of
4-fluoro-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]py-
ridin-2-yl)-1H-indazole-3-carboxamide
##STR00469##
[0754] Similar to as described in General Procedure S, methyl
4-fluoro-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]py-
ridin-2-yl)-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (28.1 mg, 34%) as a white
solid. LC-MS (ES, m/z): 394 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.70 (d, J=8.7 Hz, 1H), 8.57 (dd, J=5.1, 0.6
Hz, 1H), 8.27 (s, 1H), 7.61-7.54 (m, 1H), 7.39-7.36 (m, 1H),
7.14-7.08 (m, 1H), 3.53-3.46 (m, 2H), 2.95 (s, 3H), 2.68-2.60 (m,
1H), 2.40-2.31 (m, 1H).
Example WW and Example XX
Synthesis of
(4R)-4-C-cyclopropane-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
and
(4S)-4-C-cyclopropane-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
Step 1: Synthesis of ethyl
1-(4-iodopyridin-2-yl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00470##
[0756] Similar to as described in General Procedure A, ethyl
4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted with
2-fluoro-4-iodopyridine to give the title compound (420 mg, 71%) as
a yellow solid. LC-MS (ES, m/z): 412 [M+H].sup.+.
Step 2: Synthesis of
4-amino-1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxami-
de
##STR00471##
[0758] A solution of ethyl
1-(4-iodopyridin-2-yl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
(420 mg, 1.02 mmol, 1.00 equiv), Ti(i-PrO).sub.4 (579 mg, 2.00
equiv) in methanol (saturated with ammonia, 5 mL) was stirred for 3
h at room temperature. Sodium borohydride (58 mg, 1.53 mmol, 1.5
equiv) was added and the resulting solution was stirred for 3 h at
room temperature. The reaction was quenched by water, extracted
with ethyl acetate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified on a silica gel
column with dichloromethane/methanol (10:1) to give 320 mg (82%) of
the title compound as a yellow solid. LC-MS (ES, m/z): 384
[M+H].sup.+.
Step 3: Synthesis of
4-C-cyclopropane-1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,-
4-diamido
##STR00472##
[0760] Cyclopropanecarbonyl chloride (255 mg, 2.44 mmol, 3.00
equiv) was added to a suspension of
4-amino-1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxami-
de (310 mg, 0.81 mmol, 1.00 equiv), and cesium carbonate (1.06 g,
3.25 mmol, 4.00 equiv) in N,N-dimethylformamide (2 mL) at room
temperature. After 6 h the mixture was diluted with water,
extracted with ethyl acetate, washed with brine, dried over
anhydrous sodium sulfate and, concentrated under vacuum. The
residue was purified on a silica gel column with
dichloromethane/methanol (10:1) to give 200 mg (55%) of the title
compound as a white solid. LC-MS (ES, m/z): 452 [M+H].sup.+.
Step 4:
(4R)-4-C-cyclopropane-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrol-
idin-3-yl]ethynyl]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
and
(4S)-4-C-cyclopropane-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidi-
n-3-yl]ethynyl]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
##STR00473##
[0762] Similar to as described in General Procedure E,
4-C-cyclopropane-1-(4-iodopyridin-2-yl)-4,5,6,7-tetrahydro-1H-indazole-3,-
4-diamido was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give a mixture
of the title compounds which were separated by Chiral-Prep-HPLC
with the following conditions (Prep-HPLC-032): Column, Chiralpak
AD-H, 2.times.25 cm; mobile phase, Hex and ethanol (hold 50.0%
ethanol in 55 min); Detector, UV 254/220 nm. The stereochemistry at
position 4 was arbitrarily assigned for both isomers.
[0763] Isomer A (5R): 25.2 mg (27%) as a light yellow solid.
t.sub.R=1.39 min (CHIRALPAK IA-3, 25.degree. C., 254 nm, Hex (0.1%
TEA):EtOH 50:50, 1.2 mL/min). LC-MS (ES, m/z): 463 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.45 (d, J=5.1 Hz, 1H),
8.10 (s, 1H), 7.36 (d, J=5.1 Hz, 1H), 5.35-5.34 (m, 1H), 3.52-3.43
(m, 3H), 3.05-3.02 (m, 1H), 2.94 (s, 3H), 2.65-2.57 (m, 1H),
2.39-2.29 (m, 1H), 2.07-2.02 (m, 1H), 1.90-1.81 (m, 2H), 1.77-1.73
(m, 1H), 1.55-1.50 (m, 1H), 0.96-0.82 (m, 2H), 0.72-0.69 (m,
2H).
[0764] Isomer B (5S): 18.6 mg (20%) as a white solid. t.sub.R=2.20
min (CHIRALPAK IA-3, 25.degree. C., 254 nm, Hex (0.1%
TEA):EtOH=50:50, 1.2 mL/min). LC-MS (ES, m/z): 463 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.45 (d, J=5.1 Hz, 1H),
8.10 (s, 1H), 7.36 (d, J=5.1 Hz, 1H), 5.35-5.34 (m, 1H), 3.52-3.43
(m, 3H), 3.05-3.02 (m, 1H), 2.94 (s, 3H), 2.65-2.57 (m, 1H),
2.39-2.29 (m, 1H), 2.07-2.02 (m, 1H), 1.90-1.81 (m, 2H), 1.77-1.73
(m, 1H), 1.55-1.50 (m, 1H), 0.96-0.82 (m, 2H), 0.72-0.69 (m,
2H).
Example YY and Example ZZ
Synthesis of ethyl
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
and ethyl
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-y-
l]ethynyl]phenyl)-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00474##
[0766] Similar to as described in General Procedure C, ethyl
4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (1 g, 19%)
as a yellow solid. LC-MS (ES, m/z): 363, 365 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-car-
boxylate
##STR00475##
[0768] Under an inert atmosphere of nitrogen trimethyl aluminium
(2.0 M in toluene, 1.54 mL, 1.2 equiv) was added into a solution of
ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
(930 mg, 2.56 mmol, 1.00 equiv) in dichloromethane (25 mL) at
0.degree. C. After being stirred for 2 h the reaction was quenched
by water, extracted with dichloromethane, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
purified on a silica gel column with ethyl acetate/petroleum ether
(1:10) to give 700 mg (71%) of the title compound as a yellow oil.
LC-MS (ES, m/z): 379, 381 [M+H].sup.+.
Step 3: Synthesis of ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-4-meth yl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00476##
[0770] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-4-hydroxy-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-car-
boxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (230 mg) as yellow oil. LC-MS (ES, m/z): 438
[M+H].sup.+.
Step 4: Synthesis of
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
and
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00477##
[0772] Similar to as described in General Procedure S, ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-4-methyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was
reacted with ammonia in methanol to give the two title compounds
which were separated by Chiral-Prep-HPLC with the following
conditions: Column, Chiralpak IC, 2.times.25 cm, 5 um; mobile
phase, methanol; Detector, UV 254/220 nm. The stereochemistry at
position 4 was arbitrary assigned.
[0773] Isomer A (4S): 32.2 mg (21%), white solid. t.sub.R=5.98 min
(Chiralpak IC, 25.degree. C., UV-254 nm, MeOH, 1.0 mL/min). LC-MS
(ES, m/z): 391 [M-18+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.13 (s, 1H), 7.77 (s, 1H), 7.70 (s, 1H), 7.66 (t, J=8.0
Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.47 (d, J=8.0 Hz, 1H), 6.51 (s,
1H), 6.30 (s, 1H), 3.37-3.30 (m, 2H), 2.84-2.80 (m, 4H), 2.67-2.61
(m, 1H), 2.51-2.41 (m, 1H), 2.22-2.17 (m, 1H), 2.15-1.95 (m, 1H),
1.93-1.73 (m, 3H), 1.42 (s, 3H).
[0774] Isomer B (4R): 32.9 mg (21%), white solid. t.sub.R=7.21 min
(Chiralpak IC, 25.degree. C., UV-254 nm, MeOH, 1.0 mL/min). LC-MS
(ES, m/z): 391 [M-18+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 8.11 (s, 1H), 7.74 (s, 1H), 7.70 (s, 1H), 7.66 (t, J=8.0
Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.47 (d, J=8.0 Hz, 1H), 6.49 (s,
1H), 6.28 (s, 1H), 3.37-3.30 (m, 2H), 2.84-2.80 (m, 4H), 2.67-2.61
(m, 1H), 2.51-2.41 (m, 1H), 2.22-2.17 (m, 1H), 2.15-1.95 (m, 1H),
1.93-1.73 (m, 3H), 1.42 (s, 3H).
Example AAA
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxylate
##STR00478##
[0776] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
(2R)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol to give the
title compound (140 mg, 77%) as a light yellow solid. LC-MS (ES,
m/z): 403[M+H].sup.+.
Step 2: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxamide
##STR00479##
[0778] Similar to as described in General Procedure S, methyl
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxylate was reacted with ammonia in methanol
to give the title compound (82.7 mg, 61%) as a white solid. LC-MS
(ES, m/z): 388 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.36 (d, J=8.0 Hz, 1H), 7.98 (s, 1H), 7.91-7.85 (m, 2H),
7.67-7.55 (m, 3H), 7.41 (t, J=7.2 Hz, 1H), 2.60 (s, 3H), 2.02 (s,
3H).
Example BBB
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(pyridazin-3-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxamide
Step 1: Synthesis of 1-(3-iodophenyl)-1H-indazole-3-carboxamide
##STR00480##
[0780] Similar to as described in General Procedure S, methyl
1-(3-iodophenyl)-1H-indazole-3-carboxylate was reacted with ammonia
in methanol to give the title compound (900 mg, 89%) as a white
solid. LC-MS (ES, m/z): 364 [M+H].sup.+.
Step 2: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(pyridazin-3-yl)but-1-yn-1-yl]phenyl]-1H-indazole--
3-carboxamide
##STR00481##
[0782] Similar to as described in General Procedure E,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
(2R)-2-(pyridazin-3-yl)but-3-yn-2-ol to give the title compound
(49.4 mg, 31%) as a green solid. LC-MS (ES, m/z): 384 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 9.06-9.05 (m, 1H), 8.25
(d, J=8.0 Hz, 1H), 8.07-8.04 (dd, J=8.4, 1.6 Hz, 1H), 7.84 (s, 1H),
7.76-7.68 (m, 3H), 7.53-7.43 (m, 3H), 7.29 (t, J=7.6 Hz, 1H), 1.91
(s, 3H).
Example CCC and Example DDD
Synthesis of
(4R)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl-
)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
and
(4S)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl-
)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-chloro-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00482##
[0784] To a solution of ethyl
1-(3-bromophenyl)-4-hydroxy-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
(300 mg, 0.82 mmol, 1.00 equiv) in dichloromethane (4 mL) was added
thionyl chloride (2 mL, 27.57 mmol) and stirred for overnight at
room temperature. The resulting mixture was concentrated under
vacuum to give 280 mg (89%) of the title compound as a white
solid.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-ca-
rboxylate
##STR00483##
[0786] To a solution of ethyl
1-(3-bromophenyl)-4-chloro-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
(280 mg, 0.73 mmol, 1.00 equiv) in dichloromethane (5 mL) was added
1H-pyrazole (99 mg, 1.45 mmol, 2.00 equiv), cesium carbonate (714
mg, 2.19 mmol, 3.00 equiv) and the reaction was stirred overnight
at room temperature. The reaction mixture was diluted with
dichloromethane (20 mL), washed with brine (20 mL), concentrated
under vacuum and the crude product was purified by a silica gel
column with ethyl acetate/petroleum ether (1:2) to give 240 mg
(79%) of the title compound as a colorless oil. LC-MS (ES, m/z):
415, 417 [M+H].sup.+.
Step 3: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00484##
[0788] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-ca-
rboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (240 mg, 92%) as a red solid. LC-MS (ES, m/z): 474
[M+H].sup.+.
Step 4: Synthesis of
(4R)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl-
)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
and
(4S)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl-
)-4-(1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
##STR00485##
[0790] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-(-
1H-pyrazol-1-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was
reacted with ammonia in methanol to give the two title compounds
which were separated by Chiral-Prep-HPLC with the following
conditions: Column, Chiralpak AD-H, 2.times.25 cm; mobile phase,
Hex-HPLC and ethanol-HPLC (hold 40% ethanol-HPLC in 38 min);
Detector, UV 254/220 nm. The stereochemistry at position 4 was
arbitrary assigned.
[0791] Isomer A (4R): 16.4 mg, 7%), white solid. t.sub.R=7.8 min
(CHIRALPAK AD-H, 25.degree. C., UV-254 nm, Hex (0.1%
TEA):EtOH=50:50, 1.0 ml/min). LC-MS (ES, m/z): 445 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.82 (s, 1H), 7.73-7.69
(m, 1H), 7.59-7.57 (m, 2H), 7.48-7.46 (m, 2H), 6.23 (t, J=2.1 Hz,
1H), 5.99 (t, J=4.2 Hz, 1H), 3.53-3.49 (m, 2H), 2.96 (s, 3H),
2.91-2.86 (m, 2H), 2.66-2.58 (m, 1H), 2.39-2.24 (m, 3H), 1.98-1.72
(m, 2H).
[0792] Isomer B (4S): 30.3 mg (13%), white solid. t.sub.R=13.1 min
(CHIRALPAK AD-H, 25.degree. C., UV-254 nm, Hex (0.1%
TEA):EtOH=50:50, 1.0 ml/min). LC-MS (ES, m/z): 445 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.82 (s, 1H), 7.72-7.69
(m, 1H), 7.58 (d, J=5.2 Hz, 2H), 7.46, (d, J=2, 8 Hz, 2H), 6.22 (t,
J=2.0 Hz, 1H), 5.98 (t, J=4.0 Hz, 1H), 3.51-3.48 (m, 2H), 2.95 (s,
3H), 2.90-2.86 (m, 2H), 2.64-2.58 (m, 1H), 2.37-2.24 (m, 3H),
1.91-1.88 (m, 1H), 1.79-1.77 (m, 1H).
Example EEE
Synthesis of tert-butyl
3-carbamoyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl-
]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carboxylate
Step 1: Synthesis of tert-butyl
3-(2-ethoxy-2-oxoacetyl)-4-oxopiperidine-1-carboxylate
##STR00486##
[0794] Similar to as described in General Procedure Y Step 1,
tert-butyl 4-oxopiperidine-1-carboxylate was reacted with diethyl
oxalate to give the title compound (13.0 g, 43%) as a yellow solid.
LC-MS (ES, m/z): 300 [M+H].sup.+.
Step 2: Synthesis of 5-tert-butyl 3-ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylat-
e
##STR00487##
[0796] Similar to as described in General Procedure Y Step 2,
tert-butyl 3-(2-ethoxy-2-oxoacetyl)-4-oxopiperidine-1-carboxylate
was reacted with (3-bromophenyl)hydrazine hydrochloride to give the
title compound (500 mg, 11%) as a yellow solid. LC-MS (ES, m/z):
450, 452 [M+H].sup.+.
Step 3: Synthesis of 5-tert-butyl 3-ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate
##STR00488##
[0798] Similar to as described in General Procedure E, 5-tert-butyl
3-ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dica-
rboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (310 mg, 91%) as a yellow solid. LC-MS (ES, m/z): 509
[M+H].sup.+.
Step 4: Synthesis of tert-butyl
3-carbamoyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl-
]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carboxylate
##STR00489##
[0800] Similar to as described in General Procedure S, 5-tert-butyl
3-ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate was
reacted with ammonia in methanol to give the title compound (150
mg, 50%) as a white solid. LC-MS (ES, m/z): 424 [M-56].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.75 (s, 1H), 7.67-7.61
(m, 1H), 7.57-7.51 (m, 2H), 4.72 (s, 2H), 3.72 (t, J=5.4 Hz, 2H),
3.51-3.47 (m, 2H), 2.95-2.88 (m, 5H), 2.65-2.57 (m, 1H), 2.38-2.28
(m, 1H), 1.52 (s, 9H).
Example FFF
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00490##
[0802] HCl (gas) was introduced into a suspension of tert-butyl
3-carbamoyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl-
]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carboxylate (100
mg, 0.21 mmol, 1.00 equiv) in diethyl ether (5 mL) and stirred for
1 h at 25.degree. C. The resulting mixture was concentrated under
vacuum and the crude product (90 mg) was purified by Prep-HPLC with
the following conditions: Column, Xbridge RP18 19.times.150; mobile
phase, water with 0.05% NH.sub.3 and MeCN (10.0% MeCN up to 30.0%
in 8 min); Detector, 254/220 nm to give 24 mg (30%) of the title
compound as a white solid. LC-MS (ES, m/z): 380 [M+1].sup.+, 759
[2M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.63 (s,
1H), 7.54-7.51 (m, 1H), 7.44-7.39 (m, 2H), 3.97 (s, 2H), 3.39-3.36
(m, 2H), 2.95 (t, J=5.6 Hz, 2H), 2.83 (s, 3H), 2.76-2.69 (m, 2H),
2.51-2.45 (m, 1H), 2.25-2.18 (m, 1H).
Example GGG
Synthesis of
5-acetyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00491##
[0804] Trifluoroacetic acid (2.5 mL, 33.66 mmol, 30.30 equiv) was
added dropwise into a solution of 5-tert-butyl 3-ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylat-
e (500 mg, 1.11 mmol, 1.00 equiv) in dichloromethane (10 mL, 157.30
mmol, 141.70 equiv) and the reaction mixture was stirred for 1 h at
25.degree. C. The resulting mixture was concentrated under vacuum
to give 450 mg (87%) of crude ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
trifluoroacetic acid salt as a yellow solid. LC-MS (ES, m/z): 350,
352 [M+H].sup.+.
Step 2: Synthesis of ethyl
5-acetyl-1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carbo-
xylate
##STR00492##
[0806] Acetyl chloride (32 mg, 0.41 mmol, 1.20 equiv) was added
into a solution of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
trifluoroacetic acid salt (150 mg, 0.32 mmol, 1.00 equiv) and
triethylamine (102 mg, 1.01 mmol, 3.00 equiv) in tetrahydrofuran (5
mL) and the reaction was stirred for 1 h at 0.degree. C. The
reaction was then quenched by 3 mL of brine, extracted with ethyl
acetate, dried over anhydrous sodium sulfate, and concentrated
under vacuum. The residue was purified on a silica gel column with
ethyl acetate/petroleum ether (3:2) to give 70 mg (55%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 392, 394
[M+H].sup.+.
Step 3: Synthesis of ethyl
5-acetyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00493##
[0808] Similar to as described in General Procedure E, ethyl
5-acetyl-1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carbo-
xylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give 65 mg of
the title compound as a yellow solid. LC-MS (ES, m/z): 451
[M+H].sup.+.
Step 4: Synthesis of
5-acetyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00494##
[0810] Similar to as described in General Procedure S, ethyl
5-acetyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with ammonia in methanol to give the title compound (19.3
mg, 32%) as a white solid. LC-MS (ES, m/z): 422 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.64 (s, 1H), 7.55-7.51
(m, 1H), 7.45-7.41 (m, 2H), 4.73 (d, J=10.4 Hz, 2H), 3.77 (t, J=6.0
Hz, 1H), 3.68 (t, J=5.6 Hz, 1H), 3.38 (t, J=5.6 Hz, 2H), 2.90 (t,
J=5.6 Hz, 1H), 2.83-2.78 (m, 4H), 2.51-2.45 (m, 1H), 2.25-2.18 (m,
1H), 2.13 (s, 3H).
Example HHH
Synthesis of
5-cyclopropanecarbonyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-
-yl]ethynyl]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-cyclopropanecarbonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]py-
ridine-3-carboxylate
##STR00495##
[0812] Cyclopropanecarbonyl chloride (42 mg, 0.40 mmol, 1.20 equiv)
was added into a solution of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
trifluoroacetic acid salt (150 mg, 0.32 mmol, 1.00 equiv) and
triethylamine (102 mg, 1.01 mmol, 3.00 equiv) in THF (5 mL), and
the reaction was stirred at 0.degree. C. After 1 h the reaction was
quenched with 3 mL of brine, extracted with ethyl acetate, dried
over anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified on a silica gel column with ethyl
acetate/petroleum ether (1:2) to give 70 mg (52%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 418, 420
[M+H].sup.+.
Step 2: Synthesis of ethyl
5-cyclopropanecarbonyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-
-yl]ethynyl]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00496##
[0814] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5-cyclopropanecarbonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]py-
ridine-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give 50 mg of
the title compound (crude) as a yellow solid. LC-MS (ES, m/z): 477
[M+H].sup.+.
Step 3: Synthesis of
5-cyclopropanecarbonyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-
-yl]ethynyl]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00497##
[0816] Similar to as described in General Procedure S, ethyl
5-cyclopropanecarbonyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-
-yl]ethynyl]phenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia in methanol to give the title compound
(9.1 mg, 19%) as a white solid. LC-MS (ES, m/z): 448 [M+H].sup.+.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.: 7.73-7.68 (m, 3H),
7.58-7.46 (m, 2H), 7.39-7.35 (m, 1H), 6.50 (s, 1H), 4.91 (br s,
1H), 4.68 (m, 1H), 3.92 (m, 1H), 3.75 (m, 1H), 3.37-3.29 (m, 2H),
3.09-2.97 (m, 2H), 2.80 (s, 3H), 2.46-2.40 (m, 1H), 2.27-2.17 (m,
1H), 0.80-0.71 (m, 4H).
Example III
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
2-hydroxy-2-methylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxa-
mide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-(2-hydroxy-2-methylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,-
3-c]pyridine-3-carboxylate
##STR00498##
[0818] A solution of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
trifluoroacetic acid salt (500 mg, 1.08 mmol, 1.00 equiv),
triethylamine (327 mg, 3.23 mmol, 3.00 equiv) and
2,2-dimethyloxirane (116.5 mg, 1.62 mmol, 1.50 equiv) in CH.sub.3CN
(20 mL) was stirred for 2 days at 80.degree. C. The resulting
mixture was concentrated under vacuum and the residue was purified
on a silica gel column with ethyl acetate/petroleum ether (3:7) to
give 100 mg (22%) of the title compound as a yellow solid. LC-MS
(ES, m/z): 422, 424 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
2-hydroxy-2-methylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxy-
late
##STR00499##
[0820] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5-(2-hydroxy-2-methylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,-
3-c]pyridine-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (85 mg, 83%) as a yellow solid. LC-MS (ES, m/z): 481
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
2-hydroxy-2-m
ethylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00500##
[0822] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
2-hydroxy-2-m
ethylpropyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia in methanol to give the title compound
(15.6 mg, 20%) as a white solid. LC-MS (ES, m/z): 452 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.65 (s, 1H), 7.57-7.54
(m, 1H), 7.44-7.39 (m, 2H), 4.51 (s, 1H), 3.81 (s, 2H), 3.39-3.36
(m, 2H), 2.85-2.81 (m, 6H), 2.52-2.46 (m, 3H), 2.25-2.18 (m, 1H),
1.19 (s, 6H).
Example JJJ and KKK
Synthesis of
(4R)-4-C-cyclopropane-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido and
(4S)-4-C-cyclopropane-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
Step 1: Synthesis of
4-amino-1-(3-bromophenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
##STR00501##
[0824] To a solution of ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
(300 mg, 0.83 mmol, 1.00 equiv) in methanol (saturated with
ammonia, 10 mL) was added Ti(1-PrO).sub.4 (470 mg, 1.65 mmol, 2.00
equiv) and the reaction was stirred overnight. Sodium borohydride
(47 mg, 1.24 mmol, 1.50 equiv) was added and the reaction mixture
was stirred for 30 minutes at room temperature. The reaction was
then quenched with 1 mL of saturated aqueous ammonia chloride,
diluted with water, extracted with ethyl acetate, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The crude
product was purified by a silica gel column with
dichloromethane/methanol (20:1) to give 265 mg (96%) of the title
compound as a light yellow solid. LC-MS (ES, m/z): 335, 337
[M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-4-C-cyclopropane-4,5,6,7-tetrahydro-1H-indazole-3,4-dia-
mido
##STR00502##
[0826] To a solution of
4-amino-1-(3-bromophenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
(265 mg, 0.79 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL) was
added cesium carbonate (1000 mg, 3.07 mmol, 3.90 equiv) and
cyclopropanecarbonyl chloride (165 mg, 1.58 mmol, 2.00 equiv). The
reaction was stirred overnight at room temperature. The resulting
mixture was quenched with 10 mL of water, extracted with ethyl
acetate, and washed with brine. The organic layer was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product was purified on a silica gel column with
dichloromethane/methanol (20:1) to give 220 mg (69%) of the title
compound as a white solid. LC-MS (ES, m/z): 403, 405
[M+H].sup.+.
Step 3: Synthesis of
(4R)-4-C-cyclopropane-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido and
(4S)-4-C-cyclopropane-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3--
yl]ethynyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3,4-diamido
##STR00503##
[0828] Similar to as described in General Procedure E,
1-(3-bromophenyl)-4-C-cyclopropane-4,5,6,7-tetrahydro-1H-indazole-3,4-dia-
mido was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the two
title compounds which were separated by Column, Chiralpak IC,
2.times.25 cm, 5 um; mobile phase, MTBE and ethanol (hold 40.0%
ethanol in 18 min); Detector, UV 254/220 nm. The stereochemistry at
position 4 was arbitrary assigned.
[0829] Isomer A (4R): off-white solid, 12 mg (7%). t.sub.R=12.6 min
(CHIRALPAK IC, 25.degree. C., UV-254 nm MTBE (0.1% TEA):EtOH=60:40,
1.0 ml/min). LC-MS (ES, m/z): 462 [M+1].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 7.72 (s, 1H), 7.55 (m, 1H), 7.53 (m, 2H),
5.34 (s, 1H), 3.48 (dd, J=7.5, 5.4 Hz, 2H), 2.94 (s, 3H), 2.79 (m,
2H), 2.64-2.58 (m, 1H), 2.37-2.31 (m, 1H), 2.09-2.01 (m, 1H),
1.91-1.70 (m, 3H), 1.55-1.51 (m, 1H), 0.95-0.85 (m, 2H), 0.74-0.70
(m, 2H).
[0830] Isomer B (4S): off-white solid, 22.9 mg (13%). t.sub.R=16.8
min (CHIRALPAK IC, 25.degree. C., UV-254 nm MTBE (0.1%
TEA):EtOH=60:40, 1.0 ml/min). LC-MS (ES, m/z): 462 [M+1].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.73 (s, 1H), 7.65-7.62
(m, 1H), 7.56-7.35 (m, 2H), 5.36-5.35 (m, 1H), 3.49 (dd, J=6.8, 5.6
Hz, 2H), 2.95 (s, 3H), 2.81-2.79 (m, 2H), 2.64-2.58 (m, 1H),
2.37-2.31 (m, 1H), 2.09-2.01 (m, 1H), 1.91-1.70 (m, 3H), 1.55-1.51
(m, 1H), 0.95-0.85 (m, 2H), 0.74-0.70 (m, 2H).
Example LLL and MMM
Synthesis of
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide and
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00504##
[0832] Similar to as described in General Procedure C, ethyl
4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (650 mg,
37%) as a light yellow solid. LC-MS (ES, m/z): 363, 365
[M+1].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-4-hydroxy-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00505##
[0834] Similar to as described in General Procedure K, ethyl
1-(3-bromophenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
was reacted with sodium borohydride to give the title compound (200
mg, 50%) as an off-white solid. LC-MS (ES, m/z): 347, 349
[M-H.sub.2O+1].sup.+.
Step 3: Synthesis of ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
##STR00506##
[0836] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-4-hydroxy-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (45 mg, 70%) as a brown solid. LC-MS
(ES, m/z): 424 [M+1].sup.+.
Step 4: Synthesis of
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide and
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
##STR00507##
[0838] Similar to as described in General Procedure S, ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate was reacted
with ammonia in methanol to give the two title compounds which were
separated by Column, CHIRALPAK OJ-H, 2.times.25 cm; mobile phase,
Hex and ethanol (hold 35.0% ethanol in 13 min); Detector, UV
254/220 nm. The stereochemistry at position 4 was arbitrary
assigned.
[0839] Isomer A (4R): 6.8 mg (16%), white solid. t.sub.R=8.4 min
(CHIRALCEL OJ-3, 25.degree. C., UV-254 nm Hex:EtOH=65:35, 1.0
ml/min). LC-MS (ES, m/z): 395 [M+1].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.62 (s, 1H), 7.53-7.52 (m, 1H), 7.42 (d, J=6.0
Hz, 2H), 4.88-4.85 (m, 1H), 3.39-3.36 (m, 2H), 2.83 (s, 3H),
2.70-2.68 (m, 1H), 2.62-2.57 (m, 1H), 2.51-2.45 (m, 1H), 2.24-2.18
(m, 1H), 2.05-2.00 (m, 1H), 1.94-1.93 (m, 1H), 1.69-1.63 (m,
2H).
[0840] Isomer B (4S): 6.7 mg (16%), white solid. t.sub.R=11.1 min
(CHIRALCEL OJ-3, 25.degree. C., UV-254 nm Hex:EtOH=65:35, 1.0
ml/min). LC-MS (ES, m/z): 395 [M+1].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.75 (s, 1H), 7.67-7.63 (m, 1H), 7.55 (d, J=3.9
Hz, 2H), 4.99 (t, J=6.0 Hz, 1H), 3.52-3.48 (m, 2H), 2.95 (s, 3H),
2.82-2.57 (m, 3H), 2.38-2.29 (m, 1H), 2.18-2.05 (m, 2H), 1.80-1.75
(m, 2H).
Example NNN
Synthesis of
2-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1,3-
-thiazole-4-carboxamide
Step 1: Synthesis of ethyl
2-(3-bromophenyl)-1,3-thiazole-4-carboxylate
##STR00508##
[0842] Similar to as described in General Procedure M, ethyl
2-bromo-1,3-thiazole-4-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (180 mg,
68%) as a white solid. LC-MS (ES, m/z): 312, 314 [M+H].sup.+.
Step 2: Synthesis of ethyl
2-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1,3-
-thiazole-4-carboxylate
##STR00509##
[0844] Similar to as described in General Procedure E, ethyl
2-(3-bromophenyl)-1,3-thiazole-4-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (150 mg, 68%) as a yellow solid. LC-MS (ES, m/z): 371
[M+H].sup.+.
Step 3: Synthesis of
2-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1,3-
-thiazole-4-carboxamide
##STR00510##
[0846] Similar to as described in General Procedure S, ethyl
2-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1,3-
-thiazole-4-carboxylate was reacted with ammonia in methanol to
give the title compound (56.9 mg, 41%) as a white solid. LC-MS (ES,
m/z): 342 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.27 (s, 1H), 8.17 (s, 1H), 8.05 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.0
Hz, 1H), 7.51 (t, J=7.6 Hz, 1H), 3.53-3.47 (m, 2H), 2.96 (s, 3H),
2.65-2.59 (m, 1H), 2.38-2.31 (m, 1H).
Example OOO
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxamide
Step 1: Synthesis of ethyl 2-oxo-2-(2-oxooxan-3-yl)acetate
##STR00511##
[0848] Similar to as described in General Procedure Y Step 1,
diethyl oxalate was reacted with oxan-2-one to give the title
compound (3.8 g, 79%) as a light yellow liquid. LC-MS (ES, m/z):
201 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-5-hydroxy-4-(3-hydroxypropyl)-1H-pyrazole-3-carboxylate
##STR00512##
[0850] Similar to as described in General Procedure Y Step 2, ethyl
2-oxo-2-(2-oxooxan-3-yl)acetate was reacted with
(3-bromophenyl)hydrazine hydrochloride to give the title compound
(463 mg, 63%) as a yellow solid. LC-MS (ES, m/z): 369, 371
[M+H].sup.+.
Step 3: Synthesis of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxylate
##STR00513##
[0852] DEAD (656 mg, 3.77 mmol, 3.00 equiv) was added slowly to a
suspension of ethyl
1-(3-bromophenyl)-5-hydroxy-4-(3-hydroxypropyl)-1H-pyrazole-3-carboxylate
(463 mg, 1.25 mmol, 1.00 equiv) and PPh.sub.3 (986 mg, 3.76 mmol,
3.00 equiv) in tetrahydrofuran (20 mL) at 0.degree. C. and the
reaction mixture was stirred overnight at room temperature. The
reaction was then quenched with 5 mL of saturated brine, extracted
with ethyl acetate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified on a silica gel
column with ethyl acetate/petroleum ether (1:9) to give 330 mg
(75%) of the title compound as a light yellow solid. LC-MS (ES,
m/z): 351, 353 [M+H].sup.+.
Step 4: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxylate
##STR00514##
[0854] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-1H,4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (90 mg, 77%) as a yellow solid. LC-MS
(ES, m/z): 410 [M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxamide
##STR00515##
[0856] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-pyrano[2,3-c]pyrazole-3-carboxylate was reacted with
ammonia in methanol to give the title compound (11.5 mg, 14%) as a
white solid. LC-MS (ES, m/z): 381[M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.94 (d, J=1.5 Hz, 1H), 7.89-7.85 (m, 1H),
7.46-7.41 (m, 2H), 4.43 (t, J=5.1 Hz, 2H), 3.49 (m, 2H), 2.94 (s,
3H), 2.83 (t, J=6.3 Hz, 2H), 2.63-2.56 (m, 1H), 2.37-2.27 (m, 1H),
2.08-2.03 (m, 2H).
Example PPP
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-1H-indazole-3-carboxylate
##STR00516##
[0858] Similar to as described in General Procedure C, methyl
1H-indazole-3-carboxylate was reacted with (3-bromophenyl)boronic
acid to give the title compound (400 mg, 43%) as a white solid.
LC-MS (ES, m/z): 331, 333 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxylate
##STR00517##
[0860] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (130 mg, 74%) as a yellow solid. LC-MS (ES, m/z): 390
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxamide
##STR00518##
[0862] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-car boxylate was reacted with ammonia in methanol to
give the title compound (49.6 mg, 40%) as a white solid. LC-MS (ES,
m/z): 375 [M+H].sup.+, 749 [2M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.37 (d, J=8.4 Hz, 1H), 7.96-7.94 (m, 1H),
7.90-7.84 (m, 2H), 7.64-7.55 (m, 3H), 7.44 (t, J=7.5 Hz, 1H),
3.54-3.49 (m, 2H), 2.96 (s, 3H), 2.65-2.57 (m, 1H), 2.39-2.29 (m,
1H).
Example QQQ
Synthesis of
1-(6-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]pyrimidin-4-
-yl)-1H-indazole-3-carboxamide
Step 1: Synthesis of
1-(6-chloropyrimidin-4-yl)-1H-indazole-3-carboxylic acid
##STR00519##
[0864] Similar to as described in General Procedure A,
1H-indazole-3-carboxylic acid was reacted with
4,6-dichloropyrimidine to give the title compound (140 mg, 55%) of
the title compound as a yellow solid. LC-MS (ES, m/z): 275
[M+H].sup.+.
Step 2: Synthesis of
1-(6-chloropyrimidin-4-yl)-1H-indazole-3-carboxamide
##STR00520##
[0866] Similar to as described in General Procedure B,
1-(6-chloropyrimidin-4-yl)-1H-indazole-3-carboxylic acid was
reacted with ammonium chloride to give the title compound (88 mg,
59%) as a yellow solid. LC-MS (ES, m/z): 274 [M+H].sup.+.
Step 3: Synthesis of
1-(6-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]pyrimidin-4-
-yl)-1H-indazole-3-carboxamide
##STR00521##
[0868] Similar to as described in General Procedure E,
1-(6-chloropyrimidin-4-yl)-1H-indazole-3-carboxamide was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (4.6 mg, 4%) as a white solid. LC-MS (ES, m/z): 377
[M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d6) .delta. 9.09 (s, 1H),
8.75 (d, J=8.7 Hz, 1H), 8.38 (s, 1H), 8.28-8.25 (m, 2H), 7.69 (s,
1H), 7.60 (t, J=7.4 Hz, 1H), 7.43 (t, J=7.4 Hz, 1H), 6.70 (s, 1H),
3.48-3.31 (m, 2H), 2.76 (s, 3H), 2.57-2.47 (m, 1H), 2.23-2.14 (m,
1H).
Example RRR and SSS
Synthesis of
(5S)-5-(benzyloxy)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carbox-
amide and
(5R)-5-(benzyloxy)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrroli-
din-3-yl]ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-
-3-carboxamide
Step 1: Synthesis of
5-(benzyloxy)-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-i-
ndazole-3-carboxylic acid
##STR00522##
[0870] Similar to as described in General Procedure A,
5-(benzyloxy)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic
acid was reacted with 2-fluoro-4-iodopyridine to give the title
compound (200 mg, 83%) as a yellow oil. LC-MS (ES, m/z): 504
[M+H].sup.+.
Step 2: Synthesis of
5-(benzyloxy)-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-i-
ndazole-3-carboxamide
##STR00523##
[0872] Similar to as described in General Procedure B,
5-(benzyloxy)-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-i-
ndazole-3-carboxylic acid was reacted with ammonium acetate to give
the title compound (210 mg, 63%) as yellow oil. LC-MS (ES, m/z):
503 [M+H].sup.+.
Step 3: Synthesis of
(5S)-5-(benzyloxy)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carbox-
amide and
(5R)-5-(benzyloxy)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrroli-
din-3-yl]ethynyl]pyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-
-3-carboxamide
##STR00524##
[0874] Similar to as described in General Procedure E,
5-(benzyloxy)-1-(4-iodopyridin-2-yl)-6,6-dimethyl-4,5,6,7-tetrahydro-1H-i-
ndazole-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the two
title compounds which were separated by Phenomenex Lux 5u
Cellulose-4, 2.12.times.25, 5 um; mobile phase, Hex and ethanol
(hold 30.0% ethanol in 28 min); Detector, UV 254/220 nm. The
stereochemistry at position 5 was arbitrary assigned.
[0875] Isomer A (5S): 21.5 mg (11%), white solid. t.sub.R=16.29 min
(Lux Cellulose-4, 25.degree. C., UV-254 nm, Hex:EtOH 70:30, 1.0
ml/min). LC-MS (ES, m/z): 514 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.39 (d, J=4.8 Hz, 1H), 8.04 (s, 1H), 7.29-7.26
(m, 6H), 4.65 (d, J=11.6 Hz, 1H), 4.45 (d, J=11.6 Hz, 1H),
3.46-3.42 (m, 3H), 3.05-2.97 (m, 4H), 2.89 (s, 3H), 2.60-2.54 (m,
1H), 2.30-2.23 (m, 1H), 1.05 (s, 3H), 0.96 (s, 3H).
[0876] Isomer B (5R): 22.6 mg (11%), white solid. t.sub.R=20.27 min
(Lux Cellulose-4, 25.degree. C., UV-254 nm, Hex:EtOH 70:30, 1.0
ml/min). LC-MS (ES, m/z): 514 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.39 (d, J=4.8 Hz, 1H), 8.04 (s, 1H), 7.29-7.26
(m, 6H), 4.65 (d, J=11.6 Hz, 1H), 4.45 (d, J=11.6 Hz, 1H),
3.46-3.42 (m, 3H), 3.05-2.97 (m, 4H), 2.89 (s, 3H), 2.60-2.54 (m,
1H), 2.30-2.23 (m, 1H), 1.05 (s, 3H), 0.96 (s, 3H).
Example TTT and UUU
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-
-3-carboxamide and
1-[3-[(3S)-3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-
-3-carboxamide
Step 1: Synthesis of methyl
1-[3-[3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-ca-
rboxylate
##STR00525##
[0878] Similar to as described in General Procedure E, methyl
1-(3-iodophenyl)-1H-indazole-3-carboxylate was reacted with
2-(1,3-oxazol-2-yl)but-3-yn-2-ol to give the title compound (170
mg, 93%) as a yellow solid. LC-MS (ES, m/z): 388 [M+H].sup.+.
Step 2: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-
-3-carboxamide and
1-[3-[(3S)-3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-
-3-carboxamide
##STR00526##
[0880] Similar to as described in General Procedure S, methyl
1-[3-[3-hydroxy-3-(1,3-oxazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-ca-
rboxylate was reacted with ammonia in methanol to give the two
title compounds which were separated by Chiral-Prep-HPLC with the
following conditions: Column, Chiralpak IC(SFC), 2.times.25 cm, 5
um; mobile phase, hex and ethanol (hold 50.0% ethanol in 15 min);
Detector, UV 254/220 nm. The stereochemistry at position 3 was
arbitrarily assigned
[0881] Isomer A (3R): white solid. t.sub.R=1.52 min (Chiralpak
IC-3, 25.degree. C., 254 nm, Hex:EtOH 50:50, 1 mL/min). LC-MS (ES,
m/z): 373 [M+H]. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.37 (d,
J=8.0 Hz, 1H), 7.98 (s, 2H), 7.90-7.85 (m, 2H), 7.66-7.55 (m, 3H),
7.41 (t, J=7.2 Hz, 1H), 7.22 (s, 1H), 1.99 (s, 3H).
[0882] Isomer B (3S): white solid. t.sub.R=2.06 min (Chiralpak
IC-3, 25.degree. C., 254 nm, Hex:EtOH 50:50, 1 mL/min). LC-MS (ES,
m/z): 373 [M+H]. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.36 (d,
J=8.0 Hz, 1H), 7.98 (s, 2H), 7.89-7.85 (m, 2H), 7.65-7.55 (m, 3H),
7.40 (t, J=7.2 Hz, 1H), 7.22 (s, 1H), 1.99 (s, 3H).
Example VVV
Synthesis of
1-[3-[(3S)-3-hydroxy-3-(1,3-thiazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazol-
e-3-carboxamide
Step 1: Synthesis of
2-(1,3-thiazol-2-yl)-4-(trimethylsilyl)but-3-yn-2-ol
##STR00527##
[0884] In an inert atmosphere of nitrogen, n-BuLi (2.5N in hexane,
18.9 mL, 47.25 mmol, 1.20 equiv) was added dropwise into a solution
of ethynyltrimethylsilane (4.63 g, 47.14 mmol, 1.20 equiv) in
tetrahydrofuran (10 mL) under -76.degree. C. After being stirred
for 3 h under -76.degree. C. a solution of
1-(1,3-thiazol-2-yl)ethan-1-one (5 g, 39.32 mmol, 1.00 equiv) in
tetrahydrofuran (15 mL) was added to the resulting mixture. The
reaction was warmed to room temperature slowly and stirred for 2 h
at room temperature. The reaction was then quenched with 10 mL of
saturated aqueous ammonium chloride, extracted with ethyl acetate,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was purified on a silica gel column with ethyl
acetate/petroleum ether (1:20) to give 4 g (45%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 226 [M+H].sup.+.
Step 2: Synthesis of (2S)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol and
(2R)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol
##STR00528##
[0886] A solution of
2-(1,3-thiazol-2-yl)-4-(trimethylsilyl)but-3-yn-2-ol (4 g, 17.75
mmol, 1.00 equiv) and potassium fluoride (3.342 g, 35.55 mmol, 2.00
equiv) in methanol (20 mL) was stirred for 2 h at 50.degree. C. The
resulting mixture was concentrated under vacuum, diluted with 5 mL
of water, extracted with ethyl acetate, and concentrated under
vacuum. The residue was purified on a silica gel column with ethyl
acetate/petroleum ether (1:9). The enantiomers were separated by
Chiral-Prep-HPLC with the following conditions: Column, Chiralpak
IC, 2.times.25 cm, Sum; mobile phase, Hex and ethanol (hold 5.0%
ethanol in 8 min); Detector, UV 254/220 nm to give 320 mg (24%) of
enantiomer A and 320 mg (24%) of enantiomer B. The stereochemistry
for either enantiomer is arbitrarily assigned. LC-MS (ES, m/z): 154
[M+H].sup.+ for enantiomer A or B.
Step 3: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(1,3-thiazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazol-
e-3-carboxamide
##STR00529##
[0888] Similar to as described in General Procedure E,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
(2R)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol to give the title compound
(58.8 mg, 46%) as a yellow solid. LC-MS (ES, m/z): 389 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.35 (d, J=8.4 Hz, 1H),
7.94 (s, 1H), 7.87-7.79 (m, 3H), 7.64-7.53 (m, 4H), 7.39 (t, J=8.4
Hz, 1H), 1.98 (s, 3H).
Step 4: Synthesis of
1-[3-[(3S)-3-hydroxy-3-(1,3-thiazol-2-yl)but-1-yn-1-yl]phenyl]-1H-indazol-
e-3-carboxamide
##STR00530##
[0890] Similar to as described in General Procedure E,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
(2S)-2-(1,3-thiazol-2-yl)but-3-yn-2-ol to give the title compound
(66.7 mg, 52%) as a yellow solid. LC-MS (ES, m/z): 389 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.35 (d, J=8.4 Hz, 1H),
7.94 (s, 1H), 7.87-7.79 (m, 3H), 7.64-7.53 (m, 4H), 7.39 (t, J=8.4
Hz, 1H), 1.98 (s, 3H).
Example WWW
Synthesis of
5-(acetamidomethyl)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyridin-2-yl)-1H-indazole-3-carboxamide
Step 1: Synthesis of
5-(hydroxymethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxylic
acid
##STR00531##
[0892] Similar to as described in General Procedure A, methyl
5-[[(tert-butyldimethylsilyl)oxy]methyl]-1H-indazole-3-carboxylate
was reacted with 2-fluoro-4-iodopyridine to give the title compound
(1 g, 51%) as a yellow solid. LC-MS (ES, m/z): 396 [M+H].sup.+.
Step 2: Synthesis of
5-(hydroxymethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00532##
[0894] Similar to as described in General Procedure B,
5-(hydroxymethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(600 mg, 54%) as a yellow solid. LC-MS (ES, m/z): 395
[M+H].sup.+.
Step 3: Synthesis of
5-(chloromethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00533##
[0896] Thionyl chloride (2 mL, 27.57 mmol, 1.00 equiv) was added
dropwise into a suspension of
5-(hydroxymethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(1 g, 2.54 mmol, 1.00 equiv) in dichloromethane (15 mL) at room
temperature. After being stirred for 1 h at room temperature the
resulting mixture was concentrated under vacuum to give 1 g (81%)
of the title compound as a yellow solid. LC-MS (ES, m/z): 413
[M+H].sup.+.
Step 4: Synthesis of
5-(azidomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00534##
[0898] Sodium azide (0.36 g, 2.00 equiv) was added in portions into
a solution of
5-(chloromethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(1.13 g, 2.74 mmol, 1.00 equiv) in DMSO (5 mL, 70.39 mmol, 25.70
equiv) at room temperature. After being stirred for 2 h at room
temperature the reaction was diluted with water, extracted with
ethyl acetate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. This resulted in 1.2 g (75%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 420
[M+H].sup.+.
Step 5: Synthesis of
5-(aminomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00535##
[0900] A solution of
5-(azidomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(1.20 g, 2.86 mmol, 1.00 equiv), triphenylphosphine (830 mg, 3.16
mmol, 1.10 equiv) and water (80 mg, 4.44 mmol, 1.50 equiv) in
tetrahydrofuran (0.23 mL, 2.84 mmol, 1.00 equiv) was stirred for 4
h at 40.degree. C. The mixture was dried over anhydrous magnesium
sulfate and concentrated under vacuum to give 2.0 g of the title
compound (crude) as a yellow solid which was used in the next step
without further purification. LC-MS (ES, m/z): 394 [M+H].sup.+.
Step 6: Synthesis of
5-(acetamidomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00536##
[0902] Acetic anhydride (62.32 mg, 0.61 mmol, 1.20 equiv) was added
into a solution of
5-(aminomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(crude, 200.00 mg, 0.51 mmol, 1.00 equiv) and triethylamine (77.21
mg, 0.76 mmol, 1.50 equiv) in dichloromethane (5 mL, 78.65 mmol,
1.00 equiv) at room temperature. After being stirred for 1 h at
room temperature the reaction mixture was concentrated under vacuum
and the residue was washed with Et.sub.2O to give 80 mg (29%) of
the title compound as a yellow solid. LC-MS (ES, m/z): 436
[M+H].sup.+.
Step 7: Synthesis of
5-(acetamidomethyl)-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyrid in-2-yl)-1H-indazole-3-carboxamide
##STR00537##
[0904] Similar to as described in General Procedure E,
5-(acetamidomethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (13.5 mg, 9%) as a white solid. LC-MS
(ES, m/z): 447 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.64 (d, J=8.7 Hz, 1H), 8.54 (d, J=5.4 Hz, 1H), 8.42 (t,
J=6.0 Hz, 1H), 8.26 (s, 1H), 8.20 (s, 1H), 8.11 (s, 1H), 7.58 (s,
1H), 7.45 (dd, J=8.7, 1.5 Hz, 1H), 7.30 (dd, J=8.7, 1.2 Hz, 1H),
6.62 (s, 1H), 4.34 (d, J=6.0 Hz, 2H), 2.76 (s, 3H), 2.44-2.41 (m,
1H), 2.19-2.15 (m, 1H), 1.82 (s, 3H).
Example XXX and Example YYY
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-1H-indazole-3-carboxamide
and
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
[(3S)-3-hydroxypyrrolidin-1-yl]methyl]-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-[(3-hydroxypyrrolidin-1-yl)methyl]-1H-indazole-3-carb-
oxylate
##STR00538##
[0906] A suspension of pyrrolidin-3-ol hydrochloride (196 mg, 1.59
mmol, 4.00 equiv), methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate (150
mg, 0.40 mmol, 1.00 equiv) and triethylamine (160 mg, 1.58 mmol,
4.00 equiv) in dichloromethane (10 mL) was stirred overnight at
room temperature. The resulting mixture was concentrated under
vacuum and the residue was purified on a silica gel column with
dichloromethane/methanol (20:1) to give 120 mg (71%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 430, 432
[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(3-hydroxypyrrolidin-1-yl)methyl]-1H-indazole-3-carboxylate
##STR00539##
[0908] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-[(3-hydroxypyrrolidin-1-yl)methyl]-1H-indazole-3-carb-
oxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (100 mg, 73%) as a yellow solid. LC-MS (ES, m/z): 489
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-1H-indazole-3-carboxamide
and
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
[(3S)-3-hydroxypyrrolidin-1-yl]methyl]-1H-indazole-3-carboxamide
##STR00540##
[0910] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
(3-hydroxypyrrolidin-1-yl)methyl]-1H-indazole-3-carboxylate was
reacted with ammonia in methanol to give the title compounds which
were separated by Chiral-Prep-HPLC with the following conditions
(Prep-HPLC-009): Column, Chiralpak AD-H, 2.times.25 cm; mobile
phase, Hex (0.1% DEA) and ethanol (0.1% DEA) (hold 50.0% ethanol
(0.1% DEA) in 13 min); Detector, UV 254/220 nm. The stereochemistry
for either isomer is arbitrarily assigned.
[0911] Isomer A (3R): 7.2 mg (15%), white solid. t.sub.R=9.65 min
(Chiralpak AD-3, 25.degree. C., 254 nm, Hex (0.1% TEA):EtOH 50:50,
1.0 mL/min). LC-MS (ES, m/z): 474 [M+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 8.33 (s, 1H), 7.95 (s, 1H), 7.90-7.80 (m,
2H), 7.69-7.54 (m, 3H), 4.42-4.36 (m, 1H), 3.97-3.84 (m, 2H),
3.52-3.48 (m, 2H), 2.94-2.85 (m, 5H), 2.71-2.57 (m, 3H), 2.38-2.29
(m, 1H), 2.22-2.15 (m, 1H), 1.78-1.68 (m, 1H).
[0912] Isomer B (3S): 11.9 mg (25%), white solid. t.sub.R=12.62 min
(Chiralpak AD-3, 25.degree. C., 254 nm, Hex (0.1% TEA):EtOH 50:50,
1.0 mL/min). LC-MS (ES, m/z): 474 [M+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 8.33 (s, 1H), 7.95 (s, 1H), 7.90-7.80 (m,
2H), 7.69-7.54 (m, 3H), 4.42-4.36 (m, 1H), 3.97-3.84 (m, 2H),
3.52-3.48 (m, 2H), 2.94-2.85 (m, 5H), 2.71-2.57 (m, 3H), 2.38-2.29
(m, 1H), 2.22-2.15 (m, 1H), 1.78-1.68 (m, 1H).
Example ZZZ
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrrolidin-1-yl methyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(pyrrolidin-1-ylmethyl)-1H-indazole-3-carboxylate
##STR00541##
[0914] A suspension of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate (100
mg, 0.26 mmol, 1.00 equiv), pyrrolidine (75 mg, 1.05 mmol, 4.00
equiv) in dichloromethane (10 mL, 157.30 mmol, 597.20 equiv) was
stirred overnight at room temperature. The resulting mixture was
concentrated under vacuum to give 95 mg (78%) of the title compound
as a yellow solid. LC-MS (ES, m/z) 414, 416 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrrolidin-1-yl methyl)-1H-indazole-3-carboxylate
##STR00542##
[0916] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-(pyrrolidin-1-ylmethyl)-1H-indazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (95 mg, 83%) as a yellow solid. LC-MS
(ES, m/z): 473 [M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrrolidin-1-ylmethyl)-1H-indazole-3-carboxamide
##STR00543##
[0918] Similar to as described in General Procedure S,
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrrolidin-1-yl methyl)-1H-indazole-3-carboxylate was reacted with
ammonia in methanol to give the title compound (32.8 mg, 36%) as a
light yellow solid. LC-MS (ES, m/z): 458 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.28 (s, 1H), 7.90 (s, 1H), 7.84-7.74
(m, 2H), 7.61-7.51 (m, 3H), 3.79 (s, 2H), 3.51-3.46 (m, 2H), 2.94
(s, 3H), 2.64-2.59 (m, 5H), 2.38-2.28 (m, 1H), 1.87-1.84 (m,
4H).
Example AAAA
Synthesis of
5-(cyanomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate
##STR00544##
[0920] Sulfurous dichloride (5 mL) was added into a suspension of
methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate (300
mg, 0.83 mmol, 1.00 equiv) in dichloromethane (10 mL, 157.30 mmol,
189.40 equiv) at 0.degree. C. The reaction was stirred for 3 h at
room temperature and concentrated under vacuum to give 290 mg (92%)
of the title compound as a white solid. LC-MS (ES, m/z): 379, 381
[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-5-(cyanomethyl)-1H-indazole-3-carboxylate
##STR00545##
[0922] A suspension of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate (200
mg, 0.53 mmol, 1.00 equiv), tetra-n-butylammonium iodide (292 mg,
0.79 mmol, 1.50 equiv) and sodium cyanide (39 mg, 0.80 mmol, 1.50
equiv) in dichloromethane (10 mL)/water (1 mL) was stirred for 5 h
at room temperature. The reaction mixture was diluted with 5 mL of
water, extracted with dichloromethane, dried over anhydrous sodium
sulfate, and concentrated under vacuum. The residue was purified on
a silica gel column with ethyl acetate/petroleum ether (1:4) to
give 190 mg (97%) of methyl
1-(3-bromophenyl)-5-(cyanomethyl)-1H-indazole-3-carboxylate as a
white solid. LC-MS (ES, m/z): 370, 372 [M+H].sup.+.
Step 3: Synthesis of methyl
5-(cyanomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl)-1H-indazole-3-carboxylate
##STR00546##
[0924] Similar to as described in General Procedure E, methyl
5-(cyanomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl)-1H-indazole-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (160 mg, 77%) as a yellow solid. LC-MS (ES, m/z): 429
[M+H].sup.+.
Step 4: Synthesis of
5-(cyanomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl)-1H-indazole-3-carboxamide
##STR00547##
[0926] Similar to as described in General Procedure S, methyl
5-(cyanomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl)-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (60.5 mg, 39%) as a white
solid. LC-MS (ES, m/z): 414 [M+H].sup.+, 827 [2M+H].sup.+. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.38 (br s, 1H), 7.94-7.85 (m,
3H), 7.64-7.55 (m, 3H), 4.10 (s, 2H), 3.55-3.47 (m, 2H), 2.95 (s,
3H), 2.65-2.59 (m, 1H), 2.38-2.31 (m, 1H).
Example BBBB
Synthesis of
1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxylate
##STR00548##
[0928] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
(3S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (160 mg, 91%) as a yellow oil. LC-MS (ES, m/z): 390
[M+H].sup.+.
Step 2: Synthesis of
1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-carboxamide
##STR00549##
[0930] Similar to as described in General Procedure S,
1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-3-car boxylate was reacted with ammonia in methanol to
give the title compound (33.8 mg, 22%) as a white solid. LC-MS (ES,
m/z): 375 [M+H].sup.+, 392 [M+NH.sub.4].sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.36 (d, J=8.4 Hz, 1H), 7.96 (s, 1H),
7.89-7.82 (m, 2H), 7.65-7.56 (m, 3H), 7.41 (t, J=7.6 Hz, 1H),
3.55-3.46 (m, 2H), 2.95 (s, 3H), 2.66-2.60 (m, 1H), 2.38-2.31 (m,
1H).
Example CCCC
Synthesis of
1-[3-(3-hydroxy-3-methylbut-1-yn-1-yl)phenyl]-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-[3-(3-hydroxy-3-methylbut-1-yn-1-yl)phenyl]-1H-indazole-3-carboxylate
##STR00550##
[0932] Similar to as described in General Procedure E,
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
2-methylbut-3-yn-2-ol to give the title compound (140 mg, 92%) as a
yellow oil. LC-MS (ES, m/z): 335 [M+H].sup.+.
Step 2: Synthesis of
1-[3-(3-hydroxy-3-methylbut-1-yn-1-yl)phenyl]-1H-indazole-3-carboxamide
##STR00551##
[0934] Similar to as described in General Procedure S, methyl
1-[3-(3-hydroxy-3-methylbut-1-yn-1-yl)phenyl]-1H-indazole-3-carboxylate
was reacted with ammonia in methanol to give the title compound
(29.6 mg, 22%) as a white solid. LC-MS (ES, m/z): 320 [M+H].sup.+,
639 [2M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.36
(d, J=8.0 Hz, 1H), 7.87-7.79 (m, 3H), 7.63-7.51 (m, 3H), 7.41 (t,
J=7.2 Hz, 1H), 1.61 (s, 6H).
Example DDDD and Example EEEE
Synthesis of
1-[3-[(3R)-3-(dimethylcarbamoyl)-3-hydroxy-3-methylprop-1-yn-1-yl]phenyl]-
-1H-indazole-3-carboxamide and
1-[3-[(3S)-3-(dimethylcarbamoyl)-3-hydroxy-3-methylprop-1-yn-1-yl]phenyl]-
-1H-indazole-3-carboxamide
##STR00552##
[0936] Similar to as described in General Procedure M,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
2-hydroxy-N,N,2-trimethylbut-3-ynamide to give the title compounds
which were separated by Chiral-Prep-HPLC with the following
conditions: Column, Chiralpak AD-H, 2.times.25 cm; mobile phase,
Hex and ethanol (hold 40.0% ethanol in 10 min); Detector, UV
254/220 nm. The stereochemistry for either isomer is arbitrarily
assigned.
[0937] Isomer A (3R): 32.4 mg (41%), white solid. t.sub.R=7.28 min
(ADH, 25.degree. C., 254 nm, Hex (0.1% TEA):EtOH 50:50, 1.0 mL/min.
LC-MS (ES, m/z): 377 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.35 (d, J=8.1 Hz, 1H), 7.90-7.81 (m, 3H), 7.65-7.52 (m,
3H), 7.39 (t, J=7.5 Hz, 1H), 3.46 (s, 3H), 3.02 (s, 3H), 1.77 (s,
3H).
[0938] Isomer B (3S): 33.4 mg (42%), white solid. t.sub.R=9.62 min
(ADH, 25.degree. C., 254 nm, Hex (0.1% TEA):EtOH 50:50, 1.0
mL/min). LC-MS (ES, m/z): 377 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.35 (d, J=8.1 Hz, 1H), 7.90-7.81 (m, 3H),
7.65-7.52 (m, 3H), 7.39 (t, J=7.5 Hz, 1H), 3.46 (s, 3H), 3.02 (s,
3H), 1.77 (s, 3H).
Example FFFF
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxylate
##STR00553##
[0940] Similar to as described in General Procedure E,
1-(3-bromophenyl)-1H-indazole-3-carboxylate was reacted with
(2R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol to give the
title compound (150 mg, 82%) as a yellow oil. LC-MS: (ES, m/z): 403
[M+H].sup.+.
Step 2: Synthesis of
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxamide
##STR00554##
[0942] Similar to as described in General Procedure S, methyl
1-[3-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-yn-1-yl]pheny-
l]-1H-indazole-3-carboxylate was reacted with ammonia in methanol
to give the title compound (39.7 mg, 27%) as a white solid. LC-MS
(ES, m/z): 388 [M+H].sup.+, 429 [M+CH.sub.3CN+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.35 (d, J=8.1 Hz, 1H), 7.95 (s, 1H),
7.89-7.84 (m, 2H), 7.65-7.54 (m, 3H), 7.40 (t, J=7.2 Hz, 1H), 2.64
(s, 3H), 1.95 (s, 3H).
Example GGGG
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl 5-methoxy-1H-indazole-3-carboxylate
##STR00555##
[0944] Similar to as described in General Procedure Z, the title
compound was prepared from
5-methoxy-2,3-dihydro-1H-indole-2,3-dione. Yield (2.15 g, 37%,
brown solid). LC-MS (ES, m/z): 207 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-5-methoxy-1H-indazole-3-carboxylate
##STR00556##
[0946] Similar to as described in General Procedure C, methyl
5-methoxy-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (135 mg,
39%) as an off-white solid. LC-MS (ES, m/z): 361, 363
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-indazole-3-carboxylate
##STR00557##
[0948] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-methoxy-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (60 mg, 45%) as a yellow oil. LC-MS (ES, m/z): 420
[M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-indazole-3-carboxamide
##STR00558##
[0950] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound (13.2 mg, 23%) as an off-white
solid. LC-MS (ES, m/z): 405 [M+H].sup.+, 427 [M+Na].sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD) .delta. 7.92 (s, 1H), 7.85 (d, J=7.8 Hz,
1H), 7.76-7.70 (m, 2H), 7.63-7.53 (m, 2H), 7.9 (d, J=9.0 Hz, 1H),
3.90 (s, 3H), 3.54-3.47 (m, 2H), 2.94 (s, 3H), 2.67-2.57 (m, 1H),
2.38-2.28 (m, 1H).
Example HHHH
Synthesis of
5-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl 5-fluoro-1H-indazole-3-carboxylate
##STR00559##
[0952] Similar to as described in General Procedure Z, the title
compound was prepared from
5-fluoro-2,3-dihydro-1H-indole-2,3-dione. Yield (5 g, 43%, brown
solid). LC-MS (ES, m/z): 195 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-5-fluoro-1H-indazole-3-carboxylate
##STR00560##
[0954] Similar to as described in General Procedure C, methyl
5-fluoro-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (50 mg, 14%)
as an off-white solid. LC-MS (ES, m/z): 349,351 [M+H].sup.+.
Step 3: Synthesis of methyl
5-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxylate
##STR00561##
[0956] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-fluoro-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (35 mg, 60%) as a yellow oil. LC-MS (ES, m/z): 408
[M+H].sup.+, 449[M+CH.sub.3CN+H].sup.+.
Step 4: Synthesis of
5-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxamide
##STR00562##
[0958] Similar to as described in General Procedure S, methyl
5-fluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-indazole-3-carboxylate was reacted with ammonia in
methanol to give the title compound 15.7 mg, 47%) as a white solid.
LC-MS (ES, m/z): 393 [M+H].sup.+, 785 [2M+H].sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.00-7.93 (m, 2H), 7.89-7.83 (m, 2H),
7.66-7.58 (m, 2H), 7.41-7.37 (m, 1H), 3.52-3.46 (m, 2H), 2.95 (s,
3H), 2.65-2.59 (m, 1H), 2.38-2.31 (m, 1H).
Example IIII and Example JJJJ
Synthesis of ethyl
(5aS)-5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carb-
oxylate and
(5aR)-5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carb-
oxylate
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f-
]indazole-3-carboxylate
##STR00563##
[0960] Similar to as described in General Procedure C, ethyl
5,5-difluoro-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]
indazole-3-carboxylate was reacted with (3-bromophenyl)boronic acid
to give the title compound (500 mg, 30%) as a white solid. LC-MS
(ES, m/z): 411, 413 [M+H].sup.+.
Step 2: Synthesis of ethyl
5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyny-
l]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxylat-
e
##STR00564##
[0962] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f-
]indazole-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (200 mg, 88%) as a yellow oil. LC-MS (ES, m/z): 470
[M+H].sup.+.
Step 3: Synthesis of ethyl
(5aS)-5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carb-
oxylate and
(5aR)-5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]-
ethynyl]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carb-
oxylate
##STR00565##
[0964] Similar to as described in General Procedure S, ethyl
5,5-difluoro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyny-
l]phenyl)-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxylat-
e was reacted with ammonia in methanol to give the title compounds
which were separated by Chiral-Prep-HPLC with the following
conditions: Column, Chiralpak IC, 2.times.25 cm, 5 um; mobile
phase, Hex and ethanol (hold 50.0% ethanol in 17 min); Detector, UV
254/220 nm. The stereochemistry for either isomer is arbitrarily
assigned.
[0965] Isomer A (5aS): 21.7 mg (11%), white solid. t.sub.R=5.72 min
(Chiralpak IC-3, 25.degree. C., UV-254 nm, Hex:EtOH 50:50, 1.0
mL/min). LC-MS (ES, m/z): 441 [M+H].sup.+, 463[M+Na].sup.+. .sup.1H
NMR: (300 MHz, CD.sub.3OD) .delta. 7.70 (s, 1H), 7.66-7.52 (m, 3H),
3.56-3.47 (m, 2H), 3.34-2.98 (m, 4H), 2.95 (s, 3H), 2.65-2.57 (m,
1H), 2.38-2.28 (m, 1H), 1.76-1.69 (m, 1H), 1.41 (s, 3H).
[0966] Isomer B (5aR): 34.4 mg (17%), white solid. t.sub.R=7.76 min
(Chiralpak IC-3, 25.degree. C., UV-254 nm, Hex:EtOH 50:50, 1.0
mL/min.). LC-MS (ES, m/z): 441 [M+H].sup.+, 463[M+Na].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.70 (s, 1H), 7.66-7.52
(m, 3H), 3.56-3.47 (m, 2H), 3.34-2.98 (m, 4H), 2.95 (s, 3H),
2.65-2.57 (m, 1H), 2.38-2.28 (m, 1H), 1.76-1.69 (m, 1H), 1.41 (s,
3H).
Example KKKK
Synthesis of
5-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of (3-iodo-1H-indazol-5-yl)methanol
##STR00566##
[0968] Under nitrogen diisobutyl aluminium hydride (1 M in
n-hexane, mL, 45.00 mmol, 2.83 equiv) was added dropwise to a
solution of methyl 3-iodo-1H-indazole-5-carboxylate (4.8 g, 15.89
mmol, 1.00 equiv) in dichloromethane (300 mL) at -76.degree. C.
After being stirred at room temperature for 1 h the reaction was
quenched with saturated aqueous Rochelle salt solution. The
resulting mixture was concentrated under vacuum to afford 14 g
(crude) of (3-iodo-1H-indazol-5-yl)methanol as an off-white solid
which was used for the next step without further purification.
LC-MS (ES, m/z): 275 [M+H].sup.+.
Step 2: Synthesis of methyl
5-(hydroxymethyl)-1H-indazole-3-carboxylate
##STR00567##
[0970] To a solution of (3-iodo-1H-indazol-5-yl)methanol (14.00 g,
51.08 mmol, 1.00 equiv), triethylamine (30 mL) in methanol (250 mL)
was added Pd(dppf)Cl.sub.2.CH.sub.2Cl.sub.2 (8.34 g, 10.21 mmol,
0.20 equiv). The mixture was flushed with carbon monoxide gas for
several minutes and then sealed with carbon monoxide balloon and
heated to 50.degree. C. for 6 h. The mixture was concentrated under
vacuum and the residue was purified on silica gel column
chromatography eluting with dichloromethane/methanol (19:1) to give
3.0 g (28%) of the title compound as a yellow solid. LC-MS (ES,
m/z): 207 [M+H].sup.+.
Step 3: Synthesis of methyl
5-[[(tert-butyldimethylsilyl)oxy]methyl]-1H-indazole-3-carboxylate
##STR00568##
[0972] A solution of methyl
5-(hydroxymethyl)-1H-indazole-3-carboxylate (2.00 g, 9.70 mmol,
1.00 equiv), tert-butyldimethylsilylchloride (2.19 g, 14.53 mmol,
1.50 equiv), imidazole (1.32 g, 19.39 mmol, 2.00 equiv) in
dichloromethane (200 mL) was stirred overnight at room temperature.
The reaction mixture was concentrated under vacuum and the residue
was purified by silica gel column chromatography eluting with
dichloromethane/methanol (19:1) to afford the title compound (2 g,
crude) as a yellow solid. LC-MS: (ES, m/z): 321 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-5-[[(tert-butyldimethylsilyl)oxy]methyl]-1H-indazole-3--
carboxylate
##STR00569##
[0974] Similar to as described in General Procedure C, methyl
5-[[(tert-butyldimethylsilyl)oxy]methyl]-1H-indazole-3-carboxylate
was reacted with (3-bromophenyl)boronic acid to give the title
compound (2.0 g, 56%) as a yellow solid. LC-MS (ES, m/z): 475
[M+H].sup.+.
Step 5: Synthesis of methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate
##STR00570##
[0976] A solution of methyl
1-(3-bromophenyl)-5-[[(tert-butyldimethylsilyl)oxy]methyl]-1H-indazole-3--
carboxylate (2.00 g, 4.21 mmol, 1.00 equiv) and tetrabutylazanium
fluoride (2.20 g, 8.41 mmol, 2.00 equiv) in tetrahydrofuran (100
mL) was stirred for 1 h at room temperature. The reaction was
diluted with ethyl acetate and washed with brine. The organic layer
was dried over sodium sulfate and concentrated under vacuum. The
residue was purified by silica gel column chromatography eluting
with dichloromethane/methanol (19:1) to give the title compound
(1.5 g, 99%) as an off-white solid. LC-MS (ES, m/z): 361
[M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-bromophenyl)-5-formyl-1H-indazole-3-carboxylate
##STR00571##
[0978] A solution of methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate (0.80
g, 2.21 mmol, 1.00 equiv), 1,1-bis(acetyloxy)-3-oxo-3H-11
[5],2-benziodaoxol-1-yl acetate (1.41 g, 3.32 mmol, 1.50 equiv) in
dichloromethane (100 mL) was stirred for 2 h at room temperature.
The reaction mixture was concentrated under vacuum and the residue
was purified by silica gel column chromatography eluting with ethyl
acetate/petroleum ether (1:9) to afford the title compound (800 mg,
crude) as an off-white solid. LC-MS (ES, m/z): 359 [M+H].sup.+.
Step 7: Synthesis of methyl
1-(3-bromophenyl)-5-cyano-1H-indazole-3-carboxylate
##STR00572##
[0980] A solution of methyl
1-(3-bromophenyl)-5-formyl-1H-indazole-3-carboxylate (126.00 mg,
0.35 mmol, 1.00 equiv), hydroxylamine hydrochloride (48.76 mg, 0.70
mmol, 2.00 equiv), sodium acetate (57.56 mg, 0.70 mmol, 2.00 equiv)
in acetic acid (4 mL) was stirred overnight at 120.degree. C. The
reaction mixture was diluted with dichloromethane and washed with
brine. The organic layer was dried over anhydrous sodium sulfate
and concentrated under vacuum to afford the title compound (150 mg,
crude) as a yellow solid. LC-MS: (ES, m/z): 356 [M+H].sup.+.
Step 8: Synthesis of methyl
5-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate
##STR00573##
[0982] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-cyano-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (200 mg, crude) as a yellow solid. LC-MS (ES, m/z):
415 [M+H].sup.+.
Step 9: Synthesis of
5-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
##STR00574##
[0984] Similar to as described in General Procedure S, methyl
5-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate was reacted with ammonia in methanol
to give the title compound as an off-white solid. LC-MS (ES, m/z):
400 [M+H].sup.+. .sup.1HNMR (300 MHz, CD.sub.3OD) .delta. 8.79 (s,
1H), 8.02-7.96 (m, 2H), 7.89-7.80 (m, 2H), 7.67-7.63 (m, 2H),
3.53-3.49 (m, 2H), 2.96 (s, 3H), 2.70-2.60 (m, 1H), 2.37-2.32 (m,
1H).
Example LLLL
Synthesis of
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of 1H-indazole-6-carbonitrile
##STR00575##
[0986] A suspension of 6-bromo-1H-indazole (1.00 g, 5.08 mmol, 1.00
equiv), zinc cyanide (1.19 g, 10.13 mmol, 2.00 equiv), XantPhos
(880 mg, 1.52 mmol, 0.30 equiv), Pd.sub.2(dba).sub.3.CHCl.sub.3
(530 mg, 0.51 mmol, 0.10 equiv) and
[2-(dimethylamino)ethyl]dimethylamine (2 mL, 13.25 mmol, 2.60
equiv) in N,N-dimethylformamide (8 mL, 20.40 equiv) was irradiated
with microwave radiation for 5 min at 160.degree. C. The reaction
was then quenched by 20 mL of water. The solid was collected and
washed with 3.times.20 mL of diethyl ether to give the title
compound (1.2 g, crude) as a brown solid. LC-MS (ES, m/z): 144
[M+H].sup.+, 185 [M+CH.sub.3CN].sup.+.
Step 2: Synthesis of 3-iodo-1H-indazole-6-carbonitrile
##STR00576##
[0988] To a solution of 1H-indazole-6-carbonitrile (450.00 mg, 3.14
mmol, 1.00 equiv) in N,N-dimethylformamide (10.00 mL, 129.22 mmol,
41.10 equiv) was added iodine (1595.78 mg, 6.29 mmol, 2.00 equiv)
and potassium hydroxide (440.94 mg, 7.86 mmol, 2.50 equiv) at room
temperature. After being stirred for 2.5 h at room temperature, the
reaction was quenched by 10 mL of brine, extracted with ethyl
acetate, washed with sat. aq. sodium thiosulfate and brine, dried
over anhydrous sodium sulfate, and concentrated under vacuum. This
resulted in 500 mg (59%) of the title compound as a brown solid.
LC-MS (ES, m/z): 270 [M+H].sup.+.
Step 3: Synthesis of methyl 6-cyano-1H-indazole-3-carboxylate
##STR00577##
[0990] Similar to as described in General Procedure O,
3-iodo-1H-indazole-6-carbonitrile was reacted with carbon monoxide
to give the title compound (200 mg, 61%) as an off-white solid.
LC-MS (ES, m/z): 202 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-6-cyano-1H-indazole-3-carboxylate
##STR00578##
[0992] Similar to as described in General Procedure C, methyl
6-cyano-1H-indazole-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (220 mg,
62%) as an off-white solid. LC-MS (ES, m/z): 356, 358
[M+H].sup.+.
Step 5: Synthesis of methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate
##STR00579##
[0994] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-6-cyano-1H-indazole-3-carboxylate was reacted
with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the
title compound (200 mg, 78%) as a yellow oil. LC-MS (ES, m/z): 415
[M+H].sup.+.
Step 6: Synthesis of
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxamide
##STR00580##
[0996] Similar to as described in General Procedure S, methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-indazole-3-carboxylate was reacted with ammonia in methanol
to give the title compound (55.2 mg, 19%) as a white solid. LC-MS
(ES, m/z): 400 [M+H].sup.+. .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta. 8.53 (d, J=5.4 Hz, 1H), 8.30 (s, 1H), 7.99-7.96 (m, 1H),
7.90-7.86 (m, 1H), 7.68-7.60 (m, 3H), 3.55-3.47 (m, 2H), 2.94 (s,
3H), 2.66-2.58 (m, 1H), 2.36-2.29 (m, 1H).
Example MMMM
Synthesis of
1-[3-[(3R)-3-hydroxy-3-(pyridin-2-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3--
carboxamide
##STR00581##
[0998] Similar to as described in General Procedure E,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
(2R)-2-(pyridin-2-yl)but-3-yn-2-ol to give the title compound (10.5
mg, 10%) as an off-white solid. LC-MS (ES, m/z): 383 [M+H].sup.+.
.sup.1H NMR (CD.sub.3OD, 300 MHz) .delta. 8.57-8.53 (m, 1H), 8.35
(d, J=8.4 Hz, 1H), 7.95-7.82 (m, 5H), 7.64-7.54 (m, 3H), 7.42-7.35
(m, 2H), 1.90 (s, 3H).
Example NNNN and Example OOOO
Synthesis of
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide and
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-hydroxy-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxyla-
te
##STR00582##
[1000] Similar to as described in General Procedure K, ethyl
1-(3-bromophenyl)-4-oxo-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate
was reacted with sodium borohydride to give the title compound (84
mg, 66%) as a brown oil. LC-MS (ES, m/z): 351, 353 [M+H].sup.+.
Step 2: Synthesis of ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-1H,4H, 5H,6H-cyclopenta[c]pyrazole-3-carboxylate
##STR00583##
[1002] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-4-hydroxy-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxyla-
te was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (10 mg, 135%) as a brown oil. LC-MS (ES, m/z): 410
[M+H].sup.+.
Step 3: Synthesis of
(4R)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide and
(4S)-4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide
##STR00584##
[1004] Similar to as described in General Procedure S, ethyl
4-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-1H,4H, 5H,6H-cyclopenta[c]pyrazole-3-carboxylate was reacted
with ammonia in methanol to give the title compounds which were
separated by Chiral-Prep-HPLC with the following conditions:
Column, Chiralpak IC, 2.times.25 cm, 5 um; mobile phase, MTBE and
ethanol (hold 40.0% ethanol in 18 min); Detector, UV 254/220 nm.
The stereochemistry for position 4 for either isomer is arbitrarily
assigned.
[1005] Isomer A (4R): 13.7 mg (13%), light yellow solid.
t.sub.R=6.27 min (CHIRALPAK IC, 25.degree. C., UV-254 nm
DCM:EtOH=70:30, 1.0 ml/min). LC-MS (ES, m/z): 403 [M+Na].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.78 (s, 1H), 7.77-7.64
(m, 1H), 7.40 (t, J=8.0 Hz, 1H), 7.33 (d, J=4.2 Hz, 1H), 5.17 (dd,
J=8.0, 2.8 Hz, 1H), 3.40-3.39 (m, 2H), 3.13-3.11 (m, 1H), 2.93-2.89
(m, 2H), 2.83 (s, 3H), 2.52-2.46 (m, 1H), 2.40-2.39 (m, 1H),
2.25-2.20 (m, 1H).
[1006] Isomer B (4S): 12.3 mg (12%), light yellow solid.
t.sub.R=7.22 min (CHIRALPAK IC, 25.degree. C., UV-254 nm
DCM:EtOH=70:30, 1.0 ml/min). LC-MS (ES, m/z): 381 [M+H].sup.+.
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.89 (s, 1H), 7.88-7.75
(m, 1H), 7.52 (t, J=8.0 Hz, 1H), 7.48 (d, J=4.2 Hz, 1H), 5.28 (dd,
J=6.6, 2.0 Hz, 1H), 3.55-3.49 (m, 2H), 3.07-2.99 (m, 1H), 2.93-2.89
(m, 2H), 2.94 (s, 3H), 2.62-2.56 (m, 1H), 2.52-2.32 (m, 1H),
2.34-2.30 (m, 1H).
Example PPPP
Synthesis of
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of (3-bromo-5-cyanophenyl)boronic acid
##STR00585##
[1008] 3-Bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
(1.5 g, 4.87 mmol, 1.00 equiv) was added to hydrogen chloride (15
mL, 493.68 mmol, 101.40 equiv) at room temperature, and it was
stirred for 10 hours at that temperature. The solid was collected
by filtration to give 750 mg (68%) of the title compound as a white
solid.
Step 2: Synthesis of methyl
1-(3-bromo-5-carbamoylphenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00586##
[1010] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromo-5-cyanophenyl)boronic acid to give the title compound (170
mg, 47%) as a green solid. LC-MS (ES, m/z): 375, 377
[M+1].sup.+.
Step 3: Synthesis of methyl
1-(3-bromo-5-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00587##
[1012] To a stirred solution of methyl
1-(3-bromo-5-carbamoylphenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
(120.00 mg, 0.32 mmol, 1.00 equiv) in dichloromethane (20 mL) was
added methyl N--[(triethylazaniumyl)sulfonyl]carbamate oxidanide
(152.44 mg, 0.64 mmol, 2.00 equiv) at room temperature. The
reaction mixture was stirred for 12 hours at that temperature,
diluted with of dichloromethane, washed with water, extracted with
dichloromethane, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified by a silica gel
column eluting with ethyl acetate/petroleum ether (2:3) to give 70
mg (61%) of the title compound as a white solid. LC-MS (ES, m/z):
357, 359 [M+1].sup.+.
Step 4: Synthesis of methyl
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00588##
[1014] Similar to as described in General Procedure E, methyl
1-(3-bromo-5-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (60 mg, 37%) as a white solid. LC-MS
(ES, m/z): 416 [M+1].sup.+.
Step 5: Synthesis of
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00589##
[1016] Similar to as described in General Procedure S, methyl
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
ammonia in methanol to give the title compound (28.8 mg, 33%) as a
white solid. LC-MS (ES, m/z): 401 [M+1].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 8.99 (dd, J=6.6, 3.6 Hz, 1H), 8.80-8.74
(m, 2H), 7.85 (s, 1H), 7.53 (dd, J=8.1, 4.5 Hz, 2H), 3.57-3.51 (m,
2H), 2.97 (s, 3H), 2.70-2.64 (m, 1H), 2.42-2.33 (m, 1H).
Example QQQQ
Synthesis of
1-[3-(cyanomethyl)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of
[(3-bromophenyl)methoxy](tert-butyl)dimethylsilane
##STR00590##
[1018] To a solution of (3-bromophenyl)methanol (5 g, 26.73 mmol,
1.00 equiv) and 1H-imidazole (3.7 g, 54.35 mmol, 2.00 equiv) in
dichloromethane (50 mL) was added a solution of TBSCl (6 g, 39.81
mmol, 1.50 equiv) in dichloromethane (25 mL) at 0.degree. C. The
resulting mixture was stirred for 2 hours at room temperature,
diluted with water, extracted with dichloromethane, dried over
anhydrous magnesium sulfate, and concentrated under vacuum. This
resulted in 7.5 g (93%) of the title compound as colorless oil.
Step 2: Synthesis of
[[3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy](tert-but-
yl)dimethylsilane
##STR00591##
[1020] To a solution of
[(3-bromophenyl)methoxy](tert-butyl)dimethylsilane (7.4 g, 24.56
mmol, 1.00 equiv) and
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxabo-
rolane (5.0 g, 19.69 mmol, 0.80 equiv) in tetrahydrofuran (5 mL)
was added
bis((1Z,5Z)-cycloocta-1,5-diene)dimethyl-2,4-dioxa-1,3-diiridabicyclo[1.1-
.0]butane-2,4-diium-1,3-diuide (166 mg, 0.25 mmol) and
4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine (200 mg, 0.75
mmol) under nitrogen. The mixture was stirred overnight at
80.degree. C. The reaction was concentrated under vacuum and the
crude product was purified by a silica gel column eluting with
ethyl acetate/petroleum ether (1:4) to give 9.0 g (86%) of the
title compound as colorless oil.
Step 3: Synthesis of methyl
1-(3-bromo-5-[[(tert-butyldimethylsilyl)oxy]methyl]phenyl)-1H-pyrazolo[3,-
4-b]pyridine-3-carboxylate
##STR00592##
[1022] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
[[3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy](tert-but-
yl)dimethylsilane to give the title compound (1.2 g, 49%) as a
white solid. LC-MS (ES, m/z): 476, 478 [M+1].sup.+.
Step 4: Synthesis of methyl
1-[3-bromo-5-(hydroxymethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxyl-
ate
##STR00593##
[1024] A solution of methyl
1-(3-bromo-5-[[(tert-butyldimethylsilyl)oxy]methyl]phenyl)-1H-pyrazolo[3,-
4-b]pyridine-3-carboxylate (600 mg, 1.26 mmol, 1.00 equiv) and
tetrabutylazanium fluoride (415 mg, 1.59 mmol, 1.30 equiv) in
tetrahydrofuran (10 mL) was stirred for overnight at room
temperature. The suspension was extracted with dichloromethane,
washed with brine, dried over anhydrous sodium sulfate, and
concentrated under vacuum. This resulted in 480 mg (79%) of the
title compound as an off-white solid. LC-MS (ES, m/z): 362, 364
[M+1].sup.+.
Step 5: Synthesis of methyl
1-[3-bromo-5-(chloromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxyla-
te
##STR00594##
[1026] To a solution of
1-[3-bromo-5-(hydroxymethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxyl-
ate (460 mg, 1.27 mmol, 1.00 equiv) in dichloromethane (10 mL) was
added thionyl chloride (5 mL, 68.92 mmol, 54.30 equiv) dropwise.
The reaction was stirred for overnight at room temperature and
concentrated under vacuum to give 500 mg (crude) of the title
compound as a white solid which was used in the next step without
further purification.
Step 6: Synthesis of methyl
1-[3-bromo-5-(cyanomethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylat-
e
##STR00595##
[1028] To a solution of methyl
1-[3-bromo-5-(chloromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxyla-
te (500 mg, 1.31 mmol, 1.00 equiv) in N,N-dimethylformamide (15 mL)
was added sodium carbonitrile (150 mg, 3.06 mmol, 2.30 equiv). The
resulting solution was stirred for 2 hours at room temperature,
diluted with water, and extracted with ethyl acetate. The organic
layers were combined and washed with saturated sodium chloride,
dried over anhydrous magnesium sulfate, and concentrated under
vacuum to give 390 mg (56%) of the title compound as a yellow
solid. LC-MS (ES, m/z): 371, 373 [M+1].sup.+.
Step 7: Synthesis of methyl
1-[3-(cyanomethyl)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00596##
[1030] Similar to as described in General Procedure E, methyl
1-[3-bromo-5-(cyanomethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylat-
e was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (260 mg, 80%) as a yellow solid. LC-MS (ES, m/z): 430
[M+1].sup.+.
Step 8: Synthesis of
1-[3-(cyanomethyl)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00597##
[1032] Similar to as described in General Procedure S, methyl
1-[3-(cyanomethyl)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]eth-
ynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted
with ammonia in methanol to give the title compound (40 mg, 16%) as
a white solid. LC-MS (ES, m/z): 415 [M+1].sup.+. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 8.76 (dd, J=8.1, 1.6 Hz, 1H), 8.66 (dd,
J=4.4, 1.6 Hz, 1H), 8.42 (s, 1H), 8.39 (s, 1H), 7.42 (s, 1H), 7.37
(dd, J=8.1, 4.4 Hz, 1H), 3.86 (s, 2H), 3.57-3.51 (m, 1H), 3.45-3.39
(m, 1H), 2.99 (s, 3H), 2.72-2.66 (m, 1H), 2.45-2.38 (m,1H).
Example RRRR
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(1-hydro-
xyethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of
[1-(3-bromophenyl)ethoxy](tert-butyl)dimethylsilane
##STR00598##
[1034] A solution of 1-(3-bromophenyl)ethan-1-ol (2.00 g, 9.95
mmol, 1.00 equiv), dichloromethane (100 mL, 1.57 mol, 158.10
equiv), 1H-imidazole (1.35 g, 19.83 mmol, 2.00 equiv),
tert-butyl(chloro)dimethylsilane (2.24 g, 14.93 mmol, 1.50 equiv)
was stirred for overnight at room temperature. The reaction was
quenched by water, extracted with dichloromethane, washed with
water, dried over anhydrous sodium sulfate, and concentrated under
vacuum to give 2 g (64%) of the title compound as a solid. LC-MS
(ES, m/z): 317, 315 [M+H].sup.+.
Step 3: Synthesis of
[1-[3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethoxy](tert-bu-
tyl)dimethylsilane
##STR00599##
[1036] To a stirred solution of
[1-(3-bromophenyl)ethoxy](tert-butyl)dimethylsilane (2.00 g, 6.34
mmol, 1.00 equiv) and
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxabo-
rolane (970 mg, 3.81 mmol, 0.60 equiv) in tetrahydrofuran (8 mL)
was added
bis((1Z,5Z)-cycloocta-1,5-diene)dimethyl-2,4-dioxa-1,3-diiridabicyclo[1.1-
.0]butane-2,4-diium-1,3-diuide (43 mg, 0.06 mmol, 0.01 equiv) and
4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine (34 mg, 0.13
mmol, 0.02 equiv). The resulting solution was stirred overnight at
80.degree. C. The precipitated solids were filtered out and the
filtrate was concentrated under vacuum to give 3 g (crude) of the
title compound as a brown oil.
Step 4: Synthesis of methyl
1-(3-bromo-5-[1-[(tert-butyldimethylsilyl)oxy]ethyl]phenyl)-1H-pyrazolo[3-
,4-b]pyridine-3-carboxylate
##STR00600##
[1038] Similar to as described in General Procedure C,
[1-[3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethoxy](tert-bu-
tyl)dimethylsilane was reacted with methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate to give the title compound
(0.5 g, 36%) as a brown oil. LC-MS (m/z): 490, 492 [M+H].sup.+.
Step 5: Synthesis of methyl
1-[3-bromo-5-(1-hydroxyethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxy-
late
##STR00601##
[1040] To a stirred solution of methyl
1-(3-bromo-5-[1-[(tert-butyldimethylsilyl)oxy]ethyl]phenyl)-1H-pyrazolo[3-
,4-b]pyridine-3-carboxylate (500 mg, 1.02 mmol, 1.00 equiv) in
tetrahydrofuran (10 mL) added tetrabutylazanium fluoride (400 mg,
1.53 mmol, 1.50 equiv) at room temperature. The reaction was
stirred overnight, quenched by water, extracted with ethyl acetate,
washed with water and brine, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was purified by a silica
gel column eluting with ethyl acetate/petroleum ether (1/5) to give
250 mg (65%) of the title compound as a white solid. LC-MS (m/z):
376, 378 [M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(1-hydro-
xyethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00602##
[1042] Similar to as described in General Procedure E, methyl
1-[3-bromo-5-(1-hydroxyethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxy-
late was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (200 mg, 72%) as a brown oil. LC-MS (m/z): 435
[M+H].sup.+.
Step 7: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(1-hydro-
xyethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00603##
[1044] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(1-hydro-
xyethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was
reacted with ammonia in methanol to give the title compound (43 mg,
22%) as a light yellow solid. LC-MS (ES, m/z): 420 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.74 (s, 1H), 8.73-8.14
(m, 1H), 8.46 (s, 1H), 7.53 (s, 1H), 7.50-7.47 (m, 1H), 4.99-4.94
(m, 1H), 3.62-3.47 (m, 2H), 2.96 (s, 3H), 2.67-2.39 (m, 1H),
2.39-2.32 (m, 1H), 1.55 (m, 3H).
Example SSSS
Synthesis of
1-[3-(difluoromethoxy)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of
2-[3-bromo-5-(difluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lane
##STR00604##
[1046] To a stirred solution of 1-bromo-3-(difluoromethoxy)benzene
(1000.00 mg, 4.48 mmol, 1.00 equiv) in tetrahydrofuran (1.5 mL) was
added
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxabo-
rolane (797.06 mg, 3.14 mmol, 0.70 equiv),
4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine (24.07 mg, 0.09
mmol, 0.02 equiv) and
bis((1Z,5Z)-cycloocta-1,5-diene)dimethyl-2,4-dioxa-1,3-diiridabicyclo[1.1-
.0]butane-2,4-diium-1,3-diuide (30 mg, 0.05 mmol, 0.01 equiv) under
nitrogen. The resulting solution was stirred for 14 hours at
80.degree. C., diluted with ethyl acetate, washed with water,
extracted with ethyl acetate, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was purified by a silica
gel column eluting with ethyl acetate/petroleum ether (1:20) to
give 703 mg (45%) of the title compound as a yellow oil.
Step 2: Synthesis of methyl
1-[3-bromo-5-(difluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carbox-
ylate
##STR00605##
[1048] Similar to as described in General Procedure C,
2-[3-bromo-5-(difluoromethoxy)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lane was reacted with methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate to give the title compound
(66 mg, 55%) as a white solid. LC-MS (ES, m/z): 398, 400
[M+1].sup.+.
Step 3: Synthesis of methyl
1-[3-(difluoromethoxy)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00606##
[1050] Similar to as described in General Procedure E,
1-[3-bromo-5-(difluoromethoxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carbox-
ylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (350 mg, 57%) as a yellow oil. LC-MS (ES, m/z): 457
[M+1].sup.+.
Step 4: Synthesis of
1-[3-(difluoromethoxy)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00607##
[1052] Similar to as described in General Procedure S, methyl
1-[3-(difluoromethoxy)-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phen yl]-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was
reacted with ammonia in methanol to give the title compound (7.3
mg, 11%) as a white solid. LC-MS (ES, m/z): 442 [M+1].sup.+.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.76 (dd, J=8.1, 1.8 Hz,
1H), 8.68 (dd, J=4.5, 1.8 Hz, 1H), 8.34-8.31 (m, 2H), 7.38 (dd,
J=8.1, 4.5 Hz, 1H), 7.18 (br s, 1H), 7.05 (br s, 1H), 6.61 (t,
J=73.2 Hz, 1H), 5.73 (br s, 1H), 3.57-3.42 (m, 2H), 3.41-3.77 (m,
1H), 2.99 (s, 3H), 2.73-2.65 (m, 1H), 2.49-2.36 (m, 1H).
Example TTTT
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(trifluo-
romethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Step 1: Synthesis of methyl
1-[3-bromo-5-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carbox-
ylate
##STR00608##
[1054] Similar to as described in General Procedure C,
2-[3-bromo-5-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lane was reacted with methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate to give the title compound
(100 mg, 21%) as a white solid. LC-MS (ES, m/z): 400, 402
[M+1].sup.+.
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(trifluo-
romethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00609##
[1056] Similar to as described in General Procedure E, methyl
1-[3-bromo-5-(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-3-carbox-
ylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (110 mg) as a light brown solid. LC-MS (ES, m/z): 459
[M+1].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(trifluo-
romethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00610##
[1058] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-(trifluo-
romethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was
reacted with ammonia in methanol to give the title compound (12.3
mg, 12%) as a white solid. LC-MS (ES, m/z): 444 [M+1].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.94 (s, 2H), 8.78-8.75
(m, 1H), 8.73 (d, J=2.0 Hz, 1H), 7.77 (s, 1H), 7.53-7.49 (m, 1H),
3.54-3.50 (m, 2H), 2.96 (s, 3H), 2.69-2.61 (m, 1H), 2.40-2.34 (m,
1H).
Example UUUU
Synthesis of
5-(acetamidomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl)-1H-indazole-3-carboxamide
Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate
##STR00611##
[1060] To a solution of methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate (500
mg, 1.38 mmol, 1.00 equiv) in dichloromethane (10 mL) was added
thionyl chloride (2 mL, 27.57 mmol, 19.90 equiv) dropwise with
stirring at 0.degree. C. and then stirred for 30 min at room
temperature. The reaction was concentrated under vacuum to give 600
mg of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate as a
yellow solid which was used in the next step without further
purification.
Step 2: Synthesis of methyl
5-(azidomethyl)-1-(3-bromophenyl)-1H-indazole-3-carboxylate
##STR00612##
[1062] A suspension of methyl
1-(3-bromophenyl)-5-(chloromethyl)-1H-indazole-3-carboxylate
(300.00 mg, 0.79 mmol, 1.00 equiv), sodium azide (102.73 mg, 1.58
mmol, 2.00 equiv) in DMSO (4.00 mL) was stirred for 90 min at room
temperature. The reaction mixture was diluted with 100 mL of
tetrahydrofuran and washed with 3.times.60 mL of brine. This
resulted in 100 mL of solution of the title compound which was used
for the next step without further purification. LC-MS (ES, m/z):
386, 388 [M+H].sup.+.
Step 3: Synthesis of methyl
5-(aminomethyl)-1-(3-bromophenyl)-1H-indazole-3-carboxylate
##STR00613##
[1064] To a solution of methyl
5-(azidomethyl)-1-(3-bromophenyl)-1H-indazole-3-carboxylate in
tetrahydrofuran (100 mL) obtained in the last step was added
triphenyl phosphane (224.12 mg, 0.85 mmol, 1.10 equiv) and water
(0.1 mL). The resulting mixture was stirred for 3 h at 40.degree.
C. and concentrated under vacuum to give 500 mg (crude) of the
title compound as a yellow solid. LC-MS (ES, m/z): 360, 362
[M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-5-(acetamidomethyl)-1H-indazole-3-carboxylate
##STR00614##
[1066] A solution of methyl
5-(aminomethyl)-1-(3-bromophenyl)-1H-indazole-3-carboxylate (200.00
mg, 0.56 mmol, 1.00 equiv), acetic anhydride (85.03 mg, 0.83 mmol,
1.50 equiv) and triethylamine (112.37 mg, 1.11 mmol, 2.00 equiv) in
dichloromethane (20 mL) was stirred for 2 h at room temperature.
The resulting mixture was concentrated under vacuum to give 200 mg
of the title compound as a yellow solid. LC-MS (ES, m/z): 402, 404
[M+H].sup.+.
Step 5: Synthesis of methyl
5-(acetamidomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl)-1H-indazole-3-carboxylate
##STR00615##
[1068] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-(acetamidomethyl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (100 mg, 49%) as a yellow solid. LC-MS (ES,
m/z): 461, 462 [M+H].sup.+.
Step 6: Synthesis of
5-(acetamidomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl)-1H-indazole-3-carboxamide
##STR00616##
[1070] Similar to as described in General Procedure S, methyl
5-(acetamidomethyl)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]phenyl)-1H-indazole-3-carboxylate was reacted with ammonia
in methanol to give the title compound (25.7 mg, 27%) as an
off-white solid. LC-MS (ES, m/z): 446 [M+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 8.16 (s, 1H), 7.84-7.81 (m, 1H), 7.78-7.70
(m, 2H), 7.54-7.40 (m, 3H), 4.44 (s, 2H), 3.46-3.37 (m, 2H), 2.84
(s, 3H), 2.55-2.47 (m, 1H), 2.28-2.18 (m, 1H), 1.93 (s, 3H).
Example VVVV
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-N-
-methyl-1H-indazole-3,5-dicarboxamide
Step 1: Synthesis of
1-(3-bromophenyl)-3-(methoxycarbonyl)-1H-indazole-5-carboxylic
acid
##STR00617##
[1072] A suspension of methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate
(144.00 mg, 0.40 mmol, 1.00 equiv), PCC (17.19 mg, 0.08 mmol, 0.20
equiv) and periodic acid (199.93 mg, 0.88 mmol, 2.20 equiv) in
acetonitrile (10 mL) was stirred for 30 min at room temperature.
The resulting solution was diluted with ethyl acetate, washed with
brine, dried over anhydrous sodium sulfate, and concentrated under
vacuum to give 150 mg (crude, brown solid) of the title compound
which was used in the next step without further purification. LC-MS
(ES, m/z): 375, 377[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-5-(methylcarbamoyl)-1H-indazole-3-carboxylate
##STR00618##
[1074] Similar to as described in General Procedure B,
1-(3-bromophenyl)-3-(methoxycarbonyl)-1H-indazole-5-carboxylic acid
was reacted with methylamine hydrochloride to give the title
compound (140 mg, 75%) as a yellow solid. LC-MS (ES, m/z): 388, 390
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
methylcarbamoyl)-1H-indazole-3-carboxylate
##STR00619##
[1076] Similar to as described in General Procedure E, methyl
1-(3-bromophenyl)-5-(methylcarbamoyl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (140 mg, 94%) as a yellow solid. LC-MS (ES,
m/z): 447 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-N-
-methyl-1H-indazole-3,5-dicarboxamide
##STR00620##
[1078] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
methylcarbamoyl)-1H-indazole-3-carboxylate was reacted with ammonia
in methanol to give the title compound (34.3 mg, 25%) as an
off-white solid. LC-MS (ES, m/z): 432 [M+H].sup.+. .sup.1H NMR
(CD.sub.3OD, 300 MHz) .delta. 8.85 (s, 1H), 8.04-7.86 (m, 4H),
7.67-7.58 (m, 2H), 3.53-3.48 (m, 2H), 2.99 (s, 3H), 2.95 (s, 3H),
2.66-2.58 (m, 1H), 2.39-2.30 (m, 1H).
Example WWWW
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-methanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-
e-3-carboxylate
##STR00621##
[1080] Methanesulfonyl chloride (37.01 mg, 0.32 mmol, 1.00 equiv)
was added to a stirred solution of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
(150.00 mg, 0.32 mmol, 1.00 equiv) and triethylamine (98.09 mg,
0.97 mmol, 3.00 equiv) in dichloromethane (2 mL) at 0.degree. C.
The mixture was stirred for 3 h at room temperature and
concentrated under vacuum. The residue was purified by a silica gel
column chromatography eluting with ethyl acetate/petroleum ether
(1:2) to afford 70 mg (51%) of the title compound as yellow oil.
LC-MS (ES, m/z): 428, 430 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00622##
[1082] Similar to as described in General Procedure E, ethyl
1-(3-bromophenyl)-5-methanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-
e-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (40 mg, 59%) as a yellow oil. LC-MS (ES, m/z): 487
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00623##
[1084] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfonyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia in methanol to give the title compound
(10.7 mg, 28%) as a white solid. LC-MS (ES, m/z): 458 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.66 (s, 1H), 7.57-7.53
(m, 1H), 7.46-7.42 (m, 2H), 4.50 (s, 2H), 3.51-3.47 (m, 2H),
3.40-3.35 (m, 2H), 2.94-2.91 (m, 2H), 2.86 (s, 1H), 2.83 (s, 1H),
2.52-2.46 (m, 1H), 2.25-2.22 (m, 1H).
##STR00624##
[1085] 2-[(3-bromobenzoyl)amino]acetic acid (1 g, 1 eq) and
N,N'-dicyclohexylcarbodiimide (1 eq) in Toluene (0.25M) were heated
for 4 hours at 100.degree. C. The reaction was cooled to room
temperature and the white solid (urea) was removed by filtration
and the resultant reaction mixture was concentrated to dryness to
afford the title compound as a crude orange solid in quantitative
yield.
Synthesis of
2-(3-bromophenyl)-4-(3,4,5,6-tetrahydropyridin-2-yl)oxazol-5(4H)-one
##STR00625##
[1087] 2-(3-bromophenyl)oxazol-5(4H)-one (0.93 g) was suspended in
Tetrahydrofuran (16 mL) whereupon
6-methoxy-2,3,4,5-tetrahydropyridine (1 eq) was added to the
solution. The reaction was heated at 80.degree. C. for 16 hours and
the solvent was removed under vacuum. The crude material was
suspended in dichloromethane and extracted with water and the
aqueous layer was back extracted once with dichloromethane. The
combined organic layers were dried with Magnesium Sulfate, filtered
and concentrated to afford orange semi-solid. The crude was
purified using Hetpanes:Ethyl acetate gradient to afford 630 mg of
the title compound.
Synthesis of
3-(3-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
##STR00626##
[1089]
2-(3-bromophenyl)-4-(3,4,5,6-tetrahydropyridin-2-yl)oxazol-5(4H)-on-
e (630 mg) was dissolved in Methanol (15 mL) and Lithium Hydroxide
monohydrate (3 eq in 1.5 mL of water) was added. The reaction was
heated to 90.degree. C. for 3 hours then concentrated to remove M
ethanol. Additional water (.about.10 mL) was added to reaction
mixture and the aqueous layer was brought to neutral pH and
extracted 3 times with DCM to afford crude
3-(3-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic
acid. Similar to General Procedure B, crude
3-(3-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic
acid (40 mg) was reacted with ammonium chloride to give crude
3-(3-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
(40 mg) following trituration from a saturated solution of ammonium
chloride.
Example XXXX
Synthesis of
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-5,-
6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
##STR00627##
[1091] Similar to as described in General Procedure E,
3-(3-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 22 mg of the title compound (12%). M+H=379.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 7.77 7.70 (m, 2H), 7.53 7.45 (m, 2H),
7.19 (s, 1H), 6.89 (s, 1H), 6.45 (s, 1H), 4.08 (t, J=5.9 Hz, 2H),
3.38-3.34 (m, 2H), 3.05 (t, J=6.4 Hz, 2H), 2.80 (s, 3H), 2.48 2.40
(m, 1H), 2.23 2.14 (m, 1H), 1.90-1.82 (m, 2H), 1.82-1.73 (m,
2H).
Synthesis of ethyl
5-amino-4-(3-bromophenyl)-1H-imidazole-2-carboxylate
##STR00628##
[1093] To a solution of ethyl thiooxamate (1 g, 1 eq) in
dichloromethane (40 mL) was slowly added trimethyloxonium
tetrafluoroborate (1.18 eq) at 0.degree. C. After 10 min the ice
bath was removed, and the reaction mixture was stirred overnight at
room temperature. The solvent was removed to afford ethyl
2-imino-2-(methylthio)acetate as tetrafluoroborate salt in assumed
quantitative yield which was used without further purification. A
solution of 2-amino-2-(3-bromophenyl)acetonitrile (1 g, 1 eq) and
2-ethoxy-1-(methylsulfanyl)-2-oxoethanaminium tetrafluoroborate
(1.2 eq) in dry 1,4-dioxane (15 mL) was stirred at 25.degree. C.
under a Nitrogen balloon for 2 days. The solution was concentrated
in vacuo. The resulting residue was purified by silica gel
chromatography using Ethyl Acetate/Heptanes gradient to afford 440
mg of ethyl 5-amino-4-(3-bromophenyl)-1H-imidazole-2-carboxylate,
as a yellow semi-solid.
Synthesis of ethyl
8-(3-bromophenyl)imidazo[1,5-a]pyrimidine-6-carboxylate
##STR00629##
[1095] Ethyl 5-amino-4-(3-bromophenyl)-1H-imidazole-2-carboxylate
(0.25 g) was suspended in EtOH (0.25M) and
1,1,3,3-tetramethoxypropane (2 eq) was added. The reaction was
heated to 150.degree. C. thermally for 1 hour and concentrated to
dryness to afford crude ethyl
8-(3-bromophenyl)imidazo[1,5-a]pyrimidine-6-carboxylate (0.18
g).
Example YYYY
Synthesis of
8-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyrimidine-6-carboxamide
##STR00630##
[1097] Similar to as described in General Procedure I, crude ethyl
8-(3-bromophenyl)imidazo[1,5-a]pyrimidine-6-carboxylate (0.13 g)
was reacted to form
8-(3-bromophenyl)imidazo[1,5-a]pyrimidine-6-carboxamide in assumed
quantitative yield. Similar to as described in General Procedure E,
8-(3-bromophenyl)imidazo[1,5-a]pyrimidine-6-carboxamide (70 mg) was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 27 mg of the title compound (31%). M+H=376.0; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 9.64 (dd, J=7.3, 1.8 Hz, 1H), 8.58 (dd,
J=3.8, 1.8 Hz, 1H), 8.52 8.44 (m, 2H), 8.15 (s, 1H), 7.75-7.67 (m,
1H), 7.50 (t, J=7.8 Hz, 1H), 7.38-7.32 (m, 1H), 7.13 (dd, J=7.3,
3.8 Hz, 1H), 6.46 (s, 1H), 3.40 3.34 (m, 2H), 2.82 (s, 3H), 2.49
2.42 (m, 1H), 2.26-2.16 (m, 1H).
Synthesis of
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxamide
##STR00631##
[1099] Ethyl 5-amino-4-(3-bromophenyl)-1H-imidazole-2-carboxylate
(117 mg) was stirred with dibromoethane (3 eq) and cesium carbonate
(3 eq) in DMF (52 eq) at 80.degree. C. for 2 hrs then cooled to
room temperature. The reaction mixture was concentrated to dryness,
suspended in DCM and filtered to remove any solids then
concentrated to dryness to form 100 mg (79%) crude ethyl
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxylate.
Similar to as described in General Procedure J, crude ethyl
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxylate
(100 mg) was reacted to form
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxylic
acid (40 mg) after elution through a biotage scx-2 cartridge.
Similar to as described in General Procedure B, crude
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxylic
acid (40 mg) was reacted with ammonium chloride to form crude
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxamide
(40 mg) following elution through a biotage scx-2 cartridge.
Example ZZZZ
Synthesis of
7-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-2,-
3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxamide
##STR00632##
[1101] Similar to as described in General Procedure E,
7-(3-bromophenyl)-2,3-dihydro-1H-imidazo[1,5-a]imidazole-5-carboxamide
(40 mg) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to give 2 mg of
the title compound (4%). M+H=366.0
Synthesis of ethyl (2E)-2-hydroxyimino-2-pyridazin-3-yl-acetate
##STR00633##
[1103] A solution 1 g of ethyl 2-pyridazin-3-ylacetate in 1.5 ml of
glacial acetic acid was cooled to 0.degree. C. in an ice bath and
sodium nitrite (1.15 eq) in 4.8 ml of water was added over a period
of 30 minutes then the mixture was stirred for an additional 30
minutes at 0.degree. C., whereupon the reaction mixture was
subsequently warmed to room temperature. Additional water (3.6 mL)
was added then the reaction was stirred for 2 more hours at room
temperature. The resultant thick slurry was washed with water (10
mL), sodium bicarbonate solution (10 mL) and then water again (10
mL) to afford 528 mg (47%) of the title compound.
Synthesis of methyl 2-amino-2-pyridazin-3-yl-acetate
hydrochloride
##STR00634##
[1105] To a mixture of ethyl
(2E)-2-hydroxyimino-2-pyridazin-3-yl-acetate (528 mg) and 10%
Palladium on Carbon (0.1 eq) in EtOH (10 mL) was added a solution
of HCl in methanol (-1.25M, 10 mL). The mixture was reacted on the
parr shaker for 4 hours at 50 psi then brought back to atmospheric
pressure. The reaction was filtered through celite to remove
Palladium and concentrated to dryness to the title compound as an
orange oil. This intermediate was taken onto the next step without
purification.
Synthesis of methyl
2-[(3-bromobenzoyl)amino]-2-pyridazin-3-yl-acetate
##STR00635##
[1107] Similar to as described in General Procedure B, crude methyl
2-amino-2-pyridazin-3-yl-acetate hydrochloride was reacted with
3-bromobenzoic acid to form 588 mg (57%) of the title compound
following purification with Heptane/Ethyl Acetate with 1%
triethylamine.
Synthesis of methyl
7-(3-bromophenyl)imidazo[1,5-b]pyridazine-5-carboxylate
##STR00636##
[1109] To a solution of methyl
2-[(3-bromobenzoyl)amino]-2-pyridazin-3-yl-acetate in Acetonitrile
(11 mL) was added phosphoryl chloride (20 eq). The reaction was
heated at 85.degree. C. for 2.5 hours then concentrated to a
minimal volume before dilution with DCM. Dropwise addition of the
solution was added via glass pipet into a stirring mixture of ice
water (50 mL). The solution was neutralized by adding solid
bicarbonate to the stirring ice water solution and extracted with
DCM to form 350 mg (63%) of the title compound which was taken on
without further purification.
Synthesis of
7-(3-bromophenyl)imidazo[1,5-b]pyridazine-5-carboxamide
##STR00637##
[1111] Similar to as described in General Procedure J, methyl
7-(3-bromophenyl)imidazo[1,5-b]pyridazine-5-carboxylate (185 mg)
was reacted to form 172 mg (97%) of
7-(3-bromophenyl)imidazo[1,5-b]pyridazine-5-carboxamide.
Example A5
Synthesis of
7-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-b]pyridazine-5-carboxamide
##STR00638##
[1113] Similar to as described in General Procedure F,
7-(3-bromophenyl)imidazo[1,5-b]pyridazine-5-carboxamide (80 mg) was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 20 mg of the title compound (22%). M+H=376; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.65 8.57 (m, 2H), 8.54 8.48 (m, 2H), 7.81
(s, 1H), 7.62-7.56 (m, 1H), 7.55-7.50 (m, 1H), 7.39 (s, 1H), 7.13
(dd, J=9.2, 4.4 Hz, 1H), 6.49 (s, 1H), 3.40 3.34 (m, 2H), 2.81 (s,
3H), 2.48 2.42 (m, 1H), 2.26-2.16 (m, 1H).
Synthesis of 1-bromo-imidazo[1,5-a]pyridine-3-carboxylic acid ethyl
ester
##STR00639##
[1115] To a solution of ethyl imidazo[1,5-a]pyridine-3-carboxylate
(152 mg) in Acetic Acid (0.25M) was added Bromine (1 eq). The
reaction was stirred at room temperature for 5 minutes then
concentrated to dryness to give 205 of the title compound. This
intermediate was taken onto the next step without purification.
Synthesis of ethyl
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-3-carboxylate
##STR00640##
[1117] Similar to as described in General Procedure U,
1-bromo-imidazo[1,5-a]pyridine-3-carboxylic acid ethyl ester (75
mg) was reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form the title compound. This intermediate was taken onto
the next step without purification.
Example B5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-3-carboxamide
##STR00641##
[1119] Similar to as described in General Procedure J, ethyl
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-3-carboxylate was reacted to form
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-3-carboxylic acid (98 mg). This intermediate
was taken onto the next step without purification. Similar to as
described in General Procedure B,
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-3-carboxylic acid (98 mg) was reacted with
ammonium chloride to give 12 mg of the title compound (11%).
M+H=375.0; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.49 (dt, J=7.2,
1.2 Hz, 1H), 8.15-7.97 (m, 4H), 7.65-7.58 (m, 1H), 7.54 7.47 (m,
1H), 7.40-7.35 (m, 1H), 7.26-7.19 (m, 1H), 7.08-7.02 (m, 1H), 6.50
(s, 1H), 3.41-3.36 (m, 2H), 2.81 (s, 3H), 2.47 2.42 (m, 1H), 2.24
2.16 (m, 1H).
Synthesis of ethyl 3-bromoimidazo[1,5-a]pyridine-1-carboxylate
##STR00642##
[1121] To a solution of ethyl imidazo[1,5-a]pyridine-1-carboxylate
(150 mg) in Acetic Acid (0.25M) was added Bromine (1 eq). The
reaction was stirred at room temperature for 5 minutes then
concentrated to dryness to give 204 of the title compound. The
solid was brought up in Water (20 mL) and extracted with DCM (20
mL). The organic layer was dried with Magnesium sulfate, filtered
and concentrated to afford the title compound as a green solid.
This intermediate was taken onto the next step without
purification.
Synthesis of ethyl
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-1-carboxylate
##STR00643##
[1123] Similar to as described in General Procedure U, ethyl
3-bromoimidazo[1,5-a]pyridine-1-carboxylate (71 mg) was reacted
with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethyny-
l)phenyl)borate to form the title compound which was taken onto the
next step without purification.
Example C5
Synthesis of
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-1-carboxamide
##STR00644##
[1125] Similar to as described in General Procedure J, ethyl
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-1-carboxylate was reacted to form
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-1-carboxylic acid (99 mg). This intermediate
was taken onto the next step without purification. Similar to as
described in General Procedure B,
3-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyridine-1-carboxylic acid (98 mg) was reacted with
ammonium chloride to give 12 mg of the title compound (12%).
M+H=375.0; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.53 (dt, J=7.2,
1.1 Hz, 1H), 8.21 (dt, J=9.1, 1.2 Hz, 1H), 7.93 7.89 (m, 2H), 7.64
7.54 (m, 3H), 7.21-7.15 (m, 2H), 6.96 6.91 (m, 1H), 6.52 (s, 1H),
3.39 3.34 (m, 2H), 2.80 (s, 3H), 2.49 2.41 (m, 1H), 2.23 2.15 (m,
1H).
Synthesis of potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate
##STR00645##
[1127] Potassium trifluoro-(3-iodophenyl)boranuide (1 eq) is
brought up in a solution of 1:1 Triethylamine (14 eq) and
N,N-dimethylformamide (26 eq). The solution was purged with
nitrogen before addition of cuprous iodide (0.05 eq),
bis(triphenylphosphine)palladium(II) dichloride (0.05 eq) and
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (1.05 eq) at
once. The reaction mixture was stirred at 40.degree. C. overnight
(18 hrs) whereupon the reaction mixture was concentrated under
vacuum to yield a dark brown oil. Water was added and the solution
was sonicated until an orange-brown solid crashed out of solution.
The solid was filtered off and the aqueous layer was concentrated
under high vacuum to afford a dark red sludge. The sludge was
azeotroped 3 times with Hexanes, brought up in Methanol, sonicated
and the subsequent light brown solid was then filtered and
collected to afford potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate in a 80% yield.
Example D5
Synthesis of
4-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]thi-
azole-2-carboxamide
##STR00646##
[1129] Similar to as described in General Procedure U, ethyl
4-bromothiazole-2-carboxylate (75 mg) was reacted with
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form ethyl
4-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]thi-
azole-2-carboxylate. This intermediate was taken onto the next step
without purification. Similar to as described in General Procedure
I, ethyl
4-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phen-
yl]thiazole-2-carboxylate was reacted to give 6 mg of the title
compound (6%). M+H=342.0.
Example E5
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-5-methyl-pyrazole-3-carboxamide
##STR00647##
[1131] Similar to as described in General Procedure A, ethyl
5-methyl-1H-pyrazole-3-carboxylate (250 mg) was reacted with
2-fluoro-4-iodo-pyridine to give ethyl
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylate. The crude
material was used directly in subsequent reactions. Ethyl
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylate (230 mg) was
subjected to General Procedure Ito afford 140 mg of
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide which was used
in the next step without further purification. Similar to as
described in General Procedure E,
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide (70 mg) was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 29 mg of the title compound (40%). M+H=340; 1H NMR (400 MHz,
DMSO-d6) .delta. 8.52 (dd, J=5.1, 1.0 Hz, 1H), 8.07 7.96 (m, 1H),
7.82 (s, 1H), 7.40 (dd, J=5.1, 1.4 Hz, 1H), 7.33 (s, 1H), 6.68 6.60
(m, 2H), 3.41-3.35 (m, 2H), 2.81 (s, 3H), 2.63 (d, J=0.9 Hz, 3H),
2.49 2.43 (m, 1H), 2.27-2.18 (m, 1H).
Example F5
Synthesis of
1-[4-[(3R)-3-hydroxy-3-(5-methylisoxazol-3-yl)but-1-ynyl]-2-pyridyl]-5-me-
thyl-pyrazole-3-carboxamide
##STR00648##
[1133] Similar to as described in General Procedure E,
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide (70 mg) was
reacted with (2R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol to give 10
mg of the title compound (13%). M+H=352; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.52 (dd, J=5.1, 0.9 Hz, 1H), 8.03-8.00 (m, 1H),
7.82 (s, 1H), 7.41 (dd, J=5.1, 1.4 Hz, 1H), 7.33 (s, 1H), 6.72-6.63
(m, 2H), 6.38 (d, J=1.0 Hz, 1H), 2.64 (d, J=0.9 Hz, 3H), 2.41 (d,
J=0.9 Hz, 3H), 1.82 (s, 3H).
Example G5
Synthesis of
4-chloro-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]--
2-pyridyl]-5-methyl-pyrazole-3-carboxamide
##STR00649##
[1135] To a solution of ethyl
1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylate (230 mg) in
DMF was added N-chlorosuccinimide (1 equiv) at once then the
reacted was heated at 50.degree. C. for 2 hours. The crude product
was triturated out of the reaction mixture by addition of water and
subsequent filtration to collect 193 mg of white solid which was
used in the next step without further purification. Similar to as
described in General Procedure J, ethyl
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylate was
reacted to afford 167 mg of
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylic acid
which was used in the next reaction without purification. Similar
to as described in General Procedure B,
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxylic acid
was reacted with ammonium chloride to afford 140 mg of
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide which
was used in the next reaction without purification. Similar to as
described in General Procedure E,
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 55 mg of the title compound (76%). M+H=374.0; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.54 (dd, J=5.2, 0.8 Hz, 1H), 8.04 (d, J=1.4
Hz, 1H), 7.93 (s, 1H), 7.51-7.43 (m, 2H), 6.64 (s, 1H), 3.40-3.34
(m, 2H), 2.81 (s, 3H), 2.61 (s, 3H), 2.48-2.42 (m, 1H), 2.27-2.17
(m, 1H).
Example H5
Synthesis of
4-chloro-1-[4-[(3R)-3-hydroxy-3-(5-methylisoxazol-3-yl)but-1-ynyl]-2-pyri-
dyl]-5-methyl-pyrazole-3-carboxamide
##STR00650##
[1137] Similar to as described in General Procedure E,
4-chloro-1-(4-iodo-2-pyridyl)-5-methyl-pyrazole-3-carboxamide was
reacted (2R)-2-(5-methylisoxazol-3-yl)but-3-yn-2-ol to give 17 mg
of the title compound (23%). M+H=386.0; .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.54 (dd, J=5.1, 0.8 Hz, 1H), 8.08-7.99 (m, 1H),
7.93 (s, 1H), 7.51-7.42 (m, 2H), 6.70 (s, 1H), 6.38 (d, J=1.0 Hz,
1H), 2.61 (s, 3H), 2.41 (d, J=0.9 Hz, 3H), 1.82 (s, 3H).
Example I5
Synthesis of
5-cyclopropyl-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethy-
nyl]-2-pyridyl]pyrazole-3-carboxamide
##STR00651##
[1139] Similar to as described in General Procedure A,
5-cyclopropyl-1H-pyrazole-3-carboxylic acid (200 mg) was reacted
with 2-fluoro-4-iodo-pyridine to give 240 mg
5-cyclopropyl-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid. The
crude material was used directly in subsequent reactions. Similar
to as described in General Procedure B,
5-cyclopropyl-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid was
reacted with ammonium chloride to afford 100 mg of
5-cyclopropyl-1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide which was
used in the next reaction without purification. Similar to as
described in General Procedure E,
5-cyclopropyl-1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide (70 mg)
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one
to give 65 mg of the title compound (90%). M+H=366.0; .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 8.54 (dd, J=5.2, 0.9 Hz, 1H), 7.98-7.94
(m, 1H), 7.78 (s, 1H), 7.44 (dd, J=5.1, 1.4 Hz, 1H), 7.31 (s, 1H),
6.64 (s, 1H), 6.48 (s, 1H), 3.41-3.35 (m, 2H), 2.81 (s, 3H),
2.49-2.42 (m, 1H), 2.27-2.17 (m, 1H), 1.12 (t, J=7.3 Hz, 1H),
1.01-0.94 (m, 2H), 0.77-0.69 (m, 2H).
Example J5
Synthesis of
5-amino-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-
-pyridyl]pyrazole-3-carboxamide
##STR00652##
[1141] To a solution of methyl 3-nitro-1H-pyrazole-5-carboxylate
(500 mg) in Ethanol (0.25M) was added 10% Palladium on Carbon (0.1
eq) and ammonium formate (8 eq) and the reaction was heated for 1
hour at 70.degree. C. then cooled to room temperature, filtered
through celite, rinsed with Methanol and concentrated to dryness.
The crude intermediate was suspended in DCM and extracted with
water. To the organic layer was added 3 eq of MP-TsOH catch and
release resin whereupon the mixture was stirred for 1 hour,
filtered to collect resin then eluted with 7N Ammonia in MeOH and
concentrated to dryness to afford 100 mg of methyl
3-amino-1H-pyrazole-5-carboxylate. To a solution of methyl
3-amino-1H-pyrazole-5-carboxylate in dioxane was added
di-tert-butyl dicarbonate (1.5 eq) and the reaction was heated at
120.degree. C. overnight, then stirred at room temperature for 6
hours before the addition of imidazole (4.5 eq). The reaction
mixture was subsequently refluxed at 130.degree. C. for 2 hrs then
stirred at room temperature overnight, concentrated to dryness,
suspended in Ethyl acetate and extracted 3.times. with 0.25N HCl
solution, dried, filtered and concentrated to afford 427 mg of
methyl 3-(tert-butoxycarbonylamino)-1H-pyrazole-5-carboxylate as a
light pink solid. Similar to as described in General Procedure A,
3-(tert-butoxycarbonylamino)-1H-pyrazole-5-carboxylate (200 mg) was
reacted with 2-fluoro-4-iodo-pyridine to give methyl
5-(tert-butoxycarbonylamino)-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylate.
The crude material was used directly in subsequent reactions. To a
solution of
5-(tertbutoxycarbonylamino)-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylate
in DCM was added 4N HCl in dioxane (10 eq). The reaction was
stirred at room temperature for 30 minutes then concentrated to
dryness to afford crude methyl
5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylate as the HCl salt.
Similar to as described in General Procedure J, methyl
5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylate was reacted to
afford 90 mg 5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid
which was used in the next step without purification. Similar as to
described in General Procedure B,
5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxylic acid was reacted
with ammonium chloride to afford 90 mg of
5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide which was used
in the next reaction without purification.
[1142] Similar to as described in General Procedure E,
5-amino-1-(4-iodo-2-pyridyl)pyrazole-3-carboxamide (90 mg) was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one to
give 14 mg of the title compound (15%). M+H=341.0; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.44 (dd, J=5.2, 0.8 Hz, 1H), 8.03-8.00 (m,
1H), 7.68 (s, 1H), 7.29, (dd, J=5.1, 1.5 Hz, 1H), 7.21 (s, 1H),
6.89 (s, 2H), 6.63 (s, 1H), 5.72 (s, 1H), 3.41-3.34 (m, 2H), 2.81
(s, 3H), 2.48 2.43 (m, 1H), 2.26-2.17 (m, 1H).
General Procedure AA: Imidazopyridine and Imidazopyrazine
Synthesis
##STR00653##
[1144] Step 1: To a solution of aminomethylpyridine/pyrazine (1 eq)
in dichloromethane (0.25 M) was added diisopropylethylamine (3 eq)
then ethyl chlorooxoacetate (1 eq) dropwise. The reaction was
stirred at room temperature until complete then concentrated to
dryness and re-suspended in a minimum amount of DCM for injection
onto a pre-equilibrated pre-packed silica flash column. The
compound was purified via ISCO automated flash column
chromatography and the fractions were concentrated to dryness and
used in the next step.
[1145] Step 2: The product from the previous step (1.0 eq.) was
either suspended in phosphoryl chloride; neat (50 eq) or 5 eq in
dichloroethane and stirred at reflux or 110.degree. C. overnight.
After in vacuo concentration, the mixture was slowly quenched with
a saturated solution of sodium bicarbonate. The quenched solution
was extracted with DCM and the organic layer was dried (MgSO.sub.4)
and concentrated in vacuo. This residue was suspended in a minimum
amount of DCM for injection onto a pre-equilibrated flash column.
The compound was purified via ISCO automated flash column
chromatography and the fractions were concentrated to dryness and
used in the next step.
[1146] Step 3: The product from the previous step was suspended in
Acetic Acid (0.5M) whereupon bromine (1 eq) was added dropwise. The
reaction was verified by LCMS to confirm completion and then
concentrated to dryness. The reaction was resuspended in DCM and
quenched with a minimum amount of triethylamine, then concentrated
to dryness again. The crude reaction mixture was re-suspended once
more in DCM for injection onto a pre-equilibrated silica flash
column. The compound was purified via ISCO automated flash column
chromatography and the fractions were concentrated to dryness and
used in subsequent steps. An alternative bromination procedure (in
case of imidazopyrazine derivative) involves the use of
N-bromosuccinimide in lieu of bromine and acetonitrile in lieu of
acetic acid. Workup and purification remains the same.
Synthesis of 2-(aminomethyl)isonicotinonitrile dihydrochloride
##STR00654##
[1148] Step 1: To a solution of methyl
2-(aminomethyl)pyridine-4-carboxylate (1 g) in Dichloromethane
(0.15 M) was added triethylamine (3 eq) followed by di-tert-butyl
dicarbonate (1.05 eq). The reaction mixture was stirred at room
temperature for 30 minutes then verified by LCMS, at which point it
was deemed complete. The reaction mixture was extracted with a
saturated NH.sub.4Cl solution, dried with sodium sulfate, filtered
and concentrated to afford crude methyl
2-[(tert-butoxycarbonylamino)methyl]pyridine-4-carboxylate as an
oil.
[1149] Step 2: The intermediate from the previous step was
suspended in 1,4-dioxane (70 eq) and an aqueous ammonium hydroxide
(25 mass %) solution was added (50 eq) and the reaction was stirred
at room temperature for several hours until complete. The reaction
mixture was then concentrated to dryness to afford 680 mg of
tert-butyl N-[(4-carbamoyl-2-pyridyl)methyl]carbamate as a light
yellow oil.
[1150] Step 3: To a solution of tert-butyl
N-[(4-carbamoyl-2-pyridyl)methyl]carbamate (580 mg) in DCM (0.25 M)
was added Et.sub.3N (2 eq) and TFAA (1.2 eq) at 0.degree. C. The
resulting solution was stirred at 0.degree. C. for 1 hour then
warmed to room temperature and stirred overnight. The reaction
mixture was extracted with water and the organic layer was dried,
filtered and concentrated to an oil. The compound was purified by
flash chromatography using a 0-50% iPrOAc/Heptane gradient over 15
minutes. Clean fractions were concentrated to give 440 mg of
tert-butyl N-[(4-cyano-2-pyridyl)methyl]carbamate as a clear
oil.
[1151] Step 4: To the intermediate from the previous reaction was
added hydrochloric acid (4 mol/L in 1,4-dioxane, 10 eq) and the
reaction was stirred at ambient temperature for 30 minutes until
the mixture became a thick white slurry. The reaction was checked
by LC-MS and deemed complete whereupon it was concentrated to
dryness to yield 388 mg of 2-(aminomethyl)pyridine-4-carbonitrile
dihydrochloride.
Example K5
Synthesis of
7-cyano-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]ph-
enyl]imidazo[1,5-a]pyridine-3-carboxamide
##STR00655##
[1153] 2-(aminomethyl)pyridine-4-carbonitrile dihydrochloride (388
mg) was subjected to General Procedure AA to afford ethyl
1-bromo-7-cyanoimidazo[1,5-a]pyridine-3-carboxylate (288 mg) as a
solid following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-cyanoimidazo[1,5-a]pyridine-3-carboxylate (200 mg) was
reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to give (R)-ethyl
7-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)imi-
dazo[1,5-a]pyridine-3-carboxylate which was taken onto the next
step without purification. Similar to as described in General
Procedure J, (R)-ethyl
7-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-7-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl-
)imidazo[1,5-a ]pyridine-3-carboxylic acid (260 mg). This
intermediate was taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-7-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl-
)imidazo[1,5-a ]pyridine-3-carboxylic acid was reacted with
ammonium chloride to give 83.3 mg of the title compound (32.1%).
M+H=400.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.48 (dd, J=7.5,
1.1 Hz, 1H), 8.87 8.85 (m, 1H), 8.29 (s, 1H), 8.12 8.07 (m, 2H),
7.83 (s, 1H), 7.55-7.50 (m, 1H), 7.47 7.43 (m, 1H), 7.21 (dd,
J=7.5, 1.6 Hz, 1H), 6.46 (s, 1H), 3.40 3.35 (m, 2H), 2.81 (s, 3H),
2.49 2.41 (m, 1H), 2.25-2.17 (m, 1H).
Example L5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-7--
(trifluoromethyl)imidazo[1,5-a]pyridine-3-carboxamide
##STR00656##
[1155] [4-(trifluoromethyl)-2-pyridyl]methanamine dihydrochloride)
(1 g) was subjected to General Procedure AA to afford 875 mg ethyl
1-bromo-7-(trifluoromethyl)imidazo[1,5-a]pyridine-3-carboxylate
(288 mg) following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-(trifluoromethyl)imidazo[1,5-a]pyridine-3-carboxylate
(135 mg) was reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(trifluo-
romethyl)imidazo[1,5-a]pyridine-3-carboxylate which was taken onto
the next step without purification. Similar to as described in
General Procedure J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(trifluo-
romethyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(tri-
fluoromethyl)imidazo[1,5-a]pyridine-3-carboxylic acid (177 mg).
This intermediate was taken onto the next step without
purification. Similar to as described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(tri-
fluoromethyl)imidazo[1,5-a]pyridine-3-carboxylic acid was reacted
with ammonium chloride to give 16.6 mg of the title compound
(9.2%). M+H=443.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.60-9.57
(m, 1H), 8.37 (q, J=1.4 Hz, 1H), 8.26 (s, 1H), 8.09 8.02 (m, 2H),
7.80 (s, 1H), 7.55 (t, J=7.7 Hz, 1H), 7.44 (dt, J=7.7, 1.3 Hz, 1H),
7.24 (dd, J=7.6, 1.8 Hz, 1H), 6.47 (s, 1H), 3.39 3.34 (m, 3H), 2.81
(s, 3H), 2.48 2.42 (m, 1H), 2.24 2.16 (m, 1H).
Example M5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]imi-
dazo[1,5-a]pyrazine-3-carboxamide
##STR00657##
[1157] 2-aminomethylpyrazine (2 g) was subjected to General
Procedure AA to afford ethyl
1-bromoimidazo[1,5-a]pyrazine-3-carboxylate (680 mg) following
purification. Similar to as described in General Procedure U, ethyl
1-bromoimidazo[1,5-a]pyrazine-3-carboxylate (75 mg) was reacted
with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)imidazo[1,5-
-a]pyrazine-3-carboxylate which was taken onto the next step
without purification. Similar to as described in General Procedure
J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)imidazo[1,5-
-a]pyrazine-3-carboxylate was reacted to form
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)imidazo-
[1,5-a]pyrazin e-3-carboxylic acid (40 mg). This intermediate was
taken onto the next step without purification. Similar to as
described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)imidazo-
[1,5-a]pyrazine-3-carboxylic acid was reacted with ammonium
chloride to give 6.3 mg of the title compound (15.8%). M+H=376.1;
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.56 (d, J=1.6 Hz, 1H), 9.22
(dd, J=4.9, 1.6 Hz, 1H), 8.28 (s, 1H), 8.17 8.08 (m, 2H), 7.88 (d,
J=5.0 Hz, 1H), 7.84 (s, 1H), 7.55 (t, J=7.8 Hz, 1H), 7.46 (dt,
J=7.7, 1.4 Hz, 1H), 6.47 (s, 1H), 3.37 (dd, J=7.3, 5.6 Hz, 2H),
2.81 (s, 3H), 2.72 (d, J=2.5 Hz, 1H), 2.48 2.41 (m, 1H), 2.25-2.16
(m, 1H).
Example N5
Synthesis of
6-chloro-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]p-
henyl]imidazo[1,5-a]pyridine-3-carboxamide
##STR00658##
[1159] (5-chloropyridin-2-yl)methanamine (1.52 g) was subjected to
General Procedure AA to afford ethyl
6-chloroimidazo[1,5-a]pyridine-3-carboxylate (1.03 g) of which 250
mg of was subjected to the bromination conditions (step 3 of
General Procedure AA) to afford ethyl
1-bromo-6-chloroimidazo[1,5-a]pyridine-3-carboxylate (191 mg)
following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-6-chloroimidazo[1,5-a]pyridine-3-carboxylate (75 mg) was
reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
6-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylate which was taken onto the next
step without purification. Similar to as described in General
Procedure J, (R)-ethyl
6-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl-
)phenyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-6-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)imidazo[1,5-a]pyridine-3-carboxylic acid (101 mg). This
intermediate was taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-6-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)imidazo[1,5-a]pyridine-3-carboxylic acid was reacted with
ammonium chloride to give 10.9 mg of the title compound (11%).
M+H=409.1; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.57 (dd, J=1.9,
0.9 Hz, 1H), 8.18 8.13 (m, 2H), 8.03 (t, J=1.7 Hz, 1H), 7.98 (dt,
J=7.9, 1.5 Hz, 1H), 7.72 (s, 1H), 7.51 (t, J=7.8 Hz, 1H), 7.40 (dt,
J=7.7, 1.4 Hz, 1H), 7.24 (dd, J=9.7, 1.8 Hz, 1H), 6.45 (s, 1H),
3.40 3.33 (m, 2H), 2.81 (s, 3H), 2.48 2.42 (m, 1H), 2.24 2.16 (m,
1H).
Example O5 and Example P5
Synthesis of
7-chloro-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]p-
henyl]imidazo[1,5-a]pyridine-3-carboxamide AND Synthesis of
1,7-bis[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]pheny-
l]imidazo[1,5-a]pyridine-3-carboxamide
##STR00659##
[1161] (4-bromopyridin-2-yl)methanamine (1 g) was subjected to
General Procedure AA to afford ethyl
1-bromo-7-chloroimidazo[1,5-a]pyridine-3-carboxylate (250 mg)
following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-chloroimidazo[1,5-a]pyridine-3-carboxylate (75 mg) was
reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form a mixture of (R)-ethyl
7-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylate and ethyl
1,7-bis(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylate which were taken onto the next
step without purification. Similar to as described in General
Procedure J, a mixture of (R)-ethyl
7-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylate and ethyl
1,7-bis(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylate were reacted to form a mixture
of
(R)-7-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)imidazo[1,5-a]pyridine-3-carboxylic acid and
1,7-bis(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylic acid (101 mg). These
intermediates were taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-7-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)imidazo[1,5-a]pyridine-3-carboxylic acid and
1,7-bis(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)im-
idazo[1,5-a]pyridine-3-carboxylic acid were reacted with ammonium
chloride to give 3.7 mg (3.6%) of
7-chloro-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]p-
henyl]imidazo[1,5-a]pyridine-3-carboxamide and 1.8 mg (1.1%) of
1,7-bis[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]pheny-
l]imidazo[1,5-a]pyridine-3-carboxamide following reverse phase
purification. M+H=409.2 and M+H=588.2
Example Q5
Synthesis of
7-(cyclobutoxy)-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]et-
hynyl]phenyl]imidazo[1,5-a]pyridine-3-carboxamide
##STR00660##
[1163] [4-(cyclobutoxy)-2-pyridyl]methanamine (1 g) was subjected
to General Procedure AA to afford ethyl
1-bromo-7-cyclobutoxyimidazo[1,5-a]pyridine-3-carboxylate (346 mg)
following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-cyclobutoxyimidazo[1,5-a]pyridine-3-carboxylate (100 mg)
was reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to (R)-ethyl
7-cyclobutoxy-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phen-
yl)imidazo[1,5-a]pyridine-3-carboxylate which was taken onto the
next step without purification. Similar to as described in General
Procedure J, (R)-ethyl
7-cyclobutoxy-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)et-
hynyl)phenyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to
(R)-7-cyclobutoxy-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)imidazo[1,5-a]pyridine-3-carboxylic acid (130.8 mg). This
intermediate was taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-7-cyclobutoxy-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)imidazo[1,5-a]pyridine-3-carboxylic acid was reacted with
ammonium chloride to give 13.6 mg of the title compound
(10.2%).
[1164] M+H=445.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.38 (d,
J=7.8 Hz, 1H), 7.98 (t, J=1.7 Hz, 1H), 7.93 (s, 1H), 7.89 (dt,
J=8.0, 1.4 Hz, 1H), 7.55-7.45 (m, 2H), 7.32 (dt, J=7.5, 1.4 Hz,
1H), 7.06 (d, J=2.4 Hz, 1H), 6.77 (dd, J=7.8, 2.4 Hz, 1H), 4.95 (p,
J=7.0 Hz, 1H), 3.39 3.34 (m, 3H), 2.81 (s, 3H), 2.47 2.39 (m, 2H),
2.25-2.08 (m, 3H), 1.91-1.79 (m, 1H), 1.79-1.68 (m, 1H).
Example R5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-7--
methoxy-imidazo[1,5-a]pyridine-3-carboxamide
##STR00661##
[1166] (4-methoxypyridin-2-yl)methanamine (2 g) was subjected to
General Procedure AA to afford ethyl
1-bromo-7-methoxyimidazo[1,5-a]pyridine-3-carboxylate (1.1 g)
following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-methoxyimidazo[1,5-a]pyridine-3-carboxylate (0.4 g) was
reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-methoxyi-
midazo[1,5-a]pyridine-3-carboxylate which was taken onto the next
step without purification. Similar to as described in General
Procedure J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)--
7-methoxyimidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-meth-
oxyimidazo[1,5-a]pyridine-3-carboxylic acid (406 mg). This
intermediate was taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-meth-
oxyimidazo[1,5-a]pyridine-3-carboxylic acid was reacted with
ammonium chloride to give 83.8 mg of the title compound (20.5%).
M+H=405.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.38 (dd, J=7.8,
0.7 Hz, 1H), 8.03 (t, J=1.6 Hz, 1H), 8.00-7.91 (m, 2H), 7.52-7.45
(m, 2H), 7.36-7.30 (m, 1H), 7.23 (dd, J=2.5, 0.8 Hz, 1H), 6.79 (dd,
J=7.8, 2.5 Hz, 1H), 6.43 (s, 1H), 3.93 (s, 3H), 3.40 3.33 (m, 2H),
2.81 (s, 3H), 2.49 2.41 (m, 1H), 2.24 2.16 (m, 1H).
Example S5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-6--
methoxy-imidazo[1,5-a]pyridine-3-carboxamide
##STR00662##
[1168] (5-methoxypyridin-2-yl)methanamine (1 g) was subjected to
General Procedure AA to afford ethyl
1-bromo-6-methoxyimidazo[1,5-a]pyridine-3-carboxylate (894 mg)
following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-6-methoxyimidazo[1,5-a]pyridine-3-carboxylate (0.1 g) was
reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-methoxyi-
midazo[1,5-a]pyridine-3-carboxylate which was taken onto the next
step without purification. Similar to as described in General
Procedure J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)--
6-methoxyimidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
oxyimidazo[1,5-a]pyridine-3-carboxylic acid (101.7 mg). This
intermediate was taken onto the next step without purification.
Similar to as described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
oxyimidazo[1,5-a]pyridine-3-carboxylic acid was reacted with
ammonium chloride to give 10 mg of the title compound (10%).
M+H=405.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.14 (dd, J=2.3,
0.8 Hz, 1H), 8.04 (dd, J=9.9, 0.8 Hz, 1H), 8.02 (td, J=1.8, 0.6 Hz,
1H), 7.99 7.95 (m, 2H), 7.49 (td, J=7.8, 0.6 Hz, 1H), 7.39 7.35 (m,
1H), 7.03 (dd, J=9.9, 2.2 Hz, 1H), 3.85 (s, 3H), 3.40 3.33 (m, 2H),
2.81 (s, 3H), 2.48 2.42 (m, 1H), 2.25-2.16 (m, 1H).
Synthesis of [4-(morpholinomethyl)-2-pyridyl]methanamine
##STR00663##
[1170] Step 1: To a solution of 4-(bromomethyl)picolinonitrile (1
g) in methanol was added morpholine (2.5 eq) and the reaction was
stirred for 15 minutes whereupon LCMS confirmed it went to
completion. The reaction mixture was subsequently concentrated to
an oil and resuspended in a minimum amount of DCM. The crude
mixture was injected onto a pre-equilibrated silica flash
chromatography column and a 0-90% gradient over 15 mins of 3:1
iPrOAc-MeOH to Heptanes was run. The clean fractions were
concentrated to afford 965 mg of
4-(morpholinomethyl)picolinonitrile as a clear oil.
[1171] Step 2: To a solution of 4-(morpholinomethyl)picolinonitrile
in acetic acid (18 mL) at room temperature was added 10 percent
palladium on carbon (48 mg) and the resulting mixture was stirred
for 2 hours under a hydrogen atmosphere. The resulting solution was
filtered through celite and the solvent was evaporated to an oil.
The crude material was then resuspended in DCM whereupon MP-TsOH
ion exchange resin (2 eq) was added and the mixture was stirred for
1 hour at ambient temperature. The resin was collected by
filtration and rinsed with DCM and the product was eluted via
addition of 20 mL (+2) of 7N ammonia in methanol solution. The
resultant solution was concentrated to dryness and crude [4
(morpholinomethyl)-2-pyridyl]methanamine (938 mg) was taken into
the next reaction without purification.
Example T5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-7--
(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxamide
##STR00664##
[1173] [4-(morpholinomethyl)-2-pyridyl]methanamine (938 mg) was
subjected to General Procedure AA to afford ethyl
1-bromo-7-(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxylate
(250 mg) following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-7-(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxylate
(250 mg) was reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(morphol-
inomethyl)imidazo[1,5-a]pyridine-3-carboxylate which was taken onto
the next step without purification. Similar to as described in
General Procedure J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(morphol-
inomethyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to form
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(mor-
pholinomethyl) imidazo[1,5-a]pyridine-3-carboxylic acid (322 mg).
This intermediate was taken onto the next step without
purification. Similar to as described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-7-(mor-
pholinomethyl) imidazo[1,5-a]pyridine-3-carboxylic acid was reacted
with ammonium chloride to give 36.5 mg of the title compound
(11.1%). M+H=474.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.43
(dd, J=7.3, 1.0 Hz, 1H), 8.06-7.92 (m, 4H), 7.56 (s, 1H), 7.54-7.48
(m, 1H), 7.37 (ddd, J=7.7, 1.7, 1.1 Hz, 1H), 7.04 (dd, J=7.4, 1.5
Hz, 1H), 6.45 (s, 1H), 3.63 3.58 (m, 4H), 3.56 (s, 2H), 3.39 3.33
(m, 2H), 2.81 (s, 3H), 2.48 2.40 (m, 5H), 2.25-2.16 (m, 1H).
Synthesis of [5-(morpholinomethyl)-2-pyridyl]methanamine
##STR00665##
[1175] Step 1: To a solution of
5-(bromomethyl)pyridine-2-carbonitrile (1.16 g) in methanol was
added morpholine (3.5 eq) and the reaction was stirred for 15
minutes whereupon LCMS confirmed it went to completion. The
reaction mixture was subsequently concentrated to an oil and
resuspended in a minimum amount of DCM. The crude mixture was
injected onto a pre-equilibrated silica flash chromatography column
and a 0-90% gradient over 15 mins of 3:1 iPrOAc-MeOH to Heptanes
was run. The clean fractions were concentrated to afford 400 mg of
5-(morpholinomethyl)picolinonitrile as a clear oil.
[1176] Step 2: To a solution of 5-(morpholinomethyl)picolinonitrile
(400 mg) in acetic acid at room temperature (7 mL) was added 10
percent palladium on carbon (19 mg) and the resulting mixture was
stirred for 2 hours under a hydrogen atmosphere. The resulting
solution was filtered through celite and the solvent was evaporated
to an oil. The crude material was then resuspended in DCM whereupon
MP-TsOH ion exchange resin (2 eq) was added and the mixture was
stirred for 1 hour at ambient temperature. The resin was collected
by filtration and rinsed with DCM and the product was eluted via
addition of 20 mL (.times.2) of 7N Ammonia in Methanol solution.
The resultant solution was concentrated to dryness and crude
[5-(morpholinomethyl)-2-pyridyl]methanamine (370 mg) was taken into
the next reaction without purification.
Example U5
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-6--
(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxamide
##STR00666##
[1178] [5-(morpholinomethyl)-2-pyridyl]methanamine (370 mg) was
subjected to General Procedure AA to afford ethyl
1-bromo-6-(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxylate
(250 mg) following purification. Similar to as described in General
Procedure U, ethyl
1-bromo-6-(morpholinomethyl)imidazo[1,5-a]pyridine-3-carboxylate
(250 mg) was reacted with potassium
(S)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3yl)ethynyl)phenyl)b-
orate to form (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(morphol-
inomethyl)imidazo[1,5-a]pyridine-3-carboxylate which was taken onto
the next step without purification. Similar to as described in
General Procedure J, (R)-ethyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(morphol-
inomethyl)imidazo[1,5-a]pyridine-3-carboxylate was reacted to
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(mor-
pholinomethyl) imidazo[1,5-a]pyridine-3-carboxylic acid (321 mg).
This intermediate was taken onto the next step without
purification. Similar to as described in General Procedure B,
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(mor-
pholinomethyl) imidazo[1,5-a]pyridine-3-carboxylic acid was reacted
with ammonium chloride to give 28.2 mg of the title compound
(8.8%). M+H=474.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.41-9.39
(m, 1H), 8.08 (dd, J=9.4, 1.0 Hz, 1H), 8.04 8.00 (m, 1H), 7.97
(ddd, J=7.9, 1.8, 1.1 Hz, 1H), 7.58 (s, 1H), 7.53 7.47 (m, 1H),
7.37 (ddd, J=7.7, 1.7, 1.1 Hz, 1H), 7.21 (dd, J=9.4, 1.4 Hz, 1H),
6.45 (s, 1H), 3.62 3.57 (m, 4H), 3.51 (s, 2H), 3.40 3.34 (m, 2H),
2.81 (s, 3H), 2.48 2.38 (m, 5H), 2.25-2.16 (m, 1H).
Example V5
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00667##
[1179] Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(1-methylpyrazol-4-yl)indazole-3-carboxylate
##STR00668##
[1181] To a stirred solution of methyl
1-(3-bromophenyl)-5-iodo-indazole-3-carboxylate (300 mg, 0.6563
mmol) in 1,2-dimethoxyethane (54.4 mmol) and water (99.82 mmol) was
added
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole
(0.7876 mmol, 1.2 equiv),
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex (0.03282 mmol, 0.05 equiv), lithium
chloride (2.297 mmol, 3.5 equiv), and sodium carbonate (3.610 mmol,
5.5 equiv) under nitrogen. The resulting solution was stirred for
18 hours at 60.degree. C. The reaction mixture was concentrated
under reduced pressure then was purified by silica gel column with
heptane/isopropyl acetate (3:2). This resulted in 120 mg (44%) of
the title compound as a white solid. LC-MS (ES, m/z): 411, 413
[M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00669##
[1183] Similar to General Procedure H, methyl
1-(3-bromophenyl)-5-(1-methylpyrazol-4-yl)indazole-3-carboxylate
(250 mg, 0.61 mmol) was reacted with formamide (0.24 mL, 6.08 mmol,
10 equiv) to give the title compound (235 mg, 97%) as an off-white
solid. LC-MS (ES, m/z): 396, 398 [M+H].sup.+.
Step 3: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00670##
[1185] As similar to described in General Procedure E,
1-(3-bromophenyl)-5-(1-methylpyrazol-4-yl)indazole-3-carboxamide
(235 mg, 0.59 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (99.04 mg, 0.71
mmol, 1.2 equiv) to give a brown oil. The crude was purified by
Prep-HPLC and this resulted in (4.9 mg, 2%) of the title compound
as an off-white solid. LC-MS (ES, m/z): 455 [M+H].sup.+. .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 8.673 (m, 1H), 8.022-7.996 (m, 2H),
7.951-7.873 (m, 3H), 7.766 (d, J=2.4 Hz, 1H), 7.677-7.638 (m, 1H),
7.529-7.507 (m, 1H), 7.079 (bs, 2H), 6.738-6.732 (m, 1H), 3.922 (s,
3H), 3.382-3.350 (m, 2H), 2.808 (s, 3H), 2.471-2.439 (m, 1H),
2.238-2.171 (m, 1H).
Example W5
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00671##
[1186] Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxylate
##STR00672##
[1188] To a stirred solution of methyl
1-(3-bromophenyl)-5-iodo-indazole-3-carboxylate (250 mg, 0.5469
mmol) in 1,2-dimethoxyethane (4.7 mL) and water (1.5 mL) was added
1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole
(143.7 mg, 0.6563 mmol, 1.2 equiv),
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex (22.8 mg, 0.02735 mmol, 0.05 equiv),
lithium chloride (81.2 mg, 1.914 mmol, 3.5 equiv), and sodium
carbonate (318.8 mg, 3.008 mmol, 5.5 equiv) under nitrogen. The
resulting solution was stirred for 18 hours at 60.degree. C. The
reaction mixture was concentrated under reduced pressure then was
purified by silica gel column with heptane/isopropyl acetate (3:2).
This resulted in 124 mg (38%) of the title compound as a white
solid. LC-MS (ES, m/z): 411, 413 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00673##
[1190] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxylate
(90 mg, 0.22 mmol) was reacted with formamide (0.09 mL, 2.19 mmol,
10 equiv) to give the title compound (85 mg, 98%) as a yellow
solid. LC-MS (ES, m/z): 396, 398 [M+H].sup.+.
Step 3: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
##STR00674##
[1192] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-indazole-3-carboxamide
(85 mg, 0.21 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (35.82 mg, 0.26
mmol, 1.2 equiv) to give the title compound (76 mg, 78%) as a
yellow solid. LC-MS (ES, m/z): 455 [M+H].sup.+. .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.379-8.376 (m, 1H), 8.23 (s, 1H), 8.00 (br
s, 1H), 7.948-7.920 (m, 1H), 7.904-7.862 (m, 3H), 7.791-7.764 (m,
1H), 7.671-7.631 (m, 1H), 7.540 (br s, 1H), 7.524-7.502 (m, 1H),
6.501 (s, 1H), 3.893 (s, 3H), 3.382-3.350 (m, 2H), 2.808 (s, 3H),
2.485-2.438 (m, 1H), (dt, J1=12 Hz, J2=4 Hz, 1H).
Example X5
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00675##
[1193] Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxylate
##STR00676##
[1195] A solution of methyl
1-(3-bromophenyl)-5-iodo-pyrazolo[3,4-b]pyridine-3-carboxylate (100
mg, 0.2074 mmol) in 1,2-dimethoxyethane (1.78 mL) and water (0.56
mL) was combined with
1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole
(136.3 mg, 0.62 mmol, 3 equiv),
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex (8.64 mg, 0.01037 mmol, 0.05 equiv),
lithium chloride (30.78 mg, 0.7260 mmol, 3.5 equiv), and sodium
carbonate (120.9 mg, 1.141 mmol, 5.5 equiv). Reaction vessel was
sparged with nitrogen gas and then heated to 90.degree. C. and left
to for 18 hours. The reaction mixture was concentrated under
reduced pressure then was purified by silica gel column with
heptane/isopropyl acetate (3:1). This resulted in 74 mg (86%) of
the title compound as a white solid. LC-MS (ES, m/z): 412, 414
[M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxylic acid
##STR00677##
[1197] Similar to General Procedure J, methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxylate (643 mg, 1.56 mmol) was reacted with lithium
hydroxide monohydrate (267.2 mg, 6.24 mmol, 4 equiv) to afford the
title compound (295 mg, 48%) as an off-white solid. LCMS (ES, m/z):
399, 401 [M+H].sup.+.
Step 3: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxamide
##STR00678##
[1199] Similar to General Procedure B,
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxylic acid (295 mg, 0.74 mmol) was reacted with ammonium
chloride (2.24 mL, 4.44 mmol, 6 equiv) to afford the title compound
(135 mg, 46%) as an off-white solid. LCMS (ES, m/z): 398, 400
[M+H].sup.+.
Step 4: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00679##
[1201] Similar to General Procedure E,
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine-
-3-carboxamide (63 mg, 0.16 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (26.48 mg, 0.19
mmol, 1.2 equiv) to give the title compound (0.8 mg, 1%) as a brown
solid. LC-MS (ES, m/z): 456 [M+H].sup.+.
Example Y5
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00680##
[1202] Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxylate
##STR00681##
[1204] To a stirred solution methyl
1-(3-bromophenyl)-5-iodo-pyrazolo[3,4-b]pyridine-3-carboxylate (300
mg, 0.6223 mmol) in 1,2-dimethoxyethane (5.3 mL) and water (1.7 mL)
was added
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole
(272.6 mg, 1.245 mmol, 2 equiv),
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex (25.9 mg, 0.03111 mmol, 0.05 equiv),
lithium chloride (92.3 mg, 2.178 mmol, 3.5 equiv), and sodium
carbonate (362.7 mg, 3.422 mmol, 5.5 equiv) under nitrogen. The
resulting solution was stirred for 18 hours at 60.degree. C. The
reaction was diluted with saturated aqueous ammonium chloride
solution and the aqueous phase was extracted three times with ethyl
acetate. The organic phases were combined, dried with sodium
sulfate, and concentrated under vacuum. This resulted in 98 mg
(38%) of the title compound as a brown solid. LC-MS (ES, m/z): 413,
415 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxylic
acid
##STR00682##
[1206] Similar to as described in General Procedure J, methyl
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxylate
(98 mg, 0.24 mmol) was reacted with was reacted with lithium
hydroxide monohydrate (40.3 mg, 0.74 mmol, 4 equiv) to afford the
title compound (96 mg, 95%) as an off-white solid. LCMS (ES, m/z):
399 [M+H].sup.+.
Step 3: Synthesis of
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxamide
##STR00683##
[1208] Similar to General Procedure B,
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxylic
acid (96 mg, 0.24 mmol) was reacted with ammonium chloride (0.05
mL, 1.44 mmol, 6 equiv) to afford the title compound (91 mg, 96%)
as an off-white solid. LCMS (ES, m/z): 398, 400 [M+H].sup.+.
Step 4: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00684##
[1210] Similar to General Procedure E,
1-(3-bromophenyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indazole-3-carboxamide
(96 mg, 0.24 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (39.7 mg, 0.4
mmol, 1.2 equiv) to give the title compound (99 mg, 91%) as a brown
solid. LC-MS (ES, m/z): 456 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.06 (s, 1H), 8.68 (d, J=2.0 Hz, 1H), 8.55
8.43 (m, 2H), 8.39 (s, 1H), 8.23 (s, 1H), 8.06 (s, 1H), 7.72 (s,
1H), 7.68-7.59 (m, 1H), 7.45 (dd, J=7.7, 1.6 Hz, 1H), 6.54 (s, 1H),
3.91 (s, 3H), 3.43 3.33 (m, 2H), 3.33 3.24 (m, 1H), 2.82 (s, 3H),
2.46 (dd, J=6.7, 5.3 Hz, 1H), 2.22 (dt, J=12.8, 7.1 Hz, 1H).
Example Z5
Synthesis of (R)-methyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-morpholi-
no-1H-pyrazol o[3,4-b]pyridine-3-carboxylate
##STR00685##
[1211] Step 1: Synthesis of methyl
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxy-
late
##STR00686##
[1213] A stirred solution of methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate (990 mg, 5.60 mmol) in DMF
(2 mL/mmol, 64.9 mmol) was cooled to 0.degree. C., then sodium
hydride (1.33 equiv., 7.43 mmol) was then added. After stirring at
0.degree. C. for 30 minutes, 2-(trimethylsilyl)ethoxymethyl
chloride (1.33 equiv., 7.43 mmol) was then added drop-wise and
solution was warmed to room temperature. After excess hydride was
quenched by the addition of water at 0.degree. C., the mixture was
extracted with EtOAc (3 times). The organic extracts were then
combined and dried with sodium sulfate then concentrated in vacuo.
Purification by flash chromatography (heptane:isopropyl acetate)
afforded the title compound (771 mg, 46%) as a white solid. LC-MS
(ES, m/z): 308 [M+H].sup.+.
Step 2: Synthesis of methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)eth-
oxy)methyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00687##
[1215] Under inert atmosphere, methyl
1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxy-
late (771 mg, 2.51 mmol), bis(pinacolato)diboron (0.878 eq., 2.20
mmol), bis(1,5-cyclooctadiene)di-mu-methoxydiiridium(I) (0.02 eq.,
0.05 mmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (0.045 eq., 0.11
mmol) were dissolved in degassed tetrahydrofuran (2.51 mL). The
reaction was heated in a sealed vial at 80.degree. C. for 18 hours.
The solution was cooled to room temperature, diluted with ethyl
acetate, filtered through celite, and concentrated to afford a red
solid. Purification by CombiFlash (heptane:isopropyl acetate)
afforded the title compound (800 mg, 71%) as a white solid. LC-MS
(ES, m/z): 434 [M+H].sup.+.
Step 3: Synthesis of
(3-(methoxycarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-
-b]pyridin-5-yl) boronic acid
##STR00688##
[1217] Under inert atmosphere, methyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)eth-
oxy)methyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (300 mg,
0.6922 mmol), ammonium acetate (267 mg, 3.46 mmol, 5.00 equiv),
sodium periodate (752 mg, 3.461 mmol, 5.00 equiv.) were combined
and dissolved in acetone (3.11 mL) and water (3.11 mL). Reaction
was stirred for 2 hours then acetone was removed under vacuum and
the remaining aqueous layer was extracted with ethyl acetate (3
times). Combined organic layers were dried with sodium sulfate,
filtered, and concentrated under reduced pressure to give the title
product (180 mg, 74%) as a white solid. LC-MS (ES, m/z): 352
[M+H].sup.+.
Step 4: Synthesis of methyl
5-morpholino-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-
e-3-carboxylate
##STR00689##
[1219] To a small vial containing
[3-methoxycarbonyl-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridin-
-5-yl]boronic acid (250 mg, 0.712 mmol), copper(II) acetate
monohydrate (30.00 mg, 0.1424 mmol, 0.2 equiv), and morpholine
(1.24 mL, 14.24 mmol, 20 equiv) are dissolved in DMF (1.42 mL). The
reaction vessel is sparged with oxygen gas and evacuated (3 times)
then pyridine (0.17 mL, 2.13 mmol, 3.0 equiv) is added drop-wise.
The reaction was stirred at 80.degree. C. for 6 hours. The reaction
was then cooled to room temperature and diluted with a saturated
solution of ammonium chloride. The aqueous phase was extracted with
ethyl acetate (3 times), dried with sodium sulfate, filtered, and
concentrated under reduced pressure to afford the crude mixture as
a yellow oil. The crude material was then purified by flash
chromatography (heptane:isopropyl acetate) to afford the title
compound (8 mg, 3%) as a white solid. LC-MS (ES, m/z): 393
[M+H].sup.+.
Step 5: Synthesis of methyl
5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00690##
[1221] Similar to General Procedure T, methyl
5-morpholino-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-
e-3-carboxylate (43 mg, 0.11 mmol) was reacted with hydrochloric
acid (1.40 mmol, 12.5 equiv) to afford the title compound as a
yellow solid (8 mg, 27%). LC-MS (ES, m/z): 263 [M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-bromophenyl)-5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00691##
[1223] Similar to as described in General Procedure C, methyl
5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (50 mg, 0.19
mmol) was reacted with (3-bromophenyl) boronic acid (57.43 mg, 0.29
mmol, 1.5 equiv) to afford the title compound as a brown solid
(18.3 mg, 80%). LC-MS (ES, m/z): 417, 419 [M+H].sup.+.
Step 7: Synthesis of
1-(3-bromophenyl)-5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00692##
[1225] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
(18.3 mg, 0.04 mmol) was reacted with formamide (0.017 mL, 0.44
mmol, 10 equiv) to give the title compound as a yellow solid. LC-MS
(ES, m/z): 402, 404 [M+H].sup.+.
Step 8: Synthesis of (R)-methyl
1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-morpholi-
no-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00693##
[1227] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-morpholino-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
(17.6 mg, 0.04 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (7.32 mg, 0.05
mmol, 1.2 equiv) to give the title compound (1 mg, 5%) as a white
solid. LC-MS (ES, m/z): 461 [M+H].sup.+.
Example A6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(4-m-
ethyl-1H-imidazol-1-yl)-1H-indazole-3-carboxamide
##STR00694##
[1228] Step 1: Synthesis of methyl
1-(3-bromophenyl)-5-(4-methyl-1H-imidazol-1-yl)-1H-indazole-3-carboxylate
##STR00695##
[1230] Methyl 1-(3-bromophenyl)-5-iodo-indazole-3-carboxylate (327
mg, 0.716153 mmol, 1.2 equiv), 4-methylimidazole (50 mg, 0.596794
mmol), cuprous iodide (113 mg, 0.596794 mmol, 1 equiv),
(1R,2R)--N,N'-dimethyl-1,2-cyclohexanediamine (0.097 mL, 0.596794
mmol, 1 equiv), and cesium carbonate (388 mg, 1.19359 mmol, 2
equiv) were combined in a small vial and dissolved in DMF (0.30 mL,
3.86 mmol). The reaction was stirred at 60.degree. C. for 2 hours
under nitrogen. The reaction was then allowed to cool to room
temperature, filtered through celite, and concentrated to give a
brown oil. The crude material was purified by flash chromatography
to afford the title compound (51 mg, 21%). LC-MS (ES, m/z): 411,
413 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-5-(4-methyl-1H-imidazol-1-yl)-1H-indazole-3-carboxamide
##STR00696##
[1232] Similar to as described in General Procedure H, methyl
1-(3-bromophenyl)-5-(4-methyl-1H-imidazol-1-yl)-1H-indazole-3-carboxylate
(67 mg, 0.16 mmol) was reacted with formamide (0.065 mL, 1.63 mmol,
10 equiv) to afford the title compound as a yellow solid (64 mg,
99%). LC-MS (ES, m/z): 396, 398 [M+H].sup.+.
Step 3: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(4-m-
ethyl-1H-imidazol-1-yl)-1H-indazole-3-carboxamide
##STR00697##
[1234] Similar to as described in General Procedure E,
1-(3-bromophenyl)-5-(4-methyl-1H-imidazol-1-yl)-1H-indazole-3-carboxamide
(64 mg, 0.14 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (27.21 mg, 0.20
mmol, 1.2 equiv) to give the title compound (65 mg, 74%) as a brown
solid. LC-MS (ES, m/z): 454, 456 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.30 (d, J=2.0 Hz, 1H), 8.14 (d, 1H), 8.10
(br s, 1H), 8.02-7.98 (m, 1H), 7.97 7.93 (m, 1H), 7.93 7.90 (m,
1H), 7.81 (dd, 1H), 7.71-7.59 (m, 2H), 7.58-7.51 (m, 1H), 7.50-7.45
(m, 1H), 6.53 (br s, 1H), 3.42-3.32 (m, 2H), 2.81 (s, 3H), 2.58
2.51 (m, 2H), 2.51-2.41 (m, 1H), 2.27 2.13 (m, 4H).
Example B6
5-(1-acetylazetidin-3-yl)-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidi-
n-3-yl]ethynyl]phenyl]pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00698##
[1235] Synthesis of methyl
5-bromo-1-(p-tolylsulfonyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00699##
[1237] Sodium hydride (1.3 eq., 81.2 mg, 2.031 mmol) was added
slowly to a solution of methyl
5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (1.0 eq., 400 mg,
1.562 mmol) in N,N-dimethylformamide (9.53 mL) at 0.degree. C.
under nitrogen atmosphere. The reaction was stirred for 30 min at
0.degree. C. and then p-toluenesulfonyl chloride (1.4 eq., 425.4
mg, 2.187 mmol) was added. The mixture was stirred at room
temperature for 3 hours. Water was added and the mixture was
filtered. The solid was redissolved in methanol and dichloromethane
and excess water was removed in vacuo to obtain 643 mg (100% yield)
of a white solid which was carried forward without further
purification.
Synthesis of methyl
5-(1-tert-butoxycarbonylazetidin-3-yl)-1-(p-tolylsulfonyl)pyrazolo[3,4-b]-
pyridine-3-carboxylate
##STR00700##
[1239] Step 1: To a dry round bottom flask was added zinc (1.40
eq., 323 mg) which was stirred in degassed N,N-dimethylacetamide
(1.77 mL) under nitrogen atmosphere. Chlorotrimethylsilane (0.12
eq., 0.054 mL) and 1,2-dibromoethane (0.10 eq., 0.030 mL) were
added and the mixture was stirred for 15 minutes at room
temperature. Tert-butyl 3-iodoazetidine-1-carboxylate (1.0 eq.,
0.613 mL, 1000 mg) in degassed N,N-Dimethylacetamide (7.06 mL) was
added slowly and the cloudy reaction was stirred at room
temperature for 1.5 hours. The resulting 0.38 M solution was used
as is in further reactions (sealed and stored in refrigerator).
[1240] Step 2: Methyl
5-bromo-1-(p-tolylsulfonyl)pyrazolo[3,4-b]pyridine-3-carboxylate
(1.0 eq., 640 mg, 1.560 mmol) was dissolved in
N,N-dimethylacetamide (3.9 mL) and purged with nitrogen gas.
[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex
with dichloromethane (1:1) (0.05 eq., 63.7 mg) and Copper(I) iodide
(0.10 eq., 29.7 mg) were added and the reaction was purged for
another 10 minutes. (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II)
iodide (1.2 eq., 4.93 mL, 1.872 mmol) was added. The reaction was
heated to 80.degree. C. overnight. Complete conversion to product
was observed by LCMS. The reaction was cooled to room temperature.
Water was added and the mixture was extracted with isopropyl
acetate twice. The organic layers were combined, dried with sodium
sulfate and concentrated. The crude mixture was purified by flash
chromatography (5-100% iPrOAc in heptanes) to afford 363.6 mg (48%
yield) of the desired product.
Synthesis of methyl
5-(1-tert-butoxycarbonylazetidin-3-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbo-
xylate
##STR00701##
[1242] Methyl
5-(1-tert-butoxycarbonylazetidin-3-yl)-1-(p-tolylsulfonyl)pyrazolo[3,4-b]-
pyridine-3-carboxylate (1.0 eq., 363.6 mg, 0.747 mmol) was
dissolved in tetrahydrofuran (1.5 mL)/methanol (1.5 mL)/water (1.5
mL). Lithium hydroxide (5.0 eq., 91.32 mg, 3.737 mmol) was added
and the mixture was stirred at room temperature for 3 hours. The
crude material was purified by flash chromatography to obtain 88.4
mg (35.6% yield) of an off-white solid.
Synthesis of methyl
1-(3-bromophenyl)-5-(1-tert-butoxycarbonylazetidin-3-yl)pyrazolo[3,4-b]py-
ridine-3-carboxylate
##STR00702##
[1244] Similar to general procedure C, to a small vial was added
methyl
5-(1-tert-butoxycarbonylazetidin-3-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbo-
xylate (1.0 eq., 88.4 mg, 0.266 mmol), (3-bromophenyl)boronic acid
(1.50 eq., 80.1 mg, 0.399 mmol), copper(II) acetate monohydrate
(0.30 eq., 16.8 mg, 0.0798 mmol) in N,N-dimethylformamide (0.532
mL) and pyridine (5.0 eq., 0.108 mL, 1.33 mmol). The reaction was
stirred under an oxygen atmosphere at 90.degree. C. for 3 h. The
reaction was diluted with saturated aqueous sodium bicarbonate
solution, and the aqueous phase was extracted with 3 times with
dichloromethane. The organic phases were combined, washed with
brine, dried with sodium sulfate and concentrated under vacuum. The
crude material was purified by flash chromatography (5-100% iPrOAc
in heptanes) to afford a light yellow oil.
Synthesis of methyl
5-(azetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00703##
[1246] Methyl
1-(3-bromophenyl)-5-(1-tert-butoxycarbonylazetidin-3-yl)pyrazolo[3,4-b]py-
ridine-3-carboxylate (1.0 eq., 0.266 mmol) was dissolved in
dichloromethane (1.33 mL). Trifluoroacetic acid (10.0 eq., 0.206
mL, 2.66 mmol) was added dropwise and the reaction was stirred at
room temperature for 2 hours. The solution was concentrated in
vacuo, diluted with saturated aqueous sodium bicarbonate solution
and extracted 2 times with dichloromethane. The organic layers were
combined, dried with sodium sulfate, and concentrated. The crude
material was carried forward without further purification.
Synthesis of methyl
5-(1-acetylazetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carb-
oxylate
##STR00704##
[1248] To a solution of methyl
5-(azetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carboxylate
(1.0 eq., 36 mg, 0.093 mmol) in dichloromethane (0.56 mL) was added
triethylamine (3.0 eq., 0.039 mL, 0.279 mmol) followed by acetic
anhydride (1.2 eq., 0.0106 mL, 0.112 mmol). The reaction was
stirred at room temperature for 2.5 hours. The mixture was diluted
with water and stirred for 10 minutes, then extracted 2 times with
dichloromethane. The organic layers were combined, dried with
sodium sulfate, and concentrated. The crude material was carried
forward without further purification.
Synthesis of
5-(1-acetylazetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carb-
oxamide
##STR00705##
[1250] Similar to general procedure H, to a solution of methyl
5-(1-acetylazetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carb-
oxylate (1.0 eq., 40 mg, 0.0932 mmol) in dimethylformamide (0.5 mL)
was added formamide (10.0 eq., 0.0372 mL, 0.932 mmol) followed by
sodium methoxide (25% in methanol, 3.0 eq., 0.0639 mL, 0.28 mmol).
The reaction was stirred at room temperature for 1 hour. The
reaction mixture was quenched with saturated ammonium chloride
solution and filtered to afford a white solid. The crude material
was carried forward without further purification.
Synthesis of
5-(1-acetylazetidin-3-yl)-1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolid-
in-3-yl]ethynyl]phenyl]pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00706##
[1252] Similar to general procedure E, to a degassed solution of
5-(1-acetylazetidin-3-yl)-1-(3-bromophenyl)pyrazolo[3,4-b]pyridine-3-carb-
oxamide (1.0 eq., 38.6 mg, 0.0932 mmol) in DMF (0.242 mL, 229 mg,
3.10 mmol) and triethylamine (0.242 mL) was added
Bis(triphenylphosphine)palladium(II)chloride (0.05 eq., 3.34 mg,
0.0047 mmol), copper (I) iodide (0.05 eq., 0.9 mg, 0.0047 mmol) and
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (1.20 eq., 15.6
mg, 0.112 mmol). The reaction was heated under inert atmosphere to
80.degree. C. for 1 hour. The reaction was cooled to room
temperature, diluted with dichloromethane and filtered over celite.
The crude material was purified by reverse-phase HPLC to afford
17.5 mg (40% yield after 2 steps) of the desired final product.
M+H=473.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.86 8.76 (m,
1H), 8.69 8.59 (m, 1H), 8.55 8.43 (m, 2H), 8.24 (br s, 1H), 7.73
(br s, 1H), 7.69 7.58 (m, 1H), 7.45 (d, J=7.5 Hz, 1H), 6.52 (s,
1H), 4.66 4.55 (m, 1H), 4.39 4.23 (m, 2H), 4.19 4.07 (m, 1H),
3.97-3.91 (m, 1H), 3.40-3.34 (m, 2H), 2.82 (s, 3H), 2.47 2.41 (m,
1H), 2.22 (dt, J=13.2, 6.9 Hz, 1H), 1.84 (s, 3H).
Example C6
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-5-o-
xo-4H-pyrazolo[4,3-b]pyridine-3-carboxamide
##STR00707##
[1253] Synthesis of 3-iodo-5-methoxy-1H-pyrazolo[4,3-b]pyridine
##STR00708##
[1255] To a solution of 5-methoxy-1H-pyrazolo[4,3-b]pyridine (1.0
eq., 300 mg, 2.011 mmol) in N,N-dimethylformamide (10.1 mL) was
added potassium hydroxide (3.0 eq., 342 mg, 6.034 mmol) followed by
iodine (1.8 eq., 918.9 mg, 3.620 mmol). The reaction was heated to
50.degree. C. for 1.5 hours. The reaction was then cooled to room
temperature and quenched with aqueous sodium thiosulfate until the
dark color disappeared. The mixture was diluted with water and
extracted 2 times with ethyl acetate. The organic layers were
combined, washed with brine, dried with sodium sulfate and
concentrated to afford 528.3 mg (95% yield) of desired product.
Synthesis of
5-methoxy-1H-pyrazolo[4,3-b]pyridine-3-carbonitrile
##STR00709##
[1257] To a solution of 3-iodo-5-methoxy-1H-pyrazolo[4,3-b]pyridine
(1.0 eq., 528 mg, 1.919 mmol) in 1-methyl-2-pyrrolidinone (4.8 mL)
in a microwave vial was added copper(I) cyanide (1.5 eq., 263.2 mg,
2.8795 mmol). The reaction was heated in the microwave to
220.degree. C. for 20 minutes. The reaction was cooled to room
temperature and diluted with dichloromethane. The solution was
filtered over celite and concentrated, then diluted with saturated
aqueous ammonium chloride solution and extracted 3 times with ethyl
acetate. The organic layers were washed with brine, dried with
sodium sulfate and concentrated. The crude material was purified by
flash chromatography (isopropyl acetate in heptane) to afford 142
mg (42.5% yield) of the desired product.
Synthesis of
1-(3-bromophenyl)-5-methoxy-pyrazolo[4,3-b]pyridine-3-carbonitrile
##STR00710##
[1259] Similar to general procedure C, to a small vial was added
5-methoxy-1H-pyrazolo[4,3-b]pyridine-3-carbonitrile (1.00 eq., 142
mg, 0.815 mmol), (3-bromophenyl)boronic acid (1.5 eq., 245.6 mg,
1.223 mmol), copper(II) acetate monohydrate (0.30 eq., 51.4 mg,
0.244 mmol) in N,N-dimethylformamide (1.63 mL) and pyridine (5.0
eq., 0.330 mL, 4.077 mmol). The reaction was stirred under an
oxygen atmosphere at 90.degree. C. for 3 hours. The reaction was
diluted with saturated aqueous sodium bicarbonate solution and the
mixture was extracted with dichloromethane (3 times). The organic
layers were combined, dried with sodium sulfate and concentrated.
The crude was purified by flash chromatography (5-100%
isopropylacetate in heptane) to afford 107.7 mg (40.1% yield) of a
light yellow solid.
Synthesis of
1-(3-bromophenyl)-5-oxo-4H-pyrazolo[4,3-b]pyridine-3-carbonitrile
##STR00711##
[1261] To a solution of
1-(3-bromophenyl)-5-methoxy-pyrazolo[4,3-b]pyridine-3-carbonitrile
(1.0 eq., 50 mg, 0.152 mmol) in acetonitrile (0.30 mL) was added
sodium iodide (3.0 eq., 68.3 mg, 0.456 mmol) and
chlorotrimethylsilane (3.0 eq., 0.058 mL, 0.456 mmol). The reaction
was heated to 85.degree. C. for 2 hours. The reaction mixture was
then treated with methanol (1 ml), and the resulting mixture was
stirred at ambient temperature for 2 hours, and then filtered. The
resulting solid was triturated in water, filtered, and used as is
in the following step.
Synthesis of
1-(3-bromophenyl)-5-oxo-4H-pyrazolo[4,3-b]pyridine-3-carboxamide
##STR00712##
[1263] Similar to General Procedure D,
1-(3-bromophenyl)-5-oxo-4H-pyrazolo[4,3-b]pyridine-3-carbonitrile
(1.0 eq., 47.8 mg, 0.152 mmol) was dissolved in ethanol (0.24 mL)
and water (0.12 mL). Hydrido(dimethylphosphinous acid-kp)[hydrogen
bis(dimethylphosphinito-kp)]platinum(II) (0.05 eq., 3.24 mg, 0.0076
mmol) was added and the reaction was heated to 90.degree. C. under
air for 7 hours. The reaction mixture was diluted with water and
extracted 2 times with dichloromethane. The organic layers were
combined, dried with sodium sulfate and concentrated. The resulting
product was used crude in the following reaction.
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]-5--
oxo-4H-pyrazolo [4,3-b]pyridine-3-carboxamide
##STR00713##
[1265] Similar to general procedure E,
1-(3-bromophenyl)-5-oxo-4H-pyrazolo[4,3-b]pyridine-3-carboxamide
(1.0 eq., 45 mg, 0.135 mmol) in triethylamine (0.35 mL) and DMF
(0.35 mL) was degassed with nitrogen.
Bis(triphenylphosphine)palladium(II)chloride (0.05 eq., 4.8 mg,
0.0067 mmol) and copper (I) iodide (0.05 eq., 1.3 mg, 0.0067 mmol)
were added under inert atmosphere, followed by
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (1.2 eq., 22.6
mg, 0.162 mmol). The reaction was heated to 80.degree. C. for 1
hour. The reaction mixture was cooled to room temperature, diluted
with dichloromethane and filtered over celite. The crude material
was purified by reverse-phase HPLC to afford 9.8 mg (18.5% yield)
of the desired product. M+H=392.2; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 10.54 (br s, 1H), 8.08 (br s, 1H), 8.03 (d, J=9.8 Hz, 1H),
7.85-7.77 (m, 2H), 7.68 (br s, 1H), 7.65-7.59 (m, 1H), 7.57-7.49
(m, 1H), 6.57 (d, J=9.8 Hz, 1H), 6.51 (s, 1H), 3.42-3.34 (m, 2H),
2.80 (s, 3H), 2.47-2.41 (m, 1H), 2.20 (dt, J=13.0, 7.1 Hz, 1H).
Example D6 and Example E6
Synthesis of
(R)-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4--
methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide and
(S)-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4--
methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00714##
[1266] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carb-
oxylate
##STR00715##
[1268] A solution of ethyl
1-(3-bromophenyl)-4-hydroxy-4-methyl-1H,4H,5H,6H-cyclopenta[c]pyrazole-3--
carboxylate (180.0 mg, 0.49 mmol, 1.00 equiv), triethylsilane
(573.1 mg, 4.93 mmol, 10.00 equiv), and boron trifluoride etherate
(139.9 mg, 0.99 mmol, 2.00 equiv) in dichloromethane (40 mL) was
stirred for 12 h at room temperature. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (2:3). This resulted
in 43.0 mg (25%) of the title compound as a reddish solid. LC-MS
(ES, m/z): 349 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4-meth-
yl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate
##STR00716##
[1270] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-4-methyl-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylat-
e was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (45.0 mg, 55%) as a yellow solid. LC-MS (ES, m/z): 408
[M+H].sup.+.
Step 3: Synthesis of
(R)-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4--
methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide and
(S)-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4--
methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00717##
[1272] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-m-
ethyl-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate was reacted
with ammonia to give 2.3 mg (2%) of the 4S-isomer as a white solid
and 3.0 mg (6%) of the 4R-isomer as a white solid. The
stereochemistry of both isomers was arbitrarily assigned. The
4S-isomer: t.sub.R=15.45 min (Chiralcel AD-H, 0.46*15 cm,
Hex:IPA=75:25, 1 ml/min); the 4R-isomer: t.sub.R=18.92 min
(Chiralcel AD-H, 0.46*15 cm, Hex:IPA=75:25, 1 ml/min); Both isomers
showed identical LC-MS and .sup.1H NMR as shown below.
[1273] LC-MS (ES, m/z): 379 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.89 (s, 1H), 7.76-7.755 (m, 1H), 7.51-7.41 (m,
2H), 3.57-3.52 (m, 2H), 3.12-3.09 (m, 1H), 2.95 (s, 3H), 2.62-2.57
(m, 1H), 2.38-2.22 (m, 2H), 1.41-1.29 (m, 6H).
Example F6
Synthesis of
(R)-1-(3-cyano-5-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl-
)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00718##
[1274] Step 1: Synthesis of
3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
##STR00719##
[1276] To a stirred solution of 3-bromobenzonitrile (2.00 g, 10.99
mmol, 1.00 equiv) and
4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxabo-
rolane (1.40 g, 5.51 mmol, 0.50 equiv) in tetrahydrofuran (5 mL,
61.71 mmol, 5.60 equiv) was added
(1,5-cyclooctadiene)(methoxy)iridium(I)
dimerdi-m-methoxobis(1,5-cyclooctadiene)diiridium (I) (150 mg, 0.23
mmol) and 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine (90 mg,
0.34 mmol) under nitrogen. The resulting solution was stirred for
14 hours at 80.degree. C. The reaction mixture was concentrated
under vacuum. The crude product was purified by a silica gel column
with ethyl acetate/petroleum ether (1:5) to give the title compound
(1.5 g, 44%) as a white solid.
Step 2: Synthesis of (3-bromo-5-cyanophenyl)boronic acid
##STR00720##
[1278] A solution of
3-bromo-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.5 g,
4.87 mmol, 1.00 equiv) in hydrogen chloride (15 mL, 493.68 mmol,
101.40 equiv) was stirred for 10 hours at room temperature. The
solids were collected by filtration to give the title compound (750
mg, 68%) as a white solid. LC-MS (ES, m/z): 223, 225
[M-H].sup.-.
Step 3: Synthesis of methyl
1-(3-bromo-5-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00721##
[1280] Similar to as described in General Procedure C,
1H-pyrazolo[3,4-b]pyridine-3-carboxylate (360.00 mg, 2.03 mmol,
1.00 equiv) was reacted with (3-bromo-5-cyanophenyl)boronic acid to
give the title compound (350 mg, 48%) as a white solid. LC-MS (ES,
m/z): 371, 373 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00722##
[1282] Similar to as described in General Procedure G, methyl
1-(3-bromo-5-cyanophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (80 mg, 40%) as a white solid. LC-MS
(ES, m/z): 430 [M+H].sup.+.
Step 5: Synthesis of
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00723##
[1284] Similar to as described in General Procedure S, methyl
1-(3-cyano-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (90.00 mg, 0.22 mmol,
1.00 equiv) was reacted with ammonia to give the title compound
(28.8 mg, 33%) as a white solid. LC-MS (ES, m/z): 401 [M+H].sup.+.
.sup.1H NMR (CD.sub.3OD) .delta. 9.01-8.98 (m, 2H), 8.80-8.73 (m,
2H), 7.85 (t, J=1.5 Hz, 1H), 7.53 (dd, J=8.1, 4.5 Hz, 1H),
3.57-3.51 (m, 2H), 2.97 (s, 3H), 2.70-2.62 (m, 1H), 2.42-2.33 (m,
1H).
Example G6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-N-5-me-
thyl-1H-indazole-3,5-dicarboxamide
##STR00724##
[1285] Step 1: Synthesis of
1-(3-bromophenyl)-3-(methoxycarbonyl)-1H-indazole-5-carboxylic
acid
##STR00725##
[1287] A suspension of methyl
1-(3-bromophenyl)-5-(hydroxymethyl)-1H-indazole-3-carboxylate
(144.00 mg, 0.40 mmol, 1.00 equiv), PCC (17.19 mg, 0.08 mmol, 0.20
equiv), periodic acid (199.93 mg, 0.88 mmol, 2.20 equiv) in
acetonitrile (10 mL) was stirred for 30 min at room temperature.
The resulting solution was diluted with ethyl acetate, washed with
brine, dried over anhydrous sodium sulfate and concentrated under
vacuum. This resulted in 150 mg (crude) of the title compound as a
yellow solid. LC-MS (ES, m/z): 375 [M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-bromophenyl)-5-(methylcarbamoyl)-1H-indazole-3-carboxylate
##STR00726##
[1289] Similar to as described in General Procedure B,
1-(3-bromophenyl)-3-(methoxycarbonyl)-1H-indazole-5-carboxylic acid
was reacted with methylamine to give the title compound (140 mg,
75%) as a yellow solid. LC-MS (ES, m/z): 388 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
methylcarbamoyl)-1H-indazole-3-carboxylate
##STR00727##
[1291] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-5-(methylcarbamoyl)-1H-indazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (140 mg, 94%) as a yellow solid. LC-MS (ES,
m/z): 447 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-N-
-methyl-1H-indazole-3,5-dicarboxamide
##STR00728##
[1293] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
methylcarbamoyl)-1H-indazole-3-carboxylate was reacted with ammonia
to give the title compound (34.3 mg, 25%) as an off-white solid.
LC-MS (ES, m/z): 432 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.85 (s, 1H), 8.04-7.90 (m, 2H), 7.89-7.86 (m, 2H),
7.67-7.58 (m, 2H), 3.53-3.48 (m, 2H), 2.99 (s, 3H), 2.95 (s, 3H),
2.66-2.58 (m, 1H), 2.39-2.30 (m, 1H).
Example H6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(1-(-
2-hydroxyethyl)-1H-pyrazol-4-yl)-1H-indazole-3-carboxamide
##STR00729##
[1294] Step 1: Synthesis of 1-(2-(tert-butyl
dimethylsilyloxy)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-
H-pyrazole
##STR00730##
[1296] Sodium hydride (148.5 mg, 6.19 mmol, 1.20 equiv) was added
in portions to a stirred solution of
4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g, 5.15
mmol, 1.00 equiv) and (2-bromoethoxy)(tert-butyl)dimethylsilane
(1.84 g, 7.69 mmol, 1.50 equiv) in DMF (5 mL) at 0.degree. C. The
resulting solution was stirred for 6 h at room temperature,
quenched by aqueous ammonium chloride, extracted with ethyl
acetate, and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (10/1).
This resulted in 400 mg of the title compound as light-yellow
oil.
Step 2: Synthesis of methyl
5-bromo-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-3-carboxylate
##STR00731##
[1298] Sodium hydride (23.5 mg, 0.98 mmol, 2.50 equiv) was added to
a solution of [2-(chloromethoxy)ethyl]trimethylsilane (97.6 mg,
0.59 mmol, 1.50 equiv) and methyl 5-bromo-1H-indazole-3-carboxylate
(100 mg, 0.39 mmol, 1.00 equiv) in THF (3 mL) at 0.degree. C. After
2 hours the reaction was quenched by water, washed with brine,
extracted with ethyl acetate, and concentrated under vacuum. This
resulted in the title compound (150 mg) as light-yellow oil. LC-MS
(ES, m/z): 385 [M+H].sup.+.
Step 3: Synthesis of methyl
5-(1-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-pyrazol-4-yl)-1-((2-(trimet-
hylsilyl)ethoxy)methyl)-1H-indazole-3-carboxylate
##STR00732##
[1300] Similar to as described in General Procedure M,
1-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-4-(tetramethyl-1,3,2-dioxaborol-
an-2-yl)-1H-pyrazole was reacted with methyl
5-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-indazole-3-carboxylate
to give the title compound (400 mg) as light-yellow oil. LC-MS (ES,
m/z): 531 [M+H].sup.+.
Step 4: Synthesis of methyl
5-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1H-indazole-3-carboxylate
##STR00733##
[1302] A solution of methyl
5-(1-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-1H-pyrazol-4-yl)-1-[[2-(trim-
ethylsilyl)ethoxy]methyl]-1H-indazole-3-carboxylate (400 mg, 0.75
mmol, 1.00 equiv) and trifluoroacetic acid (1.2 mL) in
dichloromethane (3 mL) was stirred for 3 h at room temperature. The
reaction was quenched by 10% sodium hydroxide and the pH value of
the solution was adjusted to 7 with ammonium chloride. The
resulting mixture was extracted with dichloromethane and
concentrated under vacuum. The residue was applied onto a silica
gel column with dichloromethane/methanol (20/1). This resulted in
the title compound (45 mg) as a white solid. LC-MS (ES, m/z): 287
[M+H].sup.+.
Step 5: Synthesis of methyl
1-(3-bromophenyl)-5-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1H-indazole-3-ca-
rboxylate
##STR00734##
[1304] Similar to as described in General Procedure C, methyl
5-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1H-indazole-3-carboxylate
(45 mg, 0.16 mmol, 1.00 equiv) was reacted with
(3-bromophenyl)boronic acid to give the title compound (38 mg, 55%)
as a white solid. LC-MS (ES, m/z): 443 [M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1H-indazole-3-carboxylate
##STR00735##
[1306] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-5-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1H-indazole-3-ca-
rboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (30 mg, 70%) as a white solid. LC-MS (ES, m/z): 500
[M+H].sup.+.
Step 7: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1H-indazole-3-carboxamide
##STR00736##
[1308] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-[-
1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1H-indazole-3-carboxylate was
reacted with ammonia to give the title compound (13.1 mg, 45%) as a
white solid. LC-MS (ES, m/z): 485 [M+H].sup.+. .sup.1H NMR (300
MHz, CDCl.sub.3) .delta. 8.52 (s, 1H), 8.13 (s, 1H), 7.98 (s, 2H),
7.97-7.79 (m, 3H), 7.56-7.67 (m, 2H), 4.30-4.33 (t, J=10.8 Hz, 2H),
3.95-3.98 (t, J=5.4 Hz, 2H), 3.49-3.54 (t, J=13.8 Hz, 2H), 2.96 (s,
3H), 2.59-2.67 (m, 1H), 2.31-2.40 (m, 1H).
Example I6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1H-pyr-
azolo[3,4-d]pyrimidine-3-carboxamide
##STR00737##
[1309] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00738##
[1311] To a solution of ethyl
5-amino-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate (500.00 mg,
1.61 mmol, 1.00 equiv) in formamide (10 mL) was added phosphoryl
trichloride (1 mL, 10.73 mmol, 6.70 equiv) dropwise. The mixture
was stirred overnight at 80.degree. C. and quenched by NaHCO.sub.3
in an ice-water bath. The resulting mixture was extracted ethyl
acetate, dried over anhydrous sodium sulfate, and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:4). This resulted in 60 mg (11%)
of the title compound as a yellow solid. LC-MS (ES, m/z): 347, 349
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ]pyrimidine-3-carboxylate
##STR00739##
[1313] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (80 mg, 62%) as a yellow solid. LC-MS (ES,
m/z): 406 [M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ]pyrimidine-3-carboxamide
##STR00740##
[1315] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ]pyrimidine-3-carboxylate was reacted with ammonia
to give the title compound (35.8 mg, 48%) as a white solid. LC-MS
(ES, m/z): 377 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.70 (s, 1H), 9.18 (s, 1H), 8.51 (s, 1H), 8.44-8.40 (m,
1H), 7.63-7.52 (m, 2H), 3.53-3.48 (m, 2H), 2.95 (s, 3H), 2.66-2.58
(m, 1H), 2.39-2.30 (m, 1H).
Example J6 and Example K6
Synthesis of
(R)-1-(3-((1-hydroxy-2-oxocyclopentyl)ethynyl)phenyl)-1H-indazole-3-carbo-
xamide and
(S)-1-(3-((1-hydroxy-2-oxocyclopentyl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR00741##
[1316] Step 1: Synthesis of 2-oxocyclopentyl acetate
##STR00742##
[1318] A mixture of cyclopentanone (10 g, 118.88 mmol, 1.00 equiv)
and lead tetraacetate (57.6 g, 129.91 mmol, 1.1 equiv) in
cyclohexane (100 mL) was stirred overnight at 90.degree. C. The
reaction mixture was cooled to room temperature and 100 mL of 1 N
hydrogen chloride was added. After being stirred for 1 hour the
solids were filtered out. The aqueous layer was extracted with
ethyl acetate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The crude product was purified by a
silica gel column with ethyl acetate/petroleum ether (1:10) to give
the title compound (1.6 g, 9%) as yellow oil.
Step 2: Synthesis of 2-ethynyl-2-hydroxycyclopentyl acetate
##STR00743##
[1320] To a solution of 2-oxocyclopentyl acetate (800 mg, 5.63
mmol, 1.00 equiv) in THF (5 mL) was added bromo(ethynyl)magnesium
(13.5 mL, 1.00 equiv, 0.5 M in THF) dropwise at 0.degree. C. After
being stirred for 2 hours at room temperature the reaction was
quenched with saturated aqueous ammonium chloride, extracted with
ethyl acetate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. This resulted in the title compound (680
mg, 72%) as a brown solid.
Step 3: Synthesis of 1-ethynylcyclopentane-1,2-diol
##STR00744##
[1322] To a solution of 2-ethynyl-2-hydroxycyclopentyl acetate (680
mg, 4.04 mmol, 1.00 equiv) in methanol (10 mL) was added sodium
hydroxide (1.079 g, 26.98 mmol, 6.70 equiv) in water (5 mL). After
one hour the pH value of the solution was adjusted to 7 with
hydrochloric acid (1 M). The resulting mixture was concentrated
under vacuum. The aqueous layer was extracted with ethyl acetate
and the organic layers were combined and dried over anhydrous
sodium sulfate. The concentrated residue was purified by a silica
gel column with ethyl acetate/petroleum ether (1:10) to give the
title compound (400 mg, 78%) as yellow oil.
Step 4: Synthesis of 2-ethynyl-2-hydroxycyclopentan-1-one
##STR00745##
[1324] To a solution of dimethyl sulfoxide (278.71 mg, 3.57 mmol,
1.50 equiv) in dichloromethane (24 mL) was added oxalyl chloride
(150.92 mg, 1.19 mmol, 1.50 equiv) at -78.degree. C. After one hour
1-ethynylcyclopentane-1,2-diol (300.00 mg, 2.38 mmol, 1.00 equiv)
was added. After another 2 hours triethylamine (1203.18 mg, 11.89
mmol, 5.0 equiv) was added to the stirred mixture and the reaction
was warmed slowly to room temperature. The resulting solution was
diluted with dichloromethane, washed with water, extracted with
dichloromethane, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The crude product was purified by a
silica gel column with ethyl acetate/petroleum ether (1:4) to give
the title compound (110 mg, 37%) as reddish liquid.
Step 5: Synthesis of
(R)-1-(3-((1-hydroxy-2-oxocyclopentyl)ethynyl)phenyl)-1H-indazole-3-carbo-
xamide and
(S)-1-(3-((1-hydroxy-2-oxocyclopentyl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR00746##
[1326] Similar to as described in General Procedure G,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
2-ethynyl-2-hydroxycyclopentan-1-one to give a R/S mixture. After
chiral separation 12.4 mg (15%) of the R-isomer and 14.4 mg (17%)
of the S-isomer were isolated as white solid. The stereochemistry
of both isomers was arbitrarily assigned. The R-isomer:
t.sub.R=12.41 min (Chiralcel OJ-3, 0.46*15 cm, Hex:EtOH=70:30, 1.0
ml/min); The S-isomer B: t.sub.R=16.43 min (Chiralcel OJ-3, 0.46*15
cm, Hex:EtOH=70:30, 1.0 ml/min). Both isomers showed identical
LC-MS and .sup.1H NMR as shown below. LC-MS (ES, m/z): 360
[M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.24 (s,
1H), 7.85 (s, 1H), 7.80-7.70 (m, 2H), 7.53-7.42 (m, 3H), 7.29 (t,
J=7.2 Hz, 1H), 2.45-2.07 (m, 3H), 2.03-1.94 (m, 2H).
Example L6 and Example M6
Synthesis of
(S)-1-(3-(3-hydroxy-3-(1H-1,2,3-triazol-4-yl)but-1-ynyl)phenyl)-1H-indazo-
le-3-carboxamide and
(R)-1-(3-(3-hydroxy-3-(1H-1,2,3-triazol-4-yl)but-1-ynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR00747##
[1327] Step 1: Synthesis of
1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazole
##STR00748##
[1329] Sodium hydride (5.3 g, 220.85 mmol, 1.50 equiv) was added in
portions to a stirred mixture of 1H-1,2,3-triazole (10 g, 144.79
mmol, 1.00 equiv) in THF (500 mL) at 0.degree. C. under nitrogen.
After 1 hour 2-(trimethylsilyl)ethoxymethyl chloride (36 g, 235.76
mmol, 1.60 equiv) was added and the resulting solution was stirred
for 12 h at room temperature. The reaction was quenched by water,
extracted with ethyl acetate, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:10). This
resulted in 10 g (28%) of the title compound as yellow oil. LC-MS
(ES, m/z): 200 [M+H].sup.+.
Step 2: Synthesis of
4-(trimethylsilyl)-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triaz-
ol-4-yl)but-3-yn-2-ol
##STR00749##
[1331] n-Butyllithium (2.5M in hexanes) (12 g, 187.34 mmol, 1.20
equiv) was added dropwise to a stirred solution of
1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazole (5 g, 25.08
mmol, 1.00 equiv) in THF (100 mL) at -78.degree. C. under nitrogen.
After 1 hour 4-(trimethylsilyl)but-3-yn-2-one (4.6 g, 32.80 mmol,
1.30 equiv) was added and the resulting solution was stirred for 12
h at room temperature. The reaction was quenched by saturated
aqueous ammonium chloride, extracted with ethyl acetate, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:20). This resulted in 2.3 g (22%) of the
title compound as yellow oil. LC-MS (ES, m/z): 340 [M+H].sup.+.
Step 3: Synthesis of
2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol-4-yl)but-3-yn-2--
ol
##STR00750##
[1333] A mixture of
4-(trimethylsilyl)-2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triaz-
ol-4-yl)but-3-yn-2-ol (1.97 g, 5.80 mmol, 1.00 equiv) and potassium
carbonate (370 mg, 2.68 mmol, 1.00 equiv) in dichloromethane (5
mL)/methanol (5 mL) was stirred for 1 h at room temperature. The pH
value of the solution was adjusted to 6 with 1N hydrogen chloride.
The resulting solution was extracted with ethyl acetate and dried
over anhydrous sodium sulfate. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:1). This
resulted in 1.4 g of the title compound as yellow oil. LC-MS (ES,
m/z): 268 [M+H].sup.+.
Step 4: Synthesis of methyl
1-[3-[3-hydroxy-3-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol--
4-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-carboxylate
##STR00751##
[1335] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-1H-indazole-3-carboxylate was reacted with
2-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol-4-yl)but-3-yn-2--
ol to give the title compound (200 mg, 56%) as yellow oil. LC-MS
(ES, m/z): 518 [M+H].sup.+.
Step 5: Synthesis of
1-[3-[3-hydroxy-3-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol--
4-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-carboxamide
##STR00752##
[1337] Similar to as described in General Procedure S, methyl
1-[3-[3-hydroxy-3-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol--
4-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-carboxylate was reacted
with ammonia to give the title compound (130 mg, 64%) as yellow
oil. LC-MS (ES, m/z): 503 [M+H].sup.+.
Step 6: Synthesis of
(S)-1-(3-(3-hydroxy-3-(1H-1,2,3-triazol-4-yl)but-1-ynyl)phenyl)-1H-indazo-
le-3-carboxamide and
(R)-1-(3-(3-hydroxy-3-(1H-1,2,3-triazol-4-yl)but-1-ynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR00753##
[1339] A mixture of
1-[3-[3-hydroxy-3-(1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-1,2,3-triazol--
4-yl)but-1-yn-1-yl]phenyl]-1H-indazole-3-carboxamide (150.00 mg,
0.30 mmol, 1.00 equiv), CsF (180 mg, 1.18 mmol, 4.00 equiv), and
tetrabutylammonium fluoride (78 mg, 1.00 equiv) in THF (30 mL) was
stirred overnight at room temperature. The resulting mixture was
concentrated under vacuum and the crude product (500 mg) was
purified by Prep-HPLC and separated by Chiral-Prep-HPLC. This
resulted in 30.5 mg (26%) of the 3S-isomer as a white solid and
35.6 mg (31%) of the 3R-isomer as a white solid. The
stereochemistry of both isomers was arbitrarily assigned. The
3S-isomer: t.sub.R=9.64 min (Chiralcel OJ-3, 0.46*15 cm,
Hex:EtOH=70:30, 1.0 ml/min); The 3R-isomer: t.sub.R=12.64 min
(Chiralcel OJ-3, 0.46*15 cm, Hex:EtOH=70:30, 1.0 ml/min). Both
isomers showed identical LC-MS and .sup.1H NMR as shown below.
LC-MS (ES, m/z): 373 [M+H].sup.+. .sup.1H NMR (300 Hz,
DMSO-d.sub.6) .delta. 8.32-8.29 (d, J=8.1 Hz, 1H), 8.04 (s, 1H),
7.93-7.87 (m, 4H), 7.67-7.52 (m, 4H), 7.42-7.37 (m, 1H), 6.38 (s,
1H), 1.86 (s, 1H).
Example N6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1,4,5,-
6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00754##
[1340] Step 1: Synthesis of ethyl
2-oxo-2-(2-oxocyclopentyl)acetate
##STR00755##
[1342] Similar to as described in General Procedure Y Step 1,
diethyl oxalate was reacted with cyclopentanone to give the title
compound (25 g, 76%) as yellow oil. LC-MS (ES, m/z): 185
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate
##STR00756##
[1344] Similar to as described in General Procedure Y Step 2, ethyl
2-oxo-2-(2-oxocyclopentyl)acetate was reacted with
(3-bromophenyl)hydrazine hydrochloride to give the title compound
(6 g, 66%) as a yellow solid. LC-MS (ES, m/z): 335, 337
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate
##STR00757##
[1346] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (1.1 g, crude) as a yellow solid. LC-MS
(ES, m/z): 394 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide
##STR00758##
[1348] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate was reacted with
ammonia to give the title compound (541.8 mg, 53%) as a white
solid. LC-MS (ES, m/z): 365 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.87 (s, 1H), 7.76-7.72 (m, 1H), 7.51-7.40 (m,
2H), 3.49 (t, J=6.0 Hz, 2H), 3.07 (t, J=6.9 Hz, 2H), 2.94 (s, 3H),
2.84 (t, J=6.9 Hz, 2H), 2.72-2.56 (m, 3H), 2.37-2.24 (m, 1H).
Example O6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(pyr-
imidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00759##
[1349] Step 1: Synthesis of
1-(3-bromophenyl)-5-(pyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridi-
ne-3-carboxylate
##STR00760##
[1351] A mixture of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
(200.00 mg, 0.43 mmol, 1.00 equiv) in DMF (4.00 mL),
4-chloropyrimidine hydrochloride (65.05 mg, 0.43 mmol, 1.00 equiv),
and potassium carbonate (238.17 mg, 1.72 mmol, 4.00 equiv) was
stirred for 4 h at 80.degree. C. in a sealed tube under nitrogen.
The reaction was quenched by water, extracted with ethyl acetate,
washed with brine, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (2:1). This resulted
in 160 mg (87%) of the title compound as yellow oil. LC-MS (ES,
m/z): 428, 430 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00761##
[1353] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-5-(pyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridi-
ne-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (120 mg, 70%) as yellow oil. LC-MS (ES, m/z): 487
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00762##
[1355] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia to give the title compound (15.3 mg, 14%)
as an off-white solid. LC-MS (ES, m/z): 458 [M+H].sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD) .delta. 8.53 (s, 1H), 8.20 (d, J=6.3 Hz,
1H), 7.75 (s, 1H), 7.67-7.62 (m, 1H), 7.57-7.52 (m, 2H), 6.92 (d,
J=6.3 Hz, 1H), 4.97 (s, 2H), 4.10 (t, J=5.7 Hz, 2H), 3.55-3.46 (m,
2H), 3.08-3.01 (m, 2H), 2.99 (s, 3H), 2.63-2.55 (m, 1H), 2.37-2.32
(m, 1H).
Example P6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(pyr-
imidin-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00763##
[1356] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-(pyrimidin-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridi-
ne-3-carboxylate
##STR00764##
[1358] A mixture of 2-chloropyrimidine (37.01 mg, 0.32 mmol, 1.00
equiv) in DMF (2.00 mL), ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
(150.00 mg, 0.32 mmol, 1.00 equiv), and ethyldiisopropylamine
(847.73 mg, 6.56 mmol, 20.30 equiv) in a sealed tube under nitrogen
was stirred for 12 h at 80.degree. C. The reaction was quenched by
water, extracted with ethyl acetate, and washed with brine. The
solids were filtered out and the liquid was concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:3). This resulted in 80 mg (58%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 428, 430
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00765##
[1360] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-5-(pyrimidin-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridi-
ne-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (80 mg, 88%) as yellow oil. LC-MS (ES, m/z): 487
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00766##
[1362] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
pyrimidin-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia to give the title compound (10.2 mg, 14%)
as a white solid. LC-MS (ES, m/z): 458 [M+H].sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.26 (s, 1H), 7.64 (s, 1H), 7.55-7.52
(m,1H), 7.45-7.40 (m, 2H), 6.53 (t, J=4.8 Hz, 1H), 4.95 (s, 2H),
4.04 (t, J=5.6 Hz, 2H), 3.39-3.36 (m, 2H), 2.87-2.84 (m, 2H), 2.83
(s, 3H), 2.51-2.47 (m, 1H), 2.24-2.18 (m, 1H).
Example Q6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(thi-
azol-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00767##
[1363] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-(1,3-thiazol-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyri-
dine-3-carboxylate
##STR00768##
[1365] A mixture of ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
(200.00 mg, 0.43 mmol, 1.00 equiv), 2-bromo-1,3-thiazole (2.00 mL,
22.19 mmol, 51.50 equiv), and potassium carbonate (297.71 mg, 2.15
mmol, 5.00 equiv) in a sealed tube under nitrogen was stirred for
12 h at 100.degree. C. The reaction was quenched by water,
extracted with ethyl, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5). This resulted
in 117 mg (63%) of the title compound as yellow oil. LC-MS (ES,
m/z): 433, 45 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
1,3-thiazol-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00769##
[1367] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-5-(1,3-thiazol-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyri-
dine-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (100 mg, 80%) as yellow oil. LC-MS (ES, m/z): 492
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
1,3-thiazol-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00770##
[1369] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-(-
1,3-thiazol-2-yl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia to give the title compound (17.1 mg, 18%)
as a white solid. LC-MS (ES, m/z): 463 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 7.75 (s, 1H), 7.67-7.62 (m, 1H),
7.57-7.52 (m, 2H), 7.18 (d, J=3.6 Hz, 1H), 6.76 (d, J=3.6 Hz, 1H),
4.76 (s, 2H), 3.91 (t, J=5.4 Hz, 2H), 3.55-3.50 (m, 2H), 3.09-3.03
(m, 2H), 2.93 (s, 3H), 2.63-2.55 (m, 1H), 2.36-2.27 (m, 1H).
Example R6 and Example S6
Synthesis of
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-((S)-
-methylsulfinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxami-
de and
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)--
5-((R)-methylsulfinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-car-
boxamide
##STR00771##
[1370] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-methanesulfinyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-
e-3-carboxylate
##STR00772##
[1372] Into a 250-mL round-bottom flask was placed trifluoroacetic
acid ethyl
1-(3-bromophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxyl-
ate salt (1.00 g, 2.15 mmol, 1.00 equiv), methanesulfinyl chloride
(420 mg, 4.26 mmol, 2.00 equiv), and triethylamine (870 mg, 8.60
mmol, 4.00 equiv) in dichloromethane (100 mL). The resulting
mixture was stirred for 5 min at room temperature and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (9:11). This resulted in 300 mg (34%)
of the title compound as a yellow solid. LC-MS (ES, m/z): 412, 414
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfinyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00773##
[1374] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-5-methanesulfinyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-
e-3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (100 mg, 35%) as a yellow solid. LC-MS (ES, m/z): 471
[M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfinyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00774##
[1376] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethanesulfinyl-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia to give a R/S mixture which was separated
by Chiral-Prep-HPLC. This resulted in 7.8 mg (8%) of the 5S-isomer
as a white solid and 7.4 mg (8%) of the 5R-isomer as a white solid.
The stereochemistry of both isomers was arbitrarily assigned. The
5S-isomer: t.sub.R=5.59 min (Chiralcel OJ-3, 0.46*15 cm, Hex (0.1%
TEA):EtOH=50:50, 1.2 ml/min); the 5R-isomer: t.sub.R=11.19 min
(Chiralcel OJ-3, 0.46*15 cm, Hex (0.1% TEA):EtOH=50:50, 1.2
ml/min). Both isomers showed identical LC-MS and .sup.1H NMR as
shown below. LC-MS (ES, m/z): 442 [M+H].sup.+. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 7.71-7.66 (m, 2H), 7.60-7.56 (m,1H),
7.51-7.49 (m, 1H), 4.34 (s, 2H), 3.41-3.37 (m, 4H), 3.05-2.90 (m,
2H), 2.81 (s, 3H), 2.69 (s, 3H), 2.53-2.52 (m, 1H), 2.22-2.19 (m,
1H).
Example T6, Example U6, Example V6 and Example W6
Synthesis of
1-(3-[2-[(3S,4S)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazol e-3-carboxamide,
1-(3-[2-[(3S,4R)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide,
1-(3-[2-[(3R,4R)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide and
1-(3-[2-[(3R,45)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide
##STR00775##
[1377] Step 1: Synthesis of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-hydroxy-2-methylidenebutanoate
##STR00776##
[1379] Into a 250-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed tert-butyl
N-methyl-N-(2-oxoethyl)carbamate (8.00 g, 46.19 mmol, 1.00 equiv),
methyl prop-2-enoate (39.76 g, 461.85 mmol, 10.00 equiv), and
1,4-diazabicyclo[2,2,2]octane (20.72 g, 184.71 mmol, 4.00 equiv).
After being stirred for 3 days at room temperature the reaction was
quenched by water, extracted with dichloromethane, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified by a silica gel column with ethyl
acetate/petroleum ether (1:5) to give 11 g (92%) of the title
compound as yellow oil. LC-MS (ES, m/z): 260 [M+H].sup.+.
Step 2: Synthesis of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-[(tert-butyldimethylsilyl)oxy]-
-2-methylidenebutanoate
##STR00777##
[1381] A solution of tert-butyl(chloro)dimethylsilane (15.35 g,
101.84 mmol, 2.40 equiv) in dichloromethane (20 mL) was added
dropwise to a stirred solution of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-hydroxy-2-methylidenebutanoate
(11.00 g, 42.42 mmol, 1.00 equiv) and imidazole (8.7 g, 3.00 equiv)
in dichchloromethane (100 mL) at 0.degree. C. The resulting mixture
was stirred overnight at room temperature. The solids were filtered
out and the liquid was concentrated under vacuum. The residue was
purified by a silica gel column with ethyl acetate/petroleum ether
(1:10) to give 17 g (92%) of the title compound as colorless oil.
LC-MS (ES, m/z): 374 [M+H].sup.+.
Step 3: Synthesis of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-[(tert-butyldimethylsilyl)oxy]-
-2-oxobutanoate
##STR00778##
[1383] In a 250-mL 4-necked round-bottom flask purged and
maintained with an inert atmosphere of O.sub.3 gas, a suspension of
methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-[(tert-butyldimethylsilyl)oxy]-
-2-methylidenebutanoate (8 g, 21.42 mmol, 1.00 equiv) in
dichloromethane (100 mL) was stirred for 1 h at -78.degree. C. The
reaction was then quenched by 10 mL of diethylsulfane and
concentrated under vacuum. The residue was purified by a silica gel
column with ethyl acetate/petroleum ether (1:10) to give the title
compound (7.314 g, 82%) as colorless oil. LC-MS (ES, m/z): 376
[M+H].sup.+.
Step 4: Synthesis of methyl
2-(2-[[(tert-butoxy)carbonyl](methyl)amino]-1-[(tert-butyldimethylsilyl)o-
xy]ethyl)-2-hydroxybut-3-ynoate
##STR00779##
[1385] Bromo(ethynyl)magnesium (47 mL, 181.84 mmol, 1.20 equiv) was
added dropwise to a stirred solution of methyl
4-[[(tert-butoxy)carbonyl](methyl)amino]-3-[(tert-butyldimethylsilyl)oxy]-
-2-oxobutanoate (7.314 g, 19.48 mmol, 1.00 equiv) in THF (10 mL) at
0.degree. C. under nitrogen. After being stirred for 2 h at
0.degree. C. the reaction was quenched by saturated aqueous
NH.sub.4Cl, extracted with ethyl acetate, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
purified by a silica gel column with ethyl acetate/petroleum ether
(1:5) to give the title compound (6.4 g, 74%) as yellow oil. LC-MS
(ES, m/z): 402 [M+H].sup.+.
Step 5: Synthesis of
4-[(tert-butyldimethylsilyl)oxy]-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-
-one
##STR00780##
[1387] Trifluoroacetic acid (800 mg, 7.02 mmol, 2.00 equiv) was
added to a stirred solution of methyl
2-(2-[[(tert-butoxy)carbonyl](methyl)amino]-1-[(tert-butyldimethylsilyl)o-
xy]ethyl)-2-hydroxybut-3-ynoate (1.40 g, 3.49 mmol, 1.00 equiv) in
dichloromethane (5 mL) at room temperature. After 2 h triethylamine
(1.41 g, 13.93 mmol, 4.00 equiv) in dichloromethane (15 mL) was
added and the reaction was stirred overnight. The resulting mixture
was concentrated under vacuum and the residue was purified by a
silica gel column with ethyl acetate/petroleum ether (1:3) to give
the title compound (780 mg, 75%) as a yellow solid. LC-MS (ES,
m/z): 270 [M+H].sup.+.
Step 6: Synthesis of
1-[3-(2-[4-[(tert-butyldimethylsilyl)oxy]-3-hydroxy-1-methyl-2-oxopyrroli-
din-3-yl]ethynyl)phenyl]-1H-indazole-3-carboxamide
##STR00781##
[1389] Similar to as described in General Procedure G,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
4-[(tert-butyldimethylsilyl)oxy]-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-
-one to give the title compound (540 mg) as a yellow solid. LC-MS
(ES, m/z): 505 [M+H].sup.+.
Step 7: Synthesis of
1-(3-[2-[(3S,4S)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide,
1-(3-[2-[(3S,4R)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide,
1-(3-[2-[(3R,4R)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide and
1-(3-[2-[(3R,45)-3,4-dihydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phen-
yl)-1H-indazole-3-carboxamide
##STR00782##
[1391] TBAF (1.3 g, 4.97 mmol, 2.00 equiv) was added dropwise into
a solution of
1-[3-(2-[4-[(tert-butyldimethylsilyl)oxy]-3-hydroxy-1-methyl-2-oxopyrroli-
din-3-yl]ethynyl)phenyl]-1H-indazole-3-carboxamide (1.25 g, 2.48
mmol, 1.00 equiv) in THF (50 mL) at 0.degree. C. After being
stirred overnight at room temperature the resulting mixture was
concentrated under vacuum and the crude product (200 mg) was
purified by Chiral-Prep-HPLC. This resulted in 2.5 mg of the
3S,4S-isomer, 1.7 mg of the 3S,4R-isomer, 12.8 mg (1%) of the
3R,4R-isomer, and 13.7 mg (1%) of the 3R,4S-isomer. All four
isomers are white solid. The stereochemistry of all isomers was
arbitrarily assigned. The 3R, 4R-isomer: t.sub.R=1.91 min
(Chiralcel IA-3, 0.46*5 cm, Hex (0.1% TEA):EtOH=50:50, 1.0 ml/min);
the 3S, 4S-isomer t.sub.R=3.32 min (Chiralcel IA-3, 0.46*5 cm, Hex
(0.1% TEA):EtOH=50:50, 1.0 ml/min). The 3R, 4S-isomer: t.sub.R=7.84
min (Chiralcel IC-3, 0.46*15 cm, Hex (0.1% TEA):EtOH=50:50, 1.0
ml/min); The 3S, 4R-isomer: t.sub.R=9.99 min (Chiralcel IC-3,
0.46*15 cm, Hex (0.1% TEA):EtOH=50:50, 1.0 ml/min). LC-MS (ES,
m/z): 391 [M+H].sup.+ for all four isomers. Proton NMR for 3R,
4R-isomer or 3S, 4S-isomer: .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.36 (d, J=8.0 Hz, 1H), 7.98-7.85 (m, 3H), 7.67-7.56 (m,
3H), 7.42 (t, J=7.2 Hz, 1H), 4.42-4.39 (m, 1H), 3.83-3.78 (m, 1H),
3.34-3.29 (m, 1H), 2.95 (s, 3H). Proton NMR for 3R, 4R-isomer or
3S, 4S-isomer: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.31 (d,
J=8.0 Hz, 1H), 8.04 (s, 1H), 7.93-7.86 (m, 3H), 7.66 (t, J=7.6 Hz,
1H), 7.59-7.52 (m, 3H), 7.40 (t, J=7.6 Hz, 1H), 6.56 (s, 1H), 5.80
(d, J=5.6 Hz, 1H), 4.09-4.05 (m, 1H), 3.53-3.49 (m, 1H), 3.14-3.10
(m, 1H), 2.79 (s, 3H).
Example X6
Synthesis of
(R)-4-(ethylamino)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl-
)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00783##
[1392] Step 1: Synthesis of
N-ethyl-3-iodo-1H-pyrazolo[4,3-c]pyridin-4-amine
##STR00784##
[1394] Similar to as described in General Procedure A,
4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine was reacted with
ethylamine to give the title compound (850 mg, 82%) as an off-white
solid. LC-MS (ES, m/z): 289 [M+H].sup.+.
Step 2: Synthesis of methyl
4-(ethylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00785##
[1396] Similar to as described in General Procedure O,
N-ethyl-3-iodo-1H-pyrazolo[4,3-c]pyridin-4-amine was reacted with
carbon monoxide to give the title compound (300 mg, 46%) as a brown
solid. LC-MS (ES, m/z): 221 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-bromophenyl)-4-(ethylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00786##
[1398] Similar to as described in General Procedure C, methyl
4-(ethylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted
with (3-bromophenyl)boronic acid to give the title compound (160
mg, crude) as a brown solid. LC-MS (ES, m/z): 375 [M+H].sup.+.
Step 4: Synthesis of methyl
4-(ethylamino)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00787##
[1400] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-4-(ethylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (100 mg, 54%) as an off-white solid.
LC-MS (ES, m/z): 434 [M+H].sup.+.
Step 5: Synthesis of
4-(ethylamino)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00788##
[1402] Similar to as described in General Procedure S, methyl
4-(ethylamino)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethy-
nyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted
with ammonia to give the title compound (33.2 mg, 43%) as a white
solid. LC-MS (ES, m/z): 419 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.77-7.67 (m, 3H), 7.52-7.45 (m, 2H), 6.75 (d,
J=6.4 Hz, 1H), 3.45-3.35 (m, 4H), 2.83 (s, 3H), 2.52-2.48 (m, 1H),
2.25-2.18 (m, 1H), 1.24 (t, J=7.2 Hz, 3H).
Example Y6
Synthesis of
(R)-4-(cyclopropylamino)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)e-
thynyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00789##
[1403] Step 1: Synthesis of
4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00790##
[1405] A solution of 4-chloro-1H-pyrazolo[4,3-c]pyridine (5 g,
32.56 mmol, 1.00 equiv), I.sub.2 (16.39 g, 64.58 mmol, 1.00 equiv),
potassium hydroxide (6.9 g, 122.98 mmol, 1.00 equiv) in 1,4-dioxane
(150 mL) was stirred for 4 h at 75.degree. C. The reaction was
quenched by saturated Na.sub.2S.sub.2O.sub.3 and the solids were
collected by filtration. This resulted in 3.7 g (41%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 280 [M+H].sup.+.
Step 2: Synthesis of
N-cyclopropyl-3-iodo-1H-pyrazolo[4,3-c]pyridin-4-amine
##STR00791##
[1407] Similar to as described in General Procedure A,
4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine was reacted with
cyclopropanamine (1.45 g, 25.40 mmol, 10.00 equiv) to give the
title compound (767 mg, crude) as a white solid. LC-MS (ES, m/z):
301 [M+H].sup.+.
Step 3: Synthesis of methyl
4-(cyclopropylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00792##
[1409] Similar to as described in General Procedure O,
N-cyclopropyl-3-iodo-1H-pyrazolo[4,3-c]pyridin-4-amine was reacted
with carbon monoxide to give the title compound (180 mg) as a crude
solid. LC-MS (ES, m/z): 233 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-bromophenyl)-4-(cyclopropylamino)-1H-pyrazolo[4,3-c]pyridine-3-carbo-
xylate
##STR00793##
[1411] Similar to as described in General Procedure C, methyl
4-(cyclopropylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with (3-bromophenyl)boronic acid to give the title compound
(124 mg, 41%) as a light yellow solid. LC-MS (ES, m/z): 387
[M+H].sup.+.
Step 5: Synthesis of methyl
4-(cyclopropylamino)-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-y-
l]ethynyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00794##
[1413] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-4-(cyclopropylamino)-1H-pyrazolo[4,3-c]pyridine-3-carbo-
xylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (90 mg, 63%) as a yellow solid. LC-MS (ES, m/z): 446
[M+H].sup.+.
Step 6: Synthesis of
4-(cyclopropylamino)-1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-y-
l]ethynyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00795##
[1415] Similar to as described in General Procedure S, methyl
4-(cyclopropylamino)-1-(3-[2-[(3S)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-y-
l]ethynyl]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with ammonia to give the title compound (11.7 mg, 13%) as a
white solid. LC-MS (ES, m/z): 431 [M+H].sup.+. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 7.89-7.88 (m, 2H), 7.81-7.77 (m, 1H),
7.63-7.58 (m, 2H), 6.94 (d, J=6.3 Hz, 1H), 3.51-3.30 (m, 2H), 2.93
(s, 3H), 2.89-2.84 (m, 1H), 2.62-2.56 (m, 1H), 2.37-2.28 (m, 1H),
0.93-0.87 (m, 2H), 0.64-0.59 (m, 2H).
Example Z6
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
yl-1H-pyrazolo [4,3-c]pyridine-3-carboxamide
##STR00796##
[1416] Step 1: Synthesis of
(4-chloro-6-methylpyridin-3-yl)methanol
##STR00797##
[1418] Diisobutylaluminium hydride (100 mL, 492.91 mmol, 5.00
equiv) was added dropwise to a stirred suspension of methyl
4-chloro-6-methylpyridine-3-carboxylate (6.67 g, 35.94 mmol, 1.0
equiv) in dichloromethane (120 mL) at -76.degree. C. under
nitrogen. The reaction was stirred for 2 h at room temperature,
quenched by aqueous potassium sodium tartrate, extracted with ethyl
acetate, and concentrated under vacuum. The residue was purified by
a silica gel column with ethyl acetate/petroleum ether (1:5). This
resulted 3.5 g (62%) of the title compound as a light red solid.
LC-MS (ES, m/z): 158 [M+H].sup.+.
Step 2: Synthesis of 4-chloro-6-methylpyridine-3-carbaldehyde
##STR00798##
[1420] A suspension of (4-chloro-6-methylpyridin-3-yl)methanol
(2.17 g, 13.77 mmol, 1.00 equiv) and Dess-Martin periodinane (8.74
g, 20.61 mmol, 1.50 equiv) in dichloromethane (120 mL) was stirred
for 2 h at room temperature. The resulting mixture was concentrated
under vacuum and the residue was purified by a silica gel column
with ethyl acetate/petroleum ether (1:10) to give 1.61 g (75%) of
4-chloro-6-methylpyridine-3-carbaldehyde as a light yellow solid.
LC-MS (ES, m/z): 156 [M+H].sup.+.
Step 3: Synthesis of 6-methyl-1H-pyrazolo[4,3-c]pyridine
##STR00799##
[1422] In a 30-mL sealed tube with an inert atmosphere of nitrogen,
a suspension of 4-chloro-6-methylpyridine-3-carbaldehyde (797 mg,
5.12 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (36 mL)
and hydrazine hydrate (98%) (9 mL, 184.64 mmol, 35.00 equiv) was
irradiated with microwave radiation for 3 h at 110.degree. C. The
resulting mixture was concentrated under vacuum and the residue was
purified by a silica gel column with ethyl acetate/petroleum ether
(1:5) to give 290 mg (43%) of the title compound as a light yellow
solid. LC-MS (ES, m/z): 134 [M+H].sup.+.
Step 4: Synthesis of 3-iodo-6-methyl-1H-pyrazolo[4,3-c]pyridine
##STR00800##
[1424] A suspension of 6-methyl-1H-pyrazolo[4,3-c]pyridine (270 mg,
2.03 mmol, 1.00 equiv), I.sub.2 (1.04 g, 4.10 mmol, 2.00 equiv),
and potassium hydroxide (410 mg, 7.31 mmol, 3.60 equiv) in DMF (6
mL) was stirred for 12 h at room temperature. The reaction was
quenched with saturated aqueous Na.sub.2S.sub.2O.sub.3, extracted
with ethyl acetate, and dried over anhydrous sodium sulfate. The
residue was purified by a silica gel column with ethyl
acetate/petroleum ether (1:4) to give 360 mg (69%) of the title
compound as a light yellow solid. LC-MS (ES, m/z): 260
[M+H].sup.+.
Step 5: Synthesis of methyl
6-methyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00801##
[1426] Similar to as described in General Procedure O,
3-iodo-6-methyl-1H-pyrazolo[4,3-c]pyridine was reacted with CO to
give the title compound (200 mg). LC-MS (ES, m/z): 192
[M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-bromophenyl)-6-methyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00802##
[1428] Similar to as described in General Procedure C, methyl
6-methyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (150 mg,
41%) as a gray solid. LC-MS (ES, m/z): 346, 348 [M+H].sup.+.
Step 7: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00803##
[1430] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-6-methyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (160 mg, 91%) as a brown solid. LC-MS
(ES, m/z): 405 [M+H].sup.+.
Step 8: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00804##
[1432] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (63 mg, 41%) as a white solid.
LC-MS (ES, m/z): 390 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.47 (s, 1H), 7.96 (s, 1H), 7.89-7.83 (m, 1H), 7.65-7.62
(m, 3H), 3.49 (t, J=7.5 Hz, 2H), 2.96 (s, 3H), 2.72 (s, 3H),
2.70-2.68 (m, 1H), 2.29-2.37 (m, 1H).
Example A7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1H-pyr-
azolo[4,3-c]pyridine-3-carboxamide
##STR00805##
[1433] Step 1: Synthesis of
4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00806##
[1435] A solution of 4-chloro-1H-pyrazolo[4,3-c]pyridine (1.5 g,
9.77 mmol, 1.00 equiv), 1,4-dioxane (25 mL), potassium hydroxide
(2.0 g, 35.65 mmol, 3.60 equiv), and iodine (4.95 g, 19.50 mmol,
2.00 equiv) was stirred for 4 h at 75.degree. C. The reaction was
quenched by saturated aqueous sodium thiosulfate pentahydrate and
the solids were collected by filtration. This resulted in 2.5 g
(92%) of the title compound as a light yellow solid. LC-MS (ES,
m/z): 280 [M+H].sup.+.
Step 2: Synthesis of methyl
4-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00807##
[1437] Similar to as described in General Procedure O,
4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine was reacted with CO to
give the title compound (700 mg, 66%) as a light yellow solid.
LC-MS (ES, m/z): 212 [M+H].sup.+.
Step 3: Synthesis of methyl
1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00808##
[1439] A mixture of methyl
4-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (600.0 mg, 2.84
mmol, 1.00 equiv), zinc powder (920.0 mg, 14.07 mmol, 5.00 equiv),
and acetic acid (15.0 mL) was stirred for 12 h at room temperature.
The resulting solution was diluted with water and the solids were
filtered out. The pH value of the solution was adjusted to 7 with
aqueous sodium bicarbonate. The solids were filtered out and the
liquid was extracted with ethyl acetate. The organic was washed
with brine and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:1).
This resulted in 130.0 mg (26%) of methyl
1H-pyrazolo[4,3-c]pyridine-3-carboxylate as an off-white solid.
LC-MS (ES, m/z): 187 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-iodophenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00809##
[1441] Similar to as described in General Procedure C, methyl
1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
(3-iodophenyl)boronic acid to give the title compound (90.0 mg,
42%) as an off-white solid. LC-MS (ES, m/z): 332 [M+H].sup.+.
Step 5: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[4,3-c ]pyridine-3-carboxylate
##STR00810##
[1443] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (30.0 mg, 58%) as an off-white solid. LC-MS
(ES, m/z): 391 [M+H].sup.+.
Step 6: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[4,3-c ]pyridine-3-carboxamide
##STR00811##
[1445] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[4,3-c ]pyridine-3-carboxylate was reacted with ammonia to
give the title compound (9.4 mg, 33%) as an off-white solid. LC-MS
(ES, m/z): 376 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.60 (d, J=0.9 Hz, 1H), 8.53 (d, J=6 Hz, 1H), 7.98 (d,
J=1.8 Hz, 1H), 7.89 (dd, J=6.0, 0.9 Hz, 2H), 7.65-7.61 (m, 2H),
3.51-3.47 (m, 2H), 2.94 (s, 3H), 2.65-2.55 (m, 1H), 2.35-2.25 (m,
1H).
Example B7
Synthesis of
(R)-6-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl-
)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00812##
[1446] Step 1: Synthesis of methyl
6-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00813##
[1448] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (60 mg, 35%) as a yellow solid. LC-MS
(ES, m/z): 425 [M+H].sup.+.
Step 2: Synthesis of methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00814##
[1450] A suspension of methyl
6-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (70 mg, 0.16 mmol,
1.00 equiv), Pd(PPh.sub.3).sub.4 (38 mg, 0.03 mmol, 0.20 equiv),
and zinc cyanide (97 mg, 0.83 mmol, 5.00 equiv) in DMF (3 mL) was
irradiated with microwave radiation for 1 h at 90.degree. C. The
resulting mixture was concentrated under vacuum, diluted with
brine, extracted with ethyl acetate, and dried over anhydrous
sodium sulfate. The residue was purified by a silica gel column
with dichloromethane/methanol (40:1) to give the title compound (60
mg, 88%) as a yellow solid. LC-MS (ES, m/z): 416 [M+H].sup.+.
Step 3: Synthesis of
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00815##
[1452] Similar to as described in General Procedure S, methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (5.2 mg, 27%) as a white solid.
LC-MS (ES, m/z): 401 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.58 (s, 1H), 8.75 (s, 1H), 8.00-7.96 (m,
2H), 7.70-7.59 (m, 2H), 3.40-3.37 (m, 2H), 2.81 (s, 3H), 2.50-2.43
(m, 1H), 2.24-2.19 (m, 1H).
Example C7 and Example D7
Synthesis of
(R)-6-cyano-1-(3-((7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)eth-
ynyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide and
(S)-6-cyano-1-(3-((7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)eth-
ynyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00816##
[1453] Step 1: Synthesis of
7-ethynyl-5H,6H,7H-cyclopenta[b]pyridin-7-ol
##STR00817##
[1455] A solution of 5H,6H,7H-cyclopenta[b]pyridin-7-one (200 mg,
1.50 mmol, 1.00 equiv) in THF (2 mL) was added dropwise to a
suspension of bromo(ethynyl)magnesium (3.6 mL, 0.5 M in THF) in
oxolane (8 mL) at 0.degree. C. and the resulting mixture was
stirred for 2 h at room temperature. The reaction was quenched by
saturated aqueous ammonium chloride, extracted with ethyl acetate,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was purified by a silica gel column with ethyl
acetate/petroleum ether (1:3) to give the title compound (180 mg,
75%) as a brown solid. LC-MS (ES, m/z): 160 [M+H].sup.+.
Step 2: Synthesis of methyl
6-chloro-1-[3-(2-[7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethynyl)ph-
enyl]-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00818##
[1457] Similar to as described in General Procedure G,
7-ethynyl-5H,6H,7H-cyclopenta[b]pyridin-7-ol was reacted with
methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
to give the title compound (450 mg, 74%) as a brown solid. LC-MS
(ES, m/z): 445 [M+H].sup.+.
Step 3: Synthesis of methyl
6-cyano-1-[3-(2-[7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethynyl)phe-
nyl]-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00819##
[1459] A suspension of methyl
6-chloro-1-[3-(2-[7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethynyl)ph-
enyl]-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (450 mg, 1.01 mmol,
1.00 equiv), zinc cyanide (1.183 g, 10.07 mmol, 10.00 equiv),
Pd(PPh.sub.3).sub.4 (234 mg, 0.20 mmol, 0.20 equiv) in DMF (5 mL)
was irradiated with microwave for 2 h at 90.degree. C. The
resulting mixture was concentrated under vacuum, diluted with,
extracted with ethyl acetate, and dried over anhydrous sodium
sulfate. The residue was purified by a silica gel column with
dichloromethane/methanol (40:1) to give the title compound (200 mg,
45 as a yellow solid. LC-MS (ES, m/z): 436 [M+H].sup.+.
Step 4: Synthesis of
6-cyano-1-(3-[2-[(7R)-7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethyny-
l]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide and
6-cyano-1-(3-[2-[(7S)-7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethyny-
l]phenyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00820##
[1461] Similar to as described in General Procedure S, methyl
6-cyano-1-[3-(2-[7-hydroxy-5H,6H,7H-cyclopenta[b]pyridin-7-yl]ethynyl)phe-
nyl]-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
ammonia to give a crude product which was purified by Prep-HPLC and
separated by Chiral-Prep-HPLC. This resulted in 23.9 mg (25%) of
the 7R-isomer as a white solid and 28.3 mg (29%) of the 7S-isomer
as a white solid. The stereochemistry of both compounds was
arbitrarily assigned. 7R-isomer: t.sub.R=2.40 min (Chiralcel IC-3,
0.46*5 cm, Hex:EtOH=50:50, 2.0 ml/min); 7S-isomer: t.sub.R=4.92 min
(Chiralcel IC-3, 0.46*5 cm, Hex:EtOH=50:50, 2.0 ml/min). Both
isomers showed identical LC-MS and .sup.1H NMR as shown below.
LC-MS (ES, m/z): 421 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 9.55 (s, 1H), 8.35 (s, 2H), 7.90 (s, 1H), 7.78-7.77 (m,
2H), 7.76 (d, J=3.2 Hz, 2H), 7.27-7.24 (m, 1H), 3.08-2.88 (m, 2H),
2.67-2.60 (m, 1H), 2.45-2.39 (m, 1H).
Example E7
Synthesis of
(R)-6-ethoxy-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)-1H-pyrazol o[4,3-c]pyridine-3-carboxamide
##STR00821##
[1462] Step 1: Synthesis of
1-(3-bromophenyl)-6-ethoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxylic
acid
##STR00822##
[1464] A suspension of methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
(300 mg, 0.82 mmol, 1.00 equiv) and sodium ethoxide (555.8 mg, 8.17
mmol, 10.00 equiv) in ethanol (2 mL)/DMF (3 mL) was irradiated with
microwave for 2.5 h at 110.degree. C. The pH value of the solution
was adjusted to 5 with hydrogen chloride (1 M). The resulting
mixture was concentrated under vacuum. The residue was purified by
a silica gel column with dichloromethane/methanol (20:1) to give
the title compound (220 mg, 74%) as a yellow solid. LC-MS (ES,
m/z): 362, 364 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-6-ethoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00823##
[1466] Similar to as described in General Procedure B,
1-(3-bromophenyl)-6-ethoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(200 mg, crude) as a white solid. LC-MS (ES, m/z): 361, 363
[M+H].sup.+.
Step 3: Synthesis of
6-ethoxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00824##
[1468] Similar to as described in General Procedure G,
1-(3-bromophenyl)-6-ethoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (60.4 mg, 26%) as a yellow solid. LC-MS
(ES, m/z): 420 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.20 (s, 1H), 7.94 (s, 1H), 7.88-7.82 (m, 1H), 7.63-7.58
(m, 2H), 7.02 (s, 1H), 4.45-4.42 (m, 2H), 3.52 (t, J=7.2 Hz, 2H),
2.96 (s, 3H), 2.63-2.57 (m, 1H), 2.35-2.28 (m, 1H), 1.45 (t, J=7.2
Hz, 3H).
Example F7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(pyr-
rolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00825##
[1469] Step 1: Synthesis of
1-(3-bromophenyl)-6-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carbox-
amide
##STR00826##
[1471] Similar to as described in General Procedure A,
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with pyrrolidine (2 mL) to give the title compound (200
mg, 46%) as a brown solid. LC-MS (ES, m/z): 386, 388
[M+H].sup.+.
Step 2: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00827##
[1473] Similar to as described in General Procedure G,
1-(3-bromophenyl)-6-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carbox-
amide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (52.7 mg, 23%) as a light yellow solid. LC-MS (ES, m/z):
445 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 9.08 (s,
1H), 7.89 (s, 1H), 7.83-7.80 (m, 1H), 7.61-7.49 (m, 2H), 6.38 (s,
1H), 3.55-3.45 (m, 6H), 2.94 (s, 3H), 2.65-2.57 (m, 1H), 2.38-2.28
(m, 1H). 2.09-2.05 (m, 4H).
Example G7 and Example H7
Synthesis of
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-((R)-
-3-hydroxypyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
and
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-((S)-
-3-hydroxypyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00828##
[1474] Step 1: Synthesis of
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00829##
[1476] Similar to as described in General Procedure S, methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with ammonia to give the title compound (250 mg, 52%)
as a white solid. LC-MS (ES, m/z): 351, 353 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]-1H-pyrazolo[4,3-c]pyr-
idine-3-carboxamide
##STR00830##
[1478] Similar to as described in General Procedure A,
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with (3R)-pyrrolidin-3-ol hydrochloride to give the
title compound (70 mg, 61%) as a yellow solid. LC-MS (ES, m/z):
402, 404 [M+H]
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-[-
(3R)-3-hydroxypyrrolidin-1-yl]-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00831##
[1480] Similar to as described in General Procedure G,
1-(3-bromophenyl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]-1H-pyrazolo[4,3-c]pyr-
idine-3-carboxamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (43.1 mg, 54%) as a yellow solid. LC-MS (ES, m/z): 461
[M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.99 (s,
1H), 7.79 (s, 1H), 7.72-7.70 (m, 1H), 7.51-7.40 (m, 2H), 6.30 (s,
1H), 4.45 (s, 1H), 3.58-3.49 (m, 3H), 3.40-3.37 (m, 3H), 2.83 (s,
3H), 2.53-2.47 (m, 1H), 2.26-2.19 (m, 1H), 2.11-2.05 (m, 1H),
1.99-1.96 (m, 1H).
[1481] Step 4: The (S)--OH isomer, namely,
1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-((S)-
-3-hydroxypyrrolidin-1-yl)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide,
was prepared from
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
and (3S)-pyrrolidin-3-ol hydrochloride followed the exact same
procedure as described for the (R)--OH isomer. LC-MS (ES, m/z): 461
[M+H].sup.+. .sup.1HNMR (300 MHz, CD.sub.3OD) .delta. 9.01 (s, 1H),
7.80 (s, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.8 Hz, 1H), 7.42
(d, J=8.1 Hz, 1H), 6.31 (s, 1H), 4.46 (s, 1H), 3.60-3.51 (m, 3H),
3.49-3.36 (m, 3H), 2.83 (s, 3H), 2.54-2.46 (m, 1H), 2.27-2.18 (m,
1H), 2.14-1.98 (m, 2H).
Example 17
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
oxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00832##
[1482] Step 1: Synthesis of
6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00833##
[1484] A suspension of 6-chloro-1H-pyrazolo[4,3-c]pyridine (7 g,
45.58 mmol, 1.00 equiv) in DMF (100 mL), potassium hydroxide (7.67
g, 136.71 mmol, 3.00 equiv), and I.sub.2 (20.82 g, 82.03 mmol, 1.80
equiv) was stirred for 5 h at 50.degree. C. The reaction was
quenched by saturated aqueous sodium thiosulfate and diluted with
water. The resulting solution was extracted with ethyl acetate,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was purified by a silica gel column with ethyl
acetate/dichloromethane (1:15) to give the title compound (6 g,
47%) as an orange solid. LC-MS (ES, m/z): 280 [M+H].sup.+.
Step 2: Synthesis of methyl
6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00834##
[1486] Similar to as described in General Procedure O, carbon
monoxide was reacted with
6-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine to give the title
compound (1.3 g, 86%) as a yellow solid. LC-MS (ES, m/z): 212
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00835##
[1488] Similar to as described in General Procedure C, methyl
6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (320 mg,
62%) as a white solid. LC-MS (ES, m/z): 366, 368 [M+H].sup.+.
Step 4: Synthesis of
-(3-bromophenyl)-6-methoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxylic
acid
##STR00836##
[1490] A suspension of methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
(400 mg, 1.09 mmol, 1.00 equiv), sodium methoxide (589 mg, 10.90
mmol, 10.00 equiv) in DMF (5 mL)/methanol (1 mL) was irradiated
with microwave for 3 h at 110.degree. C. The pH value of the
solution was adjusted to 5 with hydrogen chloride (1 M). The
resulting mixture was concentrated under vacuum and then diluted
with water. The solution was extracted with ethyl acetate, dried
over anhydrous sodium sulfate, and concentrated under vacuum. This
resulted in the title compound (300 mg, 39%) as a yellow solid.
LC-MS (ES, m/z): 348, 350 [M+H].sup.+.
Step 5: Synthesis of
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00837##
[1492] Similar to as described in General Procedure B,
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(480 mg, 96%) as a yellow solid. LC-MS (ES, m/z): 347, 349
[M+H].sup.+.
Step 6: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00838##
[1494] Similar to as described in General Procedure G,
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (36 mg, 12%) as a yellow solid. LC-MS
(ES, m/z): 406 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.15 (s, 1H), 7.93-7.89 (m, 2H), 7.65 (t, J=7.8 Hz, 1H),
7.51 (d, J=7.8 Hz, 1H), 7.10 (s, 1H), 3.98 (s, 3H), 3.37 (t, J=7.2
Hz, 2H), 2.81 (s, 3H), 2.47-2.43 (m, 1H), 2.28-2.18 (m, 1H).
Example J7
Synthesis of
(R)-5-((4-amino-N-methylbutanamido)methyl)-1-(4-((3-hydroxy-1-methyl-2-ox-
opyrrolidin-3-yl)ethynyl)pyridin-2-yl)-1H-indazole-3-carboxamide
##STR00839##
[1495] Step 1: Synthesis of
5-(chloromethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
##STR00840##
[1497] Thionyl chloride (6 mL, 82.71 mmol, 21.70 equiv) was added
dropwise into a solution of
5-(hydroxymethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(1.50 g, 3.81 mmol, 1.00 equiv) in dichloromethane (30 mL). The
resulting solution was stirred for 30 min at room temperature and
concentrated under vacuum. This resulted in 1.7 g (crude) of the
title compound as yellow oil. LC-MS (ES, m/z): 413 [M+H].sup.+.
Step 2: Synthesis of
1-(4-iodopyridin-2-yl)-5-[(methylamino)methyl]-1H-indazole-3-carboxamide
##STR00841##
[1499] A solution of
5-(chloromethyl)-1-(4-iodopyridin-2-yl)-1H-indazole-3-carboxamide
(1.7 g, 4.12 mmol, 1.00 equiv), triethylamine (1.96 g, 19.37 mmol,
4.70 equiv), and methyl amine (5 ml, 2.00 equiv) in dichloromethane
(100 mL) was stirred for 12 h at room temperature. The solvents
were removed to give the title compound (2.0 g, crude) as yellow
oil. LC-MS (ES, m/z): 408 [M+H].sup.+.
Step 3: Synthesis of tert-butyl
N-[3-([[3-carbamoyl-1-(4-iodopyridin-2-yl)-1H-indazol-5-yl]methyl](methyl-
)carbamoyl)propyl]carbamate
##STR00842##
[1501] A mixture of
1-(4-iodopyridin-2-yl)-5-[(methylamino)methyl]-1H-indazole-3-carboxamide
(2.00 g, 4.91 mmol, 1.00 equiv),
4-[[(tert-butoxy)carbonyl]amino]butanoic acid (2.00 g, 9.84 mmol,
2.00 equiv), ethyldiisopropylamine (2.54 g, 19.65 mmol, 4.00
equiv), and N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium
hexafluorophospate (2.80 g, 7.36 mmol, 1.50 equiv) in
dichloromethane (100 mL) was stirred for 12 h at room temperature.
The resulting mixture was concentrated under vacuum and the residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (7:3). This resulted in 600 mg (crude) of the title compound
as an off-white solid. LC-MS (ES, m/z): 593 [M+H].sup.+.
Step 4: Synthesis of tert-butyl
N-[3-([[3-carbamoyl-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyridin-2-yl)-1H-indazol-5-yl]methyl](methyl)carbamoyl)propyl]car-
bamate
##STR00843##
[1503] Similar to as described in General Procedure G, tert-butyl
N-[3-([[3-carbamoyl-1-(4-iodopyridin-2-yl)-1H-indazol-5-yl]methyl](methyl-
)carbamoyl)propyl]carbamate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (360 mg, 61%) as a yellow solid. LC-MS (ES, m/z): 604
[M+H].sup.+.
Step 5: Synthesis of
5-[(4-amino-N-methylbutanamido)methyl]-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-
-oxopyrrolidin-3-yl]ethynyl]pyridin-2-yl-1H-indazole-3-carboxamide
##STR00844##
[1505] Into a 100-mL round-bottom flask purged and maintained with
an inert atmosphere of HCl was placed tert-butyl
N-[3-([[3-carbamoyl-1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl-
]ethynyl]pyridinin-2-yl)-1H-indazol-5-yl]methyl](methyl)carbamoyl)propyl]c-
arbamate (360 mg, 0.60 mmol, 1.00 equiv) in ethyl acetate (10 mL).
The resulting solution was stirred for 10 min at room temperature.
The solids were collected by filtration and the crude product was
purified by Prep-HPLC to give the title compound (52.7 mg, 18%) as
an off-white solid. LC-MS (ES, m/z): 504 [M+H].sup.+. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.77-8.70 (m, 1H), 8.60 (d, J=4.5
Hz, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 8.14 (d, J=10.2 Hz, 1H), 7.65
(s, 1H), 7.47 (d, J=8.7 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 6.68 (s,
1H), 4.76-4.67 (m, 2H), 3.41-3.33 (m, 2H), 3.00-2.91 (m, 3H),
2.83-2.80 (m, 4H), 2.63-2.53 (m, 1H), 2.50 (s, 3H), 2.47-2.39 (m,
3H), 2.28-2.19 (m, 1H), 1.70-1.67 (m, 2H).
Example K7
Synthesis of
(R)-1-(4-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pyridin-2-yl)--
5-((N-methylbutyramido)methyl)-1H-indazole-3-carboxamide
##STR00845##
[1506] Step 1: Synthesis of
1-(4-iodopyridin-2-yl)-5-[(N-methylbutanamido)methyl]-1H-indazole-3-carbo-
xamide
##STR00846##
[1508] A suspension of
1-(4-iodopyridin-2-yl)-5-[(methylamino)methyl]-1H-indazole-3-carboxamide
(2.00 g, 4.91 mmol, 1.00 equiv), triethylamine (2.98 g, 29.45 mmol,
6.00 equiv), and butanoyl butanoate (2.33 g, 14.73 mmol, 3.00
equiv) in dichloromethane (100 mL) was stirred for 2 h at room
temperature. The resulting mixture was concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (2:3). This resulted in 200 mg (9%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 478
[M+H].sup.+.
Step 2: Synthesis of
1-(4-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]pyridin-2-y-
l)-5-[(N-methyl butanamido)methyl]-1H-indazole-3-carboxamide
##STR00847##
[1510] Similar to as described in General Procedure G,
1-(4-iodopyridin-2-yl)-5-[(N-methylbutanamido)methyl]-1H-indazole-3-carbo-
xamide was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (24.5 mg, 13%) as a light yellow solid. LC-MS (ES, m/z):
489 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta.
8.83-8.79 (m, 1H), 8.57 (d, J=5.7 Hz, 1H), 7.52 (s, 1H), 7.49 (s,
1H), 7.36 (t, J=1.5 Hz, 1H), 7.35 (d, J=1.5 Hz, 1H), 4.87-4.78 (m,
2H), 3.55-3.49 (m, 2H), 3.10-3.06 (m, 2H), 2.99-2.96 (m, 4H),
2.66-2.62 (m, 1H), 2.53-2.41 (m, 2H), 2.38-2.34 (m, 1H), 1.77-1.68
(m, 2H), 1.06-0.95 (m, 3H).
Example L7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-oxo--
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-carboxamide
##STR00848##
[1511] Step 1: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-o-
xo-1H,4H,5H, 6H-pyrrolo[3,4-c]pyrazole-3-carboxylate
##STR00849##
[1513] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-6-oxo-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (130 mg, crude) as a brown solid. LC-MS
(ES, m/z): 409 [M+H].sup.+.
Step 2: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-o-
xo-1H,4H,5H, 6H-pyrrolo[3,4-c]pyrazole-3-carboxamide
##STR00850##
[1515] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4-o-
xo-1H,4H,5H, 6H-pyrrolo[3,4-c]pyrazole-3-carboxylate was reacted
with ammonia to give the title compound (9.7 mg, 8%) as a white
solid. LC-MS (ES, m/z): 380 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.47 (s, 1H), 8.43-8.40 (m, 1H), 7.54-7.45 (m,
2H), 4.48 (s, 2H), 3.55-3.45 (m, 2H), 2.94 (s, 3H), 2.65-2.57 (m,
1H), 2.37-2.28 (m, 1H).
Example M7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1H-pyr-
azolo[3,4-d]thiazole-3-carboxamide
##STR00851##
[1516] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate
##STR00852##
[1518] A mixture of ethyl
5-amino-1-(3-bromophenyl)-4-sulfanyl-1H-pyrazole-3-carboxylate (100
mg, 0.29 mmol, 1.00 equiv), (diethoxymethoxy)ethane (215 mg, 1.45
mmol, 5.00 equiv), and boron trifluoride etherate (206 mg, 1.45
mmol, 5.00 equiv) in dichchloromethane (10 mL) was stirred for 2 h
at room temperature. The reaction was quenched by saturation sodium
bicarbonate, extracted with ethyl acetate, and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:4). This resulted in 70 mg (68%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 352
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ][1,3]thiazole-3-carboxylate
##STR00853##
[1520] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-1H-pyrazolo[3,4-d][1,3]thiazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (18 mg, 22%) as a yellow solid. LC-MS (ES,
m/z): 411 [M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ][1,3]thiazole-3-carboxamide
##STR00854##
[1522] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-d ][1,3]thiazole-3-carboxylate was reacted with
NH.sub.3 to give the title compound (14 mg, 84%) as a white solid.
LC-MS (ES, m/z): 382 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 9.28 (s, 1H), 8.49-8.48 (t, 1H), 8.42-8.38 (m, 1H),
7.61-7.47 (m, 2H), 3.57-3.43 (m, 2H), 3.97 (s, 3H), 2.68-2.60 (m,
1H), 2.40-2.31 (m, 1H).
Example N7
Synthesis of
(R)-1-(2-fluoro-5-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00855##
[1523] Step 1: Synthesis of ethyl
1-(5-bromo-2-fluorophenyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylat-
e
##STR00856##
[1525] Similar to as described in General Procedure Y Step 2, ethyl
2-oxo-2-(2-oxocyclopentyl)acetate was reacted with
(5-bromo-2-fluorophenyl)hydrazine to give the title compound (130
mg, 68%) as a yellow solid. LC-MS (ES, m/z): 353, 355
[M+H].sup.+.
Step 2: Synthesis of ethyl
3-(2-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,3aH,4H,5H,6H,6aH-cyclopenta[c]pyrazole-1-carboxylate
##STR00857##
[1527] Similar to as described in General Procedure G, ethyl
3-(5-bromo-2-fluorophenyl)-1H,3aH,4H,5H,6H,6aH-cyclopenta[c]pyrazole-1-ca-
rboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (120 mg, 86%) as yellow oil. LC-MS (ES, m/z): 412
[M+H].sup.+.
Step 3: Synthesis of
1-(2-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxamide
##STR00858##
[1529] Similar to as described in General Procedure S, ethyl
1-(2-fluoro-5-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate was reacted
with ammonia to give the title compound (20.8 mg, 20%) as a white
solid. LC-MS (ES, m/z): 383 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 7.85 (d, J=9.6 Hz, 1H), 7.58-7.55 (m, 1H),
7.38-7.35 (m, 1H), 3.50-3.47 (m, 2H), 2.94 (s, 2H), 2.88-2.84 (m,
4H), 2.66-2.64 (m, 3H), 2.35-2.28 (m, 1H).
Example O7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4,6-di-
hydro-1H-furo[3,4-c]pyrazole-3-carboxamide
##STR00859##
[1530] Step 1: Synthesis of 2-oxo-2-(4-oxooxolan-3-yl)acetate
##STR00860##
[1532] Similar to as described in General Procedure Y Step 1,
diethyl oxalate was reacted with oxolan-3-one to give 400 mg (5%)
of ethyl 2-oxo-2-(4-oxooxolan-3-yl)acetate as yellow oil.
Step 2: Synthesis of ethyl 1-(3-bromophenyl)-1H,3 aH,4H,6H,6
aH-furo[3,4-c]pyrazole-3-carboxylate
##STR00861##
[1534] Similar to as described in General Procedure Y Step 2, ethyl
2-oxo-2-(4-oxooxolan-3-yl)acetate was reacted with
(3-bromophenyl)hydrazine hydrochloride to give the title compound
(80 mg, 11%) as a yellow solid. LC-MS (ES, m/z): 337
[M+H].sup.+.
Step 3: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,6H-furo[3,4-c]pyrazole-3-carboxylate
##STR00862##
[1536] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-1H,4H,6H-furo[3,4-c]pyrazole-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (70 mg, 85%) as a yellow solid. LC-MS (ES,
m/z): 396 [M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,6H-furo[3,4-c]pyrazole-3-carboxamide
##STR00863##
[1538] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,6H-furo[3,4-c]pyrazole-3-carboxylate was reacted with ammonia to
give the title compound (17.5 mg, 27%) as an off-white solid. LC-MS
(ES, m/z): 367 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 7.82 (t, J=1.5 Hz, 1H), 7.64-7.60 (m, 1H), 7.55-7.44 (m,
2H), 5.22 (t, J=2.7 Hz, 2H), 5.05 (t, J=2.7 Hz, 2H), 3.53-3.48 (m,
2H), 2.96 (s, 3H), 2.65-2.57 (m, 1H), 2.39-2.29 (m, 1H).
Example P7
Synthesis of
(R)-3-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1H-ind-
azole-1-carboxamide
##STR00864##
[1539] Step 1: Synthesis of 3-iodo-1H-indazole
##STR00865##
[1541] A mixture of 1H-indazole (1.00 g, 8.46 mmol, 1.00 equiv),
iodine (4.30 g, 16.94 mmol, 2.00 equiv), and potassium hydroxide
(1.19 g, 21.21 mmol, 2.50 equiv) in DMF (49.98 mL) was stirred for
2 hours at room temperature. The resulting solution was diluted
with ethyl acetate, washed with water and sodium thiosulfate
pentahydrate, dried over anhydrous sodium sulfate, and concentrated
under vacuum. This resulted in the title compound (2 g, 97%) as an
off-white solid. LC-MS (ES, m/z): 245 [M+H].sup.+.
Step 2: Synthesis of
N-tert-butyl-3-iodo-1H-indazole-1-carboxamide
##STR00866##
[1543] A solution of 3-iodo-1H-indazole (1.00 g, 4.10 mmol, 1.00
equiv) and 2-isocyanato-2-methylpropane (610 mg, 6.15 mmol, 1.50
equiv) in DMF (30.00 mL) was stirred for 3 days at room
temperature. The reaction was quenched by water, extracted with
dichloromethane, washed with brine, dried over anhydrous sodium
sulfate, and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:15).
This resulted in 890 mg (63%) of the title compound as a white
solid. LC-MS (ES, m/z): 344 [M+H].sup.+.
Step 3: Synthesis of 3-iodo-1H-indazole-1-carboxamide
##STR00867##
[1545] A solution of N-tert-butyl-3-iodo-1H-indazole-1-carboxamide
(400 mg, 1.17 mmol, 1.00 equiv) and trifluoroacetic acid (10 mL) in
dichloromethane (10 mL) was stirred for overnight at room
temperature. The resulting mixture was concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:10). This resulted in the title compound
(150 mg, 45%) as a white solid. LC-MS (ES, m/z): 288
[M+H].sup.+.
Step 4: Synthesis of
3-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
indazole-1-carboxamide
##STR00868##
[1547] Similar to as described in General Procedure U,
3-iodo-1H-indazole-1-carboxamide was reacted with potassium
(R)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-
borate to give the title compound (6 mg, 3%) as a white solid.
LC-MS (ES, m/z): 375 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.43 (d, J=8.8 Hz, 1H), 8.19 (s, 1H), 8.11 (d, J=8.4 Hz,
2H), 7.64-7.57 (m, 3H), 7.47-7.43 (m, 1H), 3.56-3.47 (m, 2H), 2.96
(s, 3H), 2.67-2.61 (m, 1H), 2.39-2.32 (m, 1H).
Example Q7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-1H-pyr-
azolo[3,4-c]pyridine-3-carboxamide
##STR00869##
[1548] Step 1: Synthesis of 3-iodo-1H-pyrazolo[3,4-c]pyridine
##STR00870##
[1550] A suspension of 1H-pyrazolo[3,4-c]pyridine (300 mg, 2.52
mmol, 1.00 equiv), KOH (500 mg, 8.91 mmol, 3.50 equiv), and
diiodane (1.28 g, 5.04 mmol, 2.00 equiv) in DMF (10 mL) was stirred
overnight at room temperature. The reaction was quenched by water,
extracted with ethyl acetate, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was purified by a silica
gel column with ethyl acetate/petroleum ether (1:1) to give the
title compound (577 mg, 84%) as a yellow solid. LC-MS (ES, m/z):
246 [M+H].sup.+.
Step 2: Synthesis of 1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00871##
[1552] Similar to as described in General Procedure O,
3-iodo-1H-pyrazolo[3,4-c]pyridine was reacted with CO to give the
title compound (300 mg, 65%) as a yellow solid. LC-MS (ES, m/z):
178 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-iodophenyl)-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00872##
[1554] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-c]pyridine-3-carboxylate was reacted with
(3-iodophenyl)boronic acid to give the title compound (161 mg, 34%)
as a yellow solid. LC-MS (ES, m/z): 380 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridine-3-carboxylate
##STR00873##
[1556] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-1H-pyrazolo[3,4-c]pyridine-3-carboxylate was
reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (100 mg, 57%) as a yellow solid. LC-MS (ES,
m/z): 391 [M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridine-3-carboxamide
##STR00874##
[1558] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridine-3-carboxylate was reacted with ammonia to
give the title compound (25.1 mg, 26%) as a white solid. LC-MS (ES,
m/z): 376 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
9.38 (s, 1H), 8.49 (d, J=5.4 Hz, 1H), 8.21-8.18 (m, 2H), 8.07-8.03
(m, 1H), 7.99 (s, 1H), 7.67 (t, J=7.8 Hz, 2H), 7.55 (d, J=7.8 Hz,
1H), 6.54 (s, 1H), 3.37 (t, J=6.9 Hz, 2H), 2.81 (s, 3H), 2.51-2.43
(m, 1H), 2.25-2.18 (m, 1H).
Example R7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-meth-
yl-1H-pyrazol [3,4-c]pyridine-3-carboxamide
##STR00875##
[1559] Step 1: Synthesis of
3-iodo-5-methyl-1H-pyrazolo[3,4-c]pyridine
##STR00876##
[1561] A mixture of 5-methyl-1H-pyrazolo[3,4-c]pyridine (500.00 mg,
3.76 mmol, 1.00 equiv), iodine (953.09 mg, 3.76 mmol, 1.00 equiv),
and potassium hydroxide (526.71 mg, 9.39 mmol, 2.50 equiv) in DMF
(10.00 mL) was stirred for 4 hours at room temperature. The
resulting solution was diluted with ethyl acetate, washed with
sodium thiosulfate pentahydrate and brine, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:1). This resulted in the title compound (540 mg, 56%) as a
yellow solid. LC-MS (ES, m/z): 260 [M+H].sup.+.
Step 2: Synthesis of methyl
5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00877##
[1563] Similar to as described in General Procedure O,
3-iodo-5-methyl-1H-pyrazolo[3,4-c]pyridine was reacted with CO to
give the title compound (170 mg, 77%) as a brown solid. LC-MS (ES,
m/z): 192 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-iodophenyl)-5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00878##
[1565] Similar to as described in General Procedure C, methyl
5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate was reacted with
(3-iodophenyl)boronic acid to give the title compound (140 mg, 45%)
as a yellow solid. LC-MS (ES, m/z): 394 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00879##
[1567] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-5-methyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (140 mg, crude) as yellow oil. LC-MS
(ES, m/z): 405 [M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
##STR00880##
[1569] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethyl-1H-pyrazolo[3,4-c]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (37.9 mg, 28%) as an off-white
solid. LC-MS (ES, m/z): 390 [M+H].sup.+. .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 9.18 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H), 8.03
(d, J=30.9 MHz, 1H), 7.69-7.59 (m, 2H), 3.53-3.50 (m, 2H),
2.95-2.93 (s, 3H), 2.72 (s, 3H), 2.63-2.58 (m, 1H), 2.36-2.30 (m,
1H).
Example S7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-meth-
oxy-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
##STR00881##
[1570] Step 1: Synthesis of
3-iodo-5-methoxy-1H-pyrazolo[3,4-c]pyridine
##STR00882##
[1572] A mixture of 5-methoxy-1H-pyrazolo[3,4-c]pyridine (500.00
mg, 3.35 mmol, 1.00 equiv), potassium hydroxide (677.10 mg, 12.07
mmol, 3.60 equiv), and I.sub.2 (1701.70 mg, 6.70 mmol, 2.00 equiv)
in DMF (5 mL) was stirred for 1.5 h at room temperature. The
resulting solution was diluted with ethyl acetate, washed with sat.
aq. NaHSO.sub.3, dried over anhydrous sodium sulfate, and
concentrated under vacuum. This resulted in 780 mg (85%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 276
[M+H].sup.+.
Step 2: Synthesis of methyl
5-methoxy-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00883##
[1574] Similar to as described in General Procedure O,
3-iodo-5-methoxy-1H-pyrazolo[3,4-c]pyridine was reacted with CO to
give the title compound (260 mg, 48%) as a yellow solid. LC-MS (ES,
m/z): 208 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-iodophenyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
##STR00884##
[1576] Similar to as described in General Procedure C, methyl
5-methoxy-1H-pyrazolo[3,4-c]pyridine-3-carboxylate was reacted with
(3-iodophenyl)boronic acid to give the title compound (30 mg, 8%)
as a yellow solid. LC-MS (ES, m/z): 410 [M+H].sup.+.
Step 4: Synthesis of
3-(3-iodophenyl)-6-methoxy-3H-pyrrolo[3,4-c]pyridine-1-carboxamide
##STR00885##
[1578] Similar to as described in General Procedure S, methyl
3-(3-iodophenyl)-6-methoxy-3H-pyrrolo[3,4-c]pyridine-1-carboxylate
was reacted with ammonia to give the title compound (40 mg, crude)
as a yellow solid. LC-MS (ES, m/z): 395 [M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
##STR00886##
[1580] Similar to as described in General Procedure G,
1-(3-iodophenyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (20.3 mg, 66%) as a yellow solid. LC-MS
(ES, m/z): 406 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.98 (s, 1H), 8.03 (s, 1H), 7.96-7.93 (m, 1H), 7.68-7.58
(m, 3H), 4.04 (s, 3H), 3.54-3.49 (m, 2H), 2.96 (s, 3H), 2.66-2.59
(m, 1H), 2.40-2.33 (m, 1H).
Example T7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4,5,6,-
7-tetrahydro-1H-pyrazolo[-4,3-b]pyridine-3-carboxamide
##STR00887##
[1581] Step 1: Synthesis of 3-iodo-1H-pyrazolo[4,3-b]pyridine
##STR00888##
[1583] A mixture of 1H-pyrazolo[4,3-b]pyridine (10 g, 83.95 mmol,
1.00 equiv), potassium hydroxide (16.9 g, 301.22 mmol, 3.60 equiv),
and iodine (42.7 g, 168.24 mmol, 2.00 equiv) in DMF (150 mL) was
stirred for 16 hours at 25.degree. C. The resulting solution was
diluted with water, extracted with ethyl acetate, washed with
sodium bisulfate, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5-1:3). This
resulted in the title compound (11.7 g, 57%) as a yellow solid.
LC-MS (ES, m/z): 246 [M+H].sup.+.
Step 2: Synthesis of 1H-pyrazolo[4,3-b]pyridine-3-carboxylate
##STR00889##
[1585] Similar to as described in General Procedure O,
3-iodo-1H-pyrazolo[4,3-b]pyridine (10 g, 40.81 mmol, 1.00 equiv)
was reacted with CO to give the title compound (3 g, 41%) as a
brown solid. LC-MS (ES, m/z): 178 [M+H].sup.+.
Step 3: Synthesis of methyl
1H,4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate
##STR00890##
[1587] Into a 100-mL round-bottom flask was placed methyl
1H-pyrazolo[4,3-b]pyridine-3-carboxylate (2 g, 11.29 mmol, 1.00
equiv), platinumoxide hydrate (770 mg, 3.39 mmol, 0.30 equiv),
acetic acid (30 mL). To the above mixture was stirred at room
temperature under hydrogen for 4 hours. The solids were filtered
out and the resulting mixture was concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1/1). This resulted in 400 mg of the title
compound as a yellow solid. LC-MS (ES, m/z): 182 [M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-iodophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate
##STR00891##
[1589] Similar to as described in General Procedure C, methyl
1H,4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate was reacted
with (3-iodophenyl)boronic acid to give the title compound (210 mg,
28%) as a light yellow solid. LC-MS (ES, m/z): 384 [M+H].sup.+.
Step 5: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate
##STR00892##
[1591] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (160 mg) as a light yellow solid. LC-MS
(ES, m/z): 395 [M+H].sup.+.
Step 6: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4,5,6,-
7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxamide
##STR00893##
[1593] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H,-
4H,5H,6H,7H-pyrazolo[4,3-b]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (29.9 mg). LC-MS (ES, m/z): 380
[M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 7.73 (t,
J=1.2 Hz, 1H), 7.64-7.61 (m, 1H), 7.50-7.47 (m, 2H), 3.50-3.45 (m,
2H), 3.23 (t, J=5.4 Hz, 2H), 2.93 (s, 1H), 2.88 (t, J=6.3 Hz, 2H),
2.57-2.55 (m, 1H), 2.33-2.29 (m, 1H), 1.96 (t, J=5.4 Hz, 2H).
Example U7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-5-methylpheny-
l)-1H-pyrazol [3,4-b]pyridine-3-carboxamide
##STR00894##
[1594] Step 1: Synthesis of methyl
1-(3-bromo-5-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00895##
[1596] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromo-5-methylphenyl)boronic acid to give the title compound
(335 mg, 57%) as a white solid. LC-MS (ES, m/z): 346, 348
[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-methylph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00896##
[1598] Similar to as described in General Procedure G, methyl
1-(3-bromo-5-methylphenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (220 mg, 58%) as a yellow solid. LC-MS
(ES, m/z): 405 [M+H].sup.+.
Step 3: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-methylph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00897##
[1600] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]-5-methylph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (30 mg, 14%) as a white solid.
LC-MS (ES, m/z): 390 [M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.73 (d, J=6.4 MHz, 2H), 8.35 (s, 1H), 8.28 (s, 1H),
7.49-7.46 (m, 1H), 7.35 (s, 1H), 3.52-3.49 (m, 2H), 2.96 (s, 3H),
2.67-2.59 (m, 1H), 2.49 (s, 3H), 2.36-2.30 (m, 1H).
Example V7
Synthesis of
(R)-6-chloro-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)pheny-
l)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00898##
[1601] Step 1: Synthesis of
6-chloro-1-(3-iodophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylic
acid
##STR00899##
[1603] A suspension of methyl
6-chloro-1-(3-iodophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
(80 mg, 0.19 mmol, 1.00 equiv), lithium hydroxide (9 mg, 0.38 mmol,
1.90 equiv) in THF (5 mL), and water (5 mL) was stirred for 1 hour
at room temperature. The pH value of the solution was adjusted to 5
with hydrogen chloride (1 M). The resulting solution was extracted
with ethyl acetate and dried over anhydrous sodium sulfate. The
residue was purified by a silica gel column with
dichloromethane/methanol (20:1) to give the title compound (40 mg,
52%) as a white solid. LC-MS (ES, m/z): 400 [M+H].sup.+.
Step 2: Synthesis of
6-chloro-1-(3-iodophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00900##
[1605] Similar to as described in General Procedure B,
6-chloro-1-(3-iodophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(38 mg, 95%) as a white solid. LC-MS (ES, m/z): 399
[M+H].sup.+.
Step 3: Synthesis of
6-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00901##
[1607] Similar to as described in General Procedure E,
6-chloro-1-(3-iodophenyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (6.6 mg, 16%) as a white solid. LC-MS
(ES, m/z): 819 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.69 (d, J=8.4 Hz, 1H), 8.42 (t, J=8.4 Hz, 2H), 7.63-7.50
(m, 3H), 3.56-3.50 (m, 2H), 2.97 (s, 3H), 2.69-2.61 (m, 1H),
2.41-2.06 (m, 1H).
Example W7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
oxy-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00902##
[1608] Step 1: Synthesis of methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00903##
[1610] Similar to as described in General Procedure C, methyl
6-chloro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was reacted with
(3-bromophenyl)boronic acid to give the title compound (110 mg,
63%) as a white solid. LC-MS (ES, m/z): 366, 368 [M+H].sup.+.
Step 2: Synthesis of
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxylic
acid
##STR00904##
[1612] A suspension of methyl
1-(3-bromophenyl)-6-chloro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
(100 mg, 0.27 mmol, 1.00 equiv) and sodium methylate (149 mg, 2.76
mmol, 10.10 equiv) in DMF (3 mL)/methanol (1 mL) was irradiated
with microwave for 1 hour at 110.degree. C. The pH value of the
solution was adjusted to 5 with hydrogen chloride (1 M). The
resulting solution was extracted with ethyl acetate, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified by a silica gel column with
dichloromethane/methanol (40:1) to give the title compound (50 mg,
53%) as a white solid. LC-MS (ES, m/z): 348, 350 [M+H].sup.+.
Step 3: Synthesis of
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00905##
[1614] Similar to as described in General Procedure B,
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxylic
acid was reacted with ammonium chloride to give the title compound
(60 mg, 86%) as a yellow solid. LC-MS (ES, m/z): 347, 349
[M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00906##
[1616] Similar to as described in General Procedure G,
1-(3-bromophenyl)-6-methoxy-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (21.9 mg, 38%) as a white solid. LC-MS
(ES, m/z): 406 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 8.56 (s, 1H), 8.48 (d, J=3.0 Hz, 2H), 7.58 (t, J=8.1 Hz,
1H), 7.47 (d, J=6.3 Hz, 1H), 6.89 (d, J=8.7 Hz, 1H), 4.11 (s, 3H),
3.51 (t, J=7.8 Hz, 2H), 3.09 (s, 3H), 2.67-2.59 (m, 1H), 2.40-2.31
(m, 1H).
Example X7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-morp-
holino-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00907##
[1617] Step 1: Synthesis of
4-[3-iodo-1H-pyrazolo[3,4-b]pyridin-6-yl]morpholine
##STR00908##
[1619] Similar to as described in General Procedure A,
6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyridine was reacted with
morpholine to give the title compound (500 mg) as a yellow solid.
LC-MS (ES, m/z): 331 [M+H].sup.+.
Step 2: Synthesis of methyl
6-(morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00909##
[1621] Similar to as described in General Procedure O, carbon
monoxide was reacted with
4-[3-iodo-1H-pyrazolo[3,4-b]pyridin-6-yl]morpholine to give the
title compound (300 mg, 94%) as a yellow solid. LC-MS (ES, m/z):
263 [M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-iodophenyl)-6-(morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxyl-
ate
##STR00910##
[1623] Similar to as described in General Procedure C, methyl
6-(morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was
reacted with (3-iodophenyl)boronic acid to give the title compound
(200 mg, 40%) as a yellow solid. LC-MS (ES, m/z): 465
[M+H].sup.+.
Step 4: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00911##
[1625] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-6-(morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxyl-
ate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (150 mg, 81%) as a yellow solid. LC-MS (ES, m/z): 476
[M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00912##
[1627] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
morpholin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate was
reacted with ammonia to give the title compound (59.7 mg, 41%) as
an off-white solid. LC-MS (ES, m/z): 461 [M+H].sup.+. .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.58 (s, 1H), 8.44 (d, J=2.1 Hz, 1H),
8.35 (s, 1H), 7.55 (t, 1H), 7.43-7.40 (m, 1H), 6.99-6.96 (d, 2H),
3.89-3.86 (m, 4H), 3.75-3.72 (m, 4H), 3.53-3.49 (m, 2H), 2.97 (s,
3H), 2.65-2.57 (m, 1H), 2.40-2.31 (m, 1H).
Example Y7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(1-m-
ethyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00913##
[1628] Step 1: Synthesis of methyl
6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00914##
[1630] Similar to as described in General Procedure M, methyl
6-chloro-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (300 mg, 1.42
mmol, 1.00 equiv) was reacted with
(1-methyl-1H-pyrazol-4-yl)boronic acid to give the title compound
(220 mg, 60%) as a yellow solid. LC-MS (ES, m/z):
258[M+H].sup.+.
Step 2: Synthesis of methyl
1-(3-iodophenyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine--
3-carboxylate
##STR00915##
[1632] Similar to as described in General Procedure C, methyl
6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with (3-iodophenyl)boronic acid to give the title
compound (60 mg, 25%) as a yellow solid. LC-MS (ES, m/z): 460
[M+H].sup.+.
Step 3: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
##STR00916##
[1634] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine--
3-carboxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (90 mg) as a red solid. LC-MS (ES, m/z): 471
[M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
##STR00917##
[1636] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
was reacted with ammonia to give the title compound (28.7 mg, 30%)
as a white solid. LC-MS (ES, m/z): 456 [M+H].sup.+. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.58-8.55 (m, 2H), 8.5-8.52 (m,
1H), 8.49 (s, 1H), 8.22-8.19 (m, 2H), 7.82-7.80 (m, 1H), 7.77-7.75
(m, 2H), 7.45-7.43 (m, 1H), 6.56 (s, 1H), 3.97 (s, 1H), 3.38-3.29
(m, 2H), 2.83 (s, 3H), 2.51-2.50 (m, 1H), 2.33-2.30 (m, 1H).
Example Z7
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
yl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00918##
[1637] Step 1: Synthesis of ethyl
5-amino-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate
##STR00919##
[1639] A solution of (3-bromophenyl)hydrazine hydrochloride (5.00
g, 22.37 mmol, 1.00 equiv) and ethyl
3-cyano-2-(potassiooxy)prop-2-enoate (4.01 g, 22.38 mmol, 1.00
equiv) in ethanol (50 mL) was stirred for overnight at 90.degree.
C. The reaction residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:2) to give the title compound (3.5
g, 50%) as a yellow solid. LC-MS (ES, m/z): 310, 312
[M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-5-[(E)-[(dimethylamino)methylidene]amino]-4-formyl-1H-p-
yrazole-3-carboxylate
##STR00920##
[1641] Under nitrogen atmosphere phosphorus oxychloride (1.68 g,
10.96 mmol, 2.00 equiv) was added dropwise to a stirred solution of
ethyl 5-amino-1-(3-bromophenyl)-1H-pyrazole-3-carboxylate (1.70 g,
5.48 mmol, 1.00 equiv) in DMF (10 mL) at 0.degree. C. The resulting
solution was stirred overnight at room temperature and quenched by
water. The resulting solution was extracted with ethyl acetate,
washed with brine, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5). This resulted
in the title compound (1.9 g, 88%) as a yellow solid. LC-MS (ES,
m/z): 393, 395 [M+H].sup.+.
Step 3: Synthesis of ethyl
5-amino-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylate
##STR00921##
[1643] A solution of ethyl
1-(3-bromophenyl)-5-[(E)-[(dimethylamino)methylidene]amino]-4-formyl-1H-p-
yrazole-3-carboxylate (900 mg, 2.29 mmol, 1.00 equiv) in THF (5 mL)
was treated with concentrated hydrogen chloride (2 mL) followed by
water (5 mL). The resulting solution was stirred overnight at
40.degree. C. in an oil bath. The solids were filtered out and
dried in a vacuum oven. This resulted in 410 mg (53%) of the title
compound as a yellow solid. LC-MS (ES, m/z): 340 [M+H].sup.+.
Step 4: Synthesis of ethyl
5-(N-acetylacetamido)-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylat-
e
##STR00922##
[1645] A solution of ethyl
5-amino-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylate (200
mg, 0.59 mmol, 1.00 equiv) in pyridine (1 mL) was placed into a
10-mL sealed tube, then acetic anhydride (1 mL, 10.58 mmol, 17.90
equiv) was added and the resulting solution was stirred for 48
hours at 40.degree. C. The reaction was quenched by water,
extracted with ethyl acetate, washed with brine, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:1). This resulted in 120 mg (48%) of the
title compound as a yellow solid. LC-MS (ES, m/z): 422, 424
[M+H].sup.+.
Step 5: Synthesis of ethyl
1-(3-bromophenyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00923##
[1647] Ammonium formate (100 mg, 1.59 mmol, 5.60 equiv) was added
to a stirred solution of ethyl
5-(N-acetylacetamido)-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylat-
e (120 mg, 0.28 mmol, 1.00 equiv) in tert-butanol (5 mL) and the
resulting solution was stirred for 1 hour at 110.degree. C. The
reaction was diluted with ethyl acetate and the solids were
filtered out. The liquid was concentrated under vacuum. The residue
was applied onto a silica gel column with ethyl acetate/petroleum
ether (1:7). This resulted in 100 mg (97%) of the title compound as
a white solid. LC-MS (ES, m/z): 361, 363 [M+H].sup.+.
Step 6: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00924##
[1649] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (80 mg, 77%) as yellow oil. LC-MS (ES,
m/z): 420 [M+H].sup.+.
Step 7: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00925##
[1651] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was reacted with
ammonia to give the title compound (13.5 mg, 18%) as an off-white
solid. LC-MS (ES, m/z): 391 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 9.58 (s, 1H), 8.47-8.42 (m, 2H), 7.62-7.52 (m,
2H), 3.54-3.48 (m, 2H), 2.96 (s, 3H), 2.89 (s, 3H), 2.67-2.61 (m,
1H), 2.39-2.32 (m, 1H).
Example A8
Synthesis of
(R)-6-cyclopropyl-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00926##
[1652] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-5-(N-cyclopropanecarbonylcyclopropaneamido)-4-formyl-1H-
-pyrazole-3-carboxylate
##STR00927##
[1654] Cyclopropanecarbonyl chloride (247.31 mg, 2.37 mmol, 4.00
equiv) was added dropwise into a solution of triethylamine (1.00
mL, 7.19 mmol, 12.20 equiv) and ethyl
5-amino-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylate
(200.00 mg, 0.59 mmol, 1.00 equiv) in dichloromethane (4 mL) at
0.degree. C. After 1 h the resulting solution was diluted with
dichloromethane, washed with brine, dried over anhydrous sodium
sulfate, and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:5).
This resulted in 200 mg (71%) of the title compound as colorless
oil. LC-MS (ES, m/z): 474, 476 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-6-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylat-
e
##STR00928##
[1656] Ammonium formate (158.86 mg, 2.52 mmol, 6.00 equiv) was
added to a stirred solution of ethyl
1-(3-bromophenyl)-5-(N-cyclopropanecarbonylcyclopropaneamido)-4-formyl-4,-
5-dihydro-1H-pyrazole-3-carboxylate (200.00 mg, 0.42 mmol, 1.00
equiv) in tert-butanol (10.00 mL). The resulting solution was
stirred for 1 hour at 110.degree. C., diluted with ethyl acetate
and the solids were filtered out. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:5). This
resulted in 80 mg (49%) of the title compound as colorless oil.
LC-MS (ES, m/z): 387, 389 [M+H].sup.+.
Step 3: Synthesis of ethyl
6-cyclopropyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyn-
yl]phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00929##
[1658] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-6-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylat-
e was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (80 mg, 87%) as a yellow (solid. LC-MS (ES, m/z): 446
[M+H].sup.+.
Step 4: Synthesis of
6-cyclopropyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyn-
yl]phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00930##
[1660] Similar to as described in General Procedure S, ethyl
6-cyclopropyl-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethyn-
yl]phenyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was reacted
with ammonia to give the title compound (12.0 mg) as an off-white
solid. LC-MS (ES, m/z): 417 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 9.51 (s, 1H), 8.49 (s, 1H), 8.44 (d, J=10.8 Hz,
1H), 7.62-7.58 (m, 1H), 7.53 (d, J=8.0 Hz, 1H), 3.54-3.50 (m, 2H),
2.97 (s, 3H), 2.67-2.61 (m, 1H), 2.47-2.44 (m, 1H), 2.39-2.34 (m,
1H), 1.32-1.28 (m, 2H), 1.26-1.22 (m, 2H).
Example B8
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-(tri-
fluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00931##
[1661] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-4-formyl-5-(trifluoroacetamido)-1H-pyrazole-3-carboxyla-
te
##STR00932##
[1663] Trifluoroacetic anhydride (248.44 mg, 1.18 mmol, 2.00 equiv)
was added to a stirred solution of ethyl
5-amino-1-(3-bromophenyl)-4-formyl-1H-pyrazole-3-carboxylate
(200.00 mg, 0.59 mmol, 1.00 equiv) in dichloromethane (5.00 mL) and
triethylamine (1.00 mL, 7.19 mmol, 12.20 equiv) and the resulting
solution was stirred for 3 h at room temperature. The reaction was
diluted with dichloromethane, washed with brine, dried over sodium
sulfate, and concentrated under vacuum. The residue was applied
onto a silica gel column with ethyl acetate/petroleum ether (1:2)
to give the title compound (140 mg, 55%) as a yellow solid. LC-MS
(ES, m/z): 434, 436 [M+H].sup.+.
Step 2: Synthesis of ethyl
1-(3-bromophenyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carb-
oxylate
##STR00933##
[1665] Ammonium formate (104.57 mg, 1.66 mmol, 6.00 equiv) was
added to a stirred solution of ethyl
1-(3-bromophenyl)-4-formyl-5-(trifluoroacetamido)-1H-pyrazole-3-carboxyla-
te (120.00 mg, 0.28 mmol, 1.00 equiv) in tert-butanol (10.00 mL)
and the resulting solution was stirred for 1.5 hour at 110.degree.
C. The reaction was diluted with ethyl acetate, washed with water,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:7) to give the title compound (90 mg,
78%) as a white solid. LC-MS (ES, m/z): 415, 417 [M+H].sup.+.
Step 3: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00934##
[1667] Similar to as described in General Procedure S, ethyl
1-(3-bromophenyl)-6-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carb-
oxylate was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (80 mg, 88%) as yellow oil. LC-MS (ES, m/z): 474
[M+H].sup.+.
Step 4: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00935##
[1669] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-(-
trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was
reacted with ammonia to give the title compound (45.6 mg, 61%) as a
light yellow solid. LC-MS (ES, m/z): 445 [M+H].sup.+. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta.: 9.51 (s, 1H), 8.49 (s, 1H), 8.44 (d,
J=10.8 Hz, 1H), 7.62-7.58 (m, 1H), 7.53 (d, J=8.0 Hz, 1H),
3.54-3.50 (m, 2H), 2.97 (s, 3H), 2.67-2.61 (m, 1H), 2.47-2.44 (m,
1H), 2.39-2.34 (m, 1H), 1.32-1.28 (m, 2H), 1.26-1.22 (m, 2H).
Example C8
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6-meth-
oxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00936##
[1670] Step 1: Synthesis of
6-(methylsulfanyl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one
##STR00937##
[1672] A suspension of ethyl
4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate (5 g, 21.49
mmol, 1.00 equiv) and hydrazine hydrate (80%) (2.8 g, 55.93 mmol,
2.60 equiv) in ethanol (100 mL) was stirred for 1 hour at room
temperature. 100 mL of water was added and the solids were filtered
out. The liquid was evaporated under vacuum. A solution of sodium
hydroxide (5 g, 125.01 mmol, 5.80 equiv) in water (50 mL) was
added. The resulting solution was allowed to react for an
additional 20 min while the temperature was maintained at
100.degree. C. The pH value of the solution was adjusted to 6 with
acetic acid (25%). The solids were collected by filtration. This
resulted in 2 g (crude) of the title compound as a yellow solid.
LC-MS (ES, m/z): 183 [M+H].sup.+.
Step 2: Synthesis of
3-bromo-6-(methylsulfanyl)-1H-pyrazolo[3,4-d]pyrimidine
##STR00938##
[1674] A suspension of
6-(methylsulfanyl)-1H-pyrazolo[3,4-d]pyrimidin-3-ol (2 g, 10.98
mmol, 1.00 equiv) and phosphorus oxybromide (6.3 g, 21.98 mmol,
2.00 equiv) in acetonitrile (50 mL) was sonicated for 30 min at
room temperature. The resulting solution was allowed to react for
an additional 16 hours while the temperature was maintained at
100.degree. C. The pH value of the solution was adjusted to 8 with
ammonium hydroxide (25%). The resulting mixture was concentrated
under vacuum, diluted with ethyl acetate, and the solids were
filtered out. The resulting solution was extracted with ethyl
acetate and the organic layers were combined. The residue was
purified by a silica gel column with dichloromethane/petroleum
ether (100:0) to give 430 mg (16%) of the title compound as a white
solid. LC-MS (ES, m/z): 245, 247 [M+H].sup.+.
Step 3: Synthesis of
3-bromo-6-methanesulfonyl-1H-pyrazolo[3,4-d]pyrimidine
##STR00939##
[1676] A suspension of
3-bromo-6-(methylsulfanyl)-1H-pyrazolo[3,4-d]pyrimidine (430 mg,
1.75 mmol, 1.00 equiv), 3-chloroperoxybenzoic acid (909 mg, 5.27
mmol, 3.00 equiv) in methanol (15 mL)/dichloromethane (10 mL) was
stirred for 3 hours at 30.degree. C. The resulting mixture was
concentrated under vacuum. This resulted in 485 mg (crude) of the
title compound as a white solid. LC-MS (ES, m/z): 277, 279
[M+H].sup.+.
Step 4: Synthesis of
3-bromo-6-methoxy-1H-pyrazolo[3,4-d]pyrimidine
##STR00940##
[1678] A mixture of
3-bromo-6-methanesulfonyl-1H-pyrazolo[3,4-d]pyrimidine (485 mg,
1.75 mmol, 1.00 equiv), sodium methoxide (1.89 g, 34.98 mmol, 20.00
equiv) in methanol (15 mL) was stirred for 4 hours at 70.degree. C.
The solids were filtered out and the liquid was concentrated under
vacuum. The residue was purified by a silica gel column with ethyl
acetate/petroleum ether (1:5) to give the title compound (240 mg)
as a white solid. LC-MS (ES, m/z): 229, 231 [M+H].sup.+.
Step 5: Synthesis of ethyl
6-methoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00941##
[1680] Similar to as described in General Procedure O, carbon
monoxide was reacted with
3-bromo-6-methoxy-1H-pyrazolo[3,4-d]pyrimidine to give the title
compound (40 mg, 17%) as a white solid. LC-MS (ES, m/z): 223
[M+H].sup.+.
Step 6: Synthesis of ethyl
1-(3-iodophenyl)-6-methoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00942##
[1682] Similar to as described in General Procedure C, ethyl
6-methoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was reacted
with (3-iodophenyl)boronic acid to give the title compound (60 mg,
79%) as a white solid. LC-MS (ES, m/z): 425 [M+H].sup.+.
Step 7: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
##STR00943##
[1684] Similar to as described in General Procedure G, ethyl
1-(3-iodophenyl)-6-methoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (70 mg, crude) as yellow oil. LC-MS (ES,
m/z): 436 [M+H].sup.+.
Step 8: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide
##STR00944##
[1686] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-6-m-
ethoxy-1H-pyrazolo[3,4-d]pyrimidine-3-carboxylate was reacted with
ammonia to give the title compound (20.3 mg, 31%) as a white solid.
LC-MS (ES, m/z): 407 [M+H].sup.+. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta.: 9.44 (s, 1H), 8.47-8.40 (m, 2H), 7.63-7.50 (m, 2H), 4.18
(s, 3H), 3.51 (t, J=5.4 Hz, 2H), 2.96 (s, 3H), 2.66-2.58 (m, 1H),
2.40-2.30 (m, 1H).
Example D8
Synthesis of
(R)-5-(2-(azetidin-1-yl)ethoxy)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-
-3-yl)ethynyl)phenyl)-1H-indazole-3-carboxamide
##STR00945##
[1687] Step 1: Synthesis of
5-(2-bromoethoxy)-1-(3-iodophenyl)-1H-indazole-3-carboxamide
##STR00946##
[1689] A mixture of
5-hydroxy-1-(3-iodophenyl)-1H-indazole-3-carboxamide (100 mg, 0.26
mmol, 1.00 equiv) and potassium carbonate (100 mg, 0.72 mmol, 2.70
equiv) in-1,2-dibromoethane (10 mL) was stirred overnight at
130.degree. C. The resulting solution was diluted with ethyl
acetate, washed with water, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:3). This
resulted in 50 mg (39%) of the title compound as a yellow solid.
LC-MS (ES, m/z): 486 [M+H].sup.+.
Step 2: Synthesis of
5-[2-(azetidin-1-yl)ethoxy]-1-(3-iodophenyl)-1H-indazole-3-carboxamide
##STR00947##
[1691] A mixture of
5-(2-bromoethoxy)-1-(3-iodophenyl)-1H-indazole-3-carboxamide (40.00
mg, 0.08 mmol, 1.00 equiv), N,N-Diisopropylethylamine (43 mg, 0.33
mmol, 4.00 equiv), and azetidine (24 mg, 0.42 mmol, 5.10 equiv) in
acetonitrile (5 mL) was stirred for 4 h at 40.degree. C. The
resulting mixture was concentrated under vacuum and the residue was
applied onto a silica gel column with dichloromethane/methanol
(10:1). This resulted in 15 mg (39%) of the title compound as a
yellow solid. LC-MS (ES, m/z): 463 [M+H].sup.+.
Step 3: Synthesis of
(R)-5-(2-(azetidin-1-yl)ethoxy)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-
-3-yl)ethynyl)phenyl)-1H-indazole-3-carboxamide
##STR00948##
[1693] Similar to as described in General Procedure G,
5-[2-(azetidin-1-yl)ethoxy]-1-(3-iodophenyl)-1H-indazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (9.7 mg, 63%) as an off-white solid.
LC-MS (ES, m/z): 474 [M+H].sup.+. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 7.97 (s, 1H), 7.91-7.87 (m, 2H), 7.80-7.77
(d, J=9.3 Hz, 1H), 7.65-7.63 (t, 2H), 7.50-7.48 (d, J=7.8 Hz, 2H),
7.19-7.15 (m, 1H), 6.52 (m, 1H), 3.99-3.96 (t, 2H), 3.38-3.32 (m,
2H), 3.22-3.18 (t, 4H), 2.80 (s, 3H), 2.75 (t, 2H), 2.51-2.49 (m,
1H), 2.32-2.13 (m, 1H), 1.97 (m, 2H).
Example E8
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(2-m-
orpholinoethoxy)-1H-indazole-3-carboxamide
##STR00949##
[1694] Step 1: Synthesis of methyl
1-(3-iodophenyl)-5-methoxy-1H-indazole-3-carboxylate
##STR00950##
[1696] Similar to as described in General Procedure C, methyl
5-methoxy-1H-indazole-3-carboxylate (1.00 g, 4.85 mmol, 1.00 equiv)
was reacted with (3-iodophenyl)boronic acid to give the title
compound (700 mg, 35%) as a dark red solid. LC-MS (ES, m/z): 409
[M+H].sup.+.
Step 2: Synthesis of
1-(3-iodophenyl)-5-methoxy-1H-indazole-3-carboxamide
##STR00951##
[1698] Similar to as described in General Procedure S, methyl
1-(3-iodophenyl)-5-methoxy-1H-indazole-3-carboxylate was reacted
with ammonia to give the title compound (185 mg, 96%) as a white
solid. LC-MS (ES, m/z): 394 [M+H].sup.+.
Step 3: Synthesis of
5-hydroxy-1-(3-iodophenyl)-1H-indazole-3-carboxamide
##STR00952##
[1700] A mixture of
1-(3-iodophenyl)-5-methoxy-1H-indazole-3-carboxamide (400 mg, 1.02
mmol, 1.00 equiv) and BBr.sub.3 (2.04 g, 8.14 mmol, 8.00 equiv) in
dichloromethane (5 mL) was stirred for 12 h at 40.degree. C. The
resulting solution was allowed to react for overnight while the
temperature was maintained at 40.degree. C. The reaction was
quenched by water, diluted with ethyl acetate, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:2). This resulted in 260 mg (67%) of the title compound as a
white solid. LC-MS (ES, m/z): 380 [M+H].sup.+.
Step 4: Synthesis of
1-(3-iodophenyl)-5-[2-(morpholin-4-yl)ethoxy]-1H-indazole-3-carboxamide
##STR00953##
[1702] A mixture of
5-hydroxy-1-(3-iodophenyl)-1H-indazole-3-carboxamide (100.00 mg,
0.26 mmol, 1.00 equiv), 4-(2-chloroethyl)morpholine hydrochloride
(245 mg, 1.32 mmol, 5.00 equiv), potassium carbonate (365 mg, 2.64
mmol, 10.00 equiv), and KI (88 mg, 0.53 mmol, 2.00 equiv) in
acetone (5 mL) was stirred overnight at 60.degree. C. The resulting
solution was diluted with ethyl acetate, washed with brine, dried
over anhydrous sodium sulfate, and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane/methanol (20:1). This resulted in 50 mg (39%) of
the title compound as a white solid. LC-MS (ES, m/z): 493
[M+H].sup.+.
Step 5: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl]phenyl]-5-[-
2-(morpholin-4-yl)ethoxy]-1H-indazole-3-carboxamide
##STR00954##
[1704] Similar to as described in General Procedure G,
1-(3-iodophenyl)-5-[2-(morpholin-4-yl)ethoxy]-1H-indazole-3-carboxamide
was reacted with (3R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (18 mg, 35%) as a white solid. LC-MS
(ES, m/z): 504 [M+H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 7.89 (d, J=9.3 Hz, 2H), 7.79 (d, J=9.3 Hz, 1H), 7.69-7.61
(m, 2H), 7.50 (d, J=7.8 Hz, 1H), 7.23-7.19 (m, 1H), 4.18-4.15 (m,
2H), 3.61-3.44 (m, 4H), 3.58 (s, 2H), 2.80-2.23 (s, 3H), 2.77-2.73
(m, 2H), 2.60-2.58 (m, 2H), 2.51-2.44 (m, 1H), 2.30-2.13 (m,
1H).
Example F8
Synthesis of
1-(3-(4-(dimethylamino)-3-hydroxy-4-oxobut-1-ynyl)phenyl)-1H-indazole-3-c-
arboxamide
##STR00955##
[1705] Step 1: Synthesis of
1-(3-iodophenyl)-1H-indazole-3-carboxamide
##STR00956##
[1707] Similar to as described in General Procedure S, methyl
1-(3-iodophenyl)-1H-indazole-3-carboxylate was reacted with ammonia
to give the title compound (1.35 g, crude) as an off-white solid.
LC-MS (ES, m/z): 364 [M+H].sup.+.
Step 2: Synthesis of ethyl
4-[3-(3-carbamoyl-1H-indazol-1-yl)phenyl]-2-hydroxybut-3-ynoate
##STR00957##
[1709] Similar to as described in General Procedure E,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with ethyl
2-hydroxybut-3-ynoate to give the title compound (140 mg, 23%) as a
light yellow solid. LC-MS (ES, m/z): 364 [M+H].sup.+.
Step 3: Synthesis of
1-[3-[3-(dimethylcarbamoyl)-3-hydroxyprop-1-yn-1-yl]phenyl]-1H-indazole-3-
-carboxamide
##STR00958##
[1711] Similar to as described in General Procedure S, ethyl
4-[3-(3-carbamoyl-1H-indazol-1-yl)phenyl]-2-hydroxybut-3-ynoate was
reacted with dimethylamine to give the title compound (15 mg, 10%)
as a light yellow solid. LC-MS (ES, m/z): 363 [M+H].sup.+. .sup.1H
NMR (300 MHz, CD.sub.3OD) .delta. 8.36 (d, J=8.4 Hz 1H), 8.20 (s,
1H), 7.97 (d, J=7.8 Hz, 1H), 7.89 (d, J=8.7 Hz, 1H), 7.84-7.80 (m,
2H), 7.72 (m, 1H), 7.60-7.55 (m, 1H), 7.41 (t, J=8.1 Hz, 1H), 7.11
(d, J=16.5 Hz, 1H), 3.07 (d, J=11.4 Hz, 1H).
Example G8
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]pyr-
azolo[4,3-b]pyridine-3-carboxamide
##STR00959##
[1712] Synthesis of 1H-pyrazolo[4,3-b]pyridine-3-carbonitrile
##STR00960##
[1714] To a solution of 3-bromo-1H-pyrazolo[4,3-b]pyridine (1.0
eq., 100 mg, 0.505 mmol) in 1-methyl-2-pyrrolidinone (1.3 mL) in a
microwave vial was added copper(I) cyanide (1.5 eq., 69.2 mg, 0.757
mmol). The reaction was heated in the microwave to 220.degree. C.
for 20 minutes. The solution was then cooled to room temperature,
diluted with aqueous saturated ammonium chloride and extracted
twice with DCM. The organic layers were combined, dried with sodium
sulfate and concentrated. The crude material was purified by flash
chromatography (5-100% iPrOAc in heptanes) to afford 70 mg (96%) of
the desired product with minor impurities.
Synthesis of
1-(3-bromophenyl)pyrazolo[4,3-b]pyridine-3-carbonitrile
##STR00961##
[1716] Similar to as described in General Procedure C,
1H-pyrazolo[4,3-b]pyridine-3-carbonitrile (70 mg, 0.485 mmol) was
reacted with (3-bromophenyl)boronic acid (1.5 eq., 146.3 mg, 0.728
mmol) to afford 31.4 mg (21.6% yield) of a light yellow solid.
Synthesis of
1-(3-bromophenyl)pyrazolo[4,3-b]pyridine-3-carboxamide
##STR00962##
[1718] Similar to as described in General Procedure D,
1-(3-bromophenyl)pyrazolo[4,3-b]pyridine-3-carbonitrile (31.4 mg,
0.105 mmol) was reacted to afford the desired product which was
carried forward to the next step without further purification.
Synthesis of
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phenyl]pyr-
azolo[4,3-b]pyridine-3-carboxamide
##STR00963##
[1720] Similar to as described in General Procedure E,
1-(3-bromophenyl)pyrazolo[4,3-b]pyridine-3-carboxamide (32.6 mg,
0.103 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (17.2 mg, 0.123
mmol) to afford 16.5 mg (42.8% yield) of the title compound as a
white solid. M+H=376.2; .sup.1H NMR (400 MHz, DMSO-d6) .delta.
8.85-8.75 (m, 1H), 8.50-8.42 (m, 1H), 8.31 (br s, 1H), 8.03 (br s,
1H), 7.96-7.89 (m, 1H), 7.91-7.85 (m, 1H), 7.70-7.60 (m, 2H),
7.58-7.48 (m, 1H), 6.54 (s, 1H), 3.41-3.32 (m, 2H), 2.81 (s, 3H),
2.50-2.40 (m, 1H), 2.19 (dt, J=12.8, 7.2 Hz, 1H).
Example H8
Ethyl
2-carbamoyl-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]e-
thynyl]-2-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate
##STR00964##
[1721] Synthesis of O5-tert-butyl O3-ethyl
1-(4-iodo-2-pyridyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3,5-dicarboxy-
late
##STR00965##
[1723] Similar to as described in General Procedure A,
O5-tert-butyl O3-ethyl
1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-3,5-dicarboxylate (2.734
g, 9.258 mmol) was reacted with 2-fluoro-4-iodopyridine (2.265 g,
10.16 mmol) to afford a light yellow solid which was carried
forward to subsequent steps without further purification.
Synthesis of Tert-butyl
3-carbamoyl-1-(4-iodo-2-pyridyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-
-carboxylate
##STR00966##
[1725] Similar to as described in General Procedure H,
O5-tert-butyl O3-ethyl
1-(4-iodo-2-pyridyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3,5--
dicarboxylate (4.613 g, 9.257 mmol) was reacted to afford the title
compound as a white powder (2.629 g, 60.51%).
Synthesis of tert-butyl
3-carbamoyl-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethyny-
l]-2-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate
##STR00967##
[1727] Similar to as described in General Procedure E, Tert-butyl
3-carbamoyl-1-(4-iodo-2-pyridyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-
-carboxylate (100.8 mg, 0.215 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (34.8 mg, 0.250
mmol) to afford the title compound.
Synthesis of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine-3-carboxamide
##STR00968##
[1729] To a solution of tert-butyl
3-carbamoyl-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethyny-
l]-2-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate
(1 eq.) in dry DCM (0.3 M) was added trifluoroacetic acid (4-6
equivalents). The reaction was then stirred at room temperature
until LC/MS showed complete conversion. The reaction was then
concentrated in vacuo to afford the TFA salt of the title
compound.
Synthesis of Ethyl
2-carbamoyl-1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethyny-
l]-2-pyridyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate
##STR00969##
[1731] To a solution of
1-[4-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-2-pyridyl-
]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine-3-carboxamide (1 eq.)
in THF was added DIPEA (6 eq.). To this solution was added ethyl
chloroformate (1.2 equivalents) in THF at 0.degree. C. The reaction
was complete within 30 minutes. The solution was extracted with
ammonium chloride and DCM, dried with sodium sulfate, and
concentrated in vacuo. The crude material was purified by HPLC to
afford the title compound. M+H=453.2; .sup.1H NMR (400 MHz, DMSO-d)
.delta. 8.52-8.45 (m, 1H), 8.08 (t, J=1.1 Hz, 1H), 7.98-7.93 (m,
1H), 7.45 (s, 1H), 7.38 (dd, J=5.1, 1.5 Hz, 1H), 6.66 (s, 1H), 4.60
(s, 2H), 4.09 (q, J=7.1 Hz, 2H), 3.66 (t, J=5.8 Hz, 2H), 3.37 (ddt,
J=10.1, 6.6, 3.0 Hz, 2H), 3.21 (t, J=5.7 Hz, 2H), 2.81 (s, 3H),
2.51-2.42 (m, 1H), 2.22 (ddd, J=12.7, 7.6, 6.4 Hz, 1H), 1.21 (t,
J=7.1 Hz, 3H).
Example I8
1-[2-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-4-pyridyl]-
-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00970##
[1732] Synthesis of
1-(2-bromo-4-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid
##STR00971##
[1734] Similar to as described in General Procedure A,
4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (75.4 mg, 0.454
mmol) was reacted with 2-bromo-4-fluoro-pyridine (76.0 mg, 0.430
mmol) to afford the title compound which was carried forward to
subsequent steps without further purification.
Synthesis of
1-(2-bromo-4-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00972##
[1736] Similar to as described in General Procedure B,
1-(2-bromo-4-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxylic acid
(140 mg, 0.43 mmol) was reacted with ammonium chloride (140 mg,
2.62 mmol) to afford the title compound.
Synthesis of
1-[2-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-4-pyridyl-
]-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00973##
[1738] Similar to as described in General Procedure E,
1-(2-bromo-4-pyridyl)-4,5,6,7-tetrahydroindazole-3-carboxamide (138
mg, 0.43 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (59 mg, 0.424
mmol) to afford the title compound. M+H=380.2; .sup.1H NMR (400
MHz, DMSO-d) .delta. 8.64 (d, J=5.5 Hz, 1H), 7.86 (d, J=2.1 Hz,
1H), 7.75-7.66 (m, 2H), 7.27 (s, 1H), 6.58 (d, J=2.1 Hz, 1H), 3.36
(ddt, J=10.0, 6.5, 2.8 Hz, 2H), 2.91 (t, J=6.0 Hz, 2H), 2.81 (s,
3H), 2.75-2.66 (m, 2H), 2.50-2.42 (m, 1H), 2.21 (ddd, J=14.5, 7.4,
5.9 Hz, 1H), 1.73 (dq, J=17.5, 4.4 Hz, 4H).
Example J8
1-[4-cyano-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]phe-
nyl]-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00974##
[1739] Synthesis of
1-(3-bromo-4-cyano-phenyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid
##STR00975##
[1741] Similar to as described in General Procedure A,
4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (200 mg, 1.2 mmol)
was reacted with 2-bromo-4-fluoro-benzonitrile (260 mg, 1.3 mmol)
to afford the title compound (350.8 mg, 84%).
Synthesis of
1-(3-bromo-4-cyano-phenyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00976##
[1743] Similar to as described in General Procedure B,
1-(3-iodo-4-cyano-phenyl)-4,5,6,7-tetrahydroindazole-3-carboxylic
acid (350.8 mg, 1.103 mmol) was reacted with ammonium chloride
(326.1 mg, 6.10 mmol) to afford the title compound as a white
powder (246.6 mg, 70.5%).
Synthesis of
1-[4-cyano-3-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]ph-
enyl]-4,5,6,7-tetrahydroindazole-3-carboxamide
##STR00977##
[1745] Similar to as described in General Procedure E,
1-(3-bromo-4-cyano-phenyl)-4,5,6,7-tetrahydroindazole-3-carboxamide
(80 mg, 0.232 mmol) was reacted with
(3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one (32.3 mg, 0.232
mmol) to afford the title compound. M+H=404.2; .sup.1H NMR (400
MHz, DMSO-d) .delta. 8.06 (dd, J=8.5, 0.5 Hz, 1H), 7.97 (dd, J=2.2,
0.5 Hz, 1H), 7.87 (dd, J=8.6, 2.2 Hz, 1H), 7.67 (s, 1H), 7.25 (s,
1H), 6.63 (s, 1H), 3.47-3.23 (m, 5H), 2.81 (s, 5H), 2.71 (t, J=5.8
Hz, 2H), 2.56-2.44 (m, 1H), 2.23 (dt, J=12.7, 7.5 Hz, 1H),
1.78-1.67 (m, 4H).
Example K8 and Example L8
Synthesis of
(S)-6-hydroxy-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide and
(R)-6-hydroxy-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00978##
[1746] Step 1: Synthesis of ethyl
1-(3-bromophenyl)-6-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-car-
boxylate
##STR00979##
[1748] To a stirred solution of ethyl
1-(3-bromophenyl)-6-oxo-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxylate
(150.00 mg, 0.43 mmol, 1.00 equiv) in ethanol (20 mL) was added
sodium borohydride (32.50 mg, 0.86 mmol, 2.00 equiv) and the
resulting solution was stirred for 1 hour at 0.degree. C. After
completion the solution was diluted with ethyl acetate, washed with
1M hydrogen chloride, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified by silica gel
column chromatography eluting with ethyl acetate/petroleum ether
(2:3) to give the title compound (100 mg, 66%) as a white solid.
LC-MS (ES, m/z): 351, 352 [M+H].sup.+.
Step 2: Synthesis of ethyl
6-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-1H,4H, 5H,6H-cyclopenta[c]pyrazole-3-carboxylate
##STR00980##
[1750] Similar to as described in General Procedure G, ethyl
1-(3-bromophenyl)-6-hydroxy-1H,4H,5H,6H-cyclopenta[c]pyrazole-3-carboxyla-
te was reacted with
(R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (70 mg, 67%) as a white solid. LC-MS (ES, m/z): 410
[M+H].sup.+.
Step 3: Synthesis of
(S)-6-hydroxy-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide and
(R)-6-hydroxy-1-(3-(((R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-
phenyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
##STR00981##
[1752] Similar to as described in General Procedure S, ethyl
6-hydroxy-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]p-
henyl)-1H,4H, 5H,6H-cyclopenta[c]pyrazole-3-carboxylate was reacted
with ammonia to give the title compounds a R/S mixture. After
chiral separation 9.8 mg (12%) of the 6R-isomer (yellow solid) and
12.4 mg (15%) of the 6S-isomer (yellow solid) were isolated. The
6R-isomer: t.sub.R=3.58 min (CHIRLPAK IC3, 0.46*5 cm, Hex (0.1%
TEA):EtOH=50:50, 1.0 ml/min); The 6S-isomer: t.sub.R=4.93 min
(CHIRLPAK IC3, 0.46*5 cm, Hex (0.1% TEA):EtOH=50:50, 1.0 ml/min).
Both isomers showed identical LC-MS and .sup.1H NMR as shown below.
LC-MS (ES, m/z): 381 [M+H].sup.+. .sup.1HNMR (400 MHz, methanol-d4)
.delta. 8.09 (s, 1H), 8.01-8.00 (m, 1H), 7.49-7.44 (m, 2H), 5.28
(s, 1H), 3.32-3.31 (m, 2H), 3.13-2.94 (m, 2H), 2.93 (s, 3H),
2.77-2.62 (m, 1H), 2.61-2.57 (m, 2H), 2.36-2.30 (m, 1H).
Example M8
Synthesis of
(R)-1-(3-(3-hydroxy-3-(thiazol-2-yl)but-1-ynyl)phenyl)-1H-indazole-3-carb-
oxamide
##STR00982##
[1753] Step 1: Synthesis of
(R)-1-(3-(3-hydroxy-3-(thiazol-2-yl)but-1-ynyl)phenyl)-1H-indazole-3-carb-
oxamide
##STR00983##
[1755] Similar to as described in General Procedure G,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
(R)-2-(thiazol-2-yl)but-3-yn-2-ol to give the title compound (58.8
mg, 46%) as a yellow solid. LC-MS (ES, m/z): 389 [M+H].sup.+.
.sup.1HNM (300 MHz, CD.sub.3OD) .delta. 8.35 (d, J=8.4 Hz, 1H),
7.94 (s, 1H), 7.87-7.79 (m, 3H), 7.64-7.53 (m, 4H), 7.39 (t, J=8.4
Hz, 1H), 1.98 (s, 3H).
Example N8
Synthesis of
(R)-6-cyano-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl-
)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00984##
[1756] Step 1: Synthesis of
2,4,6-trichloropyridine-3-carbaldehyde
##STR00985##
[1758] n-BuLi (2M, 16.8 mL) was added dropwise to a stirred
solution of 2,4,6-trichloropyridine (8 g, 43.85 mmol, 1.00 equiv)
in THF (80 mL) at -78.degree. C. under nitrogen. After being
stirred at -78.degree. C. for 30 min ethyl formate (4.88 g, 65.88
mmol, 1.50 equiv) was added to the reaction mixture and the
resulting solution was stirred for another 30 min at -78.degree. C.
After completion the solution was quenched with NH.sub.4Cl solution
and extracted with ethyl acetate. The organic layers were combined,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was purified by silica gel column chromatography
eluting with ethyl acetate/petroleum ether (1:10) to give the title
compound (5 g, 54%) as a white solid. .sup.1HNMR (300 MHz,
CDCl.sub.3) .delta. 10.42 (s, 1H), 7.45 (s, 1H).
Step 2: Synthesis of 4,6-dichloro-1H-pyrazolo[4,3-c]pyridine
##STR00986##
[1760] A suspension of 2,4,6-trichloropyridine-3-carbaldehyde (5 g,
23.76 mmol, 1.00 equiv) and hydrazine hydrate (3.6 g, 57.53 mmol,
3.00 equiv, 80%) in ethylene glycol dimethyl ether (25 mL) was
stirred for 12 h at 45.degree. C. After completion the solution was
quenched with water and extracted with ethyl acetate. The organic
layers were combined, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The residue was purified by silica gel
column chromatography eluting with ethyl acetate/petroleum ether
(1:10) to give the title compound (1 g, 22%) as a light yellow
solid. LC-MS (ES, m/z): 188 [M+H].sup.+.
Step 3: Synthesis of
4,6-dichloro-3-iodo-1H-pyrazolo[4,3-c]pyridine
##STR00987##
[1762] A solution of 4,6-dichloro-1H-pyrazolo[4,3-c]pyridine (1 g,
5.32 mmol, 1.00 equiv), iodine (2.64 g, 10.40 mmol, 2.00 equiv),
and potassium hydroxide (1.16 g, 20.68 mmol, 4.00 equiv) in
1,4-dioxane (100 mL) was stirred for 12 h at 70.degree. C. The
reaction was quenched by saturated Na.sub.2S.sub.2O.sub.3 and the
resulting solids were collected by filtration. This resulted in 1 g
(60%) of the title compound as a white solid. LC-MS (ES, m/z): 314
[M+H].sup.+.
Step 4: Synthesis of
6-chloro-3-iodo-N-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine
##STR00988##
[1764] Similar to as described in General Procedure A,
4,6-dichloro-3-iodo-1H-pyrazolo[4,3-c]pyridine was reacted with
methyl amine to give the title compound (700 mg, 71%) as a white
solid. LC-MS (ES, m/z): 309 [M+H].sup.+.
Step 5: Synthesis of methyl
6-chloro-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00989##
[1766] Similar to as described in General Procedure O,
6-chloro-3-iodo-N-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine was
reacted with carbon monoxide to give the title compound (210 mg,
38%) as a white solid. LC-MS (ES, m/z): 241 [M+H].sup.+.
Step 6: Synthesis of methyl
1-(3-bromophenyl)-6-chloro-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-c-
arboxylate
##STR00990##
[1768] Similar to as described in General Procedure C, methyl
6-chloro-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
was reacted with 3-bromophenylboronic acid to give the title
compound (190 mg, 55%) as a white solid. LC-MS (ES, m/z): 395, 397
[M+H].sup.+.
Step 7: Synthesis of methyl
6-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00991##
[1770] Similar to as described in General Procedure G, methyl
1-(3-bromophenyl)-6-chloro-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-c-
arboxylate was reacted with
(R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to give the title
compound (190 mg, 87%) as a yellow solid. LC-MS (ES, m/z): 454
[M+H].sup.+.
Step 8: Synthesis of methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-4-(methyl amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate
##STR00992##
[1772] A suspension of methyl
6-chloro-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]ph-
enyl)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate (100
mg, 0.22 mmol, 1.00 equiv), zinc cyanide (100 mg, 0.85 mmol, 3.90
equiv), bis(diphenylphosphino)ferrocene (190 mg, 0.34 mmol, 1.60
equiv), and bis(dibenzylideneacetone)palladium (80 mg, 0.09 mmol,
0.40 equiv) in 1,4-dioxane (5 mL) was stirred for 2 h at
100.degree. C. under nitrogen. After completion the precipitate was
filtered out and the filtrate was concentrated under vacuum. The
residue was purified by silica gel column chromatography eluting
with dichloromethane/ethyl acetate (5:1) to give the title compound
(20 mg, 20%) as an off-white solid. LC-MS (ES, m/z): 445
[M+H].sup.+.
Step 9: Synthesis of
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-4-(methylamino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide
##STR00993##
[1774] Similar to as described in General Procedure S, methyl
6-cyano-1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phe-
nyl)-4-(methyl amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxylate was
reacted with ammonia to give the title compound (4.5 mg, 12%) as a
white solid. LC-MS (ES, m/z): 430 [M+H].sup.+. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 7.90 (s, 1H), 7.82-7.79 (m,1H), 7.66-7.61 (m,
2H), 7.37 (s, 1H), 3.52-3.47 (m, 2H), 3.12 (s, 3H), 2.95 (s, 3H),
2.65-2.59 (m,1H), 2.37-2.30 (m, 1H).
Example O8 and Example P8
Synthesis of
(R)-1-(3-((3-hydroxy-2-oxo-tetrahydrofuran-3-yl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide and
(S)-1-(3-((3-hydroxy-2-oxo-tetrahydrofuran-3-yl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR00994##
[1775] Step 1: Synthesis of 3-hydroxy-4-methoxy-4-oxobutanoic
acid
##STR00995##
[1777] A solution of 2-hydroxybutanedioic acid (7.08 g, 52.80 mmol,
1.00 equiv) in trifluoroacetic anhydride (29.6 mL, 212.81 mmol,
4.00 equiv) was stirred for 1.5 h at room temperature. Then
methanol (30 mL, 739.66 mmol, 14.00 equiv) was added and the
resulting solution was allowed to react overnight at room
temperature. The resulting mixture was concentrated under vacuum
and the product was re-crystallized from ether/hexane (1:10) to
give the title compound (5.7 g, 73%) as a white solid.
Step 2: Synthesis of methyl 2,4-dihydroxybutanoate
##STR00996##
[1779] A solution of 3-hydroxy-4-methoxy-4-oxobutanoic acid (1.42
g, 9.59 mmol, 1.00 equiv) and BH.sub.3-Me.sub.2S (3.7 mL, 39.01
mmol, 4.10 equiv) in THF (15 mL) was stirred for 3 h at 0.degree.
C. The reaction was quenched by methanol and the resulting mixture
was concentrated under vacuum. This resulted in the title compound
(0.98 g, 76%) as colorless oil.
Step 3: Synthesis of
##STR00997##
[1781] A solution of methyl 2,4-dihydroxybutanoate (2.4 g, 17.89
mmol, 1.00 equiv), tert-butyldimethylsilyl chloride (2.89 g, 19.17
mmol, 1.10 equiv) and imidazole (1.5 g, 22.03 mmol, 1.20 equiv) in
DMF (15 mL) was stirred overnight at room temperature. The solution
was quenched with water and extracted with ethyl acetate. The
organic layers were combined, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The residue was purified by silica
gel column chromatography eluting with ethyl acetate/petroleum
ether (1:4) to give the title compound (2 g, 45%) as colorless
oil.
Step 4: Synthesis of methyl
4-[(tert-butyldimethylsilyl)oxy]-2-oxobutanoate
##STR00998##
[1783] A solution of methyl
4-[(tert-butyldimethylsilyl)oxy]-2-hydroxybutanoate (2.0 g, 8.05
mmol, 1.00 equiv) and Dess-Martin periodinane (4.15 g, 9.79 mmol,
1.20 equiv) in dichloromethane (40 mL) was stirred for 3 h at room
temperature. The solids were filtered out and the filtrate was
concentrated under vacuum. The residue was purified by silica gel
column chromatography eluting with ethyl acetate/petroleum ether
(1:7) to give the title compound (1.2 g, 60%) as colorless oil.
.sup.1HNMR (300 MHz, CDCl.sub.3) .delta. 3.99-3.95 (m, 2H), 3.86
(s, 3H), 3.06-3.02 (m, 2H), 0.86 (s, 9H), 0.05 (s, 6H).
Step 5: Synthesis of methyl
2-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-2-hydroxybut-3-ynoate
##STR00999##
[1785] Bromo(ethynyl)magnesium (0.5M, 1.95 mL, 1.20 equiv) was
added dropwise to a stirred solution of methyl
4-[(tert-butyldimethylsilyl)oxy]-2-oxobutanoate (200.00 mg, 0.81
mmol, 1.00 equiv) in THF (2.00 mL) under nitrogen. The resulting
solution was stirred for 2 h at 0.degree. C., quenched by
saturation ammonium chloride solution, and extracted with ethyl
acetate. The organic layers were combined, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
purified by silica gel column chromatography eluting with ethyl
acetate/petroleum ether to give the title compound (0.17 g, 77%) as
a yellow oil.
Step 6: Synthesis of 3-ethynyl-3-hydroxyoxolan-2-one
##STR01000##
[1787] A solution of methyl
2-[2-[(tert-butyldimethylsilyl)oxy]ethyl]-2-hydroxybut-3-ynoate
(1.0 g, 3.67 mmol, 1.00 equiv) and tetrabutylammonium fluoride
(1.93 g, 7.38 mmol, 2.00 equiv) in THF (30 mL) was stirred for 2 h
at room temperature. The reaction mixture was diluted with ethyl
acetate and washed with brine. The organic layers were combined,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The residue was purified by silica gel column chromatography
eluting with ethyl acetate/petroleum ether (1:2). This resulted in
to the title compound (146 mg, 32%) as a yellow oil. .sup.1HNMR
(300 MHz, CDCl.sub.3) .delta. 4.49-4.30 (m, 2H), 3.41 (s, 1H),
2.73-2.67 (m, 2H), 2.60-2.50 (m, 1H).
Step 7: Synthesis of
(R)-1-(3-((3-hydroxy-2-oxo-tetrahydrofuran-3-yl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide and
(S)-1-(3-((3-hydroxy-2-oxo-tetrahydrofuran-3-yl)ethynyl)phenyl)-1H-indazo-
le-3-carboxamide
##STR01001##
[1789] Similar to as described in General Procedure G,
1-(3-iodophenyl)-1H-indazole-3-carboxamide was reacted with
3-ethynyl-3-hydroxyoxolan-2-one to give the title compounds as a
R/S mixture. After chiral separation 26.2 mg (14%) of the R-isomer
(off-white solid) and 28.1 mg (15%) of the S-isomer (off-white
solid) were isolated. The R-isomer: t.sub.R=6.79 min (Lux 3u
Cellulose-2, 0.46*10 cm, Hex:IPA=55:45, 1.0 ml/min); The S-isomer:
t.sub.R=9.26 min (Lux 3u Cellulose-2, 0.46*10 cm, Hex:IPA=55:45,
1.0 ml/min). Both isomers showed identical LC-MS and .sup.1H NMR as
shown below. LC-MS (ES, m/z): 362 [M+H].sup.+. .sup.1HNMR (400 MHz,
CDCl.sub.3) .delta. 8.45 (m, 1H), 7.79 (s, 1H), 7.75-7.72 (m, 1H),
7.68-7.66 (m, 1H), 7.55-7.45 (s, 3H), 7.38-7.34 (t, 1H), 7.01-6.99
(m, 1H), 5.71 (s, 1H), 4.55-4.43 (m, 2H), 2.84-2.78 (m, 1H),
2.70-2.63 (m, 1H).
Example Q8
Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-meth-
oxy-1H-pyrazolo[3,4-c]pyridazine-3-carboxamide
##STR01002##
[1790] Step 1: Synthesis of
5-chloro-3-iodo-1H-pyrazolo[3,4-c]pyridazine
##STR01003##
[1792] Boron trifluoride etherate (2.5 mL, 19.73 mmol, 2.00 equiv)
was added dropwise to a stirred solution of
5-chloro-1H-pyrazolo[3,4-c]pyridazin-3-amine (1.7 g, 10.03 mmol,
1.00 equiv) in THF (20 mL) at 0.degree. C. After cooling to
-15.degree. C. 3-methylbutyl nitrite (1.4 g, 11.95 mmol, 1.20
equiv) was added dropwise to the reaction mixture. The resulting
mixture was stirred for 30 min at -15.degree. C., diluted with cold
diethyl ether (20 mL), and the solids were collected by filtration.
The solid (a diazonium salt) was then added in portions to a cold
solution of sodium iodide (1.8 g, 12.01 mmol, 1.20 equiv) in
acetone (20 mL) at 0.degree. C. The resulting solution was allowed
to react for an additional 1 hour at room temperature. The solution
was concentrated under vacuum and the residue was purified by
silica gel column chromatography eluting with
dichloromethane/methanol (20:1). This resulted in the title
compound (1.3 g, 46%) as a light yellow solid. LC-MS (ES, m/z): 281
[M+H].sup.+.
Step 2: Synthesis of ethyl
5-chloro-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
##STR01004##
[1794] Similar to as described in General Procedure O,
5-chloro-3-iodo-1H-pyrazolo[3,4-c]pyridazine was reacted with
carbon monoxide to give the title compound (450 mg, 40%) as an
off-white solid. LC-MS (ES, m/z): 227 [M+H].sup.+.
Step 3: Synthesis of ethyl
1-(3-bromophenyl)-5-chloro-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
##STR01005##
[1796] Similar to as described in General Procedure C,
5-chloro-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate was reacted
with 3-bromophenylboronic acid to give the title compound (67 mg,
40%) as a yellow solid. LC-MS (ES, m/z): 381, 383 [M+H].sup.+.
Step 4: Synthesis of
1-(3-bromophenyl)-5-chloro-1H-pyrazolo[3,4-c]pyridazine-3-carboxamide
##STR01006##
[1798] Similar to as described in General Procedure S, methyl
1-(3-bromophenyl)-5-chloro-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
was reacted with ammonia to give the title compound (280 mg, 97%)
as a light yellow solid. LC-MS (ES, m/z): 352, 354 [M+H].sup.+.
Step 5: Synthesis of
1-(3-bromophenyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridazine-3-carboxamide
##STR01007##
[1800] Similar to as described in General Procedure A, methyl
1-(3-bromophenyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
was reacted with sodium methylate to give the title compound (100
mg) as a light yellow solid. LC-MS (ES, m/z): 348, 350
[M+H].sup.+.
Step 6: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5-m-
ethoxy-1H-pyrazolo[3,4-c]pyridazine-3-carboxamide
##STR01008##
[1802] Similar to as described in General Procedure G,
1-(3-bromophenyl)-5-methoxy-1H-pyrazolo[3,4-c]pyridazine-3-carboxamide
was reacted with (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one
to give the title compound (15.0 mg, 16%) as a light yellow solid.
LC-MS (ES, m/z): 407 [M+H].sup.+. .sup.1HNMR (300 MHz, CD.sub.3OD)
.delta. 8.60 (d, J=1.8 Hz, 1H), 8.47 (m, 1H), 7.86 (s, 1H),
7.61-7.56 (m, 1H), 7.50-7.48 (m, 1H), 4.22 (s, 3H), 3.52-3.45 (m,
2H), 2.94 (s, 3H), 2.65-2.57 (m, 1H), 2.37-2.28 (m, 1H).
Example R8
Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridazine-3-carboxamide
##STR01009##
[1803] Step 1: Synthesis of
3,6-dichloropyridazine-4-carboxamide
##STR01010##
[1805] A solution of 3,6-dichloropyridazine-4-carboxylic acid (5.0
g, 0.026 mol) in thionyl chloride (30 mL) was stirred at room
temperature. After 5 min a few drops of dry pyridine were added and
the resulting mixture was stirring for 1 h at room temperature. The
reaction was concentrated under vacuum and the crude intermediate
was dissolved in 20 mL of dichloromethane and then a solution of
ammonium hydroxide at 0.degree. C. was added. The resulting
solution was stirred for 30 min at 0.degree. C. and concentrated
under vacuum. The solid was collected by filtration to give the
title compound (3.5 g, 77%) as an off-white solid. LC-MS (ES, m/z):
192 [M+H].sup.+.
Step 2: Synthesis of 3,6-dichloropyridazine-4-carbonitrile
##STR01011##
[1807] A mixture of 3,6-dichloropyridazine-4-carboxamide (5.7 g,
29.69 mmol, 1.00 equiv) and phosphorus oxychloride (50 mL) was
heated to reflux for 1 hour. The resulting mixture was concentrated
under vacuum and the residue was dissolved in dichloromethane. The
resulting solution was washed with water and brine, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The
residue was purified by silica gel column chromatography eluting
with ethyl acetate/petroleum ether (1:5). This resulted in the
title compound (5.1 g, 99%) as a light yellow solid.
Step 3: Synthesis of
5-chloro-1H-pyrazolo[3,4-c]pyridazin-3-amine
##STR01012##
[1809] To a stirred solution of
3,6-dichloropyridazine-4-carbonitrile (2.00 g, 11.50 mmol, 1.00
equiv) in methanol (20 mL) was added hydrazine hydrate (1.15 g,
22.97 mmol, 2.00 equiv) dropwise at room temperature. The resulting
solution was heated at 60.degree. C. for 1 hour. After completion
the mixture was concentrated under vacuum and the residue was
diluted with ethyl acetate. The precipitates were collected by
filtration to give the title compound (1.8 g, 92%) as a light
yellow solid. LC-MS (ES, m/z): 170 [M+H].sup.+.
Step 4: Synthesis of 1H-pyrazolo[3,4-c]pyridazin-3-amine
##STR01013##
[1811] A solution of 5-chloro-1H-pyrazolo[3,4-c]pyridazin-3-amine
(1.7 g, 10.03 mmol, 1.00 equiv), sodium hydroxide (0.8 g, 20.06
mmol, 2 equiv), palladium on carbon (1.0 g, 9.40 mmol, 0.90 equiv)
in methanol (100 mL) was stirred for 1 h at 50.degree. C. After
completion the precipitates were filtered out and the filtrate was
concentrated under vacuum. The residue was purified by silica gel
column chromatography eluting with dichloromethane/methanol (10:1)
to give the title compound (850 mg, 63%) as a yellow solid. LC-MS
(ES, m/z): 136 [M+H].sup.+.
Step 5: Synthesis of 3-iodo-1H-pyrazolo[3,4-c]pyridazine
##STR01014##
[1813] Boron trifluoride etherate (1.79 g, 12.58 mmol, 2.00 equiv)
was added dropwise to a solution of
1H-pyrazolo[3,4-c]pyridazin-3-amine (850.00 mg, 6.29 mmol, 1.00
equiv) THF (10 mL) at 0.degree. C. under nitrogen. After cooling to
-15.degree. C., 3-methylbutyl nitrite (884.28 mg, 7.55 mmol, 1.20
equiv) was added dropwise into the reaction mixture. The resulting
mixture was stirred for 30 min at -15.degree. C. and diluted with
cold diethyl ether (20 mL). The resulting solids were collected by
filtration to afford a diazonium salt, which was added in portions
to a cold solution of sodium iodide (1.13 g, 7.55 mmol, 1.20 equiv)
in acetone (10 mL) at 0.degree. C. The resulting solution was
allowed to react for an additional 1 hour at room temperature. The
solution was then concentrated under vacuum and the residue was
purified by silica gel column chromatography eluting with
dichloromethane/methanol (20:1). This resulted in the title
compound (900 mg) as an off-white solid. LC-MS (ES, m/z): 247
[M+H].sup.+.
Step 6: Synthesis of 1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
##STR01015##
[1815] Similar to as described in General Procedure O,
3-iodo-1H-pyrazolo[3,4-c]pyridazine was reacted with carbon
monoxide to give the title compound (400 mg, 69%) as an off-white
solid. LC-MS (ES, m/z): 179 [M+H].sup.+.
Step 7: Synthesis of
1-(3-iodophenyl)-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate
##STR01016##
[1817] Similar to as described in General Procedure C, methyl
1H-pyrazolo[3,4-c]pyridazine-3-carboxylate was reacted with
(3-iodophenyl)boronic acid to give the title compound (100 mg, 22%)
as an off-white solid. LC-MS (ES, m/z): 381 [M+H].sup.+.
Step 8: Synthesis of methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridazine-3-carboxylate
##STR01017##
[1819] Similar to as described in General Procedure G, methyl
1-(3-iodophenyl)-1H-pyrazolo[3,4-c]pyridazine-3-carboxylate was
reacted with (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one to
give the title compound (50 mg, 49%) as a brown solid. LC-MS (ES,
m/z): 392 [M+H].sup.+.
Step 9: Synthesis of
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridazine-3-carboxamide
##STR01018##
[1821] Similar to as described in General Procedure S, methyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-1H--
pyrazolo[3,4-c ]pyridazine-3-carboxylate was reacted with ammonia
to give the title compound (10.4 mg, 22%) as a white solid. LC-MS
(ES, m/z): 377 [M+H].sup.+. .sup.1HNMR (300 MHz, CD.sub.3OD)
.delta. 9.35 (d, J=5.4 Hz, 1H), 8.63 (s, 1H), 8.62 (d, J=1.5 Hz,
1H), 8.58-8.56 (m, 1H), 7.63-7.56 (m, 2H), 3.53-3.48 (m, 2H), 2.95
(s, 3H), 2.69-2.61 (m, 1H), 2.39-2.32 (m, 1H).
Example S8
Synthesis of Compound 177:
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5,6,7,-
8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
##STR01019##
[1822] Step 1: Synthesis of ethyl
2-oxo-2-(pyridin-2-ylmethylamino)acetate
##STR01020##
[1824] To a solution of pyridin-2-ylmethanamine (1.00 g, 9.25 mmol,
1.00 equiv) and N,N-diisopropylethylamine (2.39 g, 18.49 mmol, 2.00
equiv) in dichloromethane (20 mL) was added ethyl
2-chloro-2-oxoacetate (1.26 g, 9.23 mmol, 1.00 equiv). The
resulting solution was stirred for 1.5 h at room temperature. After
completion the mixture was concentrated under vacuum and the
residue was purified by silica gel column chromatography eluting
with ethyl acetate/petroleum ether (1:1). This resulted in 1.2 g
(62%) of the title compound as a yellow solid. LC-MS (ES, m/z): 209
[M+H].sup.+.
Step 2: Synthesis of ethyl imidazo[1,5-a]pyridine-3-carboxylate
##STR01021##
[1826] A solution of ethyl [(pyridin-2-ylmethyl)carbamoyl]formate
(1.00 g, 4.80 mmol, 1.00 equiv) and phosphorus pentoxide (3.41 g,
24.02 mmol, 5.00 equiv) in phosphorus oxychloride (30 mL) was
stirred for 5 h at 110.degree. C. The resulting mixture was
concentrated under vacuum. The residue was purified by silica gel
column chromatography eluting with ethyl acetate/petroleum ether
(1:1). This resulted in 635 mg (70%) of the title compound as a
yellow solid. LC-MS (ES, m/z): 191 [M+H].sup.+.
Step 3: Synthesis of ethyl
5H,6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate
##STR01022##
[1828] Under hydrogen a solution of ethyl
imidazo[1,5-a]pyridine-3-carboxylate (300 mg, 1.58 mmol, 1.00
equiv) and Pd/C (10 wt %, 30 mg) in methanol (20 mL) was stirred
for 30 h at room temperature. After filtration the filtrate was
collected and concentrated under vacuum. This resulted in 325 mg of
the title compound (crude) as a white solid. LC-MS (ES, m/z): 195
[M+H].sup.+.
Step 4: Synthesis of ethyl
1-bromo-5H,6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate
##STR01023##
[1830] A solution of ethyl
5H,6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate (300 mg, 1.54
mmol, 1.00 equiv) and NBS (330 mg, 1.85 mmol, 1.20 equiv) in
acetonitrile (20 mL) was stirred for 3 h at 0.degree. C. The
resulting mixture was concentrated under vacuum. The residue was
purified by silica gel column chromatography eluting with ethyl
acetate/petroleum ether (1:2). This resulted in 100 mg (24%) of the
title compound as a white solid. LC-MS (ES, m/z): 273
[M+H].sup.+.
Step 5: Synthesis of ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5H,-
6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate
##STR01024##
[1832] A solution of ethyl
1-bromo-5H,6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate (70.0 mg,
0.26 mmol, 1.00 equiv), RuPhos-PdCl-2nd G (39.9 mg, 0.05 mmol, 0.20
equiv), potassium
(R)-trifluoro(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethyn-
yl)phenyl)borate (98.77 mg, 0.31 mmol, 1.20 equiv) and sodium
carbonate (54.3 mg, 0.51 mmol, 2.00 equiv) in ethanol (8.0 mL) and
water (0.50 mL) was stirred for 3 h at 80.degree. C. under
nitrogen. After completion the resulting mixture was concentrated
under vacuum. The residue was purified by silica gel column
chromatography eluting with dichloromethane/methanol (10:1). This
resulted in 80 mg (77%) of the title compound as a red solid. LC-MS
(ES, m/z): 408 [M+H].sup.+.
Step 6: Synthesis of
(R)-1-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5,6,7,-
8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
##STR01025##
[1834] Similar to as described in General Procedure S, ethyl
1-(3-[2-[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5H,-
6H,7H,8H-imidazo[1,5-a]pyridine-3-carboxylate was reacted with
ammonia to give the title compound (16.9 mg, 26%) as a white solid.
LC-MS (ES, m/z): 379 [M+H].sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3,
ppm) .delta. 7.83 (s, 1H), 7.73-7.71 (m, 1H), 7.45-7.37 (m, 2H),
4.52-4.48 (m, 2H), 3.52-3.47 (m, 2H), 3.17-3.03 (m, 2H), 2.96 (s,
3H), 2.65-2.57 (m, 1H), 2.38-2.33 (m, 1H), 2.04-2.03 (m, 2H),
1.95-1.91 (m, 2H).
[1835] Aryl Substitution Reactions
[1836] In the Scheme below, Q, A.sub.1-A.sub.8 and R.sup.4-R.sup.6
are defined elsewhere in the application.
##STR01026##
[1837] Compounds of type C can be prepared via Suzuki-type coupling
of 3-alkynylaryl or heteroaryl boronic acids, esters (B1) or
trifluoroborate salts (B2) to haloheterocycles A (Molander et al
Acc. Chem. Res. 2007). Compounds of type B can be prepared by
various routes including direct borylation of arenes containing
sterically accessible C--H bonds (D) (Hartwig, J. F. et al. Chem.
Rev. 2010) or Sonogashira coupling to aryl or heteroarylboronic
esters or trifluoroborates (F).
[1838] Preparation of Moieties Adjacent to the Alkynyl Portion
[1839] Moieties such as those shown below may be prepared as
described in U.S. patent application Ser. No. 13/768,873, filed
Feb. 15, 2013, and entitled "Tricyclic Compounds and Methods of Use
Therefor," which is incorporated herein by reference.
##STR01027## ##STR01028##
[1840] Optional methods for accessing these types of moieties are
also described below.
##STR01029##
[1841] Terminal alkynes (F) for use in Sonogashira coupling
reactions to haloarenes can be generated by a number of methods
including those described in the above scheme. Addition of
ethynylmagnesium bromide to substituted ketones (G) or addition of
lithium trimethylsilylacetylide followed by proteolytic removal of
the trimethylsilyl group will generate substituted propargyl
alcohols. Alternatively, aldehydes (H) can be converted to terminal
alkynes via a Corey-Fuchs process (steps 1-3 Corey Tetrahedron
Lett. 1972) or via conditions for the Bestmann-Ohira modification
of the Gilbert-Seyferth process (Bestmann Synthesis, 2004).
[1842] The following compounds were prepared using methodologies
similar to those presented above:
TABLE-US-00002 LCMS Ex. Structure Name M + H 175 ##STR01030##
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]phenyl]-
6-methyl-pyrazolo[3,4-b]pyridine-3- carboxamide 390.10 176
##STR01031## 7-fluoro-1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]indazole-3-
carboxamide 393.1 177 ##STR01032##
1-[3-[2-[(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3-yl]ethynyl]phenyl]- 5,6,7,8-tetrahydroimidazo[1,5-
a]pyridine-3-carboxamide 379.0 178 ##STR01033##
1-[3-[2-[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]imidazo[1,5- a]pyridine-3,7-dicarboxamide 418.15
179 ##STR01034## 3-[3-[2-[(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo[1,5-
a]pyridine-1,6-dicarboxamide 418.15 180 ##STR01035##
1-[3-[2-[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5-oxo-6,7-dihydro- 4H-pyrazolo[4,3-b]pyridine-3-
carboxamide 394.10 181 ##STR01036##
1-[3-[(3R)-3-hydroxy-3-(5-methyl- 1,3,4-oxadiazol-2-yl)but-1-
ynyl]phenyl]-7-methoxy- imidazo[1,5-a]pyridine-3- carboxamide 418.1
182 ##STR01037## 1-[3-[2-[(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]-5-(1H-imidazol-
2-yl)indazole-3-carboxamide 441.17 183 ##STR01038##
1-[3-[2-[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5-(3-methoxy- azetidin-1-yl)pyrazolo[3,4-
b]pyridine-3-carboxamide 461.19 184 ##STR01039##
1-[3-[2-[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-N5,N5-dimethyl- indazole-3,5-dicarboxamide 446.2
185 ##STR01040## 6-chloro-1-[3-[(3R)-3-hydroxy-
3-(5-methyl-1,3,4-oxadiazol-2- yl)but-1-ynyl]phenyl]
imidazo[1,5-a]pyridine-3- carboxamide 422.10 186 ##STR01041##
6-chloro-1-[2-fluoro-5-[2- [(3R)-3-hydroxy-1-methyl-2-
oxo-pyrrolidin-3- yl]ethynyl]phenyl]imidazo[1,5-
a]pyridine-3-carboxamide 427.1 187 ##STR01042##
7-chloro-1-[3-[(3R)-3-hydroxy- 3-(5-methyl-1,3,4-oxadiazol-2-
yl)but-1-ynyl]phenyl]imidazo[1,5 a]pyridine-3-carboxamide 422.1 188
##STR01043## 1-[3-[2-[(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]-5-methyl-5,6-
dihydro-4H-cyclopenta[c]pyrazole- 3-carboxamide 379.2 189
##STR01044## 6-fluoro-1-[3-[2-[(3R)-3-hydroxy-
1-methyl-2-oxo-pyrrolidin- 3-yl]ethynyl]phenyl]indazole-
3-carboxamide 393.0 190 ##STR01045## 1-[3-[2-[(3R)-3-hydroxy-1-
methyl-2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]pyrazolo[3,4-
d]pyridazine-3-carboxamide 377.1 191 ##STR01046##
1-[2-fluoro-5-[2-[(3R)-3-hydroxy- 1-methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-4,6- dihydrofuro[3,4-c]pyrazole-3- carboxamide
385.10 192 ##STR01047## 3-[3-[2-[(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl] ethynyl]phenyl]-6,7-dihydro-5H-
pyrrolo[1,2-c]imidazole-1- carboxamide 365.0 193 ##STR01048##
(5S)-1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5-methyl-5,6- dihydro-4H-cyclopenta[c]pyrazole-
3-carboxamide 379.18 194 ##STR01049##
(5R)-1-[3-[2-[(3R)-3-hydroxy-1- methyl-2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5-methyl-5,6- dihydro-4H-cyclopenta[c]pyrazole-
3-carboxamide 379.18 195 ##STR01050##
5-amino-2-[3-[2-[(3R)-3-hydroxy- 1-methyl-2-oxo-pyrrolidin-
3-yl]ethynyl]phenyl]thiazole- 4-carboxamide 357.10 196 ##STR01051##
1-[3-[2-[(3R)-3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl]
ethynyl]phenyl]-5-(methyl- amino)pyrazolo[3,4-d]thiazole-
3-carboxamide 411.1 197 ##STR01052##
2-[2-fluoro-5-[2-[(3R)-3-hydroxy- 1-methyl-2-oxo-pyrrolidin-3-
yl]ethynyl]phenyl]-5-methyl- thiazole-4-carboxamide 374.1 198
##STR01053## 1-[3-[2-[(3R)-3-hydroxy-1-methyl-
2-oxo-pyrrolidin-3-yl]ethynyl] phenyl]-4,5,6,7-tetrahydro-
pyrazolo[3,4-b]pyridine-3- carboxamide 380.1 199 ##STR01054##
5,5-difluoro-1-[3-[2-[(3R)-3- hydroxy-1-methyl-2-oxo-pyrrolidin-
3-yl]ethynyl]phenyl]-4,6-dihydro- cyclopenta[c]pyrazole-3-
carboxamide 401.10
[1843] NIK Enzyme Inhibition Assay:
[1844] The ability of the nuclear factor-kappa B (NF-kB)-inducing
kinase (NIK) to catalyze the hydrolysis of
adenosine-5'-triphosphate (ATP) was monitored using the
Transcreener ADP (adenosine-5'-diphosphate) assay (BellBrook Labs).
Purified NIK (0.5 nM) derived from a baculovirus-infected insect
cell expression system was incubated with test compounds for 1-3.5
hours in 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic
acid buffer (pH 7.2) containing 10 mM MgCl.sub.2, 2 mM
dithiothreitol, 10 .mu.M ATP, 0.01% Triton X-100, 0.1%
gamma-globulins from bovine blood, 1% dimethylsulfoxide (DMSO), 7
.mu.g/mL ADP antibody and 5 nM ADP-MR121 633 tracer. Reactions were
quenched by the addition of 20 mM
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid and 0.01%
Brij 35. The tracer bound to the antibody was displaced by the ADP
generated during the NIK reaction, which causes a decrease in
fluorescence polarization that was measured by laser excitation at
633 nm with a Fluorescence Correlation Spectroscopy Plus reader
(Evotec AG). Equilibrium dissociation constant (K.sub.i) values for
NIK inhibitors are calculated from plots of activity vs. inhibitor
concentration using Morrison's quadratic equation that accounts for
the potential of tight binding, and by also applying the conversion
factor that accounted for competitive inhibition and the
concentration of substrate used in the assay relative to its
Michaelis constant (K.sub.m). The compounds in listed in Table 1
have the corresponding inhibitory value (NIK ADP-FP, K.sub.i in
micromolar) for NIK described in Table 2 below.
[1845] Cellular Assay:
[1846] Several assays were developed to profile the cellular
activities of NIK inhibitors.
[1847] (1) The first assay that can be used to profile whether a
test compound can inhibit the NF-kB signal through NIK inhibition
without affecting cell viability. In this assay, human embryonic
kidney 293 cells are stably transfected with a
tetracycline-inducible NIK DNA construct containing a
cytomegalovirus promoter plus two reporter DNA constructs. One
reporter encodes firefly luciferase under the control of three
repeats of an NF-kB response element from the ELAM-1 gene and
reflects the level of NIK activity in the cells, whereas the other
reporter constitutively expresses Renilla luciferase under the
control of the herpes simplex virus thymidine kinase promoter and
serves as a general measure of cell viability. Cells are incubated
with different concentrations of compounds (0.2% DMSO final) in
medium containing 1 .mu.g/mL doxycycline and 10% tet-system
approved fetal bovine serum (Clontech) for 24 hours, after which
the reporters' signals are detected using the Dual Glo luciferase
detection system (Promega) according to the vendor's protocol.
[1848] (2) A second set of cell assay are used to define the
selectivity of NIK inhibitors toward inhibition of classical vs.
non-classical NF-kB signaling and rely on quantification of the
nuclear translocation of p52 (NF-kB2) and REL-A (p65) using high
content cellular imaging. For the p52 (non-classical NF-kB
signaling) nuclear translocation assay, HeLa cells are treated with
different concentrations of compounds (0.2% DMSO final) in medium
containing 10% fetal bovine serum and then stimulated with 100
ng/mL of an anti-lymphotoxin beta receptor antibody (R&D
Systems) for 5 hours. In the REL-A nuclear translocation assay,
HeLa cells are incubated with compounds (0.2% DMSO final) for 4.5
hours in medium containing 10% fetal bovine serum before
stimulating them with 10 ng/mL tumor necrosis factor (TNF)-.alpha.
(R&D Systems) for 30 minutes. Cells are fixed with 4%
paraformaldehyde, permeabilized by adding 0.1% Triton X-100 in
phosphate buffered saline, and then are incubated with either 2
ug/mL anti-p52 antibody (Millipore) or 400 ng/mL anti-REL-A (p65)
antibody (Santa Cruz Biotechnology). Finally, the cells are
incubated with an Alexa488-labeled secondary antibody (Invitrogen)
and DRAQ5 DNA stain (Biostatus). Imaging is carried out using an
Opera reader (Perkin Elmer) and data are analyzed with the aid of
Acapella software (Perkin Elmer). The p52 or REL-A translocation
into the nucleus is quantified by the ratio of the nuclear to
cytoplasmic signal intensity. The concentration of inhibitor
required for 50% inhibition (IC.sub.50 values) in these cell assays
are derived from the plots of signal vs. inhibitor concentration.
The compounds in listed in Table 1 have the corresponding
inhibitory value (IC.sub.50 in micromolar) for NIK p52
Translocation Assay as set forth in Table 2.
[1849] The compounds in listed in Table 1 have the corresponding
inhibitory values (IC.sub.50 in micromolar) for the Translocation
Assays as set forth in Table 2.
TABLE-US-00003 TABLE 2 NIK REL-A HeLa p52 HeLa ADP-FP Transloc
Assay Transloc Assay Ex. (K.sub.i .mu.M) (IC.sub.50) [.mu.M]
(IC.sub.50) [.mu.M] 1 0.000070 20.0 0.057 2 0.00107 20.0 0.273 3
0.00113 20.0 0.544 4 0.00292 5 0.0139 6 0.00778 10.0 0.901 7 0.0455
8 0.0724 9 0.0332 10 0.00119 20.0 0.0663 11 0.0134 12 0.00156 20.0
0.187 13 0.00027 20.0 0.073 14 0.000050 20.0 0.0678 15 0.382 16
0.00090 20.0 0.125 17 0.146 18 0.00086 20.0 0.138 19 0.0102 20
0.00489 21 0.233 22 0.00034 20.0 0.0948 23 0.00975 24 0.00762 25
0.00041 20.0 0.0446 26 0.00252 20.0 1.13 27 0.00375 20.0 0.322 28
0.0352 29 0.0367 30 0.0166 31 0.00062 20.0 0.0671 32 1.04 33 0.259
34 0.606 35 0.00148 20.0 0.737 36 0.00553 20.0 0.164 37 0.193 38
0.0101 39 0.00121 20.0 0.108 40 0.071 41 0.00032 20.0 0.0525 42
0.00064 20.0 0.392 43 0.0016 20.0 0.921 44 0.00050 20.0 0.062 45
0.00233 46 0.00050 20.0 0.123 47 0.0226 48 0.0647 49 0.000050 8.0
0.0077 50 0.17 51 0.000808 7.19 0.225 52 0.000098 20.0 0.0228 53
0.000080 20.0 0.0379 54 0.000080 2.0 0.039 55 0.0149 56 0.00087
20.0 0.355 57 0.0014 20.0 0.405 58 0.0187 59 0.0072 60 0.0137 20.0
2.31 61 0.00446 62 0.00547 63 0.00010 2.0 0.027 64 0.00306 3.03
2.31 65 0.000050 2.0 0.014 66 0.00015 20.0 0.055 67 0.00314 20.0
0.893 68 0.237 69 0.00398 20.0 0.945 70 0.00075 20.0 0.864 71
0.00064 20.0 0.178 72 0.00014 20.0 0.247 73 0.00105 20.0 0.119 74
0.000050 8.0 0.0139 75 0.00024 20.0 0.0569 76 0.000050 8.0 0.0412
77 0.000050 20.0 0.0298 78 0.0168 20.0 2.71 79 0.0108 80 0.0845 81
0.0158 82 0.0991 83 0.00587 84 0.0339 85 0.000050 19.2 0.0386 86
0.00073 20.0 0.356 87 0.0204 88 0.00478 20.0 0.24 89 0.00165 >20
0.226 90 0.000050 2.0 0.0634 91 0.00015 20.0 0.0189 92 0.00037 20.0
0.0259 93 0.000060 20.0 0.0153 94 0.000050 6.32 0.00726 95 0.000050
2.0 0.0864 96 0.00014 20.0 0.0603 97 0.000050 1.0 0.0066 98
0.000050 6.32 0.017 99 0.00152 2.0 0.231 100 0.00165 2.0 0.156 101
0.000060 6.32 0.0312 102 0.000070 20.0 0.00403 103 104 0.00010 2.0
0.0267 105 0.00063 106 0.000050 107 0.00182 108 0.00024 109 0.00958
20.0 0.209 110 0.00055 20.0 0.244 111 0.00486 20.0 0.701 112
0.000080 113 0.000070 20.0 0.44 114 0.00019 20.0 0.0394 115 0.0861
116 0.00063 117 0.00032 20.0 0.0743 118 0.0166 119 0.00043 20.0
0.0458 120 0.00052 20.0 1.43 121 0.00105 20.0 0.203 122 0.00029
20.0 0.266 123 0.018 124 0.0464 125 0.0196 126 0.591 127 0.0102 128
1.25 129 0.000050 4.47 0.00812 130 0.00011 2.0 0.0531 131 0.00031
20.0 0.087 132 0.000378 20.0 0.0887 133 0.00131 134 1.25 135
0.00070 20.0 0.0914 136 0.00039 20.0 0.0726 137 0.00025 20.0 0.0338
138 0.00019 139 0.00039 140 0.000050 8.0 0.0382 141 0.00327 142
0.00171 20.0 0.793 143 0.00154 144 0.00031 20.0 0.0331 145 0.00124
20.0 0.266 146 0.00177 20.0 0.22 147 0.000324 20.0 0.0141 148
0.00038 20.0 0.11 149 0.00108 20.0 0.215 150 0.00029 20.0 0.0573
151 0.00396 2.0 1.03 152 0.00087 20.0 0.0458 153 0.00052 2.0 0.132
154 0.000050 2.0 0.0339 155 0.00026 20.0 0.129 156 0.000090 2.0
0.0957 157 0.00068 2.0 0.157 158 0.00023 2.0 0.0462 159 0.00713 2.0
2.0 160 0.00013 20.0 0.0668 161 0.00252 2.0 0.77 162 0.00035 2.0
0.237 163 0.25 164 0.00154 20.0 0.208 165 0.00023 20.0 0.274 166
0.00119 20.0 0.32 167 0.00193 20.0 0.397 168 0.0337 169 0.00296 20
1.12 170 0.00075 17.1 0.244 171 0.00812 171 0.00812 172 0.473 173
0.00055 2 0.176 174 0.00013 2 2 175 0.000050 >2 0.135 176
0.00127 177 0.00011 >2 0.15 178 0.00010 >2 0.636 179 0.0111
180 0.00035 181 0.00010 >2 0.048 182 0.00151 183 0.00019 184
0.103 185 0.00754 >2 1.5 186 0.00010 >2 0.036 187 0.00112
>2 0.198 188 0.00085 >2 0.205 189 0.000050 >2 0.095 190
0.0068 191 0.00111 192 0.0281 193 0.00010 194 0.000050 195 0.000050
196 0.000050 197 0.000053 198 0.00029 199 0.00026 Blank = not
determined
* * * * *